Polynucleotides encoding anti-kit antibodies

ABSTRACT

Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-associated disorder or disease and methods of diagnosing a KIT-associated disorder or disease using the antibodies described herein.

This application is a divisional application of U.S. patent applicationSer. No. 13/949,931, filed Jul. 24, 2013, which claims the benefit,under 35 U.S.C. §119(e), of U.S. Provisional Application No. 61/675,751filed on Jul. 25, 2012 and U.S. Provisional Application No. 61/675,762filed on Jul. 25, 2012; the foregoing applications are herebyincorporated by reference in their entirety.

The instant application contains a Sequence Listing, which is beingconcurrently submitted as an ASCII text file named“Sequence_Listing_12638-059-999.TXT”, created Jul. 24, 2013, and being151,683 bytes in size. The Sequence Listing is hereby incorporated byreference in its entirety.

1. FIELD

Provided herein are antibodies that specifically bind to a KITpolypeptide, antigen-binding fragments thereof, conjugates of suchantibodies, polynucleotides encoding such antibodies, vectors and hostcells for producing such antibodies, kits and pharmaceuticalcompositions comprising antibodies that immunospecifically bind to a KITantigen, uses and methods for treating or managing a KIT-associateddisorder, and diagnostic methods.

2. BACKGROUND

KIT (or c-Kit) is a type III receptor tyrosine kinase encoded by thec-kit gene. KIT comprises five extracellular immunoglobulin (Ig)-likedomains, a single transmembrane region, an inhibitory cytoplasmicjuxtamembrane domain, and a split cytoplasmic kinase domain separated bya kinase insert segment (see, e.g., Yarden et al., Nature, 1986,323:226-232; Ullrich and Schlessinger, Cell, 1990, 61:203-212; Cliffordet al., J. Biol. Chem., 2003, 278:31461-31464). The human c-kit geneencoding the KIT receptor has been cloned as described by Yarden et al.,EMBO J., 1987, 6:3341-3351. KIT is also known as CD117 or stem cellfactor receptor (“SCFR”), because it is the receptor for the stem cellfactor (“SCF”) ligand (also known as Steel Factor or Kit Ligand). SCFligand binding to the first three extracellular Ig-like domains of KITinduces receptor dimerization, and thereby activates intrinsic tyrosinekinase activity through the phosphorylation of specific tyrosineresidues in the juxtamembrane and kinase domains (see, e.g., Weiss andSchlessinger, Cell, 1998, 94:277-280; Clifford et al., J. Biol. Chem.,2003, 278:31461-31464). Members of the Stat, Src, ERK, and AKT signalingpathways have been shown to be downstream signal transducers of KITsignaling.

The fourth (D4) and fifth (D5) extracellular Ig-like domains of KIT arebelieved to mediate receptor dimerization (see, e.g., InternationalPatent Application Publication No. WO 2008/153926; Yuzawa et al., Cell,2007, 130:323-334).

Expression of KIT has been detected in various cell types, such as mastcells, stem cells, brain cells, melanoblasts, ovary cells, and cancercells (e.g., leukemia cells). Studies of loss-of-function KIT mutationsindicate that KIT is important for the normal growth of hematopoieticprogenitor cells, mast cells, melanocytes, primordial germ cells, andthe interstitial cells of Cajal (see, e.g., Besmer, P., Curr. Opin. CellBiol., 1991, 3:939-946; Lyman et al., Blood, 1998, 91:1101-1134; Ashman,L. K., Int. J. Biochem. Cell Biol., 1999, 31:1037-1051; Kitamura et al.,Mutat. Res., 2001, 477:165-171; Mol et al., J. Biol. Chem., 2003,278:31461-31464). Moreover, KIT plays an important role inhematopoiesis, melanogenesis, and gametogenesis (see Ueda et al., Blood,2002, 99:3342-3349).

Abnormal KIT activity has been implicated in connection with a number ofcancers. For example, gain-of-function KIT mutations resulting inSCF-independent, constitutive activation of KIT are found in certaincancer cells and are associated with certain cancers such as leukemia(e.g., chronic myelogenous leukemia) and gastrointestinal stromal tumors(see, e.g., Mol et al., J. Biol. Chem., 2003, 278:31461-31464).

3. SUMMARY

Provided herein, in one aspect, are antibodies, antigen-bindingfragments thereof, and conjugates thereof, that immunospecifically bindto a domain 4 (D4) (or D4 region) of the extracellular domain of KIT(e.g., human KIT) and inhibit a KIT activity, as well as relatedcompositions, reagents and methods.

In one aspect, provided herein is an antibody, or an antigen bindingfragment thereof, which immunospecifically binds to a D4 of human KIT,comprising:

-   -   (i) a light chain variable region (“VL”) comprising a VL CDR1,        VL CDR2, and VL CDR3 having the amino acid sequences of SEQ ID        NO: 19, SEQ ID NO: 20, and SEQ ID NO: 21, respectively; and    -   (ii) a heavy chain variable region (“VH”) comprising VH CDR1, VH        CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NO:        16, SEQ ID NO: 17, and SEQ ID NO: 18, respectively.        In one embodiment, the VL and VH of an antibody provided herein        or an antigen-binding fragment thereof are non-immunogenic in a        human. In a particular embodiment, the antibody can be expressed        in Chinese hamster ovary (CHO) cells at a titer of at least 0.45        μg/mL. In a particular embodiment, the antibody can be expressed        in Chinese hamster ovary (CHO) cells at a titer of at least 0.3        μg/mL, at least 0.6 μg/mL, at least 0.75 μg/mL, or at least 1        μg/mL.

In a certain aspect, provided herein is antibody, or an antigen-bindingfragment thereof, or a conjugate thereof, which immunospecifically bindsto a D4 of human KIT, comprising:

-   -   a light chain variable region (“VL”) comprising the amino acid        sequence:        DIVMTQSPSX_(K1)LSASVGDRVTITCKASQNVRTNVAWYQQKPGKAPKX_(K2)LIYSAS        YRYSGVPDRFX_(K3)GSGSGTDFTLTISSLQX_(K4)EDFAX_(K5)YX_(K6)CQQYNSYPRTFGGGT        KVEIK (SEQ ID NO: 12), wherein X_(K1) is an amino acid with an        aromatic or aliphatic hydroxyl side chain, X_(K2) is an amino        acid with an aromatic or aliphatic hydroxyl side chain, X_(K3)        is an amino acid with an aliphatic hydroxyl side chain, X_(K4)        is an amino acid with an aliphatic hydroxyl side chain or is P,        X_(K5) is an amino acid with a charged or acidic side chain, and        X_(K6) is an amino acid with an aromatic side chain; and    -   a heavy chain variable region (“VH”) comprising a VH CDR1, VH        CDR2, and VH CDR3 comprising the amino acid sequences of SEQ ID        NO: 16, SEQ ID NO: 17, and SEQ ID NO: 18, respectively.

In a particular aspect, provided herein is antibody (or a fragmentthereof or a conjugate thereof), which immunospecifically binds to a D4of human KIT, comprising:

-   -   (i) a VL comprising a VL CDR1, VL CDR2, and VL CDR3 having the        amino acid sequences of SEQ ID NO: 19, SEQ ID NO: 20, and SEQ ID        NO: 21, respectively; and    -   (ii) a VH comprising the amino acid sequence:        QVQLVQSGAEX_(H1)KKPGASVKX_(H2)SCKASGYTFTDYYINWVX_(H3)QAPGKGLEWIA        RIYPGSGNTYYNEKFKGRX_(H4)TX_(H5)TAX_(H6)KSTSTAYMX_(H7)LSSLRSEDX_(H8)AVYFCA        RGVYYFDYWGQGTTVTVSS (SEQ ID NO: 11), wherein X_(H1) is an amino        acid with an aliphatic side chain, X_(H2) is an amino acid with        an aliphatic side chain, X_(H3) is an amino acid with a polar or        basic side chain, X_(H4) is an amino acid with an aliphatic side        chain, X_(H5) is an amino acid with an aliphatic side chain,        X_(H6) is an amino acid with an acidic side chain, X_(H7) is an        amino acid with an acidic or amide derivative side chain, and        X_(H8) is an amino acid with an aliphatic hydroxyl side chain.

In a particular embodiment, X_(K1) is the amino acid F or S, X_(K2) isthe amino acid A or S, X_(K3) is the amino acid T or S, X_(K4) is theamino acid S or P, X_(K5) is the amino acid D or T, and X_(K6) is theamino acid F or Y.

In a certain embodiment, X_(K1) is the amino acid S, X_(K2) is the aminoacid A, X_(K3) is the amino acid T, X_(K4) is the amino acid P, X_(K5)is the amino acid D, and X_(K6) is the amino acid F.

In a particular embodiment, X_(K1) is the amino acid F, X_(K2) is theamino acid A, X_(K3) is the amino acid T, X_(K4) is the amino acid S,X_(K5) is the amino acid D, and X_(K6) is the amino acid F.

In a particular embodiment, X_(K1) is the amino acid F or S, X_(K2) isthe amino acid A, X_(K3) is the amino acid T, X_(K4) is the amino acid Sor P, X_(K5) is the amino acid D, and X_(K6) is the amino acid F.

In a particular embodiment, X_(K1) is the amino acid S, X_(K2) is theamino acid A, X_(K3) is the amino acid T, X_(K4) is the amino acid P,X_(K5) is the amino acid D, and X_(K6) is the amino acid F.

In a particular embodiment, X_(K1) is the amino acid S, X_(K2) is theamino acid 5, X_(K3) is the amino acid S, X_(K4) is the amino acid P,X_(K5) is the amino acid T, and X_(K6) is the amino acid Y.

In one embodiment, X_(H1) is the amino acid L or V, X_(H2) is the aminoacid L or V, X_(H3) is the amino acid K or R, X_(H4) is the amino acid Vor A, X_(H5) is the amino acid L or I, X_(H6) is the amino acid E or D,X_(H7) is the amino acid Q or E, and X_(H8) is the amino acid S or T.

In a specific embodiment, X_(H1) is the amino acid V, X_(H2) is theamino acid L or V, X_(H3) is the amino acid R or Q, X_(H4) is the aminoacid A, X_(H5) is the amino acid L or I, X_(H6) is the amino acid D,X_(H7) is the amino acid Q or E, and X_(H8) is the amino acid T.

In a specific embodiment, X_(H1) is the amino acid V, X_(H2) is theamino acid L, X_(H3) is the amino acid R, X_(H4) is the amino acid A,X_(H5) is the amino acid L, X_(H6) is the amino acid D, X_(H7) is theamino acid Q, and X_(H8) is the amino acid T.

In a certain embodiment, X_(H1) is the amino acid V, X_(H2) is the aminoacid V, X_(H3) is the amino acid R, X_(H4) is the amino acid A, X_(H5)is the amino acid I, X_(H6) is the amino acid D, X_(H7) is the aminoacid E, and X_(H8) is the amino acid T.

In a certain embodiment, X_(H1) is the amino acid L, X_(H2) is the aminoacid L, X_(H3) is the amino acid K, X_(H4) is the amino acid A, X_(H5)is the amino acid L, X_(H6) is the amino acid E, X_(H7) is the aminoacid Q, and X_(H8) is the amino acid S.

In a certain embodiment, X_(H1) is the amino acid V, X_(H2) is the aminoacid L, X_(H3) is the amino acid K, X_(H4) is the amino acid A, X_(H5)is the amino acid L, X_(H6) is the amino acid E, X_(H7) is the aminoacid Q, and X_(H8) is the amino acid T.

In a certain embodiment, X_(H1) is the amino acid V, X_(H2) is the aminoacid V, X_(H3) is the amino acid R, X_(H4) is the amino acid V, X_(H5)is the amino acid I, X_(H6) is the amino acid D, X_(H7) is the aminoacid E, and X_(H8) is the amino acid T.

In a particular embodiment, X_(K1) to X_(K6) is an amino acid set forthin Table 6A, and/or X_(H1) to X_(H8) is an amino acid set forth in Table6B.

In a particular aspect, provided herein is antibody, or anantigen-binding fragment thereof, or a conjugate thereof, whichimmunospecifically binds to a D4 of human KIT, comprising:

-   -   i) a VL comprising an amino acid sequence that is: at least 90%        identical to SEQ ID NO: 7, at least 88% identical to SEQ ID NO:        8, at least 87% identical to SEQ ID NO: 9, or at least 84%        identical to SEQ ID NO: 10; and    -   ii) a VH comprising an amino acid sequence that is: at least 93%        identical to SEQ ID NO: 2, at least 92% identical to SEQ ID NO:        3, at least 90% identical to SEQ ID NO: 4, at least 87%        identical to SEQ ID NO: 5, or at least 86% identical to SEQ ID        NO: 6.

In a certain aspect, provided herein is antibody, or an antigen-bindingfragment thereof, or a conjugate thereof, which immunospecifically bindsto a D4 region of human KIT, comprising:

-   -   i) a light chain variable region (“VL”) comprising the amino        acid sequence:        DIVMTQSPSX_(K1)LSASVGDRVTITCKASQNVRTNVAWYQQKPGKAPKX_(K2)LIYSAS        YRYSGVPDRFX_(K3)GSGSGTDFTLTISSLQX_(K1)EDFAX_(K5)YX_(K6)CQQYNSYPRTFGGG        TKVEIK (SEQ ID NO: 12), wherein X_(K4) is an amino acid with an        aromatic or aliphatic hydroxyl side chain, X_(K2) is an amino        acid with an aromatic or aliphatic hydroxyl side chain, X_(K3)        is an amino acid with an aliphatic hydroxyl side chain, X_(K4)        is an amino acid with an aliphatic hydroxyl side chain or is P,        X_(K5) is an amino acid with a charged or acidic side chain, and        X_(K6) is an amino acid with an aromatic side chain; and    -   (ii) a VH comprising the amino acid sequence:        QVQLVQSGAEX_(H1)KKPGASVKX_(H2)SCKASGYTFTDYYINWVX_(H3)QAPGKGLEWIA        RIYPGSGNTYYNEKFKGRX_(H4)TX_(H5)TAX_(H6)KSTSTAYMX_(H7)LSSLRSEDX_(H8)AVYFCA        RGVYYFDYWGQGTTVTVSS (SEQ ID NO: 11), wherein X_(H1) is an amino        acid with an aliphatic side chain, X_(H2) is an amino acid with        an aliphatic side chain, X_(H3) is an amino acid with a polar or        basic side chain, X_(H4) is an amino acid with an aliphatic side        chain, X_(H5) is an amino acid with an aliphatic side chain,        X_(H6) is an amino acid with an acidic side chain, X_(H7) is an        amino acid with an acidic or amide derivative side chain, and        X_(H8) is an amino acid with an aliphatic hydroxyl side chain.

In a particular embodiment, X_(K1) to X_(K6) is an amino acid set forthin Table 6A, and/or X_(H1) to X_(H8) is an amino acid set forth in Table6B.

In a particular embodiment, an antibody described herein specificallybinds to CHO cells recombinantly expressing wild-type KIT with an EC₅₀of about 150 pM or less as determined by flow cytometry. In a particularembodiment, an antibody described herein specifically binds to arecombinant D4/D5 region of human KIT with an EC₅₀ of about 600 pM orless, or about 250 pM to about 600 pM, as determined by flow cytometry.In a certain embodiment, an antibody described herein inhibits tyrosinephosphorylation of KIT with an IC₅₀ of about 600 pM or less asdetermined by ELISA.

In a specific embodiment, an antibody described herein can be expressedin CHO cells with a titer of at least 1.0 μg/mL, or at least 1.1 μg/mL,or at least 1.2 μg/mL.

In a particular embodiment, an antibody described herein furthercomprises a human light chain constant region and a human heavy chainconstant region. In one embodiment, the human light chain constantregion of an antibody described herein is a human kappa light chainconstant region. In a particular embodiment, the human heavy chainconstant region of an antibody described herein is a human gamma heavychain constant region.

In a certain embodiment, an antibody described herein is a human IgG1 orIgG4 antibody. In a certain embodiment, an antibody described herein isan antigen-binding fragment or a Fab fragment. In a specific embodiment,an antibody described herein is an antigen-binding fragment or a Fabfragment. In a particular embodiment, an antibody described herein is abispecific antibody. In a certain embodiment, an antibody describedherein is internalized by a cell.

In a particular aspect, provided herein is a conjugate comprising anantibody described herein, or a KIT-binding fragment thereof, linked toan agent. In a specific embodiment, the agent is a toxin. In a certainembodiment, the toxin is abrin, ricin A, pseudomonas exotoxin, choleratoxin, or diphtheria toxin. In one embodiment, the conjugate isinternalized by a cell.

In a certain aspect, provided herein is a pharmaceutical compositioncomprising a conjugate described herein and a pharmaceuticallyacceptable carrier.

In another aspect, provided herein is a pharmaceutical compositioncomprising an antibody described herein and a pharmaceuticallyacceptable carrier.

In a particular aspect, provided herein is a polynucleotide comprisingnucleotide sequences encoding a VH chain region, a VL chain region, orboth a VL chain region and a VH chain region, of an antibody describedherein.

In a specific embodiment, a polynucleotide (e.g., isolatedpolynucleotide) provided herein comprises SEQ ID NO: 22, 23, 24, 25, or26 encoding a VH. In a scertain embodiment, a polynucleotide (e.g.,isolated polynucleotide) provided herein comprises SEQ ID NO: 27, 28,29, or 30 encoding a VL. In a particular embodiment, a polynucleotide(e.g., isolated polynucleotide) or a population of polynucleotides(e.g., population of isolated polynucleotides) provided herein comprisesSEQ ID NO: 22, 23, 24, 25, or 26 encoding a VH, and SEQ ID NO: 27, 28,29, or 30 encoding a VL.

In a particular embodiment, a polynucleotide (e.g., isolatedpolynucleotide) or a population of polynucleotides (e.g., population ofisolated polynucleotides) provided herein comprises SEQ ID NO: 22encoding a VH, and SEQ ID NO: 27 encoding a VL.

In a particular embodiment, a polynucleotide (e.g., isolatedpolynucleotide) or a population of polynucleotides (e.g., population ofisolated polynucleotides) provided herein comprises SEQ ID NO: 22encoding a VH, and SEQ ID NO: 28 encoding a VL.

In a particular embodiment, a polynucleotide (e.g., isolatedpolynucleotide) or a population of polynucleotides (e.g., population ofisolated polynucleotides) provided herein comprises SEQ ID NO: 22encoding a VH, and SEQ ID NO: 29 encoding a VL.

In a particular embodiment, a polynucleotide (e.g., isolatedpolynucleotide) or a population of polynucleotides (e.g., population ofisolated polynucleotides) provided herein comprises SEQ ID NO: 22encoding a VH, and SEQ ID NO: 30 encoding a VL.

In a particular embodiment, a polynucleotide (e.g., isolatedpolynucleotide) or a population of polynucleotides (e.g., population ofisolated polynucleotides) provided herein comprises SEQ ID NO: 23encoding a VH, and SEQ ID NO: 27 encoding a VL.

In a particular embodiment, a polynucleotide (e.g., isolatedpolynucleotide) or a population of polynucleotides (e.g., population ofisolated polynucleotides) provided herein comprises SEQ ID NO: 23encoding a VH, and SEQ ID NO: 28 encoding a VL.

In a particular embodiment, a polynucleotide (e.g., isolatedpolynucleotide) or a population of polynucleotides (e.g., population ofisolated polynucleotides) provided herein comprises SEQ ID NO: 23encoding a VH, and SEQ ID NO: 29 encoding a VL.

In a particular embodiment, a polynucleotide (e.g., isolatedpolynucleotide) or a population of polynucleotides (e.g., population ofisolated polynucleotides) provided herein comprises SEQ ID NO: 23encoding a VH, and SEQ ID NO: 30 encoding a VL.

In a particular embodiment, a polynucleotide (e.g., isolatedpolynucleotide) or a population of polynucleotides (e.g., population ofisolated polynucleotides) provided herein comprises SEQ ID NO: 24encoding a VH, and SEQ ID NO: 27 encoding a VL.

In a particular embodiment, a polynucleotide (e.g., isolatedpolynucleotide) or a population of polynucleotides (e.g., population ofisolated polynucleotides) provided herein comprises SEQ ID NO: 24encoding a VH, and SEQ ID NO: 28 encoding a VL.

In a particular embodiment, a polynucleotide (e.g., isolatedpolynucleotide) or a population of polynucleotides (e.g., population ofisolated polynucleotides) provided herein comprises SEQ ID NO: 24encoding a VH, and SEQ ID NO: 29 encoding a VL.

In a particular embodiment, a polynucleotide (e.g., isolatedpolynucleotide) or a population of polynucleotides (e.g., population ofisolated polynucleotides) provided herein comprises SEQ ID NO: 24encoding a VH, and SEQ ID NO: 30 encoding a VL.

In a particular embodiment, a polynucleotide (e.g., isolatedpolynucleotide) or a population of polynucleotides (e.g., population ofisolated polynucleotides) provided herein comprises SEQ ID NO: 25encoding a VH, and SEQ ID NO: 27 encoding a VL.

In a particular embodiment, a polynucleotide (e.g., isolatedpolynucleotide) or a population of polynucleotides (e.g., population ofisolated polynucleotides) provided herein comprises SEQ ID NO: 25encoding a VH, and SEQ ID NO: 28 encoding a VL.

In a particular embodiment, a polynucleotide (e.g., isolatedpolynucleotide) or a population of polynucleotides (e.g., population ofisolated polynucleotides) provided herein comprises SEQ ID NO: 25encoding a VH, and SEQ ID NO: 29 encoding a VL.

In a particular embodiment, a polynucleotide (e.g., isolatedpolynucleotide) or a population of polynucleotides (e.g., population ofisolated polynucleotides) provided herein comprises SEQ ID NO: 25encoding a VH, and SEQ ID NO: 30 encoding a VL.

In a particular embodiment, a polynucleotide (e.g., isolatedpolynucleotide) or a population of polynucleotides (e.g., population ofisolated polynucleotides) provided herein comprises SEQ ID NO: 26encoding a VH, and SEQ ID NO: 27 encoding a VL.

In a particular embodiment, a polynucleotide (e.g., isolatedpolynucleotide) or a population of polynucleotides (e.g., population ofisolated polynucleotides) provided herein comprises SEQ ID NO: 26encoding a VH, and SEQ ID NO: 28 encoding a VL.

In a particular embodiment, a polynucleotide (e.g., isolatedpolynucleotide) or a population of polynucleotides (e.g., population ofisolated polynucleotides) provided herein comprises SEQ ID NO: 26encoding a VH, and SEQ ID NO: 29 encoding a VL.

In a particular embodiment, a polynucleotide (e.g., isolatedpolynucleotide) or a population of polynucleotides (e.g., population ofisolated polynucleotides) provided herein comprises SEQ ID NO: 26encoding a VH, and SEQ ID NO: 30 encoding a VL.

In one aspect, provided herein is a vector comprising a polynucleotidedescribed herein for expressing an anti-KIT antibody or a fragmentthereof. In a certain embodiment, a vector provided herein is amammalian expression vector.

In a certain aspect, provided herein is a host cell comprising a vectorprovided herein or one or more polynucleotides provided herein forexpressing an anti-KIT antibody or a fragment thereof.

In a particular aspect, provided herein is a cell producing an antibodydescribed herein. In one embodiment, a cell provided herein comprisesone or more polynucleotides described herein, wherein the cell canexpress an antibody which specifically binds to a D4 of human KIT. In acertain embodiment, the cell comprises a vector described herein.

In a specific aspect, provided herein is a kit comprising an antibody(or antigen-binding fragment thereof or conjugate thereof) describedherein. In a particular embodiment, a kit comprises a conjugatedescribed herein.

In a certain aspect, provided herein is a method for treating ormanaging a KIT-associated disorder (e.g., cancer), comprisingadministering to a subject in need thereof a therapeutically effectiveamount of an antibody described herein or an antigen-binding fragmentthereof or a conjugate thereof.

In one aspect, provided herein is a method for treating or managing aKIT-associated disorder, comprising administering to a subject in needthereof a therapeutically effective amount of a conjugate describedherein.

In a particular embodiment, the KIT-associated disorder is cancer, aninflammatory condition, or fibrosis. In a specific embodiment, thecancer is leukemia, chronic myelogenous leukemia, lung cancer, smallcell lung cancer, or gastrointestinal stromal tumors. In one embodiment,the cancer is refractory to treatment by a tyrosine kinase inhibitor. Ina further embodiment embodiment, the tyrosine kinase inhibitor isimatinib mesylate or SU11248.

In a certain embodiment, a method provided herein further comprisesadministering a second agent. In a specific embodiment, the second agentis a chemotherapeutic agent, tyrosine kinase inhibitor, a histonedeacetylase inhibitor, an antibody, or a cytokine. In a particularembodiment, the tyrosine kinase inhibitor is imatinib mesylate orSU11248.

In a specific aspect, provided herein is a method for diagnosing asubject with a KIT-associated disorder comprising contacting cells or asample obtained from the subject with an antibody described herein (oran antigen-binding fragment thereof or a conjugate thereof) anddetecting the expression level of KIT in the cells or the sample. Forexample, detection of the binding of an antibody described herein to aKIT antigen present in the cell or sample can be correlated to theexpression level of KIT in the cell or sample. In a particularembodiment, the antibody is conjugated to a detectable molecule. In acertain embodiment, the detectable molecule is an enzyme, a fluorescentmolecule, a luminescent molecule, or a radioactive molecule.

In a particular aspect, provided herein is a method for inhibiting KITactivity in a cell expressing KIT comprising contacting the cell with aneffective amount of an antibody described herein (or an antigen-bindingfragment thereof or a conjugate thereof).

In a particular aspect, provided herein is a method for inducing orenhancing apoptosis in a cell expressing KIT comprising contacting thecell with an effective amount an antibody described herein (or anantigen-binding fragment thereof or a conjugate thereof).

In a particular aspect, provided herein is a method for inducing celldifferentiation comprising contacting a cell expressing KIT with aneffective amount of an antibody described herein (or an antigen-bindingfragment thereof or a conjugate thereof). In a particular embodiment,the cell is a stem cell.

In a certain aspect, provided herein is a method of making an antibodywhich immunospecifically binds to a D4 region of human KIT comprisingculturing a cell or host cell described herein. In a certain aspect,provided herein is a method of making an antibody whichimmunospecifically binds to a D4 region of human KIT comprisingexpressing the antibody using a cell or host cell described herein. In aparticular embodiment, the cell is an isolated cell. In a particularembodiment, the method further comprises the step of purifying theantibody obtained from the cell or host cell.

In one aspect, provided herein is an antibody or antigen-bindingfragment thereof, which immunospecifically binds to a D4 region of humanKIT, wherein said antibody or antigen-binding fragment thereofcomprises:

-   (i) a light chain variable region (“VL”) comprising a VL CDR1, VL    CDR2, and VL CDR3 selected from the group set forth in Tables 10-12;    and-   (ii) a heavy chain variable region (“VH”) comprising VH CDR1, VH    CDR2, and VH CDR3 selected from the group set forth in Tables 13-15.

In a certain aspect, described herein is an antibody or antigen-bindingfragment thereof, wherein said antibody or antigen-binding fragmentthereof comprises:

-   (i) VL comprising a VL FR1, VL FR2, VL FR3, AND VL FR4 selected from    the group set forth in Tables 20-23; and-   (ii) a VH comprising Vh FR1, VH FR2, VH FR3, and VH FR4 selected    from the group set forth in Tables 16-19.

In a particular aspect, the antibody or antigen-binding fragmentdescribed herein comprises an Fc region with an amino acid modification.In a certain aspect, the antibody or antigen-binding fragment describedherein comprises an Fc region which is an IgG1 isotype or an IgG4isotype. In one aspect, the antibody or antigen-binding fragmentdescribed herein is a humanized antibody. In a particular aspect, theantibody or antigen-binding fragment thereof described herein is abispecific antibody.

In a certain aspect, described herein is an antibody or antigen-bindingfragment thereof which is conjugated to another agent.

In one aspect, provided herein is a composition comprising an antibodyor antigen-binding fragment thereof described herein.

In a particular aspect, provided herein is a polynucleotide comprisingnucleotide sequences encoding a VH chain region, a VL chain region, orboth a VL chain region and a VH chain region, of an antibody orantigen-binding fragment thereof described herein (e.g., antibody orantigen binding fragment thereof comprising sequences set forth inTables 10-15). Also provided is a vector comprising the polynucleotidedescribed herein. In one aspect, the vector is a mammalian expressionvector.

In a certain aspect, provided herein is a host cell comprising a vectorof or one or more polynucleotides described herein. In one aspect,provided herein is a cell producing an antibody or antigen-bindingfragment thereof described herein (e.g., antibody or antigen bindingfragment thereof comprising sequences set forth in Tables 10-15).

In a particular aspect, provided herein is a kit comprising an antibodyor antigen-binding fragment thereof described herein (e.g., antibody orantigen binding fragment thereof comprising sequences set forth inTables 10-15).

In a certain aspect, provided herein is a method for treating ormanaging a KIT-associated disorder, comprising administering to asubject in need thereof a therapeutically effective amount of anantibody or antigen-binding fragment thereof described herein (e.g.,antibody or antigen binding fragment thereof comprising sequences setforth in Tables 10-15). In one embodiment, the KIT-associated disorderis cancer, an inflammatory condition, or fibrosis. In a particularembodidment, the cancer is leukemia, chronic myelogenous leukemia, lungcancer, small cell lung cancer, or gastrointestinal stromal tumors.

In a particular aspect, the method for treating or managing aKIT-associated disorder described herein further comprises administeringa second agent. In a particular embodiment, the second agent is achemotherapeutic agent, tyrosine kinase inhibitor, a histone deacetylaseinhibitor, an antibody, a cytokine, an HSP90 inhibitor, a PGP inhibitor,or a proteosome inhibitor.

In one aspect, provided herein is a method for diagnosing a subject witha KIT-associated disorder comprising contacting cells or a sampleobtained from the subject with an antibody or antigen-binding fragmentthereof described herein (e.g., antibody or antigen binding fragmentthereof comprising sequences set forth in Tables 10-15) and detectingthe expression level of KIT in the cells or the sample. In a certainembodiment, the antibody is conjugated to a detectable molecule.

In a certain aspect, provided herein is a method for inhibiting KITactivity in a cell expressing KIT comprising contacting the cell with aneffective amount of an antibody or antigen-binding fragment thereofdescribed herein (e.g., antibody or antigen binding fragment thereofcomprising sequences set forth in Tables 10-15).

A method for inducing or enhancing apoptosis in a cell expressing KITcomprising contacting the cell with an effective amount of an antibodyor antigen-binding fragment thereof described herein (e.g., antibody orantigen binding fragment thereof comprising sequences set forth inTables 10-15).

A method of making an antibody which immunospecifically binds to a D4region of human KIT comprising culturing, and/or expressing the antibodyusing, a cell described herein.

4. BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 depicts the amino acid sequence of full length human KIT (SEQ IDNO: 1), GenBank™ accession number AAC50969. The first through fifthextracellular Ig-like domains (i.e., D1, D2, D3, D4, and D5) areindicated; “{” depicts the amino-terminal residue of each domain and “}”depicts the carboxyl-terminal residue of each domain. The D1 domain isdepicted at P34 to R112, the D2 domain is depicted at D113 to P206, theD3 domain is depicted at A207 to D309, the D4 domain is depicted at K310to N410 (SEQ ID NO: 15), the hinge region between D4 and D5 is locatedat V409 to N410, and the D5 domain is depicted at T411 to K509. Also,the D1/D2 hinge region is located at D113 to L117; the D2/D3 hingeregion is located at P206 to A210; and the D3/D4 hinge region is locatedat D309 to G311. The D4/D5 region comprises K310 to K509. Thetransmembrane domain comprises residues F525 to Q545, and the kinasedomain comprises residues K589 to 5933.

FIG. 2 depicts the amino acid sequence of a recombinant KIT D4/D5. HumanKIT amino acids V308 to H515 (SEQ ID NO: 73) are depicted in bold. Thepolypeptide depicted (SEQ ID NO: 14) contains (i) the first 33 aminoacids (i.e., M1 to E33) of the amino terminus of human KIT (includingthe signal peptide, underlined, not bold), (ii) the D4/D5 region ofhuman KIT (bold), and (iii) a 5×His tag (italics) at the carboxylterminus.

FIG. 3A depicts the amino acid sequence (SEQ ID NO: 2) of the H1 VHdomain, and a DNA (SEQ ID NO:22) encoding the amino acid sequence. Theframework regions (FR1, FR2, FR3, and FR4), and CDRs (CDR1, CDR2, andCDR3) are indicated. Both Kabat numbering and numerical numbering of theamino acid residues are indicated.

FIG. 3B depicts the amino acid sequence (SEQ ID NO: 3) of the H2 VHdomain and a DNA (SEQ ID NO:23) encoding the amino acid sequence. Theframework regions (FR1, FR2, FR3, and FR4), and CDRs (CDR1, CDR2, andCDR3) are indicated. Both Kabat numbering and numerical numbering of theamino acid residues are indicated.

FIG. 3C depicts the amino acid sequence (SEQ ID NO: 4) of the H3 VHdomain and a DNA (SEQ ID NO:24) encoding the amino acid sequence. Theframework regions (FR1, FR2, FR3, and FR4), and CDRs (CDR1, CDR2, andCDR3) are indicated. Both Kabat numbering and numerical numbering of theamino acid residues are indicated.

FIG. 3D depicts the amino acid sequence (SEQ ID NO: 5) of the H4 VHdomain and a DNA (SEQ ID NO:25) encoding the amino acid sequence. Theframework regions (FR1, FR2, FR3, and FR4), and CDRs (CDR1, CDR2, andCDR3) are indicated. Both Kabat numbering and numerical numbering of theamino acid residues are indicated.

FIG. 3E depicts the amino acid sequence (SEQ ID NO: 6) of the H5 VHdomain and a DNA (SEQ ID NO:26) encoding the amino acid sequence. Theframework regions (FR1, FR2, FR3, and FR4), and CDRs (CDR1, CDR2, andCDR3) are indicated. Both Kabat numbering and numerical numbering of theamino acid residues are indicated.

FIG. 3F depicts the amino acid sequence (SEQ ID NO: 7) of the L1 VLdomain and a DNA (SEQ ID NO:27) encoding the amino acid sequence. Theframework regions (FR1, FR2, FR3, and FR4), and CDRs (CDR1, CDR2, andCDR3) are indicated. Both Kabat numbering and numerical numbering of theamino acid residues are indicated.

FIG. 3G depicts the amino acid sequence (SEQ ID NO: 8) of the L2 VLdomain and a DNA (SEQ ID NO:28) encoding the amino acid sequence. Theframework regions (FR1, FR2, FR3, and FR4), and CDRs (CDR1, CDR2, andCDR3) are indicated. Both Kabat numbering and numerical numbering of theamino acid residues are indicated.

FIG. 3H depicts the amino acid sequence (SEQ ID NO: 9) of the L3 VLdomain and a DNA (SEQ ID NO:29) encoding the amino acid sequence. Theframework regions (FR1, FR2, FR3, and FR4), and CDRs (CDR1, CDR2, andCDR3) are indicated. Both Kabat numbering and numerical numbering of theamino acid residues are indicated.

FIG. 3I depicts the amino acid sequence (SEQ ID NO: 10) of the L4 VLdomain and a DNA (SEQ ID NO:30) encoding the amino acid sequence. Theframework regions (FR1, FR2, FR3, and FR4), and CDRs (CDR1, CDR2, andCDR3) are indicated. Both Kabat numbering and numerical numbering of theamino acid residues are indicated.

FIG. 4A depicts the consensus sequence (SEQ ID NO: 11) of a VH domain.X_(H1-H8) indicate amino acids which can be any amino acid.

FIG. 4B depicts the consensus sequence (SEQ ID NO: 12) of a VL domain.X_(K1-K6) indicate amino acids which can be any amino acid.

FIG. 5 depicts the binding activity of antibodies Hum17, Hum8, Hum4, andHum10, as well as a chimera of antibody 37M (“chimera”), to arecombinant polypeptide of the D4/D5 region of human KIT as determinedby solid phase ELISA. The EC₅₀ value for each antibody is indicated.

FIG. 6 depicts a graph of the results of binding assays performed byflow cytomery with CHO cells recombinantly expressing wild-type humanKIT to characterize the KIT binding activity of antibodies Hum17, Hum8,Hum4, and Hum10, in comparison to a chimera of antibody 37M (“chimera”).The EC₅₀ value for each antibody is indicated.

FIG. 7 depicts a graph of the results of KIT phosphorylation inhibitionassays performed by ELISA with CHO cells recombinantly expressingwild-type KIT to characterize the phosphorylation blocking activity ofantibodies Hum17, Hum8, Hum4, and Hum10, in comparison to a chimera ofantibody 37M (“chimera”). The IC₅₀ values for each antibody areindicated.

5. DETAILED DESCRIPTION

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as is commonly understood by one of ordinary skillin the art.

As used herein, the terms “about” or “approximately” mean within plus orminus 10% of a given value or range.

Provided herein are antibodies, and antigen-binding fragments thereof,that immunospecifically bind to a KIT polypeptide (e.g., a KITpolypeptide containing a human KIT D4 domain), and conjugates thereof.Also provided are isolated nucleic acids (polynucleotides) encoding suchantibodies, and antigen-binding fragments thereof. Further provided arevectors (e.g., expression vectors) and cells (e.g., host cells)comprising nucleic acids encoding such antibodies or antigen-bindingfragments thereof. Also provided are methods of making such antibodies,cells, e.g., host cells. Also provided herein are methods and uses fortreating or managing a KIT-associated disorder or disease (e.g., cancer,inflammatory condition, or fibrosis) or one or more effects of suchKIT-associated disorder or disease comprising administering one or moreantibodies described herein, or an antigen-binding fragment thereof or aconjugate thereof. Also provided herein is are methods for diagnosing aKIT-associated disorder or disease (e.g., cancer, inflammatorycondition, or fibrosis) comprising contacting a sample with one or moreantibodies (or antigen-binding fragment thereof) described herein anddetermining the expression level of KIT in the sample relative to areference sample (e.g., a control sample). Further provided herein aremethods and uses for inhibiting KIT activity in a cell expressing KITcomprising contacting the cell with an effective amount of an antibodyor an antigen-binding fragment thereof. Also further provided herein aremethods for inducing or enhancing cell differentiation or apoptosis in acell expressing KIT comprising contacting the cell with an effectiveamount of an antibody or antibodies described herein.

As used herein, the terms “D4/D5 region” or “D4/D5 domain” refer to aregion within a KIT polypeptide spanning the fourth Ig-likeextracellular (“D4”) domain, the fifth Ig-like extracellular (“D5”)domain, and the hinge region in between the D4 and D5 domains (“D4-D5hinge region”), of KIT, in the following order from the amino terminusto the carboxyl terminus: D4, D4-D5 hinge region, and D5. As usedherein, amino acids V308 to H515 of FIG. 1 and the polypeptide depictedat FIG. 2 herein are considered examples of a D4/D5 region or domain.

As used herein, the terms “KIT” or “KIT receptor” or “KIT polypeptide”refer to any form of full-length KIT including, but not limited to,native KIT, an isoform of KIT, an interspecies KIT homolog, or a KITvariant, e.g., naturally occurring (for example, allelic or splicevariant, or mutant, e.g., somatic mutant) or artificially constructedvariant (for example, a recombinant or chemically modified variant). KITis a type III receptor tyrosine kinase encoded by the c-kit gene (see,e.g., Yarden et al., Nature, 1986, 323:226-232; Ullrich andSchlessinger, Cell, 1990, 61:203-212; Clifford et al., J. Biol. Chem.,2003, 278:31461-31464; Yarden et al., EMBO J., 1987, 6:3341-3351; Mol etal., J. Biol. Chem., 2003, 278:31461-31464). GenBank™ accession numberNM_000222 provides an exemplary human KIT nucleic acid sequence.GenBank™ accession numbers NP_001087241, P10721, and AAC50969 provideexemplary human KIT amino acid sequences. GenBank™ accession numberAAH75716 provides an exemplary murine KIT amino acid sequence. NativeKIT comprises five extracellular immunoglobulin (Ig)-like domains (D1,D2, D3, D4, D5), a single transmembrane region, an inhibitorycytoplasmic juxtamembrane domain, and a split cytoplasmic kinase domainseparated by a kinase insert segment (see, e.g., Yarden et al., Nature,1986, 323:226-232; Ullrich and Schlessinger, Cell, 1990, 61:203-212;Clifford et al., J. Biol. Chem., 2003, 278:31461-31464). An exemplaryamino acid sequence of the D4/D5 region of human KIT is provided in FIG.1, at amino acid residues V308 to H515. In a specific embodiment, KIT ishuman KIT. In a particular embodiment, KIT can exist as a monomer,dimer, multimer, native form, or denatured form.

In the context of a peptide or a polypeptide, the term “fragment” asused herein refers to a peptide or polypeptide that comprises a lessthan full length amino acid sequence. Such a fragment can arise, forexample, from a truncation at the amino terminus, a truncation at thecarboxy terminus, and/or an internal deletion of a residue(s) from theamino acid sequence. Fragments can, for example, result from alternativeRNA splicing or from in vivo protease activity. In certain embodiments,KIT fragments or antibody fragments (e.g., antibody fragments thatimmunospecifically bind to a KIT polypeptide) include polypeptidescomprising an amino acid sequence of at least 5 contiguous amino acidresidues, at least 10 contiguous amino acid residues, at least 15contiguous amino acid residues, at least 20 contiguous amino acidresidues, at least 25 contiguous amino acid residues, at least 40contiguous amino acid residues, at least 50 contiguous amino acidresidues, at least 60 contiguous amino residues, at least 70 contiguousamino acid residues, at least 80 contiguous amino acid residues, atleast 90 contiguous amino acid residues, at least contiguous 100 aminoacid residues, at least 125 contiguous amino acid residues, at least 150contiguous amino acid residues, at least 175 contiguous amino acidresidues, at least 200 contiguous amino acid residues, or at least 250contiguous amino acid residues of the amino acid sequence of a KITpolypeptide or an antibody (e.g., an antibody that immunospecificallybinds to a KIT polypeptide), respectively. In a specific embodiment, afragment of a KIT polypeptide or an antibody (e.g., an antibody thatimmunospecifically binds to a KIT polypeptide) retains at least 1, atleast 2, or at least 3 functions of the polypeptide or antibody.

As used herein, the term “host cell” refers to a particular cell thatcomprises an exogenous nucleic acid molecule, e.g., a cell that has beentransfected or transformed with a nucleic acid molecule, and the progenyor potential progeny of such a parent cell. Progeny of such a cell maynot be identical to the parent cell due to mutations or environmentalinfluences that can occur in succeeding generations or integration ofthe nucleic acid molecule into the host cell genome.

5.1 Antibodies

As used herein, the terms “antibody” and “immunoglobulin” and “Ig” areterms of art and can be used interchangeably herein and refer to amolecule with an antigen binding site that immunospecifically binds anantigen.

As used herein, an “antigen” is a moiety or molecule that contains anepitope, and, as such, also is specifically bound by antibody. In aspecific embodiment, the antigen, to which an antibody described hereinbinds, is KIT (e.g., human KIT), or a fragment thereof, for example, anextracellular domain of KIT (e.g., human KIT) or a D4 region of KIT(e.g., human KIT).

As used herein, an “epitope” is a term in the art and refers to alocalized region of an antigen to which an antibody can specificallybind. A region or a polypeptide contributing to an epitope can becontiguous amino acids of the polypeptide or an epitope can cometogether from two or more non-contiguous regions of the polypeptide.

As used herein, the terms “antigen binding domain,” “antigen bindingregion,” “antigen binding fragment,” and similar terms refer to aportion of an antibody molecule which comprises the amino acid residuesthat interact with an antigen and confer on the antibody molecule itsspecificity for the antigen (e.g., the complementarity determiningregions (CDR)). The antigen binding region can be derived from anyanimal species, such as rodents (e.g., mouse, rat or hamster) andhumans. The CDRs of an antibody molecule can be determined by any methodwell known to one of skill in the art. In particular, the CDRs can bedetermined according to the Kabat numbering system (see Kabat et al.(1991) Sequences of Proteins of Immunological Interest. (U.S. Departmentof Health and Human Services, Washington, D.C.) 5^(th) ed.). In certainaspects, the CDRs of an antibody can be determined according to (i) theChothia numbering scheme, which will be referred to herein as the“Chothia CDRs” (see, e.g., Chothia and Lesk, 1987, J. Mol. Biol.,196:901-917; Al-Lazikani et al., 1997, J. Mol. Biol., 273:927-948; andU.S. Pat. No. 7,709,226); or (ii) the IMGT numbering system, forexample, as described in Lefranc, M.-P., 1999, The Immunologist,7:132-136 and Lefranc, M.-P. et al., 1999, Nucleic Acids Res.,27:209-212.

As used herein, a “conformational epitope” or “non-linear epitope” or“discontinuous epitope” refers to one comprised of at least two aminoacids which are not consecutive amino acids in a single protein chain.For example, a conformational epitope can be comprised of two or moreamino acids which are separated by a stretch of intervening amino acidsbut which are close enough to be recognized by an antibody (e.g., ananti-KIT antibody) described herein as a single epitope. As a furtherexample, amino acids which are separated by intervening amino acids on asingle protein chain, or amino acids which exist on separate proteinchains, can be brought into proximity due to the conformational shape ofa protein structure or complex to become a conformational epitope whichcan be bound by an anti-KIT antibody described herein. It will beappreciated by one of skill in the art that, in general, a linearepitope bound by an anti-KIT antibody described herein may or may not bedependent on the secondary, tertiary, or quaternary structure of the KITreceptor. For example, in some embodiments, an anti-KIT antibodydescribed herein binds to a group of amino acids regardless of whetherthey are folded in a natural three dimensional protein structure. Inother embodiments, an anti-KIT antibody described herein does notrecognize the individual amino acid residues making up the epitope, andrequire a particular conformation (bend, twist, turn or fold) in orderto recognize and bind the epitope.

As used herein, the term “constant region” or “constant domain” refersto an antibody portion, e.g., a carboxyl terminal portion of a lightand/or heavy chain which is not directly involved in binding of anantibody to antigen but which exhibits various effector functions, suchas interaction with the Fc receptor. The terms refer to a portion of animmunoglobulin molecule having a generally more conserved amino acidsequence relative to an immunoglobulin variable domain.

As used herein, the term “heavy chain” when used in reference to anantibody refers to any distinct types, e.g., alpha (α), delta (δ),epsilon (ε), gamma (γ) and mu (μ), based on the amino acid sequence ofthe constant domain, which give rise to IgA, IgD, IgE, IgG and IgMclasses of antibodies, respectively, including subclasses of IgG, e.g.,IgG₁, IgG₂, IgG₃ and IgG₄. In a specific embodiment, the heavy chain isa human heavy chain.

As used herein, the terms “immunospecifically binds,”“immunospecifically recognizes,” “specifically binds,” and “specificallyrecognizes” are analogous terms in the context of antibodies and referto molecules that bind to an antigen (e.g., epitope or immune complex)as such binding is understood by one skilled in the art. For example, amolecule that specifically binds to an antigen may bind to otherpeptides or polypeptides, generally with lower affinity as determinedby, e.g., immunoassays, Biacore™, KinExA 3000 instrument (SapidyneInstruments, Boise, Id.), or other assays known in the art. In aspecific embodiment, molecules that immunospecifically bind to anantigen bind to the antigen with a K_(a) that is at least 2 logs, 2.5logs, 3 logs, 4 logs or greater than the K_(a) when the molecules bindto another antigen. In another specific embodiment, molecules thatimmunospecifically bind to an antigen do not cross react with otherproteins. In another specific embodiment, molecules thatimmunospecifically bind to an antigen do not cross react with othernon-KIT proteins.

As used herein, an “isolated” or “purified” antibody is substantiallyfree of cellular material or other contaminating proteins from the cellor tissue source from which the antibody is derived, or substantiallyfree of chemical precursors or other chemicals when chemicallysynthesized.

The terms “Kabat numbering,” and like terms are recognized in the artand refer to a system of numbering amino acid residues in the heavy andlight chain variable regions of an antibody, or an antigen bindingportion thereof (Kabat et al. (1971) Ann. NY Acad. Sci. 190:382-391 and,Kabat et al. (1991) Sequences of Proteins of Immunological Interest,Fifth Edition, U.S. Department of Health and Human Services, NIHPublication No. 91-3242). Using the Kabat numbering system, CDRs withinan antibody heavy chain molecule are typically present at amino acidpositions 31 to 35 (“CDR1”), amino acid positions 50 to 65 (“CDR2”), andamino acid positions 95 to 102 (“CDR3”). Using the Kabat numberingsystem, CDRs within an antibody light chain molecule are typicallypresent at amino acid positions 24 to 34 (CDR1), amino acid positions 50to 56 (CDR2), and amino acid positions 89 to 97 (CDR3).

As used herein, the term “light chain” when used in reference to anantibody refers to any distinct types, e.g., kappa (κ) of lambda (λ)based on the amino acid sequence of the constant domains. Light chainamino acid sequences are well known in the art. In specific embodiments,the light chain is a human light chain.

As used herein, the term “monoclonal antibody” refers to an antibodyobtained from a population of homogenous or substantially homogeneousantibodies, and each monoclonal antibody will typically recognize asingle epitope on the antigen. The term “monoclonal” is not limited toany particular method for making the antibody. Generally, a populationof monoclonal antibodies can be generated by cells, a population ofcells, or a cell line. In specific embodiments, a “monoclonal antibody,”as used herein, is an antibody produced by a single hybridoma or othercell (e.g., host cell producing a recombinant antibody), wherein theantibody immunospecifically binds to a KIT epitope (e.g., an epitope ofa D4 of human KIT) as determined, e.g., by ELISA or otherantigen-binding or competitive binding assay known in the art or in theExamples provided herein. Monoclonal antibodies described herein can,for example, be made by the hybridoma method as described in Kohler etal.; Nature, 256:495 (1975) or can be isolated from phage librariesusing the techniques as described herein, for example. Other methods forthe preparation of clonal cell lines and of monoclonal antibodiesexpressed thereby are well known in the art (see, for example, Chapter11 in: Short Protocols in Molecular Biology, (2002) 5th Ed., Ausubel etal., eds., John Wiley and Sons, New York).

As used herein, the term “polyclonal antibodies” refers to an antibodypopulation that includes a variety of different antibodies directed tothe same and to different epitopes within an antigen or antigens.Methods for producing polyclonal antibodies are known in the art (See,e.g., see, for example, Chapter 11 in: Short Protocols in MolecularBiology, (2002) 5th Ed., Ausubel et al., eds., John Wiley and Sons, NewYork).

As used herein, the term “recombinant human antibody” includes humanantibodies that are isolated, prepared, expressed, or created byrecombinant means, such as antibodies expressed using a recombinantexpression vector transfected into a host cell, antibodies isolated froma recombinant, combinatorial human antibody library, antibodies isolatedfrom an animal (e.g., a mouse, rabbit, goat, or cow) that is transgenicand/or transchromosomal for human immunoglobulin genes (see e.g.,Taylor, L. D. et al. (1992) Nucl. Acids Res. 20:6287-6295) or antibodiesprepared, expressed, created or isolated by any other means thatinvolves creation, e.g., via synthesis, genetic engineering of DNAsequences that encode human immunoglobulin sequences, or splicing ofsequences that encode human immunoglobulins, e.g., human immunoglobulingene sequences, to other such sequences. Such recombinant humanantibodies can have variable and constant regions derived from humangermline immunoglobulin sequences. In certain embodiments, the aminoacid sequences of such recombinant human antibodies have been modifiedsuch thus the amino acid sequences of the VH and/or VL regions of therecombinant antibodies are sequences that, while derived from andrelated to human germline VH and VL sequences, do not naturally existwithin the human antibody germline repertoire in vivo. As a non-limitingexample, a recombinant human antibody can be obtained by assemblingseveral human sequence fragments into a composite human sequence of arecombinant human antibody.

As used herein, the terms “variable region” or “variable domain” referto a portion of an antibody, generally, a portion of a light or heavychain, typically about the amino-terminal 110 to 120 amino acids in themature heavy chain and about 90 to 100 amino acids in the mature lightchain, which differ extensively in sequence among antibodies and areused in the binding and specificity of a particular antibody for itsparticular antigen. The variability in sequence is concentrated in thoseregions called complementarity determining regions (CDRs) while the morehighly conserved regions in the variable domain are called frameworkregions (FR). Without wishing to be bound by any particular mechanism ortheory, it is believed that the CDRs of the light and heavy chains areprimarily responsible for the interaction of the antibody with antigen.In a specific embodiment, numbering of amino acid positions ofantibodies described herein is according to the EU Index, as in Kabat etal. (1991) Sequences of Proteins of Immunological Interest, FifthEdition, U.S. Department of Health and Human Services, NIH PublicationNo. 91-3242 (“Kabat et al.”). In certain aspects, the CDRs of anantibody can be determined according to (i) the Chothia numberingscheme, which will be referred to herein as the “Chothia CDRs” (see,e.g., Chothia and Lesk, 1987, J. Mol. Biol., 196:901-917; Al-Lazikani etal., 1997, J. Mol. Biol., 273:927-948; and U.S. Pat. No. 7,709,226); or(ii) the IMGT numbering system, for example, as described in Lefranc,M.-P., 1999, The Immunologist, 7:132-136 and Lefranc, M.-P. et al.,1999, Nucleic Acids Res., 27:209-212. In certain embodiments, thevariable region is a human variable region. In certain embodiments, thevariable region comprises rodent or murine CDRs and human frameworkregions (FRs). In particular embodiments, the variable region is aprimate (e.g., non-human primate) variable region. In certainembodiments, the variable region comprises rodent or murine CDRs andprimate (e.g., non-human primate) framework regions (FRs). As anon-limiting example, a variable region described herein is obtainedfrom assembling two or more fragments of human sequences into acomposite human sequence.

In specific aspects, provided herein are antibodies (includingantigen-binding fragments thereof), such as humanized antibodies, thatimmunospecifically bind to a D4 of human KIT and a D4/D5 region of KIT,e.g., human KIT. Amino acid residues V308 to H515 (SEQ ID NO: 73) ofFIGS. 1 and 2 represent an exemplary D4/D5 region of human KIT, andamino acids K310 to N410 (SEQ ID NO: 15), as depicted in FIGS. 1 and 2,represent an exemplary D4 of human KIT. In another specific embodiment,an antibody described herein (or an antigen-binding fragment thereof)immunospecifically binds to a D5 domain of KIT, e.g., human KIT, withlower affinity than to a D4 domain of KIT, e.g., human KIT. In aparticular embodiment, an antibody described herein (or anantigen-binding fragment thereof) immunospecifically binds to a D4domain of KIT, e.g., human KIT, with higher affinity than to a D5 domainof KIT, e.g., human KIT; for example, the higher affinity is at least 10fold, 20 fold, 50 fold, 100 fold, 500 fold, or 1000 fold as determinedby methods known in the art, e.g., ELISA or Biacore assays.

In a specific embodiment, an antibody described herein (or anantigen-binding fragment thereof) immunospecifically binds to a D4 orD4/D5 region of KIT, e.g., human KIT, and has higher affinity for a KITantigen consisting essentially of a D4 domain only than a KIT antigenconsisting essentially of a D5 domain only. In a particular embodiment,an antibody described herein (or an antigen-binding fragment thereof)immunospecifically binds to a D4 or D4/D5 region of KIT, e.g., humanKIT, and has at least 1 fold, 2 fold, 3 fold, 4 fold, 5 fold, or 10 foldhigher affinity for a KIT antigen consisting essentially of a D4 domainonly than a KIT antigen consisting essentially of a D5 domain only. In aparticular embodiment, an antibody described herein (or anantigen-binding fragment thereof) immunospecifically binds to a D4 orD4/D5 region of KIT, e.g., human KIT, and has higher binding affinity(e.g., approximately a 2 fold to 3 fold higher affinity) for a KITantigen consisting essentially of a D4 domain only or a D4/D5 regiononly, than a KIT antigen consisting essentially of a D5 domain only.

In a particular embodiment, an antibody described herein (or anantigen-binding fragment thereof) immunospecifically binds to a KITantigen comprising or consisting essentially of the amino acid sequenceof SEQ ID NO: 15. In a specific embodiment, an antibody described herein(or an antigen-binding fragment thereof) immunospecifically binds to aD4 domain of KIT, e.g., human KIT. In a particular embodiment, anantibody described herein immunospecifically binds to a KIT antigencomprising or consisting essentially of a D4 of human KIT. In aparticular embodiment, an antibody described herein (or anantigen-binding fragment thereof) immunospecifically binds to a KITantigen comprising or consisting essentially of the amino acid sequenceof SEQ ID NO: 14 or 73.

In particular aspects, provided herein are antibodies or antigen-bindingfragments thereof, which immunospecifically bind to a KIT polypeptide(e.g., a D4 region of KIT, for example, human KIT, e.g., SEQ ID NO: 15[a human D4 sequence]) and comprise an amino acid sequence as describedherein.

In specific aspects, described herein are antibodies (e.g., human orhumanized antibodies), including antigen-binding fragments thereof,comprising:

(i) VH CDRs of a VH domain comprising the amino acid sequence of SEQ IDNO: 31 SEQ ID NO: 69 (QVQLKQSGAELVRPGASVKLSCKASGYTFTDYYINWVKQRPGQGLEWIARIYPGSGNTYYNEKFKGKATLTAEKSSSTAYMQLSSLTSEDSAVYFCARG VYYFDYWGQGTTLTVSS) or(QVQLKQSGAELVRPGASVKLSCKASGYTFTDYYINWVKQRPGQGLEWIARIYPGSGNTYYNEKFKGKATLTAEKSSSTAYMQLSSLTSEDSAVYFCARG VYYFDYWGQGTTLTVSA),and (ii) VL CDRs of a VL domain comprising the amino acid sequence ofSEQ ID NO: 32 (DIVMTQSQKFMSTSVGDRVSVTCKASQNVRTNVAWYQQKPGQSPKALIYSASYRYSGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYNSYPRTFG GGTKLEIKR).

In a specific embodiment, an antibody (e.g., a human or humanizedantibody) described herein, which immunospecifically binds to a KITpolypeptide (e.g., the D4 region of human KIT), comprises the VH CDRs(SEQ ID NOs: 16-18) and VL CDRs (SEQ ID NOs: 19-21) described inTable 1. In a specific embodiment, an antibody (e.g., a human orhumanized antibody) described herein, which immunospecifically binds toa KIT polypeptide (e.g., the D4 region of human KIT), comprises the VHCDRs and VL CDRs described in Table 2 (e.g., set 1 or set 2). In acertain embodiment, an antibody (e.g., a human or humanized antibody)described herein, which immunospecifically binds to a KIT polypeptide(e.g., the D4 region of human KIT), comprises the VH CDRs and VL CDRsdescribed in Table 3 (AbM CDRs or Contact CDRs).

TABLE 1 CDR Amino Acid Sequences amino acid sequence SEQ ID NO: VL CDR1KASQNVRTNVA 19 VL CDR2 SASYRYS 20 VL CDR3 QQYNSYPRT 21 VH CDR1 DYYIN 16VH CDR2 RIYPGSGNTYYNEKFKG 17 VH CDR3 GVYYFDY 18

TABLE 2 CDR Amino Acid Sequences Set 1 Set 2 amino acid SEQ ID amino SEQID sequence NO: acid sequence NO: VL CDR1 KASQNVRTNVA 19 SQNVRTN 59 VLCDR2 SASYRYS 20 SAS 60 VL CDR3 QQYNSYPRT 21 YNSYPR 61 VH CDR1 GYTFTDY 56GYTFTDY 56 VH CDR2 YPGSGN 57 PGSG 62 VH CDR3 GVYYFDYW 58 VYYFDY 63

TABLE 3 CDR Amino Acid Sequences AbM Contact amino acid SEQ ID amino SEQID sequence NO: acid sequence NO: VL CDR1 KASQNVRTNVA 19 RTNVAWY 66 VLCDR2 SASYRYS 20 ALIYSASYRY 67 VL CDR3 QQYNSYPRT 21 QQYNSYPR 68 VH CDR1GYTFTDYYIN 64 TDYYIN 70 VH CDR2 RIYPGSGNTY 65 WIARIYPGSGNTY 71 VH CDR3GVYYFDYW 58 ARGVYYFDY 72

TABLE 4 VL and VH domains of Antibodies Hum1-20 VH domain H1 H2 H3 H4 H5VL (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID domain NO: 2) NO: 3) NO: 4)NO: 5) NO: 6) L1 Hum1 Hum2 Hum3 Hum4 Hum5 (SEQ ID NO: 7) L2 Hum6 Hum7Hum8 Hum9 Hum10 (SEQ ID NO: 8) L3 Hum11 Hum12 Hum13 Hum14 Hum15 (SEQ IDNO: 9) L4 Hum16 Hum17 Hum18 Hum19 Hum20 (SEQ ID NO: 10)

In certain aspects, provided herein are VH domains (e.g., H1, H2, H3, H4and H5 comprising SEQ ID NOs: 2-6, respectively) and VL domains (e.g.,L1, L2, L3, and L4 comprising SEQ ID NOs: 7-10, respectively). Incertain embodiments, provided herein are antibodies comprising such VHand VL domains, as set forth, for example, in Table 4 (i.e., antibodiesHum1-Hum20). In particular embodiments, these antibodies comprise VHCDRs1-3 and VL CDRs 1-3 comprising SEQ ID NOs: 16-18 and 19-21,respectively.

In certain embodiments, an antibody described herein, or anantigen-binding fragment thereof, comprises a variable light (VL) chainregion comprising an amino acid sequence described herein, for example,any one of SEQ ID NOs: 7-10 (e.g., see FIGS. 3F-3I) or SEQ ID NO: 12.

In certain embodiments, an antibody described herein, or anantigen-binding fragment thereof, comprises a variable heavy (VH) chainregion comprising an amino acid sequence described herein, for exampleany one of SEQ ID NOs: 2-6 (e.g., see FIGS. 3A-3E) or SEQ ID NO: 11.

For example, described herein is an antibody that immunospecificallybinds to a KIT polypeptide (e.g., the D4 region of human KIT) andcomprises (i) the VH domain H1 (SEQ ID NO: 2), H2 (SEQ ID NO: 3), H3(SEQ ID NO: 4), H4 (SEQ ID NO: 5), or H5 (SEQ ID NO: 6) and/or (ii) theVL domain L1 (SEQ ID NO: 7), L2 (SEQ ID NO: 8), L3 (SEQ ID NO: 9), or L4(SEQ ID NO: 10). In a particular example, an antibody described herein,or an antigen-binding fragment thereof, can immunospecifically bind to aKIT polypeptide (e.g., the D4 region of human KIT) and comprise a VHdomain and/or a VL domain of any one of antibodies Hum1-Hum20 (see Table4). In a particular example, an antibody described herein, or anantigen-binding fragment thereof, comprises a VH domain and/or a VLdomain of any one of antibodies Hum4, Hum8, Hum10, or Hum17.

In a particular embodiment, an antibody, which immunospecifically bindsto a KIT polypeptide (e.g., the D4 region of human KIT), comprises H1(SEQ ID NO: 2) and L1 (SEQ ID NO: 7). In a particular embodiment, anantibody, which immunospecifically binds to a KIT polypeptide (e.g., theD4 region of human KIT), comprises H1 (SEQ ID NO: 2) and L2 (SEQ ID NO:8). In a specific embodiment, an antibody, which immunospecificallybinds to a KIT polypeptide (e.g., the D4 region of human KIT), comprisesH1 (SEQ ID NO: 2) and L3 (SEQ ID NO: 9). In a specific embodiment, anantibody, which immunospecifically binds to a KIT polypeptide (e.g., theD4 region of human KIT), comprises H1 (SEQ ID NO: 2) and L4 (SEQ ID NO:10). In a specific embodiment, an antibody, which immunospecificallybinds to a KIT polypeptide (e.g., the D4 region of human KIT), comprisesH2 (SEQ ID NO: 3) and L1 (SEQ ID NO: 7). In a specific embodiment, anantibody, which immunospecifically binds to a KIT polypeptide (e.g., theD4 region of human KIT), comprises H2 (SEQ ID NO: 3) and L2 (SEQ ID NO:8). In a specific embodiment, an antibody, which immunospecificallybinds to a KIT polypeptide (e.g., the D4 region of human KIT), comprisesH2 (SEQ ID NO: 3) and L3 (SEQ ID NO: 9). In a specific embodiment, anantibody, which immunospecifically binds to a KIT polypeptide (e.g., theD4 region of human KIT), comprises H2 (SEQ ID NO: 3) and L4 (SEQ ID NO:10). In a specific embodiment, an antibody, which immunospecificallybinds to a KIT polypeptide (e.g., the D4 region of human KIT), comprisesH3 (SEQ ID NO: 4) and L1 (SEQ ID NO: 7). In a specific embodiment, anantibody, which immunospecifically binds to a KIT polypeptide (e.g., theD4 region of human KIT), comprises H3 (SEQ ID NO: 4) and L2 (SEQ ID NO:8). In a specific embodiment, an antibody, which immunospecificallybinds to a KIT polypeptide (e.g., the D4 region of human KIT), comprisesH3 (SEQ ID NO: 4) and L3 (SEQ ID NO: 9). In a specific embodiment, anantibody, which immunospecifically binds to a KIT polypeptide (e.g., theD4 region of human KIT), comprises H3 (SEQ ID NO: 4) and L4 (SEQ ID NO:10). In a specific embodiment, an antibody, which immunospecificallybinds to a KIT polypeptide (e.g., the D4 region of human KIT), comprisesH4 (SEQ ID NO: 5) and L1 (SEQ ID NO: 7). In a specific embodiment, anantibody, which immunospecifically binds to a KIT polypeptide (e.g., theD4 region of human KIT), comprises H4 (SEQ ID NO: 5) and L2 (SEQ ID NO:8). In a specific embodiment, an antibody, which immunospecificallybinds to a KIT polypeptide (e.g., the D4 region of human KIT), comprisesH4 (SEQ ID NO: 5) and L3 (SEQ ID NO: 9). In a specific embodiment, anantibody, which immunospecifically binds to a KIT polypeptide (e.g., theD4 region of human KIT), comprises H4 (SEQ ID NO: 5) and L4 (SEQ ID NO:10). In a specific embodiment, an antibody, which immunospecificallybinds to a KIT polypeptide (e.g., the D4 region of human KIT), comprisesH5 (SEQ ID NO: 6) and L1 (SEQ ID NO: 7). In a specific embodiment, anantibody, which immunospecifically binds to a KIT polypeptide (e.g., theD4 region of human KIT), comprises H5 (SEQ ID NO: 6) and L2 (SEQ ID NO:8). In a specific embodiment, an antibody, which immunospecificallybinds to a KIT polypeptide (e.g., the D4 region of human KIT), comprisesH5 (SEQ ID NO: 6) and L3 (SEQ ID NO: 9). In a specific embodiment, anantibody, which immunospecifically binds to a KIT polypeptide (e.g., theD4 region of human KIT), comprises H5 (SEQ ID NO: 6) and L4 (SEQ ID NO:10).

In certain aspects, an antibody, or an antigen-binding fragment thereof,is non-immunogenic in a human. In a particular embodiment, anon-immunogenic amino acid sequence is devoid of epitopes identified tobe binders to human MHC class II, e.g., epitopes that are non-humangermline binders to human MHC class II. In a particular embodiment,amino acid sequences substantially devoid of epitopes identified to bebinders to human MHC class II, e.g., epitopes that are non-humangermline binders to human MHC class II. For example, in silico tools toidentify the location of both B- and T-cell epitopes and to assess thepotential for immunogenicity have been developed, and such tools providean alternative to in vitro or in vivo immunogenicity assays. Forexample, computational epitope prediction methods and manually curateddatabases containing experimentally derived epitope data have beendeveloped (See Bryson et al., Biodrugs, 2010, 24(1): 1-8). Non-limitingexamples of epitope databases include the Immune Epitope Database (IEDB)and the proprietary T Cell Epitope Database™ (TCEDTm). Such epitopedatabases can be used alone or in combination with in vitro assaysdescribed in the art, e.g., MHC class II binding assays and T cellactivation or proliferation assays. Alternatively, such in vitro assayscan be used independently of such epitope databases. Methods fordetermining immunogenicity of an agent, such as an antibody, or forremoving or reducing immunogenicity of an agent, such as an antibody,have been described in the art, see, e.g., Altschul et al., NucleicAcids Res., 1997, 25:3389-3402; Baker et al., Curr. Opin. Drug Discov.Devel., 2007, 10:219; Hill et al., Arthritis Res. Ther., 2003,1:R40-R48; Jones et al., J. Thromb. Haemost., 2005, 3:991-1000; Holgateet al., IDrugs, 2009, 12:233-237; Jones et al., Methods Mol. Biol.,2009, 525:405-423; and Baker et al., Curr. Drug Saf., 2010, 5:308-313.In a particular embodiment, an antibody described herein whichimmunospecifically binds to a D4 region of human KIT comprises a VHdomain and a VL domain that are not immunogenic, as determined by the TCell Epitope Database™ (TCED™). In a certain embodiment, an antibodydescribed herein immunospecifically binds to a D4 region of human KIT,and comprises a VH domain and a VL domain that are not immunogenic, asdetermined by an in vitro assay described in the art, see, e.g., Wang etal., 2008, PLoS Coomputational Biology, 2008, 4(4):e1000048; and Arnoldet al., 2002, J. Immunol., 169:739-749.

In certain aspects, provided herein is an antibody (e.g., human orhumanized antibody) or an antigen-binding fragment thereof, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprising a VH domain that has at least 93% sequenceidentity to H1 (SEQ ID NO: 2). In a particular embodiment, an antibody,which immunospecifically binds to a KIT polypeptide (e.g., the D4 regionof human KIT), comprises a VH domain that has at least 94%, or at least95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%sequence identity to H1 (SEQ ID NO: 2). In a particular embodiment, theVH domain is non-immunogenic, for example as determined by the absenceof epitopes that binds to MHC class II, e.g., non-human germline bindersto MHC class II. In a certain embodiment, such antibody orantigen-binding fragment thereof comprises a VH domain comprising VHCDR1, VH CDR2, and VH CDR3 comprising the amino acid sequences of SEQ IDNOs: 16-18, respectively.

In certain aspects, provided herein is an antibody or an antigen-bindingfragment thereof, which immunospecifically binds to a KIT polypeptide(e.g., the D4 region of human KIT), comprising a VH domain that has atleast 92% sequence identity to H2 (SEQ ID NO: 3). In a particularembodiment, an antibody, which immunospecifically binds to a KITpolypeptide (e.g., the D4 region of human KIT), or antigen-bindingfragment thereof, comprises a VH domain that has at least 93%, at least94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%,or at least 99% sequence identity to H2 (SEQ ID NO: 3). In a particularembodiment, the VH domain is non-immunogenic, for example as determinedby the absence of epitopes that bind to MHC class II, e.g., non-humangermline binders to MHC class II. In a certain embodiment, suchantibody, or antigen-binding fragment thereof, comprises a VH domaincomprising VH CDR1, VH CDR2, and VH CDR3 comprising the amino acidsequences of SEQ ID NOs: 16-18, respectively.

In certain aspects, provided herein is an antibody or an antigen-bindingfragment thereof, which immunospecifically binds to a KIT polypeptide(e.g., the D4 region of human KIT), comprising a VH domain that has atleast 90% sequence identity to H3 (SEQ ID NO: 4). In a particularembodiment, an antibody or an antigen-binding fragment thereof, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprises a VH domain that has at least 92%, at least 93%,at least 94%, or at least 95%, or at least 96%, or at least 97%, or atleast 98%, or at least 99% sequence identity to H3 (SEQ ID NO: 4). In aparticular embodiment, the VH domain is non-immunogenic, for example asdetermined by the absence of epitopes that binds to MHC class II, e.g.,non-human germline binders to MHC class II. In a certain embodiment,such antibody or antigen-binding fragment thereof comprises a VH domaincomprising VH CDR1, VH CDR2, and VH CDR3 comprising the amino acidsequences of SEQ ID NOs: 16-18, respectively.

In certain aspects, provided herein is an antibody or an antigen-bindingfragment thereof, which immunospecifically binds to a KIT polypeptide(e.g., the D4 region of human KIT), comprising a VH domain that has atleast 87% sequence identity to H4 (SEQ ID NO: 5). In a particularembodiment, an antibody or an antigen-binding fragment thereof, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprises a VH domain that has at least 92%, at least 93%,at least 94%, or at least 95%, or at least 96%, or at least 97%, or atleast 98%, or at least 99% sequence identity to H4 (SEQ ID NO: 5). In aparticular embodiment, the VH domain is non-immunogenic, for example asdetermined by the absence of epitopes that binds to MHC class II, e.g.,non-human germline binders to MHC class II. In a certain embodiment,such antibody or antigen-binding fragment thereof comprises a VH domaincomprising VH CDR1, VH CDR2, and VH CDR3 comprising the amino acidsequences of SEQ ID NOs: 16-18, respectively.

In certain aspects, provided herein is an antibody or an antigen-bindingfragment thereof, which immunospecifically binds to a KIT polypeptide(e.g., the D4 region of human KIT), comprising a VH domain that has atleast 86% sequence identity to H5 (SEQ ID NO: 6). In a particularembodiment, an antibody or an antigen-binding fragment thereof, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprises a

VH domain that has at least 92%, at least 93%, at least 94%, or at least95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%sequence identity to H5 (SEQ ID NO: 6). In a particular embodiment, theVH domain is non-immunogenic, for example as determined by the absenceof epitopes that binds to MHC class II, e.g., non-human germline bindersto MHC class II. In a certain embodiment, such antibody orantigen-binding fragment thereof comprises a VH domain comprising VHCDR1, VH CDR2, and VH CDR3 comprising the amino acid sequences of SEQ IDNOs: 16-18, respectively.

In certain aspects, provided herein is an antibody or an antigen-bindingfragment thereof, which immunospecifically binds to a KIT polypeptide(e.g., the D4 region of human KIT), comprising a VL domain that has atleast 90% sequence identity to L1 (SEQ ID NO: 7). In a particularembodiment, an antibody or an antigen-binding fragment thereof, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprises a VL domain that has at least 92%, at least 93%,at least 94%, or at least 95%, or at least 96%, or at least 97%, or atleast 98%, or at least 99% sequence identity to L1 (SEQ ID NO: 7). In aparticular embodiment, the VL domain is non-immunogenic, for example asdetermined by the absence of epitopes that binds to MHC class II, e.g.,non-human germline binders to MHC class II. In a certain embodiment,such antibody or antigen-binding fragment thereof comprises a VL domaincomprising VL CDR1, VL CDR2, and VL CDR3 comprising the amino acidsequences of SEQ ID NO: 19-21, respectively.

In certain aspects, provided herein is an antibody or an antigen-bindingfragment thereof, which immunospecifically binds to a KIT polypeptide(e.g., the D4 region of human KIT), comprising a VL domain that has atleast 88% sequence identity to L2 (SEQ ID NO: 8). In a particularembodiment, an antibody, which immunospecifically binds to a KITpolypeptide (e.g., the D4 region of human KIT), comprises a VL domainthat has at least 92%, at least 93%, at least 94%, or at least 95%, orat least 96%, or at least 97%, or at least 98%, or at least 99% sequenceidentity to L2 (SEQ ID NO: 8). In a particular embodiment, the VL domainis non-immunogenic, for example as determined by the absence of epitopesthat binds to MHC class II, e.g., non-human germline binders to MHCclass II. In a certain embodiment, such antibody or antigen-bindingfragment thereof comprises a VL domain comprising VL CDR1, VL CDR2, andVL CDR3 comprising the amino acid sequences of SEQ ID NO: 19-21,respectively.

In certain aspects, provided herein is an antibody or an antigen-bindingfragment thereof, which immunospecifically binds to a KIT polypeptide(e.g., the D4 region of human KIT), comprising a VL domain that has atleast 87% sequence identity to L3 (SEQ ID NO: 9). In a particularembodiment, an antibody or an antigen-binding fragment thereof, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprises a VL domain that has at least 92%, at least 93%,at least 94%, or at least 95%, or at least 96%, or at least 97%, or atleast 98%, or at least 99% sequence identity to L3 (SEQ ID NO: 9). In aparticular embodiment, the VL domain is non-immunogenic, for example asdetermined by the absence of epitopes that binds to MHC class II, e.g.,non-human germline binders to MHC class II. In a certain embodiment,such antibody or antigen-binding fragment thereof comprises a VL domaincomprising VL CDR1, VL CDR2, and VL CDR3 comprising the amino acidsequences of SEQ ID NO: 19-21, respectively.

In certain aspects, provided herein is an antibody or an antigen-bindingfragment thereof, which immunospecifically binds to a KIT polypeptide(e.g., the D4 region of human KIT), comprising a VL domain that has atleast 84% sequence identity to L4 (SEQ ID NO: 10). In a particularembodiment, an antibody or an antigen-binding fragment thereof, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprises a VL domain that has at least 92%, at least 93%,at least 94%, or at least 95%, or at least 96%, or at least 97%, or atleast 98%, or at least 99% sequence identity to L4 (SEQ ID NO: 10). In aparticular embodiment, the VL domain is non-immunogenic, for example asdetermined by the absence of epitopes that binds to MHC class II, e.g.,non-human germline binders to MHC class II. In a certain embodiment,such antibody or antigen-binding fragment thereof comprises a VL domaincomprising VL CDR1, VL CDR2, and VL CDR3 comprising the amino acidsequences of SEQ ID NO: 19-21, respectively.

In specific embodiments, provided herein is an antibody (e.g., human orhumanized antibody) or an antigen-binding fragment thereof, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprising (i) a VH domain comprising an amino acid sequencethat has at least 93% or at least 95% sequence identity to H1 (SEQ IDNO: 2); and (ii) a VL domain comprising an amino acid sequence that hasat least 90% or at least 92% sequence identity to L1 (SEQ ID NO: 7). Ina particular embodiment, the VL and VH domains are non-immunogenic, forexample as determined by the absence of epitopes that binds to MHC classII, e.g., non-human germline binders to MHC class II. In a certainembodiment, such antibody or antigen-binding fragment thereof comprisesVL CDRs 1-3 comprising the amino acid sequences of SEQ ID NOs: 19-21,respectively, and VH CDRs 1-3 comprising the amino acid sequences of SEQID NOs: 16-18, respectively.

In specific embodiments, provided herein is an antibody (e.g., human orhumanized antibody) or an antigen-binding fragment thereof, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprising (i) a VH domain comprising an amino acid sequencethat has at least 92% or at least 94% sequence identity to H2 (SEQ IDNO: 3); and (ii) a VL domain comprising an amino acid sequence that hasat least 90% or at least 92% sequence identity to L1 (SEQ ID NO: 7). Ina particular embodiment, the VL and VH domains are non-immunogenic, forexample as determined by the absence of epitopes that binds to MHC classII, e.g., non-human germline binders to MHC class II. In a certainembodiment, such antibody or antigen-binding fragment thereof comprisesVL CDRs 1-3 comprising the amino acid sequences of SEQ ID NOs: 19-21,respectively, and VH CDRs 1-3 comprising the amino acid sequences of SEQID NOs: 16-18, respectively.

In specific embodiments, provided herein is an antibody (e.g., human orhumanized antibody) or an antigen-binding fragment thereof, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprising (i) a VH domain comprising an amino acid sequencethat has at least 90% or at least 92% sequence identity to H3 (SEQ IDNO: 4); and (ii) a VL domain comprising an amino acid sequence that hasat least 90% or at least 92% sequence identity to L1 (SEQ ID NO: 7). Ina particular embodiment, the VL and VH domains are non-immunogenic, forexample as determined by the absence of epitopes that binds to MHC classII, e.g., non-human germline binders to MHC class II. In a certainembodiment, such antibody or antigen-binding fragment thereof comprisesVL CDRs 1-3 comprising the amino acid sequences of SEQ ID NOs: 19-21,respectively, and VH CDRs 1-3 comprising the amino acid sequences of SEQID NOs: 16-18, respectively.

In specific embodiments, provided herein is an antibody (e.g., human orhumanized antibody) or an antigen-binding fragment thereof, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprising (i) a VH domain comprising an amino acid sequencethat has at least 87% or at least 90% sequence identity to H4 (SEQ IDNO: 5); and (ii) a VL domain comprising an amino acid sequence that hasat least 90% or at least 92% sequence identity to L1 (SEQ ID NO: 7). Ina particular embodiment, the VL and VH domains are non-immunogenic, forexample as determined by the absence of epitopes that binds to MHC classII, e.g., non-human germline binders to MHC class II. In a certainembodiment, such antibody or antigen-binding fragment thereof comprisesVL CDRs 1-3 comprising the amino acid sequences of SEQ ID NOs: 19-21,respectively, and VH CDRs 1-3 comprising the amino acid sequences of SEQID NOs: 16-18, respectively.

In specific embodiments, provided herein is an antibody (e.g., human orhumanized antibody) or an antigen-binding fragment thereof, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprising (i) a VH domain comprising an amino acid sequencethat has at least 86% or at least 88% sequence identity to H5 (SEQ IDNO: 6); and (ii) a VL domain comprising an amino acid sequence that hasat least 90% or at least 92% sequence identity to L1 (SEQ ID NO: 7). Ina particular embodiment, the VL and VH domains are non-immunogenic, forexample as determined by the absence of epitopes that binds to MHC classII, e.g., non-human germline binders to MHC class II. In a certainembodiment, such antibody or antigen-binding fragment thereof comprisesVL CDRs 1-3 comprising the amino acid sequences of SEQ ID NOs: 19-21,respectively, and VH CDRs 1-3 comprising the amino acid sequences of SEQID NOs: 16-18, respectively.

In specific embodiments, provided herein is an antibody (e.g., human orhumanized antibody) or an antigen-binding fragment thereof, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprising (i) a VH domain comprising an amino acid sequencethat has at least 93% or at least 95% sequence identity to H1 (SEQ IDNO: 2); and (ii) a VL domain comprising an amino acid sequence that hasat least 88% or at least 90% sequence identity to L2 (SEQ ID NO: 8). Ina particular embodiment, the VL and VH domains are non-immunogenic, forexample as determined by the absence of epitopes that binds to MHC classII, e.g., non-human germline binders to MHC class II. In a certainembodiment, such antibody or antigen-binding fragment thereof comprisesVL CDRs 1-3 comprising the amino acid sequences of SEQ ID NOs: 19-21,respectively, and VH CDRs 1-3 comprising the amino acid sequences of SEQID NOs: 16-18, respectively.

In specific embodiments, provided herein is an antibody (e.g., human orhumanized antibody) or an antigen-binding fragment thereof, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprising (i) a VH domain comprising an amino acid sequencethat has at least 92% or at least 94% sequence identity to H2 (SEQ IDNO: 3); and (ii) a VL domain comprising an amino acid sequence that hasat least 88% or at least 90% sequence identity to L2 (SEQ ID NO: 8). Ina particular embodiment, the VL and VH domains are non-immunogenic, forexample as determined by the absence of epitopes that binds to MHC classII, e.g., non-human germline binders to MHC class II. In a certainembodiment, such antibody or antigen-binding fragment thereof comprisesVL CDRs 1-3 comprising the amino acid sequences of SEQ ID NOs: 19-21,respectively, and VH CDRs 1-3 comprising the amino acid sequences of SEQID NOs: 16-18, respectively.

In specific embodiments, provided herein is an antibody (e.g., human orhumanized antibody) or an antigen-binding fragment thereof, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprising (i) a VH domain comprising an amino acid sequencethat has at least 90% or at least 92% sequence identity to H3 (SEQ IDNO: 4); and (ii) a VL domain comprising an amino acid sequence that hasat least 88% or at least 90% sequence identity to L2 (SEQ ID NO: 8). Ina particular embodiment, the VL and VH domains are non-immunogenic, forexample as determined by the absence of epitopes that binds to MHC classII, e.g., non-human germline binders to MHC class II. In a certainembodiment, such antibody or antigen-binding fragment thereof comprisesVL CDRs 1-3 comprising the amino acid sequences of SEQ ID NOs: 19-21,respectively, and VH CDRs 1-3 comprising the amino acid sequences of SEQID NOs: 16-18, respectively.

In specific embodiments, provided herein is an antibody (e.g., human orhumanized antibody) or an antigen-binding fragment thereof, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprising (i) a VH domain comprising an amino acid sequencethat has at least 87% or at least 90% sequence identity to H4 (SEQ IDNO: 5); and (ii) a VL domain comprising an amino acid sequence that hasat least 88% or at least 90% sequence identity to L2 (SEQ ID NO: 8). Ina particular embodiment, the VL and VH domains are non-immunogenic, forexample as determined by the absence of epitopes that binds to MHC classII, e.g., non-human germline binders to MHC class II. In a certainembodiment, such antibody or antigen-binding fragment thereof comprisesVL CDRs 1-3 comprising the amino acid sequences of SEQ ID NOs: 19-21,respectively, and VH CDRs 1-3 comprising the amino acid sequences of SEQID NOs: 16-18, respectively.

In specific embodiments, provided herein is an antibody (e.g., human orhumanized antibody) or an antigen-binding fragment thereof, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprising (i) a VH domain comprising an amino acid sequencethat has at least 86% or at least 88% sequence identity to H5 (SEQ IDNO: 6); and (ii) a VL domain comprising an amino acid sequence that hasat least 88% or at least 90% sequence identity to L2 (SEQ ID NO: 8). Ina particular embodiment, the VL and VH domains are non-immunogenic, forexample as determined by the absence of epitopes that binds to MHC classII, e.g., non-human germline binders to MHC class II. In a certainembodiment, such antibody or antigen-binding fragment thereof comprisesVL CDRs 1-3 comprising the amino acid sequences of SEQ ID NOs: 19-21,respectively, and VH CDRs 1-3 comprising the amino acid sequences of SEQID NOs: 16-18, respectively.

In specific embodiments, provided herein is an antibody (e.g., human orhumanized antibody) or an antigen-binding fragment thereof, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprising (i) a VH domain comprising an amino acid sequencethat has at least 93% or at least 95% sequence identity to H1 (SEQ IDNO: 2); and (ii) a VL domain comprising an amino acid sequence that hasat least 87% or at least 90% sequence identity to L3 (SEQ ID NO: 9). Ina particular embodiment, the VL and VH domains are non-immunogenic, forexample as determined by the absence of epitopes that binds to MHC classII, e.g., non-human germline binders to MHC class II. In a certainembodiment, such antibody or antigen-binding fragment thereof comprisesVL CDRs 1-3 comprising the amino acid sequences of SEQ ID NOs: 19-21,respectively, and VH CDRs 1-3 comprising the amino acid sequences of SEQID NOs: 16-18, respectively.

In specific embodiments, provided herein is an antibody (e.g., human orhumanized antibody) or an antigen-binding fragment thereof, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprising (i) a VH domain comprising an amino acid sequencethat has at least 92% or at least 94% sequence identity to H2 (SEQ IDNO: 3); and (ii) a VL domain comprising an amino acid sequence that hasat least 87% or at least 90% sequence identity to L3 (SEQ ID NO: 9). Ina particular embodiment, the VL and VH domains are non-immunogenic, forexample as determined by the absence of epitopes that binds to MHC classII, e.g., non-human germline binders to MHC class II. In a certainembodiment, such antibody or antigen-binding fragment thereof comprisesVL CDRs 1-3 comprising the amino acid sequences of SEQ ID NOs: 19-21,respectively, and VH CDRs 1-3 comprising the amino acid sequences of SEQID NOs: 16-18, respectively.

In specific embodiments, provided herein is an antibody (e.g., human orhumanized antibody) or an antigen-binding fragment thereof, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprising (i) a VH domain comprising an amino acid sequencethat has at least 90% or at least 92% sequence identity to H3 (SEQ IDNO: 4); and (ii) a VL domain comprising an amino acid sequence that hasat least 87% or at least 90% sequence identity to L3 (SEQ ID NO: 9). Ina particular embodiment, the VL and VH domains are non-immunogenic, forexample as determined by the absence of epitopes that binds to MHC classII, e.g., non-human germline binders to MHC class II. In a certainembodiment, such antibody or antigen-binding fragment thereof comprisesVL CDRs 1-3 comprising the amino acid sequences of SEQ ID NOs: 19-21,respectively, and VH CDRs 1-3 comprising the amino acid sequences of SEQID NOs: 16-18, respectively.

In specific embodiments, provided herein is an antibody (e.g., human orhumanized antibody) or an antigen-binding fragment thereof, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprising (i) a VH domain comprising an amino acid sequencethat has at least 87% or at least 90% sequence identity to H4 (SEQ IDNO: 5); and (ii) a VL domain comprising an amino acid sequence that hasat least 87% or at least 90% sequence identity to L3 (SEQ ID NO: 9). Ina particular embodiment, the VL and VH domains are non-immunogenic, forexample as determined by the absence of epitopes that binds to MHC classII, e.g., non-human germline binders to MHC class II. In a certainembodiment, such antibody or antigen-binding fragment thereof comprisesVL CDRs 1-3 comprising the amino acid sequences of SEQ ID NOs: 19-21,respectively, and VH CDRs 1-3 comprising the amino acid sequences of SEQID NOs: 16-18, respectively.

In specific embodiments, provided herein is an antibody (e.g., human orhumanized antibody) or an antigen-binding fragment thereof, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprising (i) a VH domain comprising an amino acid sequencethat has at least 86% or at least 88% sequence identity to H5 (SEQ IDNO: 6); and (ii) a VL domain comprising an amino acid sequence that hasat least 87% or at least 90% sequence identity to L3 (SEQ ID NO: 9). Ina particular embodiment, the VL and VH domains are non-immunogenic, forexample as determined by the absence of epitopes that binds to MHC classII, e.g., non-human germline binders to MHC class II. In a certainembodiment, such antibody or antigen-binding fragment thereof comprisesVL CDRs 1-3 comprising the amino acid sequences of SEQ ID NOs: 19-21,respectively, and VH CDRs 1-3 comprising the amino acid sequences of SEQID NOs: 16-18, respectively.

In specific embodiments, provided herein is an antibody (e.g., human orhumanized antibody) or an antigen-binding fragment thereof, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprising (i) a VH domain comprising an amino acid sequencethat has at least 93% or at least 95% sequence identity to H1 (SEQ IDNO: 2); and (ii) a VL domain comprising an amino acid sequence that hasat least 84% or at least 86% sequence identity to L4 (SEQ ID NO: 10). Ina particular embodiment, the VL and VH domains are non-immunogenic, forexample as determined by the absence of epitopes that binds to MHC classII, e.g., non-human germline binders to MHC class II. In a certainembodiment, such antibody or antigen-binding fragment thereof comprisesVL CDRs 1-3 comprising the amino acid sequences of SEQ ID NOs: 19-21,respectively, and VH CDRs 1-3 comprising the amino acid sequences of SEQID NOs: 16-18, respectively.

In specific embodiments, provided herein is an antibody (e.g., human orhumanized antibody) or an antigen-binding fragment thereof, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprising (i) a VH domain comprising an amino acid sequencethat has at least 92% or at least 94% sequence identity to H2 (SEQ IDNO: 3); and (ii) a VL domain comprising an amino acid sequence that hasat least 84% or at least 86% sequence identity to L4 (SEQ ID NO: 10). Ina particular embodiment, the VL and VH domains are non-immunogenic, forexample as determined by the absence of epitopes that binds to MHC classII, e.g., non-human germline binders to MHC class II. In a certainembodiment, such antibody or antigen-binding fragment thereof comprisesVL CDRs 1-3 comprising the amino acid sequences of SEQ ID NOs: 19-21,respectively, and VH CDRs 1-3 comprising the amino acid sequences of SEQID NOs: 16-18, respectively.

In specific embodiments, provided herein is an antibody (e.g., human orhumanized antibody) or an antigen-binding fragment thereof, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprising (i) a VH domain comprising an amino acid sequencethat has at least 90% or at least 92% sequence identity to H3 (SEQ IDNO: 4); and (ii) a VL domain comprising an amino acid sequence that hasat least 84% or at least 86% sequence identity to L4 (SEQ ID NO: 10). Ina particular embodiment, the VL and VH domains are non-immunogenic, forexample as determined by the absence of epitopes that binds to MHC classII, e.g., non-human germline binders to MHC class II. In a certainembodiment, such antibody or antigen-binding fragment thereof comprisesVL CDRs 1-3 comprising the amino acid sequences of SEQ ID NOs: 19-21,respectively, and VH CDRs 1-3 comprising the amino acid sequences of SEQID NOs: 16-18, respectively.

In specific embodiments, provided herein is an antibody (e.g., human orhumanized antibody) or an antigen-binding fragment thereof, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprising (i) a VH domain comprising an amino acid sequencethat has at least 87% or at least 90% sequence identity to H4 (SEQ IDNO: 5); and (ii) a VL domain comprising an amino acid sequence that hasat least 84% or at least 86% sequence identity to L4 (SEQ ID NO: 10). Ina particular embodiment, the VL and VH domains are non-immunogenic, forexample as determined by the absence of epitopes that binds to MHC classII, e.g., non-human germline binders to MHC class II. In a certainembodiment, such antibody or antigen-binding fragment thereof comprisesVL CDRs 1-3 comprising the amino acid sequences of SEQ ID NOs: 19-21,respectively, and VH CDRs 1-3 comprising the amino acid sequences of SEQID NOs: 16-18, respectively.

In specific embodiments, provided herein is an antibody (e.g., human orhumanized antibody) or an antigen-binding fragment thereof, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprising (i) a VH domain comprising an amino acid sequencethat has at least 86% or at least 88% sequence identity to H5 (SEQ IDNO: 6); and (ii) a VL domain comprising an amino acid sequence that hasat least 84% or at least 86% sequence identity to L4 (SEQ ID NO: 10). Ina particular embodiment, the VL and VH domains are non-immunogenic, forexample as determined by the absence of epitopes that binds to MHC classII, e.g., non-human germline binders to MHC class II. In a certainembodiment, such antibody or antigen-binding fragment thereof comprisesVL CDRs 1-3 comprising the amino acid sequences of SEQ ID NOs: 19-21,respectively, and VH CDRs 1-3 comprising the amino acid sequences of SEQID NOs: 16-18, respectively.

To determine the percent identity of two amino acid sequences or of twonucleic acid sequences, the sequences are aligned for optimal comparisonpurposes (e.g., gaps can be introduced in the sequence of a first aminoacid or nucleic acid sequence for optimal alignment with a second aminoacid or nucleic acid sequence). The amino acid residues or nucleotidesat corresponding amino acid positions or nucleotide positions are thencompared. When a position in the first sequence is occupied by the sameamino acid residue or nucleotide as the corresponding position in thesecond sequence, then the molecules are identical at that position. Thepercent identity between the two sequences is a function of the numberof identical positions shared by the sequences (i.e., % identity=numberof identical overlapping positions/total number of positions X 100%). Inone embodiment, the two sequences are the same length. In a certainembodiment, the percent identity is determined over the entire length ofan amino acid sequence or nucleotide sequence.

The determination of percent identity between two sequences (e.g., aminoacid sequences or nucleic acid sequences) can also be accomplished usinga mathematical algorithm. A preferred, non-limiting example of amathematical algorithm utilized for the comparison of two sequences isthe algorithm of Karlin and Altschul, 1990, Proc. Natl. Acad. Sci.U.S.A. 87:2264 2268, modified as in Karlin and Altschul, 1993, Proc.Natl. Acad. Sci. U.S.A. 90:5873 5877. Such an algorithm is incorporatedinto the NBLAST and)(BLAST programs of Altschul et al., 1990, J. Mol.Biol. 215:403. BLAST nucleotide searches can be performed with theNBLAST nucleotide program parameters set, e.g., for score=100,wordlength=12 to obtain nucleotide sequences homologous to a nucleicacid molecules described herein. BLAST protein searches can be performedwith the)(BLAST program parameters set, e.g., to score 50, wordlength=3to obtain amino acid sequences homologous to a protein moleculedescribed herein. To obtain gapped alignments for comparison purposes,Gapped BLAST can be utilized as described in Altschul et al., 1997,Nucleic Acids Res. 25:3389 3402. Alternatively, PSI BLAST can be used toperform an iterated search which detects distant relationships betweenmolecules (Id.). When utilizing BLAST, Gapped BLAST, and PSI Blastprograms, the default parameters of the respective programs (e.g., ofXBLAST and NBLAST) can be used (see, e.g., National Center forBiotechnology Information (NCBI) on the worldwide web,ncbi.nlm.nih.gov). Another preferred, non limiting example of amathematical algorithm utilized for the comparison of sequences is thealgorithm of Myers and Miller, 1988, CABIOS 4:11 17. Such an algorithmis incorporated in the ALIGN program (version 2.0) which is part of theGCG sequence alignment software package. When utilizing the ALIGNprogram for comparing amino acid sequences, a PAM120 weight residuetable, a gap length penalty of 12, and a gap penalty of 4 can be used.

The percent identity between two sequences can be determined usingtechniques similar to those described above, with or without allowinggaps. In calculating percent identity, typically only exact matches arecounted.

In a particular aspect, provided herein is an antibody or anantigen-binding fragment thereof, which immunospecifically binds to aKIT polypeptide (e.g., the D4 region of human KIT), comprising: (i) a VHdomain comprising VH CDR1, VH CDR2, and VH CDR3 comprising the aminoacid sequences of SEQ ID NOs: 16-18, respectively, and one, two, threeor four framework regions of H1, H2, H3, H4 or H5 (see Table 5A); and/or(ii) a VL domain comprising VL CDR1, VL CDR2, and VL CDR3 comprising theamino acid sequences of SEQ ID NO: 19-21, respectively, and one, two,three or four framework regions of L1, L2, L3, or L4 (see Table 5B).

In one embodiment, an antibody described herein, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprises a VH domain comprising VH CDR1, VH CDR2, and VHCDR3 comprising the amino acid sequences of SEQ ID NOs: 16-18,respectively, and framework region FR1 of H1, H2, H3, H4 or H5. In oneembodiment, an antibody described herein, which immunospecifically bindsto a KIT polypeptide (e.g., the D4 region of human KIT), comprises a VHdomain comprising VH CDR1, VH CDR2, and VH CDR3 comprising the aminoacid sequences of SEQ ID NOs: 16-18, respectively, and framework regionFR2 of H1, H2, H3, H4 or H5. In one embodiment, an antibody describedherein, which immunospecifically binds to a KIT polypeptide (e.g., theD4 region of human KIT), comprises a VH domain comprising VH CDR1, VHCDR2, and VH CDR3 comprising the amino acid sequences of SEQ ID NOs:16-18, respectively, and framework region FR3 of H1, H2, H3, H4 or H5.In one embodiment, an antibody described herein, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprises a VH domain comprising VH CDR1, VH CDR2, and VHCDR3 comprising the amino acid sequences of SEQ ID NOs: 16-18,respectively, and framework region FR4 of H1, H2, H3, H4 or H5.

In one embodiment, an antibody described herein, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprises a VH domain comprising VH CDR1, VH CDR2, and VHCDR3 comprising the amino acid sequences of SEQ ID NOs: 16-18,respectively, and framework regions FR1 and FR2 of H1, H2, H3, H4 or H5.In one embodiment, an antibody described herein, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprises a VH domain comprising VH CDR1, VH CDR2, and VHCDR3 comprising the amino acid sequences of SEQ ID NOs: 16-18,respectively, and framework regions FR1, FR2, and FR3 of H1, H2, H3, H4or H5. In one embodiment, an antibody described herein, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprises a VH domain comprising VH CDR1, VH CDR2, and VHCDR3 comprising the amino acid sequences of SEQ ID NOs: 16-18,respectively, and framework regions FR1, FR2, FR3, and FR4 of H1, H2,H3, H4 or H5.

In one embodiment, an antibody described herein, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprises a VH domain comprising VH CDR1, VH CDR2, and VHCDR3 comprising the amino acid sequences of SEQ ID NOs: 16-18,respectively, and framework regions FR1 and FR3 of H1, H2, H3, H4 or H5.In one embodiment, an antibody described herein, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprises a VH domain comprising VH CDR1, VH CDR2, and VHCDR3 comprising the amino acid sequences of SEQ ID NOs: 16-18,respectively, and framework regions FR1, FR3, and FR4 of H1, H2, H3, H4or H5.

In one embodiment, an antibody described herein, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprises a VH domain comprising VH CDR1, VH CDR2, and VHCDR3 comprising the amino acid sequences of SEQ ID NOs: 16-18,respectively, and framework regions FR1 and FR4 of H1, H2, H3, H4 or H5.

In one embodiment, an antibody described herein, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprises a VH domain comprising VH CDR1, VH CDR2, and VHCDR3 comprising the amino acid sequences of SEQ ID NOs: 16-18,respectively, and framework regions FR1, FR2, and FR4 of H1, H2, H3, H4or H5.

In one embodiment, a human or humanized antibody described herein, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprises a VH domain comprising VH CDR1, VH CDR2, and VHCDR3 comprising the amino acid sequences of SEQ ID NOs: 16-18,respectively, and framework regions FR2 and FR3 of H1, H2, H3, H4 or H5.In one embodiment, an antibody described herein, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprises a VH domain comprising VH CDR1, VH CDR2, and VHCDR3 comprising the amino acid sequences of SEQ ID NOs: 16-18,respectively, and framework regions FR2, FR3, and FR4 of H1, H2, H3, H4or H5.

In one embodiment, an antibody described herein, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprises a VH domain comprising VH CDR1, VH CDR2, and VHCDR3 comprising the amino acid sequences of SEQ ID NOs: 16-18,respectively, and framework regions FR3 and FR4 of H1, H2, H3, H4 or H5.

In one embodiment, an antibody described herein, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprises a VL domain comprising VL CDR1, VL CDR2, and VLCDR3 comprising the amino acid sequences of SEQ ID NOs: 19-21,respectively, and framework region FR1 of L1, L2, L3, or L4. In oneembodiment, an antibody described herein, which immunospecifically bindsto a KIT polypeptide (e.g., the D4 region of human KIT), comprises a VLdomain comprising VL CDR1, VL CDR2, and VL CDR3 comprising the aminoacid sequences of SEQ ID NOs: 19-21, respectively, and framework regionFR2 of L1, L2, L3, or L4. In one embodiment, an antibody describedherein, which immunospecifically binds to a KIT polypeptide (e.g., theD4 region of human KIT), comprises a VL domain comprising VL CDR1, VLCDR2, and VL CDR3 comprising the amino acid sequences of SEQ ID NOs:19-21, respectively, and framework region FR3 of L1, L2, L3, or L4. Inone embodiment, an antibody described herein, which immunospecificallybinds to a KIT polypeptide (e.g., the D4 region of human KIT), comprisesa VL domain comprising VL CDR1, VL CDR2, and VL CDR3 comprising theamino acid sequences of SEQ ID NOs: 19-21, respectively, and frameworkregion FR4 of L1, L2, L3, or L4.

In one embodiment, an antibody described herein, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprises a VL domain comprising VL CDR1, VL CDR2, and VLCDR3 comprising the amino acid sequences of SEQ ID NOs: 19-21,respectively, and framework regions FR1 and FR2 of L1, L2, L3, or L4. Inone embodiment, an antibody described herein, which immunospecificallybinds to a KIT polypeptide (e.g., the D4 region of human KIT), comprisesa VL domain comprising VL CDR1, VL CDR2, and VL CDR3 comprising theamino acid sequences of SEQ ID NOs: 19-21, respectively, and frameworkregions FR1, FR2, and FR3 of L1, L2, L3, or L4. In one embodiment, anantibody described herein, which immunospecifically binds to a KITpolypeptide (e.g., the D4 region of human KIT), comprises a VL domaincomprising VL CDR1, VL CDR2, and VL CDR3 comprising the amino acidsequences of SEQ ID NOs: 19-21, respectively, and framework regions FR1,FR2, FR3, and FR4 of L1, L2, L3, or L4.

In one embodiment, an antibody described herein, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprises a VL domain comprising VL CDR1, VL CDR2, and VLCDR3 comprising the amino acid sequences of SEQ ID NOs: 19-21,respectively, and framework regions FR1 and FR3 of L1, L2, L3, or L4. Inone embodiment, an antibody described herein, which immunospecificallybinds to a KIT polypeptide (e.g., the D4 region of human KIT), comprisesa VL domain comprising VL CDR1, VL CDR2, and VL CDR3 comprising theamino acid sequences of SEQ ID NOs: 19-21, respectively, and frameworkregions FR1, FR3, and FR4 of L1, L2, L3, or L4.

In one embodiment, an antibody described herein, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprises a VL domain comprising VL CDR1, VL CDR2, and VLCDR3 comprising the amino acid sequences of SEQ ID NOs: 19-21,respectively, and framework regions FR1 and FR4 of L1, L2, L3, or L4.

In one embodiment, an antibody described herein, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprises a VL domain comprising VL CDR1, VL CDR2, and VLCDR3 comprising the amino acid sequences of SEQ ID NOs: 19-21,respectively, and framework regions FR1, FR2, and FR4 of L1, L2, L3, orL4.

In one embodiment, an antibody described herein, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprises a VL domain comprising VL CDR1, VL CDR2, and VLCDR3 comprising the amino acid sequences of SEQ ID NOs: 19-21,respectively, and framework regions FR2 and FR3 of L1, L2, L3, or L4. Inone embodiment, an antibody described herein, which immunospecificallybinds to a KIT polypeptide (e.g., the D4 region of human KIT), comprisesa VL domain comprising VL CDR1, VL CDR2, and VL CDR3 comprising theamino acid sequences of SEQ ID NOs: 19-21, respectively, and frameworkregions FR2, FR3, and FR4 of L1, L2, L3, or L4.

In one embodiment, an antibody described herein, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprises a VL domain comprising VL CDR1, VL CDR2, and VLCDR3 comprising the amino acid sequences of SEQ ID NOs: 19-21,respectively, and framework regions FR3 and FR4 of L1, L2, L3, or L4.

In a particular aspect, provided herein is an antibody or anantigen-binding fragment thereof, which immunospecifically binds to aKIT polypeptide (e.g., the D4 region of human KIT), comprising: (i) a VHdomain comprising VH CDR1, VH CDR2, and VH CDR3 comprising the aminoacid sequences of SEQ ID NOs: 16-18, respectively, and framework regionsFR1-FR4 of any one of VH domains HH257-HH281 (see Table 5C); and (ii) aVL domain comprising VL CDR1, VL CDR2, and VL CDR3 comprising the aminoacid sequences of SEQ ID NO: 19-21, respectively, and FR1-FR4 of any oneof VL domains LL65-LL76 (see Table 5D).

In a particular aspect, provided herein is an antibody or anantigen-binding fragment thereof, which immunospecifically binds to aKIT polypeptide (e.g., the D4 region of human KIT), comprising: (i) a VHdomain comprising VH CDR1, VH CDR2, and VH CDR3 comprising a combinationof amino acid sequences set forth in Table 2 or 3, and framework regionsFR1-FR4 of any one of VH domains H1-H5 (Table 5A) and HH257-HH281 (seeTable 5C); and (ii) a VL domain comprising VL CDR1, VL CDR2, and VL CDR3comprising a combination of amino acid sequences set forth in eitherTable 2 (set 1 or set 2) or 3 (AbM or Contact CDRs), respectively, andFR1-FR4 of any one of VL domains L1-L4 (Table 5B) and LL65-LL76 (seeTable 5D).

In a particular aspect, provided herein is an antibody or anantigen-binding fragment thereof, which immunospecifically binds to aKIT polypeptide (e.g., the D4 region of human KIT), comprising: (i) a VHdomain comprising VH CDR1, VH CDR2, and VH CDR3 comprising a combinationof amino acid sequences set forth in Table 2 or 3, and correspondingframework regions FR1-FR4 comprising sequences flanking the VH CDRs forexample, as depicted in any one of FIGS. 3A-3I; and (ii) a VL domaincomprising VL CDR1, VL CDR2, and VL CDR3 comprising a combination ofamino acid sequences set forth in in either Table 2 (set 1 or set 2) or3 (AbM or Contact CDRs), respectively, and corresponding frameworkregions FR1-FR4 comprising sequences flanking the VL CDRs, for exampleas depicted in any one of FIGS. 3A-3I.

TABLE 5A VH domain Framework Regions (FRs) VH FR1 VH FR2 VH FR3 VH FR4H1 QVQLVQSGAELK WVKQAPGKGLE RATLTAEKSTSTA WGQGTTVTVSS KPGASVKLSCKA WIAYMQLSSLRSEDS (SEQ ID NO: 36) SGYTFT (SEQ ID NO: 34) AVYFCAR (SEQ ID NO:33) (SEQ ID NO: 35) H2 QVQLVQSGAEVK WVKQAPGKGLE RATLTAEKSTSTAWGQGTTVTVSS KPGASVKLSCKA WIA YMQLSSLRSEDT (SEQ ID NO: 36) SGYTFT (SEQ IDNO: 34) AVYFCAR (SEQ ID NO: 37) (SEQ ID NO: 38) H3 QVQLVQSGAEVKWVRQAPGKGLE RATLTADKSTST WGQGTTVTVSS KPGASVKLSCKA WIA AYMQLSSLRSED (SEQID NO: 36) SGYTFT (SEQ ID NO: 39) TAVYFCAR (SEQ ID NO: 37) (SEQ ID NO:40) H4 QVQLVQSGAEVK WVRQAPGKGLE RATITADKSTSTA WGQGTTVTVSS KPGASVKVSCKAWIA YMELSSLRSEDTA (SEQ ID NO: 36) SGYTFT (SEQ ID NO: 39) VYFCAR (SEQ IDNO: 41) (SEQ ID NO: 42) H5 QVQLVQSGAEVK WVRQAPGKGLE RVTITADKSTSTAWGQGTTVTVSS KPGASVKVSCKA WIA YMELSSLRSEDTA (SEQ ID NO: 36) SGYTFT (SEQID NO: 39) VYFCAR (SEQ ID NO: 41) (SEQ ID NO: 43)

TABLE 5B VL domain Framework Regions (FRs) VL FR1 VL FR2 VL FR3 VL FR4L1 DIVMTQSPSFLSAS WYQQKPGKAPKA GVPDRFTGSGSGTD FGGGTKVEIK VGDRVTITC LIYFTLTISSLQSEDFAD (SEQ ID NO: 47) (SEQ ID NO: 44) (SEQ ID NO: 45) YFC (SEQID NO: 46) L2 DIVMTQSPSSLSAS WYQQKPGKAPKA GVPDRFTGSGSGTD FGGGTKVEIKVGDRVTITC LIY FTLTISSLQPEDFAD (SEQ ID NO: 47) (SEQ ID NO: 48) (SEQ IDNO: 45) YFC (SEQ ID NO: 49) L3 DIVMTQSPSSLSAS WYQQKPGKAPKAGVPDRFSGSGSGTD FGGGTKVEIK VGDRVTITC LIY FTLTISSLQPEDFAD (SEQ ID NO: 47)(SEQ ID NO: 48) (SEQ ID NO: 45) YFC (SEQ ID NO: 50) L4 DIVMTQSPSSLSASWYQQKPGKAPKS GVPDRFSGSGSGTD FGGGTKVEIK VGDRVTITC LIY FTLTISSLQPEDFAT(SEQ ID NO: 47) (SEQ ID NO: 48) (SEQ ID NO: 51) YYC (SEQ ID NO: 52)

TABLE 5C Framework region sequences of VH domains HH257 to HH281 VHdomain VH FR1 VH FR2 VH FR3 VH FR4 HH257 SEQ ID NO: 33 SEQ ID NO: 39 SEQID NO: 35 SEQ ID NO: 36 HH258 SEQ ID NO: 33 SEQ ID NO: 34 SEQ ID NO: 38SEQ ID NO: 36 HH259 SEQ ID NO: 33 SEQ ID NO: 39 SEQ ID NO: 38 SEQ ID NO:36 HH260 SEQ ID NO: 33 SEQ ID NO: 34 SEQ ID NO: 40 SEQ ID NO: 36 HH261SEQ ID NO: 33 SEQ ID NO: 39 SEQ ID NO: 40 SEQ ID NO: 36 HH262 SEQ ID NO:33 SEQ ID NO: 34 SEQ ID NO: 42 SEQ ID NO: 36 HH263 SEQ ID NO: 33 SEQ IDNO: 39 SEQ ID NO: 42 SEQ ID NO: 36 HH264 SEQ ID NO: 33 SEQ ID NO: 34 SEQID NO: 43 SEQ ID NO: 36 HH265 SEQ ID NO: 33 SEQ ID NO: 39 SEQ ID NO: 43SEQ ID NO: 36 HH266 SEQ ID NO: 37 SEQ ID NO: 34 SEQ ID NO: 35 SEQ ID NO:36 HH267 SEQ ID NO: 37 SEQ ID NO: 39 SEQ ID NO: 35 SEQ ID NO: 36 HH268SEQ ID NO: 37 SEQ ID NO: 39 SEQ ID NO: 38 SEQ ID NO: 36 HH269 SEQ ID NO:37 SEQ ID NO: 34 SEQ ID NO: 40 SEQ ID NO: 36 HH270 SEQ ID NO: 37 SEQ IDNO: 34 SEQ ID NO: 42 SEQ ID NO: 36 HH271 SEQ ID NO: 37 SEQ ID NO: 39 SEQID NO: 42 SEQ ID NO: 36 HH272 SEQ ID NO: 37 SEQ ID NO: 34 SEQ ID NO: 43SEQ ID NO: 36 HH273 SEQ ID NO: 37 SEQ ID NO: 39 SEQ ID NO: 43 SEQ ID NO:36 HH274 SEQ ID NO: 41 SEQ ID NO: 34 SEQ ID NO: 35 SEQ ID NO: 36 HH275SEQ ID NO: 41 SEQ ID NO: 39 SEQ ID NO: 35 SEQ ID NO: 36 HH276 SEQ ID NO:41 SEQ ID NO: 34 SEQ ID NO: 38 SEQ ID NO: 36 HH277 SEQ ID NO: 41 SEQ IDNO: 39 SEQ ID NO: 38 SEQ ID NO: 36 HH278 SEQ ID NO: 41 SEQ ID NO: 34 SEQID NO: 40 SEQ ID NO: 36 HH279 SEQ ID NO: 41 SEQ ID NO: 39 SEQ ID NO: 40SEQ ID NO: 36 HH280 SEQ ID NO: 41 SEQ ID NO: 34 SEQ ID NO: 42 SEQ ID NO:36 HH281 SEQ ID NO: 41 SEQ ID NO: 34 SEQ ID NO: 43 SEQ ID NO: 36

TABLE 5D Framework region sequences of VL domains LL65 to LL76 VL domainVL FR1 VL FR2 VL FR3 VL FR4 LL65 SEQ ID NO: 44 SEQ ID NO: 51 SEQ ID NO:46 SEQ ID NO: 47 LL66 SEQ ID NO: 44 SEQ ID NO: 45 SEQ ID NO: 49 SEQ IDNO: 47 LL67 SEQ ID NO: 44 SEQ ID NO: 51 SEQ ID NO: 49 SEQ ID NO: 47 LL68SEQ ID NO: 44 SEQ ID NO: 45 SEQ ID NO: 50 SEQ ID NO: 47 LL69 SEQ ID NO:44 SEQ ID NO: 51 SEQ ID NO: 50 SEQ ID NO: 47 LL70 SEQ ID NO: 44 SEQ IDNO: 45 SEQ ID NO: 52 SEQ ID NO: 47 LL71 SEQ ID NO: 44 SEQ ID NO: 51 SEQID NO: 52 SEQ ID NO: 47 LL72 SEQ ID NO: 48 SEQ ID NO: 45 SEQ ID NO: 46SEQ ID NO: 47 LL73 SEQ ID NO: 48 SEQ ID NO: 51 SEQ ID NO: 46 SEQ ID NO:47 LL74 SEQ ID NO: 48 SEQ ID NO: 51 SEQ ID NO: 49 SEQ ID NO: 47 LL75 SEQID NO: 48 SEQ ID NO: 51 SEQ ID NO: 50 SEQ ID NO: 47 LL76 SEQ ID NO: 48SEQ ID NO: 45 SEQ ID NO: 52 SEQ ID NO: 47

In a particular aspect, provided herein is an antibody (e.g., human orhumanized antibody) or an antigen-binding fragment thereof, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprising: (i) a VH domain comprising the amino acidsequence:QVQLVQSGAEX_(H1)KKPGASVKX_(H2)SCKASGYTFTDYYINWVX_(H3)QAPGKGLEWIARIYPGSGNTYYNEKFKGRX_(H4)TX_(H5)TAX_(H6)KSTSTAYMX_(H7)LSSLRSEDX_(H8)AVYFCARGVYYFDYWGQGTTVTVSS (SEQ ID NO: 11), wherein X_(H1) at Kabat position 11, X_(H2)at Kabat position 20, X_(H3) at Kabat position 38, X_(H4) at Kabatposition 67, X_(H5) at Kabat position 69, X_(H6) at Kabat position 72,X_(H7) at Kabat position 81, and X_(H8) at Kabat position 87 areindependently selected from any amino acid; and/or (ii) a VL domaincomprising the amino acid sequenceDIVMTQSPSX_(K1)LSASVGDRVTITCKASQNVRTNVAWYQQKPGKAPKX_(K2)LIYSASYRYSGVPDRFX_(K3)GSGSGTDFTLTISSLQX_(K4)EDFAX_(K5)YX_(K6)CQQYNSYPRTFGGGTKVEIK(SEQ ID NO: 12), wherein X_(K1) at Kabat position 10, X_(K2) at Kabatposition 46, X_(K3) at Kabat position 63, X_(K4) at Kabat position 80,X_(K5) at Kabat position 85, and X_(K6) at Kabat position 87 areindependently selected from any amino acid. In a particular embodiment,the VH and/or VL domain is non-immunogenic, for example as determined bythe absence of epitopes that binds to MHC class II, e.g., non-humangermline binders to MHC class II.

In a particular aspect, provided herein is an antibody, whichimmunospecifically binds to a KIT polypeptide (e.g., the D4 region ofhuman KIT), comprising: (i) a VH domain comprising the amino acidsequence:QVQLVQSGAEX_(H1)KKPGASVKX_(H2)SCKASGYTFTDYYINWVX_(H3)QAPGKGLEWIARIYPGSGNTYYNEKFKGRX_(H4)TX_(H5)TAX_(H6)KSTSTAYMX_(H7)LSSLRSEDX_(H8)AVYFCARGVYYFDYWGQGTTVTVSS (SEQ ID NO: 11), wherein X_(H1) at Kabat position 11, X_(H2)at Kabat position 20, X_(H3) at Kabat position 38, X_(H4) at Kabatposition 67, X_(H5) at Kabat position 69, X_(H6) at Kabat position 72,X_(H7) at Kabat position 81, and X_(H8) at Kabat position 87 areselected from the combination of amino acids set forth in Table 6B;and/or (ii) a VL domain comprising the amino acid sequence:DIVMTQSPSX_(K1)LSASVGDRVTITCKASQNVRTNVAWYQQKPGKAPKX_(K2)LIYSASYRYSGVPDRFX_(K3)GSGSGTDFTLTISSLQX_(K4)EDFAX_(K5)YX_(K6)CQQYNSYPRTFGGGTKVEIK(SEQ ID NO: 12), wherein X_(K1) at Kabat position 10, X_(K2) at Kabatposition 46, X_(K3) at Kabat position 63, X_(K4) at Kabat position 80,X_(K5) at Kabat position 85, and X_(K6) at Kabat position 87 areselected from the combination of amino acids set forth in Table 6A. In aparticular embodiment, the VH and/or VL domain is non-immunogenic, forexample as determined by the absence of epitopes that binds to MHC classII, e.g., non-human germline binders to MHC class II.

In one embodiment, X_(H1) at Kabat position 11 is an amino acid with analiphatic side chain (e.g., hydrophobic side chain, or nonpolar sidechain branched-chain amino acid (BCAA)), such as L or V. In oneembodiment, X_(H2) at Kabat position 20 is an amino acid with analiphatic side chain (e.g., hydrophobic side chain, or nonpolar sidechain branched-chain amino acid (BCAA)), such as L or V. In oneembodiment, X_(H3) at Kabat position 38 is an amino acid with a polarside chain (e.g., hydrophilic side chain, basic side chain, or chargedside chain, e.g., positively charged side chain or negatively chargedside chain), such as K or R. In one embodiment, X_(H4) at Kabat position67 is an amino acid with an aliphatic side chain (e.g., hydrophobic sidechain, or nonpolar side chain branched-chain amino acid (BCAA)), such asV or A. In one embodiment, X_(H5) at Kabat position 69 is an amino acidwith an aliphatic side chain (e.g., hydrophobic side chain, or nonpolarside chain branched-chain amino acid (BCAA)), such as L or I. In oneembodiment, X_(H6) at Kabat position 72 is an amino acid with an acidicside chain, such as E or D. In one embodiment, X_(H7) at Kabat position81 is an amino acid with an acidic side chain or its amide derivative,such as Q (uncharged/amide derivative of E) or E. In one embodiment,X_(H8) at Kabat position 87 is an amino acid with an aliphatic hydroxylgroup or a hydrophilic side chain, such as S or T.

In one embodiment, X_(H1) at Kabat position 11 is an aliphatic aminoacid, such as a branched-chain amino acid (BCAA), for example V; X_(H2)at Kabat position 20 is an aliphatic amino acid, such as abranched-chain amino acid (BCAA), for example L; X_(H3) at Kabatposition 38 is an amino acid with a polar side chain, such as R; X_(H4)at Kabat position 67 is an amino acid with an aliphatic side chain, suchas A; X_(H5) at Kabat position 69 is an amino acid with an aliphaticside chain, such as L; X_(H6) at Kabat position 72 is an amino acid witha polar side chain, such as D; X_(H7) at Kabat position 81 is an aminoacid with an an amide derivative of an acidic amino acid, such as Q; andX_(H8) at Kabat position 87 is an amino acid with an aliphatic hydroxylside chain, such as T.

In one embodiment, X_(H1) at Kabat position 11 is an aliphatic aminoacid, such as a branched-chain amino acid (BCAA), for example V; X_(H2)at Kabat position 20 is an aliphatic amino acid, such as abranched-chain amino acid (BCAA), for example V; X_(H3) at Kabatposition 38 is an amino acid with a polar side chain, such as R; X_(H4)at Kabat position 67 is an amino acid with an aliphatic side chain, suchas A; X_(H5) at Kabat position 69 is an amino acid with an aliphaticside chain, such as I; X_(H6) at Kabat position 72 is an amino acid witha polar side chain, such as D; X_(H7) at Kabat position 81 is an acidicamino acid, such as E; and X_(H8) at Kabat position 87 is an amino acidwith an aliphatic hydroxyl side chain, such as T.

In a specific embodiment, X_(K1) at Kabat position 10 is an aromaticamino acid such as F or an amino acid with an aliphatic hydroxyl sidechain such as S. In a certain embodiment, X_(K2) at Kabat position 46 isan amino acid with an aliphatic side chain (e.g., hydrophobic aminoacid) such as A or an amino acid with an aliphatic hydroxyl side chainsuch as S. In one embodiment, X_(K3) at Kabat position 63 is an aminoacid with an aliphatic hydroxyl side chain such as T or S. In a specificembodiment, X_(K4) at Kabat position 80 is an amino acid with analiphatic hydroxyl side chain such as S or an aromatic amino acid suchas P. In a certain embodiment, X_(K5) at Kabat position 85 is an acidicamino acid such as D or an amino acid with an aliphatic hydroxyl sidechain such as T. In one embodiment, X_(K6) at Kabat position 87 is anaromatic amino acid such as F or Y.

In a specific embodiment, X_(K1) at Kabat position 10 is an amino acidwith an aliphatic hydroxyl side chain such as S; X_(K2) at Kabatposition 46 is an amino acid with an aliphatic side chain (e.g.,hydrophobic amino acid) such as A; X_(K3) at Kabat position 63 is anamino acid with an aliphatic hydroxyl side chain such as T; X_(K4) atKabat position 80 is an aromatic amino acid such as P; X_(K5) at Kabatposition 85 is an acidic amino acid such as D; and X_(K6) at Kabatposition 87 is an aromatic amino acid such as F.

In a specific embodiment, X_(K1) at Kabat position 10 is an aromaticamino acid such as F; X_(K2) at Kabat position 46 is an amino acid withan aliphatic side chain (e.g., hydrophobic amino acid) such as A; X_(K3)at Kabat position 63 is an amino acid with an aliphatic hydroxyl sidechain such as T; X_(K4) at Kabat position 80 is an aliphatic hydroxylside chain such as S; X_(K5) at Kabat position 85 is an acidic aminoacid such as D; and X_(K6) at Kabat position 87 is an aromatic aminoacid such as F.

In a particular embodiment, an antibody described herein or aantigen-binding fragment thereof, which immunospecifically binds to aKIT polypeptide (e.g., the D4 region of human KIT), comprises: (i) a VHdomain comprising the amino acid sequence:QVQLVQSGAEX_(H1)KKPGASVKX_(H2)SCKASGYTFTDYYINWVX_(H3)QAPGKGLEWIARIYPGSGNTYYNEKFKGRX_(H4)TX_(H5)TAX_(H6)KSTSTAYMX_(H7)LSSLRSEDX_(H8)AVYFCARGVYYFDYWGQGTTVTVSS (SEQ ID NO: 11), wherein X_(H1) at Kabat position 11 is anamino acid with an aliphatic side chain such as V, X_(H2) at Kabatposition 20 is an amino acid with an aliphatic side chain such as L,X_(H3) at Kabat position 38 is an amino acid with a polar side chainsuch as K, X_(H4) at Kabat position 67 is an amino acid with analiphatic side chain such as A, X_(H5) at Kabat position 69 is an aminoacid with an aliphatic side chain such as L, X_(H6) at Kabat position 72is an acidic amino acid such as D, X_(H7) at Kabat position 81 is anacidic amino acid or an amide derivative thereof such as Q, and X_(H8)at Kabat position 87 is an amino acid with an aliphatic hydroxyl sidechain such as T; and (ii) a VL domain comprising the amino acid sequenceDIVMTQSPSX_(K1)LSASVGDRVTITCKASQNVRTNVAWYQQKPGKAPKX_(K2)LIYSASYRYSGVPDRFX_(K3)GSGSGTDFTLTISSLQX_(K4)EDFAX_(K5)YX_(K6)CQQYNSYPRTFGGGTKVEIK(SEQ ID NO: 12), wherein X_(K1) at Kabat position 10 is an amino acidwith an aliphatic hydroxyl side chain such as S, X_(K2) at Kabatposition 46 is an amino acid with an aliphatic side chain such as A,X_(K3) at Kabat position 63 is an amino acid with an aliphatic hydroxylside chain such as T, X_(K4) at Kabat position 80 is an aromatic aminoacid such as P, X_(K5) at Kabat position 85 is an acidic amino acid suchas D, and X_(K6) at Kabat position 87 is an aromatic amino acid such asF.

In a particular particular embodiment, an antibody described herein or aantigen-binding fragment thereof, which immunospecifically binds to aKIT polypeptide (e.g., the D4 region of human KIT), comprises: (i) a VHdomain comprising the amino acid sequence:QVQLVQSGAEX_(H1)KKPGASVKX_(H2)SCKASGYTFTDYYINWVX_(H3)QAPGKGLEWIARIYPGSGNTYYNEKFKGRX_(H4)TX_(H5)TAX_(H6)KSTSTAYMX_(H7)LSSLRSEDX_(H8)AVYFCARGVYYFDYWGQGTTVTVSS (SEQ ID NO: 11), wherein X_(H1) at Kabat position 11 is anamino acid with an aliphatic side chain such as V, X_(H2) at Kabatposition 20 is an amino acid with an aliphatic side chain such as V,X_(H3) at Kabat position 38 is an amino acid with a polar side chainsuch as R, X_(H4) at Kabat position 67 is an amino acid with analiphatic side chain such as A, X_(H5) at Kabat position 69 is an aminoacid with an aliphatic side chain such as I, X_(H6) at Kabat position 72is an acidic amino acid such as D, X_(H7) at Kabat position 81 is anacidic amino acid such as E, and X_(H8) at Kabat position 87 is an aminoacid with an aliphatic hydroxyl side chain such as T; and (ii) a VLdomain comprising the amino acid sequenceDIVMTQSPSX_(K1)LSASVGDRVTITCKASQNVRTNVAWYQQKPGKAPKX_(K2)LIYSASYRYSGVPDRFX_(K3)GSGSGTDFTLTISSLQX_(K4)EDFAX_(K5)YX_(K6)CQQYNSYPRTFGGGTKVEIK(SEQ ID NO: 12), wherein X_(K1) at Kabat position 10 is an aromaticamino acid such as F, X_(K2) at Kabat position 46 is an amino acid withan aliphatic side chain such as A, X_(K3) at Kabat position 63 is anamino acid with an aliphatic hydroxyl side chain such as T, X_(K4) atKabat position 80 is an amino acid with an aliphatic hydroxyl side chainsuch as S, X_(K5) at Kabat position 85 is an acidic amino acid such asD, and X_(K6) at Kabat position 87 is an aromatic amino acid such as F.

In a particular embodiment, an antibody described herein or anantigen-binding fragment thereof, which immunospecifically binds to aKIT polypeptide (e.g., the D4 region of human KIT), comprises (i) a VHdomain comprising VH CDR1, VH CDR2, and VH CDR3 comprising the aminoacid sequences of SEQ ID NOs: 16-18, respectively; and (ii) a VL domaincomprising SEQ ID NO: 7, 8, 9, or 10.

In a particular embodiment, an antibody described herein or anantigen-binding fragment thereof, which immunospecifically binds to aKIT polypeptide (e.g., the D4 region of human KIT), comprises (i) a VHdomain comprising VH CDR1, VH CDR2, and VH CDR3 comprising the aminoacid sequences of SEQ ID NOs: 16-18, respectively; and (ii) a VL domaincomprising the amino acid sequenceDIVMTQSPSX_(K1)LSASVGDRVTITCKASQNVRTNVAWYQQKPGKAPKX_(K2)LIYSASYRYSGVPDRFX_(K3)GSGSGTDFTLTISSLQX_(K4)EDFAX_(K5)YX_(K6)CQQYNSYPRTFGGGTKVEIK(SEQ ID NO: 12), wherein X_(K1) at Kabat position 10, X_(K2) at Kabatposition 46, X_(K3) at Kabat position 63, X_(K4) at Kabat position 80,X_(K5) at Kabat position 85, and X_(K6) at Kabat position 87 areselected from the combination of amino acids set forth in Table 6A.

In a particular embodiment, an antibody described herein or anantigen-binding fragment thereof, which immunospecifically binds to aKIT polypeptide (e.g., the D4 region of human KIT), comprises (i) a VHdomain comprising the amino acid sequence of SEQ ID NO: 2, 3, 4, or 5;and (ii) a VL domain comprising VL CDR1, VL CDR2, and VL CDR3 comprisingthe amino acid sequences of SEQ ID NOs: 19-21, respectively.

In a particular embodiment, an antibody described herein or anantigen-binding fragment thereof, which immunospecifically binds to aKIT polypeptide (e.g., the D4 region of human KIT), comprises (i) a VHdomain comprising the amino acid sequence:QVQLVQSGAEX_(H1)KKPGASVKX_(H2)SCKASGYTFTDYYINWVX_(H3)QAPGKGLEWIARIYPGSGNTYYNEKFKGRX_(H4)TX_(H5)TAX_(H6)KSTSTAYMX_(H7)LSSLRSEDX_(H8)AVYFCARGVYYFDYWGQGTTVTVSS (SEQ ID NO: 11), wherein X_(H1) at Kabat position 11, X_(H2)at Kabat position 20, X_(H3) at Kabat position 38, X_(H4) at Kabatposition 67, X_(H5) at Kabat position 69, X_(H6) at Kabat position 72,X_(H7) at Kabat position 81, and X_(H8) at Kabat position 87 areselected from the combination of amino acids set forth in Table 6B; and(ii) a VL domain comprising VL CDR1, VL CDR2, and VL CDR3 comprising theamino acid sequences of SEQ ID NOs: 19-21, respectively.

TABLE 6A VK domain Amino Acid Substitutions X_(K1) X_(K2) X_(K3) X_(K4)X_(K5) X_(K6) Kabat position 10 46 63 80 85 87 Numerical position of SEQID NO: 12 10 46 Aromatic Aliphatic 80 or or 63 Proline or 85 Amino acidside aliphatic aliphatic aliphatic aliphatic Charged 87 chain hydroxylhydroxyl hydroxyl hydroxyl or acidic aromatic L1 F A T S D F L2 S A T PD F L3 S A T P D F L4 S S S P T Y LL1 S A T S D F LL2 F S T S D F LL3 SS T S D F LL4 F A S S D F LL5 S A S S D F LL6 F S S S D F LL7 S S S S DF LL8 F A T P D F LL9 S A T P D F LL10 F S T P D F LL11 S S T P D F LL12F A S P D F LL13 S A S P D F LL14 F S S P D F LL15 S S S P D F LL16 F AT S T F LL17 S A T S T F LL18 F S T S T F LL19 S S T S T F LL20 F A S ST F LL21 S A S S T F LL22 F S S S T F LL23 S S S S T F LL24 F A T P T FLL25 S A T P T F LL26 F S T P T F LL27 S S T P T F LL28 F A S P T F LL29S A S P T F LL30 F S S P T F LL31 S S S P T F LL32 S A T S D Y LL33 F ST S D Y LL34 S S T S D Y LL35 F A S S D Y LL36 S A S S D Y LL37 F S S SD Y LL38 S S S S D Y LL39 F A T P D Y LL40 S A T P D Y LL41 F S T P D YLL42 S S T P D Y LL43 F A S P D Y LL44 S A S P D Y LL45 F S S P D Y LL46S S S P D Y LL47 F A T S T Y LL48 S A T S T Y LL49 F S T S T Y LL50 S ST S T Y LL51 F A S S T Y LL52 S A S S T Y LL53 F S S S T Y LL54 S S S ST Y LL55 F A T P T Y LL56 S A T P T Y LL57 F S T P T Y LL58 S S T P T YLL59 F A S P T Y LL60 S A S P T Y LL61 F S S P T Y LL62 S S S P T Y

TABLE 6B VH domain Amino Acid Substitutions X_(H1) X_(H2) X_(H3) X_(H4)X_(H5) X_(H6) X_(H7) X_(H8) Kabat position 11 20 38 67 69 72 81 87Numerical position of SEQ ID NO: 11 82 38 Acidic or 91 Amino acid 11 20Polar or 68 70 73 amide aliphatic side chain Aliphatic Aliphatic basicAliphatic Aliphatic Acidic derivative hydroxyl H1 L L K A L E Q S H2 V LK A L E Q T H3 V L R A L D Q T H4 V V R A I D E T H5 V V R V I D E T HH1L L K A L E Q S HH2 V L K A L E Q S HH3 L V K A L E Q S HH4 V V K A L EQ S HH5 L L R A L E Q S HH6 V L R A L E Q S HH7 L V R A L E Q S HH8 V VR A L E Q S HH9 L L K V L E Q S HH10 V L K V L E Q S HH11 L V K V L E QS HH12 V V K V L E Q S HH13 L L R V L E Q S HH14 V L R V L E Q S HH15 LV R V L E Q S HH16 V V R V L E Q S HH17 L L K A I E Q S HH18 V L K A I EQ S HH19 L V K A I E Q S HH20 V V K A I E Q S HH21 L L R A I E Q S HH22V L R A I E Q S HH23 L V R A I E Q S HH24 V V R A I E Q S HH25 L L K V IE Q S HH26 V L K V I E Q S HH27 L V K V I E Q S HH28 V V K V I E Q SHH29 L L R V I E Q S HH30 V L R V I E Q S HH31 L V R V I E Q S HH32 V VR V I E Q S HH33 L L K A L D Q S HH34 V L K A L D Q S HH35 L V K A L D QS HH36 V V K A L D Q S HH37 L L R A L D Q S HH38 V L R A L D Q S HH39 LV R A L D Q S HH40 V V R A L D Q S HH41 L L K V L D Q S HH42 V L K V L DQ S HH43 L V K V L D Q S HH44 V V K V L D Q S HH45 L L R V L D Q S HH46V L R V L D Q S HH47 L V R V L D Q S HH48 V V R V L D Q S HH49 L L K A ID Q S HH50 V L K A I D Q S HH51 L V K A I D Q S HH52 V V K A I D Q SHH53 L L R A I D Q S HH54 V L R A I D Q S HH55 L V R A I D Q S HH56 V VR A I D Q S HH57 L L K V I D Q S HH58 V L K V I D Q S HH59 L V K V I D QS HH60 V V K V I D Q S HH61 L L R V I D Q S HH62 V L R V I D Q S HH63 LV R V I D Q S HH64 V V R V I D Q S HH65 L L K A L E E S HH66 V L K A L EE S HH67 L V K A L E E S HH68 V V K A L E E S HH69 L L R A L E E S HH70V L R A L E E S HH71 L V R A L E E S HH72 V V R A L E E S HH73 L L K V LE E S HH74 V L K V L E E S HH75 L V K V L E E S HH76 V V K V L E E SHH77 L L R V L E E S HH78 V L R V L E E S HH79 L V R V L E E S HH80 V VR V L E E S HH81 L L K A I E E S HH82 V L K A I E E S HH83 L V K A I E ES HH84 V V K A I E E S HH85 L L R A I E E S HH86 V L R A I E E S HH87 LV R A I E E S HH88 V V R A I E E S HH89 L L K V I E E S HH90 V L K V I EE S HH91 L V K V I E E S HH92 V V K V I E E S HH93 L L R V I E E S HH94V L R V I E E S HH95 L V R V I E E S HH96 V V R V I E E S HH97 L L K A LD E S HH98 V L K A L D E S HH99 L V K A L D E S HH100 V V K A L D E SHH101 L L R A L D E S HH102 V L R A L D E S HH103 L V R A L D E S HH104V V R A L D E S HH105 L L K V L D E S HH106 V L K V L D E S HH107 L V KV L D E S HH108 V V K V L D E S HH109 L L R V L D E S HH110 V L R V L DE S HH111 L V R V L D E S HH112 V V R V L D E S HH113 L L K A I D E SHH114 V L K A I D E S HH115 L V K A I D E S HH116 V V K A I D E S HH117L L R A I D E S HH118 V L R A I D E S HH119 L V R A I D E S HH120 V V RA I D E S HH121 L L K V I D E S HH122 V L K V I D E S HH123 L V K V I DE S HH124 V V K V I D E S HH125 L L R V I D E S HH126 V L R V I D E SHH127 L V R V I D E S HH128 V V R V I D E S HH129 L L K A L E Q T HH130V L K A L E Q T HH131 L V K A L E Q T HH132 V V K A L E Q T HH133 L L RA L E Q T HH134 V L R A L E Q T HH135 L V R A L E Q T HH136 V V R A L EQ T HH137 L L K V L E Q T HH138 V L K V L E Q T HH139 L V K V L E Q THH140 V V K V L E Q T HH141 L L R V L E Q T HH142 V L R V L E Q T HH143L V R V L E Q T HH144 V V R V L E Q T HH145 L L K A I E Q T HH146 V L KA I E Q T HH147 L V K A I E Q T HH148 V V K A I E Q T HH149 L L R A I EQ T HH150 V L R A I E Q T HH151 L V R A I E Q T HH152 V V R A I E Q THH153 L L K V I E Q T HH154 V L K V I E Q T HH155 L V K V I E Q T HH156V V K V I E Q T HH157 L L R V I E Q T HH158 V L R V I E Q T HH159 L V RV I E Q T HH160 V V R V I E Q T HH161 L L K A L D Q T HH162 V L K A L DQ T HH163 L V K A L D Q T HH164 V V K A L D Q T HH165 L L R A L D Q THH166 V L R A L D Q T HH167 L V R A L D Q T HH168 V V R A L D Q T HH169L L K V L D Q T HH170 V L K V L D Q T HH171 L V K V L D Q T HH172 V V KV L D Q T HH173 L L R V L D Q T HH174 V L R V L D Q T HH175 L V R V L DQ T HH176 V V R V L D Q T HH177 L L K A I D Q T HH178 V L K A I D Q THH179 L V K A I D Q T HH180 V V K A I D Q T HH181 L L R A I D Q T HH182V L R A I D Q T HH183 L V R A I D Q T HH184 V V R A I D Q T HH185 L L KV I D Q T HH186 V L K V I D Q T HH187 L V K V I D Q T HH188 V V K V I DQ T HH189 L L R V I D Q T HH190 V L R V I D Q T HH191 L V R V I D Q THH192 V V R V I D Q T HH193 L L K A L E E T HH194 V L K A L E E T HH195L V K A L E E T HH196 V V K A L E E T HH197 L L R A L E E T HH198 V L RA L E E T HH199 L V R A L E E T HH200 V V R A L E E T HH201 L L K V L EE T HH202 V L K V L E E T HH203 L V K V L E E T HH204 V V K V L E E THH205 L L R V L E E T HH206 V L R V L E E T HH207 L V R V L E E T HH208V V R V L E E T HH209 L L K A I E E T HH210 V L K A I E E T HH211 L V KA I E E T HH212 V V K A I E E T HH213 L L R A I E E T HH214 V L R A I EE T HH215 L V R A I E E T HH216 V V R A I E E T HH217 L L K V I E E THH218 V L K V I E E T HH219 L V K V I E E T HH220 V V K V I E E T HH221L L R V I E E T HH222 V L R V I E E T HH223 L V R V I E E T HH224 V V RV I E E T HH225 L L K A L D E T HH226 V L K A L D E T HH227 L V K A L DE T HH228 V V K A L D E T HH229 L L R A L D E T HH230 V L R A L D E THH231 L V R A L D E T HH232 V V R A L D E T HH233 L L K V L D E T HH234V L K V L D E T HH235 L V K V L D E T HH236 V V K V L D E T HH237 L L RV L D E T HH238 V L R V L D E T HH239 L V R V L D E T HH240 V V R V L DE T HH241 L L K A I D E T HH242 V L K A I D E T HH243 L V K A I D E THH244 V V K A I D E T HH245 L L R A I D E T HH246 V L R A I D E T HH247L V R A I D E T HH248 V V R A I D E T HH249 L L K V I D E T HH250 V L KV I D E T HH251 L V K V I D E T HH252 V V K V I D E T HH253 L L R V I DE T HH254 V L R V I D E T HH255 L V R V I D E T HH256 V V R V I D E T

In a specific embodiment, the position (i.e., boundary) of a VL chainregion described herein relative to the constant region may change byone, two, three, or four amino acid positions so long as immunospecificbinding to KIT (e.g., the D4 region of human KIT) is maintained (e.g.,substantially maintained, for example, at least 50%, at least 60%, atleast 70%, at least 80%, at least 90%, at least 95%). In a specificembodiment, the position (i.e., boundary) of a VH chain region describedherein relative to the constant region may change by one, two, three, orfour amino acid positions so long as immunospecific binding to KIT(e.g., the D4 region of human KIT) is maintained (e.g., substantiallymaintained, for example, at least 50%, at least 60%, at least 70%, atleast 80%, at least 90%, at least 95%).

In specific aspects, provided herein is a moiety comprising VH CDRsand/or VL CDRs described herein, for example as set forth in Tables 1-3and 10-15, wherein the VH CDRs and VL CDRs are arranged in a spatialorientation that confers specific binding to a D4 region of human KIT.

In specific aspects, provided herein is a moiety comprising VH CDRscomprising the amino acid sequences of SEQ ID NOs: 16-18 and VL CDRscomprising the amino acid sequences of SEQ ID NOs: 19-21, VH CDRscomprising the amino acid sequences of SEQ ID NOs: 56, 62 and 63 and VLCDRs comprising the amino acid sequences of SEQ ID NOs: 59-61, VH CDRscomprising the amino acid sequences of SEQ ID NOs: 70-72 and VL CDRscomprising the amino acid sequences of SEQ ID NOs: 66-68, wherein the VHCDRs and VL CDRs are arranged in a spatial orientation that confersspecific binding to a D4 region of human KIT. In certain embodiments,the moiety is an antibody or an antigen-binding fragment thereof. In aparticular embodiment, the moiety is a protein, such as a fusion proteincomprising an Fc region.

In specific aspects, provided herein is a moiety comprising VH CDRsselected from Tables 13-15 and/or VL CDRs selected from Tables 10-12,wherein the VH CDRs and VL CDRs are arranged in a spatial orientationthat confers specific binding to a D4 region of human KIT. In certainembodiments, the moiety is an antibody or an antigen-binding fragmentthereof. In a particular embodiment, the moiety is a protein, such as afusion protein comprising an Fc region.

In specific aspects, provided herein is a moiety, such as an antibody oran antigen-binding fragment thereof, comprising VH CDRs 1-3 and VL CDRs1-3 selected from the ones presented in Tables 10-15, wherein the VHCDRs and VL CDRs are arranged in a spatial orientation that confersspecific binding to a D4 region of human KIT. In particular aspects, amoiety described herein comprises linkers, such as peptide linkers, thatlink the VH CDRs 1-3 and/or VL CDRs 1-3 in the spatial orientation thatconfers specific binding to a D4 region of human KIT.

In particular aspects, a moiety described herein comprises linkers, suchas peptide linkers, that links the VH CDRs and/or VL CDRs in a spatialorientation that confers specific binding to a D4 region of human KIT.

In certain aspects, provided herein is an antibody or an antigen-bindingfragment thereof comprising VL CDRs 1-3 and VH CDRs 1-3 selected fromthe ones presented in Tables 10-15, wherein the antibody orantigen-binding fragment thereof immunospecifically binds a D4 region ofKIT, such as human KIT.

In a specific embodiment, the “X” amino acid of a CDR in any one ofTables 10-15 is any naturally occurring amino acid that maintainsspecific binding affinity to a D4 region of human KIT. In a specificembodiment, the “X” amino acid of a CDR in any one of Tables 10-15 is anon-natural amino acid that maintains specific binding affinity to a D4region of human KIT. In a specific embodiment, the “X” amino acid of aCDR in any one of Tables 10-15 is a conservative substitution of thecorresponding amino acid of the CDRs having the amino acid sequences ofSEQ ID NOs: 16-21, wherein specific binding affinity to a D4 region ofhuman KIT is maintained.

In a specific embodiment, the “X” amino acid of a CDR in any one ofTables 10-15 is, independently, amino acid A, G, T, K, or L. In aparticular embodiment, the “X” amino acid of a CDR in any one of Tables10-15 is amino acid A, G, T, Y, C, or S. In certain aspects of theseembodiments, specific binding affinity to a D4 region of human KIT ismaintained.

In a certain embodiment, an antibody described herein or anantigen-binding fragment thereof comprises VH CDRs and/or VL CDRsselected from those presented in Tables 10-15.

In a particular embodiment, a CDR, such as any one of VL CDRs 1-3 and VHCDRs 1-3 depicted in Tables 10-15, comprises one or more (e.g., two,three, four, or five) “X” amino acids, wherein each “X” amino acid canbe any amino acid which can maintain specific binding of the antibody orfragment thereof to a D4 region of human KIT.

TABLE 10 VL CDR1 VL CDR1 SEQ ID NO:     K A S Q N V R T N V A 19      X A S Q N V R T N V A 74     K X  S Q N V R T N V A 75     K A X  Q N V RT N V A 76     K A S X  N V R T N V A 77     K A S Q X  V R T N V A 78    K A S Q (A/G/T/Y/C/S) V R T N V A 79     K A S Q N X  R T N V A 80    K A S Q N V X  T N V A 81     K A S Q N V R X  N V A 82     K A S QN V R T X  V A 83     K A S Q N V R T (A/G/T/Y/C/S) V A 84     K A S Q NV R T N X  A 85     K A S Q N V R T N V X 86   C K A S Q N V R T N V 87I C K A S Q N V R T N 88       A S Q N V R T N V A W 89         S Q N VR T N V A W Y 90           Q N V R T N V A W Y Q 91

TABLE 11 VL CDR2 VL CDR2 SEQ ID NO:       S A S Y R Y S 20        X  A SY R Y S 92       S X  S Y R Y S 93       S A X  Y R Y S 94       S A S X R Y S 95       S A S Y X  Y S 96       S A S Y R X  S 97       S A S YR Y X 98     Y S A S Y R Y 99   I Y S A S Y R 100 L I Y S A S Y 101        A S Y R Y S G 102           S Y R Y S G V 103             Y R YS G V P 104

TABLE 12 VL CDR3 VL CDR3 SEQ ID NO:       Q Q Y N S Y P R T 21       Q X Y N S Y P R T 105       Q Q X  N S Y P R T 106       Q Q Y X  S Y P R T107       Q Q Y N X  Y P R T 108       Q Q Y N S X  P R T 109       Q QY N S Y X  R T 110       Q Q Y N S Y P X  T 111       Q Q Y N S Y P R X112       Q Q Y N S Y P R 113     C Q Q Y N S Y P 114   F C Q Q Y N S Y115 Y F C Q Q Y N S 116         Q Y N S Y P R F 117           Y N S Y PR F G 118               S Y P R F G G 119

TABLE 13 VH CDR1 VH CDR1 SEQ ID NO:            D Y Y I N 16            X  Y Y I N 120            D X  Y I N 121       D Y X  I N 122       D YY X  N 123       D Y Y I X 124     T D Y Y I 125   F T D Y Y 126 T F T DY 127         Y Y I N W 128         Y Y I N W V 129             I N W VR 130

TABLE 14 VH CDR2 SEQ ID VH CDR2 NO:       R I Y P G S G N T Y Y N E K FK G 17        X  I Y P G S G N T Y Y N E K F K G 131       R X  Y P G SG N T Y Y N E K F K G 132       R I X  P G S G N T Y Y N E K F K G 133      R I Y X  G S G N T Y Y N E K F K G 134       R I Y P X  S G N T YY N E K F K G 135       R I Y P G X  G N T Y Y N E K F K G 136       R IY P G S X  N T Y Y N E K F K G 137       R I Y P G S G X  T Y Y N E K FK G 138       R I Y P G S G N X  Y Y N E K F K G 139       R I Y P G S GN T X  Y N E K F K G 140       R I Y P G S G N T Y X  N E K F K G 141      R I Y P G S G N T Y Y X  E K F K G 142       R I Y P G S G N T Y YN X  K F K G 143       R I Y P G S G N T Y Y N E X  F K G 144       R IY P G S G N T Y Y N E K X  K G 145       R I Y P G S G N T Y Y N E K F X G 146       R I Y P G S G N T Y Y N E K F K X 147     A R I Y P G S G NT Y Y N E K F 148   I A R I Y P G S G N T Y Y N E K 149 W I A R I Y P GS G N T Y Y N E 150         I Y P G S G N T Y Y N E K F K G R 151          Y P G S G N T Y Y N E K F K G R A 152             P G S G N TY Y N E K F K G R A T 153

TABLE 15 VH CDR3 VH CDR3 SEQ ID NO:             G V Y Y F D Y 18             X  V Y Y F D Y 154             G X  Y Y F D Y 155            G V X  Y F D Y 156             G V Y X  F D Y 157       G VY Y X  D Y 158       G V Y Y F X  Y 159       G V Y Y F D X 160     R GV Y Y F D 161   A R G V Y Y F 162 C A R G V Y Y 163       G V Y Y F D YW 164         V Y Y F D Y W G 165           Y Y F D Y W G Q 166

In certain aspects, provided herein is an antibody or an antigen-bindingfragment thereof comprising VL FRs 1-4 selected from the ones presentedin Tables 20-23 and/or VH FRs 1-4 selected from the ones presented inTables 16-19, wherein the antibody or antigen-binding fragment thereofimmunospecifically binds a D4 region of KIT, such as human KIT.

In a specific embodiment, the “X” amino acid of an FR in any one ofTables 16-23 is any naturally occurring amino acid that maintainsspecific binding affinity to a D4 region of human KIT. In a specificembodiment, the “X” amino acid of a CDR in any one of Tables 16-23 is anon-natural amino acid that maintains specific binding affinity to a D4region of human KIT. In a specific embodiment, the “X” amino acid of aCDR in any one of Tables 16-23 is a conservative substitution of thecorresponding amino acid of the CDRs having the amino acid sequences ofSEQ ID NOs: 16-21, wherein specific binding affinity to a D4 region ofhuman KIT is maintained.

In a specific embodiment, the “X” amino acid of a CDR in any one ofTables 16-23 is amino acid A, G, T, K, or L. In a particular embodiment,the “X” amino acid of a CDR in any one of Tables 16-23 is amino acid A,G, T, Y, C, or S. In certain aspects of these embodiments, specificbinding affinity to a D4 region of human KIT is maintained. In a certainembodiment, an antibody described herein or an antigen-binding fragmentthereof comprises VH CDRs and/or VL CDRs selected from those presentedin Tables 16-23.

In a particular embodiment, an FR, such as any one of VL FRs 1-4 and VHFRs 1-4 depicted in Tables 16-23, comprises one or more (e.g., two,three, four, or five) “X” amino acids, wherein each “X” amino acid canbe any amino acid which can maintain specific binding of the antibody orfragment thereof to a D4 region of human KIT.

TABLE 16 VH FR1 SEQ ID VH FR1 NO: H1 QVQLVQSGAELKKPGASVKLSCKASGYTFT 33H2/H3 QVQLVQSGAEVKKPGASVKLSCKASGYTFT 37 H4/H5QVQLVQSGAEVKKPGASVKVSCKASGYTFT 41 XVQLVQSGAE(L/V)KKPGASVK(L/V)SCKASGYTFT 167 Q XQLVQSGAE(L/V)KKPGASVK(L/V)SCKASGYTFT 168 QV XLVQSGAE(LN)KKPGASVK(L/V)SCKASGYTFT 169 QVQ XVQSGAE(L/V)KKPGASVK(LN)SCKASGYTFT 170 QVQL XQSGAE(L/V)KKPGASVK(L/V)SCKASGYTFT 171 QVQLV XSGAE(L/V)KKPGASVK(L/V)SCKASGYTFT 172 QVQLVQ XGAE(L/V)KKPGASVK(L/V)SCKASGYTFT 173 QVQLVQS XAE(L/V)KKPGASVK(L/V)SCKASGYTFT 174 QVQLVQSG XE(L/V)KKPGASVK(L/V)SCKASGYTFT 175 QVQLVQSGA X(L/V)KKPGASVK(L/V)SCKASGYTFT 176 QVQLVQSGAE X KKPGASVK(L/V)SCKASGYTFT177 QVQLVQSGAE(L/V) X KPGASVK(L/V)SCKASGYTFT 178 QVQLVQSGAE(L/V)K XPGASVK(L/V)SCKASGYTFT 179 QVQLVQSGAE(L/V)KK X GASVK(L/V)SCKASGYTFT 180QVQLVQSGAE(L/V)KKP X ASVK(L/V)SCKASGYTFT 181 QVQLVQSGAE(L/V)KKPG XSVK(L/V)SCKASGYTFT 182 QVQLVQSGAE(L/V)KKPGA X VK(L/V)SCKASGYTFT 183QVQLVQSGAE(L/V)KKPGAS X K(L/V)SCKASGYTFT 184 QVQLVQSGAE(L/V)KKPGASV X(L/V)SCKASGYTFT 185 QVQLVQSGAE(L/V)KKPGASVK X SCKASGYTFT 186QVQLVQSGAE(L/V)KKPGASVK(L/V) X CKASGYTFT 187QVQLVQSGAE(L/V)KKPGASVK(L/V)S X KASGYTFT 188QVQLVQSGAE(L/V)KKPGASVK(L/V)SC X ASGYTFT 189QVQLVQSGAE(L/V)KKPGASVK(L/V)SCK X SGYTFT 190QVQLVQSGAE(L/V)KKPGASVK(L/V)SCKA X GYTFT 191QVQLVQSGAE(L/V)KKPGASVK(L/V)SCKAS X YTFT 192QVQLVQSGAE(L/V)KKPGASVK(L/V)SCKASG X TFT 193QVQLVQSGAE(L/V)KKPGASVK(L/V)SCKASGY X FT 194QVQLVQSGAE(L/V)KKPGASVK(L/V)SCKASGYT X T 195QVQLVQSGAE(L/V)KKPGASVK(L/V)SCKASGYTF X 196

TABLE 17 VH FR2 VH FR2 SEQ ID NO: H1/H2 WVKQAPGKGLEWIA 34 H3/H4/H5WVRQAPGKGLEWIA 39 X V(R/K)QAPGKGLEWIA 197 W X (R/K)QAPGKGLEWIA 198 WV XQAPGKGLEWIA 199 WV(R/K) X APGKGLEWIA 200 WV(R/K)Q X PGKGLEWIA 201WV(R/K)QA X GKGLEWIA 202 WV(R/K)QAP X KGLEWIA 203 WV(R/K)QAPG X GLEWIA204 WV(R/K)QAPGK X LEWIA 205 WV(R/K)QAPGKG X EWIA 206 WV(R/K)QAPGKGL XWIA 207 WV(R/K)QAPGKGLE X IA 208 WV(R/K)QAPGKGLEW X A 209WV(R/K)QAPGKGLEWI X 210

TABLE 18 VH FR3 SEQ ID VH FR3 NO: H1 RATLTAEKSTSTAYMQLSSLRSEDSAVYFCAR 35H2 RATLTAEKSTSTAYMQLSSLRSEDTAVYFCAR 38 H3RATLTADKSTSTAYMQLSSLRSEDTAVYFCAR 40 H4 RATITADKSTSTAYMELSSLRSEDTAVYFCAR42 H5 RVTITADKSTSTAYMELSSLRSEDTAVYFCAR 43 X(A/V)T(I/L)TADKSTSTAYM(E/Q)LSSLRSED(S/T)AVYFCAR 211 R XT(I/L)TADKSTSTAYM(E/Q)LSSLRSED(S/T)AVYFCAR 212 R(A/V) X(I/L)TADKSTSTAYM(E/Q)LSSLRSED(S/T)AVYFCAR 213 R(A/V)T XTADKSTSTAYM(E/Q)LSSLRSED(S/T)AVYFCAR 214 R(A/V)T(I/L) XADKSTSTAYM(E/Q)LSSLRSED(S/T)AVYFCAR 215 R(A/V)T(I/L)T XDKSTSTAYM(E/Q)LSSLRSED(S/T)AVYFCAR 216 R(A/V)T(I/L)TA XKSTSTAYM(E/Q)LSSLRSED(S/T)AVYFCAR 217 R(A/V)T(I/L)TAD XSTSTAYM(E/Q)LSSLRSED(S/T)AVYFCAR 218 R(A/V)T(I/L)TADK XTSTAYM(E/Q)LSSLRSED(S/T)AVYFCAR 219 R(A/V)T(I/L)TADKS XSTAYM(E/Q)LSSLRSED(S/T)AVYFCAR 220 R(A/V)T(I/L)TADKST XTAYM(E/Q)LSSLRSED(S/T)AVYFCAR 221 R(A/V)T(I/L)TADKSTS XAYM(E/Q)LSSLRSED(S/T)AVYFCAR 222 R(A/V)T(I/L)TADKSTST XYM(E/Q)LSSLRSED(S/T)AVYFCAR 223 R(A/V)T(I/L)TADKSTSTA XM(E/Q)LSSLRSED(S/T)AVYFCAR 224 R(A/V)T(I/L)TADKSTSTAY X(E/Q)LSSLRSED(S/T)AVYFCAR 225 R(A/V)T(I/L)TADKSTSTAYM XLSSLRSED(S/T)AVYFCAR 226 R(A/V)T(I/L)TADKSTSTAYM(E/Q) XSSLRSED(S/T)AVYFCAR 227 R(A/V)T(I/L)TADKSTSTAYM(E/Q)L XSLRSED(S/T)AVYFCAR 228 R(A/V)T(I/L)TADKSTSTAYM(E/Q)LS XLRSED(S/T)AVYFCAR 229 R(A/V)T(I/L)TADKSTSTAYM(E/Q)LSS X RSED(S/T)AVYFCAR230 R(A/V)T(I/L)TADKSTSTAYM(E/Q)LSSL X SED(S/T)AVYFCAR 231R(A/V)T(I/L)TADKSTSTAYM(E/Q)LSSLR X ED(S/T)AVYFCAR 232R(A/V)T(I/L)TADKSTSTAYM(E/Q)LSSLRS X D(S/T)AVYFCAR 233R(A/V)T(I/L)TADKSTSTAYM(E/Q)LSSLRSE X (S/T)AVYFCAR 234R(A/V)T(I/L)TADKSTSTAYM(E/Q)LSSLRSED X AVYFCAR 235R(A/V)T(I/L)TADKSTSTAYM(E/Q)LSSLRSED(S/T) X VYFCAR 236R(A/V)T(I/L)TADKSTSTAYM(E/Q)LSSLRSED(S/T)A X YFCAR 237R(A/V)T(I/L)TADKSTSTAYM(E/Q)LSSLRSED(S/T)AV X FCAR 238R(A/V)T(I/L)TADKSTSTAYM(E/Q)LSSLRSED(S/T)AVY X CAR 239R(A/V)T(I/L)TADKSTSTAYM(E/Q)LSSLRSED(S/T)AVYF X AR 240R(A/V)T(I/L)TADKSTSTAYM(E/Q)LSSLRSED(S/T)AVYFC X R 241R(A/V)T(I/L)TADKSTSTAYM(E/Q)LSSLRSED(S/T)AVYFCA X 242

TABLE 19 VH FR4 VH FR4 SEQ ID NO: H1-H5 WGQGTTVTVSS 36 X GQGTTVTVSS 243W X QGTTVTVSS 244 WG X GTTVTVSS 245 WGQ X TTVTVSS 246 WGQG X TVTVSS 247WGQGT X VTVSS 248 WGQGTT X TVSS 249 WGQGTTV X VSS 250 WGQGTTVT X SS 251WGQGTTVTV X S 252 WGQGTTVTVS X 253

TABLE 20 VL FR1 VL FR1 SEQ ID NO: L1 DIVMTQSPSFLSASVGDRVTITC 44 L2/L3/L4DIVMTQSPSSLSASVGDRVTITC 48 X IVMTQSPS(F/S)LSASVGDRVTITC 254 D XVMTQSPS(F/S)LSASVGDRVTITC 255 DI X MTQSPS(F/S)LSASVGDRVTITC 256 DIV XTQSPS(F/S)LSASVGDRVTITC 257 DIVM X QSPS(F/S)LSASVGDRVTITC 258 DIVMT XSPS(F/S)LSASVGDRVTITC 259 DIVMTQ X PS(F/S)LSASVGDRVTITC 260 DIVMTQS XS(F/S)LSASVGDRVTITC 261 DIVMTQSP X (F/S)LSASVGDRVTITC 262 DIVMTQSPS XLSASVGDRVTITC 263 DIVMTQSPS(F/S) X SASVGDRVTITC 264 DIVMTQSPS(F/S)L XASVGDRVTITC 265 DIVMTQSPS(F/S)LS X SVGDRVTITC 266 DIVMTQSPS(F/S)LSA XVGDRVTITC 267 DIVMTQSPS(F/S)LSAS X GDRVTITC 268 DIVMTQSPS(F/S)LSASV XDRVTITC 269 DIVMTQSPS(F/S)LSASVG X RVTITC 270 DIVMTQSPS(F/S)LSASVGD XVTITC 271 DIVMTQSPS(F/S)LSASVGDR X TITC 272 DIVMTQSPS(F/S)LSASVGDRV XITC 273 DIVMTQSPS(F/S)LSASVGDRVT X TC 274 DIVMTQSPS(F/S)LSASVGDRVTI X C275 DIVMTQSPS(F/S)LSASVGDRVTIT X 276

TABLE 21 VL FR2 VL FR2 SEQ ID NO: L1/L2/L3 WYQQKPGKAPKALIY 45 L4WYQQKPGKAPKSLIY 51 X YQQKPGKAPK(S/A)LIY 277 W X QQKPGKAPK(S/A)LIY 278 WYX QKPGKAPK(S/A)LIY 279 WYQ X KPGKAPK(S/A)LIY 280 WYQQ X PGKAPK(S/A)LIY281 WYQQK X GKAPK(S/A)LIY 282 WYQQKP X KAPK(S/A)LIY 283 WYQQKPG XAPK(S/A)LIY 284 WYQQKPGK X PK(S/A)LIY 285 WYQQKPGKA X K(S/A)LIY 286WYQQKPGKAP X (S/A)LIY 287 WYQQKPGKAPK X LIY 288 WYQQKPGKAPK(S/A) X IY289 WYQQKPGKAPK(S/A)L X Y 290 WYQQKPGKAPK(S/A)LI X 291

TABLE 22 VL FR3 SEQ ID VL FR3 NO: L1 GVPDRFTGSGSGTDFTLTISSLQSEDFADYFC 46L2 GVPDRFTGSGSGTDFTLTISSLQPEDFADYFC 49 L3GVPDRFSGSGSGTDFTLTISSLQPEDFADYFC 50 L4 GVPDRFSGSGSGTDFTLTISSLQPEDFATYYC52 X VPDRF(S/T)GSGSGTDFTLTISSLQ(P/S)EDFA(D/T)Y(F/Y)C 292 G XPDRF(S/T)GSGSGTDFTLTISSLQ(P/S)EDFA(D/T)Y(F/Y)C 293 GV XDRF(S/T)GSGSGTDFTLTISSLQ(P/S)EDFA(D/T)Y(F/Y)C 294 GVP XRF(S/T)GSGSGTDFTLTISSLQ(P/S)EDFA(D/T)Y(F/Y)C 295 GVPD XF(S/T)GSGSGTDFTLTISSLQ(P/S)EDFA(D/T)Y(F/Y)C 296 GVPDR X(S/T)GSGSGTDFTLTISSLQ(P/S)EDFA(D/T)Y(F/Y)C 297 GVPDRF XGSGSGTDFTLTISSLQ(P/S)EDFA(D/T)Y(F/Y)C 298 GVPDRF(S/T) XSGSGTDFTLTISSLQ(P/S)EDFA(D/T)Y(F/Y)C 299 GVPDRF(S/T)G XGSGTDFTLTISSLQ(P/S)EDFA(D/T)Y(F/Y)C 300 GVPDRF(S/T)GS XSGTDFTLTISSLQ(P/S)EDFA(D/T)Y(F/Y)C 301 GVPDRF(S/T)GSG XGTDFTLTISSLQ(P/S)EDFA(D/T)Y(F/Y)C 302 GVPDRF(S/T)GSGS XTDFTLTISSLQ(P/S)EDFA(D/T)Y(F/Y)C 303 GVPDRF(S/T)GSGSG XDFTLTISSLQ(P/S)EDFA(D/T)Y(F/Y)C 304 GVPDRF(S/T)GSGSGT XFTLTISSLQ(P/S)EDFA(D/T)Y(F/Y)C 305 GVPDRF(S/T)GSGSGTD XTLTISSLQ(P/S)EDFA(D/T)Y(F/Y)C 306 GVPDRF(S/T)GSGSGTDF XLTISSLQ(P/S)EDFA(D/T)Y(F/Y)C 307 GVPDRF(S/T)GSGSGTDFT XTISSLQ(P/S)EDFA(D/T)Y(F/Y)C 308 GVPDRF(S/T)GSGSGTDFTL XISSLQ(P/S)EDFA(D/T)Y(F/Y)C 309 GVPDRF(S/T)GSGSGTDFTLT XSSLQ(P/S)EDFA(D/T)Y(F/Y)C 310 GVPDRF(S/T)GSGSGTDFTLTI XSLQ(P/S)EDFA(D/T)Y(F/Y)C 311 GVPDRF(S/T)GSGSGTDFTLTIS XLQ(P/S)EDFA(D/T)Y(F/Y)C 312 GVPDRF(S/T)GSGSGTDFTLTISS XQ(P/S)EDFA(D/T)Y(F/Y)C 313 GVPDRF(S/T)GSGSGTDFTLTISSL X(P/S)EDFA(D/T)Y(F/Y)C 314 GVPDRF(S/T)GSGSGTDFTLTISSLQ X EDFA(D/T)Y(F/Y)C315 GVPDRF(S/T)GSGSGTDFTLTISSLQ(P/S) X DFA(D/T)Y(F/Y)C 316GVPDRF(S/T)GSGSGTDFTLTISSLQ(P/S)E X FA(D/T)Y(F/Y)C 317GVPDRF(S/T)GSGSGTDFTLTISSLQ(P/S)ED X A(D/T)Y(F/Y)C 318GVPDRF(S/T)GSGSGTDFTLTISSLQ(P/S)EDF X (D/T)Y(F/Y)C 319GVPDRF(S/T)GSGSGTDFTLTISSLQ(P/S)EDFA X Y(F/Y)C 320GVPDRF(S/T)GSGSGTDFTLTISSLQ(P/S)EDFA(D/T) X (F/Y)C 321GVPDRF(S/T)GSGSGTDFTLTISSLQ(P/S)EDFA(D/T)Y X C 322GVPDRF(S/T)GSGSGTDFTLTISSLQ(P/S)EDFA(D/T)Y(F/Y) X 323

TABLE 23 VL FR4 VL FR4 SEQ ID NO: L1-L4 FGGGTKVEIK 47 X GGGTKVEIK 324 FX GGTKVEIK 325 FG X GTKVEIK 326 FGG X TKVEIK 327 FGGG X KVEIK 328 FGGGTX VEIK 329 FGGGTK X EIK 330 FGGGTKV X IK 331 FGGGTKVE X K 332 FGGGTKVEIX 333

In one aspect, an antibody described herein comprises an Fc region thatcomprises one or more amino acid deletions, additions and/ormodifications.

An “Fc region,” as used herein, includes polypeptides comprising aconstant region of an antibody excluding the first constant regionimmunoglobulin domain, and thus refers to the last two constant regionimmunoglobulin domains of IgA, IgD, and IgG, the last three constantregion immunoglobulin domains of IgE and IgM, and the flexible hingeN-terminal to these domains. For IgA and IgM, an Fc region may includethe J chain. For IgG, an Fc region may comprise immunoglobulin domainsCgamma2 and Cgamma3 (Cγ2 and Cγ3) and the hinge between Cgamma1 (Cγ1)and Cgamma2 (Cγ2). Although the boundaries of an Fc region may vary, thehuman IgG heavy chain Fc region generally comprises residues C226 orP230 to its carboxyl-terminus, wherein the numbering is according to theEU index as in Kabat et al. (1991, NIH Publication 91-3242, NationalTechnical Information Service, Springfield, Va.). The “EU index as setforth in Kabat” refers to the residue numbering of the human IgG1 EUantibody as described in Kabat et al. supra. In a certain embodiment, anFc region comprises a non-naturally occurring Fc region. In certainaspects, one or more polymorphisms are present one or more Fc positions,including but not limited to Kabat 270, 272, 312, 315, 356, and 358.

In one aspect, provided herein is an antibody, as described herein,which specifically binds to a D4 region of KIT, or an antigen-bindingfragment thereof, comprising an Fc region which has altered bindingproperties for an Fc ligand (e.g., an Fc receptor, such as Clq) relativeto a comparable antibody (e.g., one having the same amino acid sequenceexcept having a wild type Fc region).

The affinities and binding properties of an Fc region for its ligand,may be determined by a variety of in vitro assay methods (biochemical orimmunological based assays) known in the art for determining Fc-FcγRinteractions, i.e., specific binding of an Fc region to an FcγRincluding but not limited to, equilibrium methods (e.g., enzyme-linkedimmunoabsorbent assay (ELISA), or radioimmunoassay (RIA)), or kinetics(e.g., BIACORE® analysis), and other methods such as indirect bindingassays, competitive inhibition assays, fluorescence resonance energytransfer (FRET), gel electrophoresis and chromatography (e.g., gelfiltration). These and other methods may utilize a label on one or moreof the components being examined and/or employ a variety of detectionmethods including but not limited to chromogenic, fluorescent,luminescent, or isotopic labels.

In one embodiment, an Fc region of an antibody described herein hasenhanced binding to one or more Fc ligand relative to a comparablemolecule. In a specific embodiment, an Fc region of an antibodydescribed herein has enhanced binding to an Fc receptor. In anotherspecific embodiment, an Fc region of an antibody described herein hasenhanced binding to the Fc receptor FcγRIIIA In one specific embodiment,an Fc region of an antibody described herein has enhanced binding to theFc receptor FcRn. In another specific embodiment, an Fc region of anantibody described herein has enhanced binding to Clq relative to acomparable molecule.

In a certain aspect, the serum half-life of proteins comprising Fcregions may be increased by increasing the binding affinity of the Fcregion for FcRn. In one embodiment, an Fc region of an antibodydescribed herein has enhanced serum half-life relative to comparablemolecule.

“Antibody-dependent cell-mediated cytotoxicity” or “ADCC” refers to aform of cytotoxicity in which secreted Ig bound onto Fc receptors (FcRs)present on certain cytotoxic cells (e.g., Natural Killer (NK) cells,neutrophils, and macrophages) enables these cytotoxic cells to bindspecifically to an antigen-bearing target cell and subsequently kill thetarget cell with cytotoxins. Specific high-affinity IgG antibodiesdirected to the surface of target cells “arm” the cytotoxic cells, forsuch killing. Lysis of the target cell involves direct cell-to-cellcontact, and does not involve complement. It is contemplated that, inaddition to antibodies, other proteins comprising Fc regions,specifically Fc fusion proteins, having the capacity to bindspecifically to an antigen-bearing target cell will be able to effectcell-mediated cytotoxicity. For simplicity, the cell-mediatedcytotoxicity resulting from the activity of an Fc fusion protein is alsoreferred to herein as ADCC activity.

The ability of any particular protein, e.g., antibody, comprising an Fcregion to mediate lysis of the target cell by ADCC can be assayed. Toassess ADCC activity, of an Fc region, a target cell-binding antibodycomprising the Fc region is added to target cells in combination withimmune effector cells, which may be activated by the antigen-antibodycomplexes resulting in cytolysis of the target cell. Cytolysis isgenerally detected by the release of label (e.g. radioactive substrates,fluorescent dyes or natural intracellular proteins) from the lysedcells. Useful effector cells for such assays include peripheral bloodmononuclear cells (PBMC) and Natural Killer (NK) cells. Specificexamples of in vitro ADCC assays are described in Wisecarver et al.,1985 79:277-282; Bruggemann et al., 1987, J Exp. Med. 166:1351-1361;Wilkinson et al., 2001, J Immunol. Methods 258:183-191; Patel et al.,1995 J Immunol. Methods 184:29-38. Alternatively, or additionally, ADCCactivity of a protein comprising an Fc region may be assessed in vivo,e.g., in a animal model such as that disclosed in Clynes et al., 1998,Proc. Natl. Acad. Sci. USA 95:652-656.

In one embodiment, a protein, e.g., an antibody described herein,comprising an Fc region has enhanced ADCC activity relative to acomparable protein, e.g., antibody. In another specific embodiment, anantibody described herein comprising an Fc region has enhanced bindingto the Fc receptor FcγRIIIA and has enhanced ADCC activity relative to acomparable antibody. In some embodiments, an antibody described hereincomprising an Fc region has both enhanced ADCC activity and enhancedserum half-life relative to a comparable antibody.

“Complement dependent cytotoxicity” and “CDC” refer to the lysing of atarget cell in the presence of complement. The complement activationpathway is initiated by the binding of the first component of thecomplement system (Clq) to a molecule, an antibody for example,complexed with a cognate antigen. To assess complement activation, a CDCassay, as described in Gazzano-Santoro et al., 1996, J. Immunol.Methods, 202:163, may be performed, for example. In one embodiment, anantibody described herein comprising an Fc region has enhanced CDCactivity relative to a comparable antibody. In other embodiments, anantibody described herein comprising an Fc region has both enhanced CDCactivity and enhanced serum half life relative to a comparable antibody.

In one embodiment, an antibody described herein comprises an Fc regionthat comprises an amino acid modification (e.g., substitution, deletionor addition, or a non-naturally occurring amino acid residue) at one ormore positions (e.g., at one, two, three, or four positions) selectedfrom the group consisting of 234, 235, 236, 239, 240, 241, 243, 244,245, 247, 252, 254, 256, 262, 263, 264, 265, 266, 267, 269, 296, 297,298, 299, 313, 325, 326, 327, 328, 329, 330, 332, 333, and 334 asnumbered by the EU index as set forth in Kabat. Optionally, the Fcregion may comprise an amino acid modification (e.g., substitution,deletion or addition) or a non-naturally occurring amino acid residue atadditional and/or alternative positions known to one skilled in the art(see, e.g., U.S. Pat. Nos. 5,624,821; 6,277,375; 6,737,056; PCT PatentPublications WO 01/58957; WO 04/016750; WO 04/029207; WO 04/035752 andWO 05/040217, each of which is incorporated herein in its entirety, butparticularly for the disclosure of such modifications). In a furtherembodiment, one or more functions of an Fc region is maintained (e.g.,substantially maintained, for example, at least 50%, at least 60%, atleast 70%, at least 80%, at least 90%, at least 95%) by the Fc regioncomprising an amino acid modification (e.g., substitution, deletion oraddition) or a non-naturally occurring amino acid residue at one or morepositions. For example, such Fc functions can include effector function,such as CDC or ADCC, or binding affinity to an Fc receptor. In a certainembodiment, the Fc region, comprising an amino acid modification (e.g.,substitution, deletion or addition) or a non-naturally occurring aminoacid residue at one or more positions, exhibits at least one or moreenhanced Fc activity, e.g., enhanced half-life, or enhanced effectorfunction, such as ADCC or CDC. In a particular embodiment, the Fcregion, comprising an amino acid modification (e.g., substitution,deletion or addition) or a non-naturally occurring amino acid residue atone or more positions, exhibits decreased Fc activity, e.g., decreasedstability/half-life, or decreased effector function, such as ADCC orCDC.

In a specific embodiment, an antibody described herein comprises an Fcregion, wherein the Fc region comprises at least one (e.g., one, two,three, or four) amino acid modification (e.g., substitution, deletion oraddition) or at least one non-naturally occurring amino acid residue(e.g., one, two, three, or four) selected from the group consisting of234D, 234E, 234N, 234Q, 234T, 234H, 234Y, 234I, 234V, 234F, 235A, 235D,235R, 235W, 235P, 235S, 235N, 235Q, 235T, 235H, 235Y, 235I, 235V, 235F,236E, 239D, 239E, 239N, 239Q, 239F, 239T, 239H, 239Y, 240I, 240A, 240T,240M, 241W, 241 L, 241Y, 241E, 241R. 243W, 243L 243Y, 243R, 243Q, 244H,245A, 247V, 247G, 252Y, 254T, 256E, 262I, 262A, 262T, 262E, 2631, 263A,263T, 263M, 264L, 264I, 264W, 264T, 264R, 264F, 264M, 264Y, 264E, 265G,265N, 265Q, 265Y, 265F, 265V, 265I, 265L, 265H, 265T, 266I, 266A, 266T,266M, 267Q, 267L, 269H, 269Y, 269F, 269R, 296E, 296Q, 296D, 296N, 296S,296T, 296L, 296I, 296H, 269G, 297S, 297D, 297E, 298H, 298I, 298T, 298F,299I, 299L, 299A, 299S, 299V, 299H, 299F, 299E, 313F, 325Q, 325L, 3251,325D, 325E, 325A, 325T, 325V, 325H, 327G, 327W, 327N, 327L, 328S, 328M,328D, 328E, 328N, 328Q, 328F, 328I, 328V, 328T, 328H, 328A, 329F, 329H,329Q, 330K, 330G, 330T, 330C, 330L, 330Y, 330V, 330I, 330F, 330R, 330H,332D, 332S, 332W, 332F, 332E, 332N, 332Q, 332T, 332H, 332Y, and 332A asnumbered by the EU index as set forth in Kabat. Optionally, the Fcregion may comprise additional and/or alternative non-naturallyoccurring amino acid residues known to one skilled in the art (see,e.g., U.S. Pat. Nos. 5,624,821; 6,277,375; 6,737,056; PCT PatentPublications WO 01/58957; WO 04/016750; WO 04/029207; WO 04/035752 andWO 05/040217).

In a certain aspect, provided herein is an antibody comprising an Fcregion, wherein the Fc region comprises at least a non-naturallyoccurring amino acid at one or more positions selected from the groupconsisting of 239, 330 and 332, as numbered by the EU index as set forthin Kabat. In a specific embodiment, provided herein is an antibodycomprising an Fc region, wherein the Fc region comprises at least onenon-naturally occurring amino acid selected from the group consisting of239D, 330L and 332E, as numbered by the EU index as set forth in Kabat.Optionally, the Fc region may further comprise additional non-naturallyoccurring amino acid at one or more positions selected from the groupconsisting of 252, 254, and 256, as numbered by the EU index as setforth in Kabat. In a specific embodiment, provided herein is an antibodycomprising an Fc region, wherein the Fc region comprises at least onenon-naturally occurring amino acid selected from the group consisting of239D, 330L and 332E, as numbered by the EU index as set forth in Kabatand at least one non-naturally occurring amino acid at one or morepositions are selected from the group consisting of 252Y, 254T and 256E,as numbered by the EU index as set forth in Kabat. In one embodiment, anFc region comprising such sequence exhibits one or more Fc activity, forexample, binding affinity to an Fc receptor or effector function, suchas ADCC or CDC. In a specific embodiment, an Fc region comprising suchsequence exhibits reduced Fc activity, for example, reduced bindingaffinity to an Fc receptor or reduced effector function, such as ADCC orCDC. In a particular embodiment, an Fc region comprising such sequenceexhibits enhanced Fc activity, for example, enhanced half-life, enhancedbinding affinity to an Fc receptor, or enhanced effector function, suchas ADCC or CDC.

Non-limiting examples of Fc region modifications are provided in Ghetieet al., 1997, Nat Biotech. 15:637-40; Duncan et al, 1988, Nature332:563-564; Lund et al., 1991, J. Immunol 147:2657-2662; Lund et al,1992, Mol Immunol 29:53-59; Alegre et al, 1994, Transplantation57:1537-1543; Hutchins et al., 1995, Proc Natl. Acad Sci USA92:11980-11984; Jefferis et al, 1995, Immunol Lett. 44:111-117; Lund etal., 1995, Faseb J 9:115-119; Jefferis et al, 1996, Immunol Lett54:101-104; Lund et al, 1996, J Immunol 157:4963-4969; Armour et al.,1999, Eur J Immunol 29:2613-2624; Idusogie et al, 2000, J Immunol164:4178-4184; Reddy et al, 2000, J Immunol 164:1925-1933; Xu et al.,2000, Cell Immunol 200:16-26; Idusogie et al, 2001, J Immunol166:2571-2575; Shields et al., 2001, J Biol Chem 276:6591-6604; Jefferiset al, 2002, Immunol Lett 82:57-65; Presta et al., 2002, Biochem SocTrans 30:487-490); U.S. Pat. Nos. 5,624,821; 5,885,573; 5,677,425;6,165,745; 6,277,375; 5,869,046; 6,121,022; 5,624,821; 5,648,260;6,528,624; 6,194,551; 6,737,056; 6,821,505; 6,277,375; 8,163,882;7,355,008; 7,960,512; 8,039,592; 8,039,359; 8,101,720; 7,214,775;7,682,610; 7,741,442; U.S. Patent Publication Nos. 2004/0002587 and PCTPublications WO 94/29351; WO 99/58572; WO 00/42072; WO 04/029207; WO04/099249; WO 04/063351.

In a particular embodiment, an antibody described herein comprises oneor more (e.g., one, two, three, or four) modifications to an IgG1 Fcregion, such as a human IgG1 Fc region. In a certain embodiment, anantibody described herein comprises one or more (e.g., one, two, three,or four) modifications to an IgG2 Fc region, such as a human IgG2 Fcregion. In one embodiment, an antibody described herein comprises one ormore (e.g., one, two, three, or four) modifications to an IgG4 Fcregion, such as a human IgG4 Fc region.

In some aspects, an antibody described herein comprises an Fc region,wherein the Fc region comprises one or more (e.g., one, two, three, orfour) glycoform modifications (e.g., removal or substitution of one ormore glycoforms), such as engineered glycoforms, i.e., a carbohydratecomposition that is covalently attached to a molecule comprising an Fcregion. Engineered glycoforms may be useful for a variety of purposes,including but not limited to enhancing or reducing effector function.Engineered glycoforms may be generated by any method known to oneskilled in the art, for example by using engineered or variantexpression strains, by co-expression with one or more enzymes, forexample DI N-acetylglucosaminyltransferase III (GnTI11), by expressing amolecule comprising an Fc region in various organisms or cell lines fromvarious organisms, or by modifying carbohydrate(s) after the moleculecomprising Fc region has been expressed. Methods for generatingengineered glycoforms are known in the art, and include but are notlimited to those described in Umana et al, 1999, Nat. Biotechnol17:176-180; Davies et al., 20017 Biotechnol Bioeng 74:288-294; Shieldset al, 2002, J Biol Chem 277:26733-26740; Shinkawa et al., 2003, J BiolChem 278:3466-3473) U.S. Pat. No. 6,602,684; U.S. application Ser. Nos.10/277,370; 10/113,929; PCT WO 00/61739A1; PCT WO 01/292246A1; PCT WO02/311140A1; PCT WO 02/30954A1; WO 00061739; US 20030115614; and Okazakiet al., 2004, JMB, 336: 1239-49. Methods for generating modifiedglycoforms of an antibody described herein are described in the art, andinclude but are not limited to those described in U.S. Pat. Nos.7,517,670; 8,021,856; 8,080,415; 8,084,222; 7,700,321; and 8,071,336.

In a particular embodiment, glycosylation of an Fc region can bemodified to increase or decrease effector function. Accordingly, in oneembodiment, an Fc region of an antibody described herein comprisesmodified glycosylation of amino acid residues. In another embodiment,the modified glycosylation of amino acid residues results in loweredeffector function, such as ADCC or CDC. In another embodiment, themodified glycosylation of the amino acid residues results in increasedeffector function. In some embodiments, the glycosylation patterns ofthe antibodies provided herein are modified to enhance ADCC and CDCeffector function (see, for example, Shields et al., (2002) JBC.277:26733; Shinkawa et al., (2003) JBC. 278:3466 and Okazaki et al.,(2004) J. Mol. Biol., 336: 1239). In a specific embodiment, suchmodified glycosylation is different than glycosylation of an Fc regionfound naturally in vivo, or such modified glycosylation is anon-naturally occurring glycosylation of an Fc region. For example,modified glycosylation of an Fc region can be achieved by modifying anamino acid or by expressing the protein/antibody in a cell that has beenengineered to contain a different glycosylation machinery than itsparental cell that has not been modified. In this regard, such a cellcan be engineered to not express a certain glycosylation enzyme or toexpress a certain glycosylation enzyme that is not present in theparental cell.

Methods for generating non-naturally occurring Fc regions are known inthe art. For example, amino acid substitutions and/or deletions can begenerated by mutagenesis methods, including, but not limited to,site-directed mutagenesis (Kunkel, Proc. Natl. Acad. Sci. USA 82:488-492(1985)), PCR mutagenesis (Higuchi, in “PCR Protocols: A Guide to Methodsand Applications”, Academic Press, San Diego, pp. 177-183 (1990)), andcassette mutagenesis (Wells et al., Gene 34:315-323 (1985)).Site-directed mutagenesis can be performed by the overlap-extension PCRmethod (Higuchi, in “PCR Technology: Principles and Applications for DNAAmplification”, Stockton Press, New York, pp. 61-70 (1989)).Alternatively, the technique of overlap-extension PCR (Higuchi, ibid.)can be used to introduce any desired mutation(s) into a target sequence(the starting DNA). Other methods useful for the generation of Fc regionmodifications are known in the art (see, e.g., U.S. Pat. Nos. 5,624,821;5,885,573; 5,677,425; 6,165,745; 6,277,375; 5,869,046; 6,121,022;5,624,821; 5,648,260; 6,528,624; 6,194,551; 6,737,056; 6,821,505;6,277,375; U.S. Patent Publication Nos. 2004/0002587 and PCTPublications WO 94/29351; WO 99/58572; WO 00/42072; WO 02/060919; WO04/029207; WO 04/099249; WO 04/063351).

In a specific embodiment, the Fc region has reduced fucosylation. Inanother embodiment, the Fc region is afucosylated (see for examples,U.S. Patent Application Publication No. 2005/0226867).

In a certain aspect, an antibody described herein is a non-fucosylatedantibody, for example an Fc region of the antibody does not containsugar chains with a fucose, e.g., a fucose bound to N-acetylglucosamines(see, e.g., U.S. Pat. Nos. 7,214,775; 7,682,610; and 7,741,442). Methodsfor making non-fucosylated antibodies are known in the art, see, e.g.,U.S. Pat. No. 7,708,992. For example, non-fucosylated antibodies can begenerated using engineered host cells, see, e.g., U.S. Pat. Nos.6,946,292; 7,425,446; 8,067,232; 7,846,725; and 7,393,683. Knock-outanimals for generating non-fucosylated antibodies also have beendescribed, see, e.g., U.S. Pat. No. 7,737,325. In a particularembodiment, a non-fucosylated antibody described herein, whichspecifically binds to a D4 region of human KIT, exhibits increased ADCC.

In a particular aspect, an antibody described herein comprises a fucosecontent of less than 100%, for example, less than 65%, relative to thefucose content of a reference antibody (see, e.g., U.S. Pat. Nos.7,931,895 and 7,846,434). In a certain embodiment, an antibody describedherein is characterized by a fucose content wherein at least about 60%of the N-linked oligosaccharides, e.g. N-linked oligosaccharides in theCH2-derived domains, contain no fucose. In specific embodiments, thepercentage of N-linked oligosaccharides, e.g. N-linked oligosaccharidesin the CH2-derived domains, that contain no fucose is at least about65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95% ormore, and exhibits altered effector function, for example enhanced ADCCor reduced ADCC. In a particular embodiment, an antibody describedherein, which specifically binds to a D4 region of human KIT, comprisesa fucose content of less than 65% and exhibits increased ADCC.

In particular aspects, an antibody described herein comprises an Fcregion with altered FcγR binding activity displaying reduced binding toan FcγR and comprises an amino acid modification at any one or more(e.g., one, two, three, or four) of amino acid positions 238, 239, 248,249, 252, 254, 265, 268, 269, 270, 272, 278, 289, 292, 293, 294, 295,296, 298, 301, 303, 322, 324, 327, 329, 333, 335, 338, 340, 373, 376,382, 388, 389, 414, 416, 419, 434, 435, 437, 438 or 439 of the Fcregion, wherein the numbering of the residues in the Fc region is thatof the EU index as in Kabat (see, e.g., U.S. Pat. No. 7,183,387). Forexample, an antibody described herein comprising an Fc region displaysreduced binding to an FcγRI and comprise an amino acid modification atany one or more (one, two, three, or four) of amino acid positions 238,265, 269, 270, 327 or 329 of the Fc region, wherein the numbering of theresidues in the Fc region is that of the EU index as in Kabat.

In a particular embodiment, an antibody described herein comprising anFc region displays reduced binding to an FcγRII and comprises an aminoacid modification at any one or more (e.g., one, two, three, or four) ofamino acid positions 238, 265, 269, 270, 292, 294, 295, 298, 303, 324,327, 329, 333, 335, 338, 373, 376, 414, 416, 419, 435, 438 or 439 of theFc region, wherein the numbering of the residues in the Fc region isthat of the EU index as in Kabat.

In a specific embodiment, an antibody described herein comprising an Fcregion displays reduced binding to an FcγRIII and comprises an aminoacid modification at one or more (e.g., one, two, three, or four) ofamino acid positions 238, 239, 248, 249, 252, 254, 265, 268, 269, 270,272, 278, 289, 293, 294, 295, 296, 301, 303, 322, 327, 329, 338, 340,373, 376, 382, 388, 389, 416, 434, 435 or 437 of the Fc region, whereinthe numbering of the residues in the Fc region is that of the EU indexas in Kabat.

In certain aspects, the serum half-life of a protein, such as anantibody described herein, comprising an Fc region, is increased byincreasing the binding affinity of an Fc region for FcRn.

In a particular embodiment, an antibody described herein or anantigen-binding fragment thereof specifically binds to a KIT polypeptide(e.g., the D4 region of human KIT) with an EC₅₀ (half maximal effectiveconcentration) value of about 50 nM or less as determined by ELISA.

In a particular embodiment, an antibody described herein or anantigen-binding fragment thereof specifically binds to a KIT polypeptide(e.g., the D4 region of human KIT) with an EC₅₀ value of about 150 pM orless as determined by FACs with CHO-WT-KIT cells (CHO cells engineeredto recombinantly express wild-type human KIT).

In a particular embodiment, an antibody described herein or anantigen-binding fragment thereof, which specifically binds to a KITpolypeptide (e.g., the D4 region of human KIT), is capable of blockingKIT phosphorylation with IC₅₀ (50% inhibition concentration) value ofabout 600 pM or less.

In a particular embodiment, an antibody described herein or anantigen-binding fragment thereof, which specifically binds to a KITpolypeptide (e.g., the D4 region of human KIT), be recombinentlyexpressed in CHO cells at an average titer of at least 0.5 μg/mL. In aparticular embodiment, an antibody described herein or anantigen-binding fragment thereof, which specifically binds to a KITpolypeptide (e.g., the D4 region of human KIT), be recombinentlyexpressed in CHO cells at an average titer of at least 1.0 μg/mL.

In a specific embodiment, an antibody described herein or anantigen-binding fragment thereof, which specifically binds to a KITpolypeptide (e.g., the D4 region of human KIT), comprises a VH domainand a VL domain that are non-immunogenic, for example, the VH domain andVL domain do not contain T cell epitopes.

In particular embodiments, an antibody described herein (or anantigen-binding fragment thereof) does not bind the extracellular ligandbinding site of KIT, e.g., the SCF binding site of KIT. In particularembodiments, an antibody described herein (or an antigen-bindingfragment thereof) does not inhibit ligand binding to KIT, e.g., does notinhibit KIT ligand (e.g., SCF) binding to KIT.

In specific aspects, antibodies (e.g., human or humanized antibodies)described herein are inhibitory antibodies, that is, antibodies thatinhibit (e.g., partially inhibit) KIT activity, i.e., one or more KITactivities. In a specific embodiment, partial inhibition of a KITactivity results in, for example, about 25% to about 65% or 75%inhibition. In a specific embodiment, partial inhibition of a KITactivity results in, for example, about 35% to about 85% or 95%inhibition. Non-limiting examples of KIT activities include KITdimerization, KIT phosphorylation (e.g., tyrosine phosphorylation),signaling downstream of KIT (e.g., Stat, AKT, MAPK, or Ras signaling),induction or enhancement of gene transcription (e.g., c-Myc), inductionor enhancement of cell proliferation or cell survival. In a particularembodiment, an antibody described herein inhibits KIT phosphorylation(e.g., ligand-induced phosphorylation). In a specific embodiment, anantibody described herein inhibits KIT tyrosine phosphorylation in theKIT cytoplasmic domain. In another particular embodiment, an antibodydescribed herein inhibits cell proliferation. In yet another particularembodiment, an antibody described herein inhibits cell survival. In aspecific embodiment, an antibody described herein induces apoptosis. Inanother specific embodiment, an antibody described herein induces celldifferentiation, e.g., cell differentiation in a cell expressing KIT,e.g., human KIT. In a particular embodiment, an antibody describedherein inhibits KIT activity but does not inhibit KIT dimerization. Inanother particular embodiment, an antibody described herein inhibits KITactivity and does not inhibit ligand binding to KIT, e.g., does notinhibit KIT ligand (e.g., SCF) binding to KIT, but does inhibit KITdimerization.

In a particular embodiment, an antibody described herein inhibits a KITactivity, such as ligand-induced tyrosine phosphorylation of a KITcytoplasmic domain, by about 25% to about 65% or 75%, as determined by acell-based phosphorylation assay well known in the art, for example, thecell-based phosphorylation assay described herein. In a certainembodiment, an antibody described herein inhibits a KIT activity, suchas ligand-induced tyrosine phosphorylation of a KIT cytoplasmic domain,by about 35% to about 85% or 95%, as determined by a cell-basedphosphorylation assay well known in the art, for example, the cell-basedphosphorylation assay described herein. In a particular embodiment, anantibody described herein, or an antigen-binding fragment thereof or aconjugate thereof, inhibits a KIT activity, such as ligand-inducedtyrosine phosphorylation of a KIT cytoplasmic domain, with a 50%inhibition concentration (IC₅₀) of less than about 600 pM, or less thanabout 500 pM, or less than about 250 pM, as determined by a cell-basedphosphorylation assay well known in the art, for example, the cell-basedphosphorylation assay described herein. In a specific embodiment, theIC₅₀ is less than about 550 pM or 200 pM. In a specific embodiment, theIC₅₀ is in the range of about 50 pM to about 225 pM, or in the range of100 pM to about 600 pM. In a specific embodiment, the IC₅₀ is in therange of about 50 pM to about 550 pM, or about 50 pM to about 600 pM, orabout 150 pM to about 550 pM.

In a specific embodiment, an antibody described herein, or anantigen-binding fragment thereof or a conjugate thereof, (i)immunospecifically binds to a KIT polypeptide comprising the D4 regionof human KIT, (ii) inhibits KIT phosphorylation (e.g., tyrosinephosphorylation), and (iii) does not affect KIT ligand (e.g., SCF)binding to KIT. In yet another specific embodiment, such an antibodydoes not inhibit KIT dimerization. In yet another specific embodiment,such an antibody can be recombinently expressed by CHO cells at anaverage titer of at least 0.5 μg/mL, for example at least 1.0 μg/mL. Ina further specific embodiment, such an antibody comprises a VH domainand a VL domain that are non-immunogenic, for example, the VH domain andVL domain do not contain T cell epitopes.

In other specific embodiments, an antibody described herein, or anantigen-binding fragment thereof or a conjugate thereof,immunospecifically binds to a monomeric form of KIT (e.g., human KIT).In particular embodiments, an antibody described herein does notimmunospecifically bind to a monomeric form of KIT (e.g., human KIT). Inspecific embodiments, an antibody described herein, or anantigen-binding fragment thereof or a conjugate thereof,immunospecifically binds to a dimeric form of KIT (e.g., human KIT). Inspecific embodiments, an antibody described herein, or anantigen-binding fragment thereof or a conjugate thereof, does not bindto a monomeric form of KIT and specifically binds to a dimeric form ofKIT or multimeric form of KIT. In certain embodiments, an antibody hashigher affinity for a KIT monomer than a KIT dimer. In certainembodiments, an antibody has higher affinity for a KIT monomer than aKIT multimer.

In specific embodiments, an anti-KIT antibody described herein (or anantigen-binding fragment thereof or a conjugate thereof) specificallybinds to a native isoform or native variant of KIT (that is a naturallyoccurring isoform or variant of KIT in an animal (e.g., monkey, mouse,goat, donkey, dog, cat, rabbit, pig, rat, human, frog, or bird) that canbe isolated from an animal, preferably a human). In particularembodiments, an antibody described herein immunospecifically binds tohuman KIT or a fragment thereof. In specific embodiments, an anti-KITantibody described herein (or an antigen-binding fragment thereof or aconjugate thereof) specifically binds to human KIT or a fragment thereofand does not specifically bind to a non-human KIT (e.g., monkey, mouse,goat, donkey, dog, cat, rabbit, pig, rat, or bird) or a fragmentthereof. In specific embodiments, an anti-KIT antibody described herein(or an antigen-binding fragment thereof or a conjugate thereof)specifically binds to human KIT or a fragment thereof and does notspecifically bind to murine KIT. In certain embodiments, an anti-KITantibody described herein specifically binds to human KIT or a fragmentthereof (e.g., a D4 region of human KIT) and to canine (dog) andnon-human primate (e.g., monkey) KIT. In certain embodiments, ananti-KIT antibody described herein specifically binds to human KIT or afragment thereof (e.g., a D4 region of human KIT) and to canine (dog)KIT. In certain embodiments, an anti-KIT antibody described hereinspecifically binds to human KIT or a fragment thereof (e.g., a D4 regionof human KIT) and to non-human primate (e.g., monkey) KIT. In certainembodiments, an anti-KIT antibody described herein specifically binds tohuman KIT or a fragment thereof (e.g., a D4 region of human KIT) and tocanine (dog) and non-human primate (e.g., monkey) KIT, but does notspecifically bind to murine KIT or a fragment thereof (e.g., a D4 regionof murine KIT).

In certain embodiments, an antibody described herein or antigen-bindingfragment thereof binds to an extracellular domain of human KITcomprising a mutation, for example a somatic mutation associated withcancer (e.g., GIST), such as a mutation in exon 9 of human KIT whereinthe Ala and Tyr residues at positions 502 and 503 are duplicated. Incertain embodiments, an antibody described herein or antigen-bindingfragment thereof binds to an extracellular domain of wild-type human KITand an extracellular domain of human KIT comprising a mutation, forexample a somatic mutation associated with cancer (e.g., GIST), such asa mutation in exon 9 of human KIT wherein the Ala and Tyr residues atpositions 502 and 503 are duplicated (see, e.g., Marcia et al., (2000)Am. J. Pathol. 156(3):791-795; and Debiec-Rychter et al., (2004)European Journal of Cancer. 40:689-695, which are both incorporatedherein by reference in their entireties, describing KIT mutations).

In certain embodiments, an antibody described herein or antigen-bindingfragment thereof binds to an extracellular domain of human KIT which isglycosylated. In certain embodiments, an antibody described herein orantigen-binding fragment thereof binds to two different glycosylatedforms of an extracellular domain of human KIT. For example, two forms ofhuman KIT with different molecular weights, indicating differentglycosylation patterns, have been observed by immunoblotting. In certainembodiments, an antibody described herein may specifically bind to bothof these forms of human KIT which have different glycosylation patterns,e.g., one form is more glycosylated than the other. In certainembodiments, an antibody described herein or antigen-binding fragmentthereof binds to an extracellular domain of human KIT which is notglycosylated.

In a particular embodiment, an antibody described herein does notimmunospecifically bind to a KIT epitope described by InternationalPatent Application No. WO 2008/153926, for example an epitope consistingessentially of the amino acid sequence SELHLTRLKGTEGGTYT (SEQ ID NO: 38)or LTRLKGTEGG (SEQ ID NO: 39).

In certain embodiments, an anti-KIT antibody described herein is not anantibody selected from the group consisting of: SR-1 antibody (see U.S.Patent Application Publication No. US 2007/0253951 A1; InternationalPatent Application Publication No. WO 2007/127317); anti-KIT antibodyobtained from hybridoma cell lines DSM ACC 2007, DSM ACC 2008, or DSMACC 2009, which have been deposited at the Deutsche Sammlung vonMikroorganismen und Zellkulturen GmbH, DSM, Mascheroder Weg 1 b, D-38124Braumschweig, Germany (see U.S. Pat. No. 5,545,533; International PatentApplication Publication No. WO 92/021766); antibody produced byhybridoma cell line DSM ACC 2247 (or A3C6E2; Deposit No. DSM ACC 2247,at the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, DSM,Mascheroder Weg 1 b, D-38124 Braumschweig, Germany) (see U.S. Pat. No.5,808,002); and anti-KIT antibodies designated K27, K44, K45, K49, K57,K69, and K94 (see, e.g., Blechman et al., Stem Cells, 1993, 11:12-21;Blechman et al., Cell, 1995, 80:103-113; Lev et al., Mol. Cell. Biol.,1993, 13:2224-2234; and European Patent Application Publication No.EP0548867 A2). In certain embodiments, an anti-KIT antibody describedherein does not comprise a CDR of an antibody selected from such group.In particular embodiments, an anti-KIT antibody described herein doesnot comprise one or more (e.g., two, three, four, five, or six) CDRs(e.g., 3 VL CDRs and/or 3 VH CDRs) of an antibody selected from suchgroup. In another embodiment, an antibody described herein is notcompetitively blocked (e.g., competitively blocked in a dose-dependentmanner) by one of those antibodies, for example, as determined bycompetition binding assays (e.g., ELISAs). In certain embodiments, ananti-KIT antibody described herein is not antibody Ab1 or Ab21, which isdescribed in U.S. Provisional Application No. 61/426,387, filed Dec. 22,2010. In certain embodiments, an anti-KIT antibody described herein isnot an antibody selected from the group consisting of: Ab1, Ab2, Ab3,Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, Ab10, Ab11, Ab12, Ab13, Ab14, Ab15, Ab16,Ab17, Ab18, Ab19, Ab20, and Ab21, as described in U.S. ProvisionalApplication No. 61/426,387, filed Dec. 22, 2010 and Ab24-Ab192 asdescribed in PCT International Patent Application No. PCT/US2011/29980filed Mar. 25, 2011. In certain embodiments, an anti-KIT antibodydescribed herein does not comprise a CDR, or one or more CDRs (e.g., 3VL CDRs and/or 3VH CDRs), of an antibody selected from the groupconsisting of: Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, Ab10, Ab11,Ab12, Ab13, Ab14, Ab15, Ab16, Ab17, Ab18, Ab19, Ab20, and Ab21, asdescribed in U.S. Provisional Application No. 61/426,387, filed Dec. 22,2010, and Ab24-Ab192 as described in PCT International PatentApplication No. PCT/US2011/29980 filed Mar. 25, 2011. In particularembodiments, an anti-KIT antibody described herein does not comprise aCDR, or one or more CDRs (e.g., 3 VL CDRs and/or 3VH CDRs), VL chainregion, or VH chain region of an antibody selected from the antibodies(e.g., antibodies Ab1-Ab21 and Ab24-Ab192) described in U.S. ProvisionalApplication No. 61/426,387 filed Dec. 22, 2010 or PCT InternationalPatent Application No. PCT/US2011/29980 filed Mar. 25, 2011. In certainembodiments, an anti-KIT antibody described herein is not antibody Ab1or Ab21, or an antibody comprising CDRs (e.g., one, two, three, four,five, or six CDRs) of antibody Ab1 or Ab21, as described in U.S.Provisional Application No. 61/426,387, filed Dec. 22, 2010. In aparticular embodiment, an antibody described herein is not antibody 37Mor 37C as described in PCT International Patent Application No.PCT/US2012/022471 filed Jan. 25, 2012. In a certain embodiment, anantibody described herein does not comprise a VL domain comprising SEQID NO: 32 or a VH domain comprising SEQ ID NO: 31.

In a particular embodiment, an antibody described herein orantigen-binding fragment thereof, which immunospecifically bind to a KITpolypeptide (e.g., the D4 region of KIT, for example, human KIT), doesnot comprise one or more (e.g., two, three, four, five, or six) CDRs(e.g., VL CDR1, VL CDR2, VL CDR3, VH CDR1, VH CDR2, and VH CDR3) of anantibody described in US Patent Application Publication NO. US2008/0287309, for example antibody 36C1, 84H7, 63C10, or 65A12.

In a specific embodiment, an antibody described herein is not a human orhumanized version of an antibody produced by the hybridoma (BA7.3C.9)having the American Type Culture Collection (ATCC) Accession numberHB10716, as described for example in U.S. Pat. Nos. 5,919,911 or5,489,516. In another specific embodiment, an antibody described hereindoes not comprise the CDRs (e.g., VL CDR1, VL CDR2, VL CDR3, VH CDR1, VHCDR2, and/or VH CDR3) of the antibody produced by the hybridoma(BA7.3C.9) having the American Type Culture Collection (ATCC) Accessionnumber HB10716, as described for example in U.S. Pat. Nos. 5,919,911 or5,489,516. In another specific embodiment, an antibody described hereindoes not comprise the CDRs of the SR-1 antibody described for example inU.S. Pat. Nos. 5,919,911 or 5,489,516 or U.S. Patent ApplicationPublication No. US 2007/0253951 A1 (see, e.g., ¶ [0032] or ¶ [0023]). Ina further embodiment, an antibody described herein is not an antibody ofthe antibody produced by the hybridoma (BA7.3C.9) having the AmericanType Culture Collection (ATCC) Accession number HB10716, as describedfor example in U.S. Pat. Nos. 5,919,911 or 5,489,516.

In a specific embodiment, an antibody described herein is not thehumanized antibodies of the SR-1 antibody as described in U.S. PatentApplication Publication No. US 2007/0253951 A1. In a specificembodiment, an antibody described herein does not comprise one or moreamino acid sequences selected from the group consisting of: SEQ ID NO:2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, and SEQ ID NO: 10referenced in U.S. Patent Application Publication No. US 2007/0253951A1. In a particular embodiment, an antibody described herein does notcomprise the amino acid sequences of SEQ ID NOs: 2 and 4 or of SEQ IDNOs: 2 and 6 referenced in U.S. Patent Application Publication No. US2007/0253951 A1. In a specific embodiment, an antibody described hereindoes not comprise one or more amino acid sequence that is at least 90%identical to the amino acid sequence selected from the group consistingof: SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, and SEQ IDNO: 10 referenced in U.S. Patent Application Publication No. US2007/0253951 A1. In a particular embodiment, an antibody describedherein does not comprise one or more CDRs described in U.S. PatentApplication Publication No. US 2007/0253951 A1, for example, amino acids44 to 58 of SEQ ID NO: 8 (VL CDR1 of antibody SR-1; RASESVDIYGNSFMH),amino acids 74 to 80 of SEQ ID NO: 8 (VL CDR2 of antibody SR-1;LASNLES), amino acids 111 to 121 of SEQ ID NO: 8 (VL CDR3 of antibodySR-1; QQNNEDPYT), amino acids 50 to 54 of SEQ ID NO: 10 (VH CDR1 ofantibody SR-1; SYNMH), amino acids 69 to 85 of SEQ ID NO: 10 (VH CDR2 ofantibody SR-1; VIYSGNGDTSYNQKFKG), and/or amino acids 118 to 125 of SEQID NO: 10 (VH CDR3 of antibody SR-1; RDTRFGN), where SEQ ID NOs: 8 and10 are those referenced in U.S. Patent Application Publication No. US2007/0253951 A1 (see, e.g., ¶ [0032] or ¶[0023]). In a particularembodiment, an antibody described herein does not comprise one or moreCDRs described in U.S. Patent Application Publication No. US2007/0253951 A1, for example, amino acids 43 to 58 of SEQ ID NO: 2 (VLCDR1), amino acids 74 to 80 of SEQ ID NO: 2 (VL CDR2), amino acids 113to 121 of SEQ ID NO: 2 (VL CDR3), amino acids 50 to 54 of SEQ ID NO: 4(VH CDR1), amino acids 69 to 85 of SEQ ID NO: 4 (VH CDR2), and/or aminoacids 118 to 125 of SEQ ID NO: 4 (VH CDR3), where SEQ ID NOs: 2 and 4are those referenced in U.S. Patent Application Publication No. US2007/0253951 A1. In a particular embodiment, an antibody describedherein is not an antibody of antibody SR-1 as described in U.S. PatentApplication Publication No. US 2007/0253951 A1.

In a specific embodiment, an antibody described herein is not anantibody selected from the group consisting of: antibody Anti-S100,ACK2, and ACK4 as described in U.S. Pat. Nos. 6,989,248 or 7,449,309. Ina particular embodiment, an antibody described herein is not a human orhumanized version of an antibody selected from such group. In a specificembodiment, an antibody described herein is not an antibody comprisingone or more CDRs (e.g., 3 VL CDRs and/or 3 VH CDRs) of an antibodyselected from the group consisting of: antibody Anti-S100, ACK2, andACK4 as described in U.S. Pat. Nos. 6,989,248 or 7,449,309.

In certain aspects, competition binding assays can be used to assist inidentifying a target epitope of an antibody or to determine whether anantibody is competitively blocked, e.g., in a dose dependent manner, byanother antibody for example, an antibody that binds essentially thesame epitope, or overlapping epitopes, as a reference antibody, when thetwo antibodies recognize identical or sterically overlapping epitopes incompetition binding assays such as competition ELISA assays, which canbe configured in all number of different formats, using either labeledantigen or labeled antibody. Numerous types of competitive bindingassays are known, for example: solid phase direct or indirectradioimmunoassay (RIA), solid phase direct or indirect enzymeimmunoassay (EIA), sandwich competition assay (see Stahli et al., (1983)Methods in Enzymology 9:242); solid phase direct biotin-avidin EIA (seeKirkland et al., (1986) J. Immunol. 137:3614); solid phase directlabeled assay, solid phase direct labeled sandwich assay (see Harlow andLane, (1988) Antibodies: A Laboratory Manual, Cold Spring Harbor Press);solid phase direct label RIA using 1-125 label (see Morel et al., (1988)Mol. Immunol. 25(1):7); solid phase direct biotin-avidin EIA (Cheung etal., (1990) Virology 176:546); and direct labeled MA. (Moldenhauer etal., (1990) Scand J. Immunol. 32:77). Typically, such an assay involvesthe use of purified antigen (e.g., KIT, such as extracellular domain ofKIT or a D4 region of KIT) bound to a solid surface or cells bearingeither of these, an unlabeled test immunoglobulin and a labeledreference immunoglobulin. Competitive inhibition can be measured bydetermining the amount of label bound to the solid surface or cells inthe presence of the test immunoglobulin. Usually the test immunoglobulinis present in excess. In certain aspects, when a competing antibody ispresent in excess, it will inhibit specific binding of a referenceantibody to a common antigen by at least 50-55%, 55-60%, 60-65%, 65-70%70-75% or more. In a common version of this assay, the antigen isimmobilized on a 96-well plate. The ability of unlabeled antibodies toblock the binding of labeled antibodies to the antigen is then measuredusing radioactive or enzyme labels. For further details see, forexample, Wagener et al., J. Immunol., 1983, 130:2308-2315; Wagener etal., J. Immunol. Methods, 1984, 68:269-274; Kuroki et al., Cancer Res.,1990, 50:4872-4879; Kuroki et al., Immunol. Invest., 1992, 21:523-538;Kuroki et al., Hybridoma, 1992, 11:391-407, and Using Antibodies: ALaboratory Manual, Ed Harlow and David Lane editors (Cold Springs HarborLaboratory Press, Cold Springs Harbor, N.Y., 1999), pp. 386-389.

In certain aspects, an antibody described herein whichimmunospecifically binds to a D4 region of a KIT polypeptide (e.g.,human KIT polypeptide) may be described by its VL chain region (e.g.,any one of SEQ ID NOs: 7-10) or VH chain region (e.g., any one of SEQ IDNOs: 2-6), or by its 3 VL CDRs or its 3 VH CDRs. See, for example, Raderet al., 1998, Proc. Natl. Acad. Sci. USA, 95: 8910-8915, which isincorporated herein by reference in its entirety, which describes thehumanization of the mouse anti-αvβ3 antibody by identifying acomplementing light chain or heavy chain from a human light chain orheavy chain library, respectively, resulting in humanized antibodyvariants having affinities as high or higher than the affinity of theoriginal antibody. See also, Clackson et al., 1991, Nature, 352:624-628,which is incorporated herein by reference in its entirety, describingmethods of producing antibodies that bind a specific antigen by using aspecific VL (or VH) domain and screening a library for the complimentaryvariable domains. The screen produced 14 new partners for a specific VHdomains and 13 new partners for a specific VL domain, which were strongbinders as determined by ELISA.

Thus, in certain aspects, provided herein is an antibody, whichimmunospecifically binds to a D4 region of a KIT polypeptide (e.g.,human KIT polypeptide), comprising a VL domain comprising the amino acidsequence of SEQ ID NO: 7 or 8. In some embodiments, provided herein isan antibody, which immunospecifically binds to a D4 region of a KITpolypeptide (e.g., human KIT polypeptide), comprising a VH domaincomprising the amino acid sequence of SEQ ID NO: 4 or 5.

In certain aspects, the CDRs of an antibody described herein isdetermined according to the method of Chothia and Lesk, 1987, J. Mol.Biol., 196:901-917, which will be referred to herein as the “ChothiaCDRs” (see also, e.g., U.S. Pat. No. 7,709,226). Using the Kabatnumbering system of numbering amino acid residues in the VH chain regionand VL chain region, Chothia CDRs within an antibody heavy chainmolecule are typically present at amino acid positions 26 to 32(“CDR1”), amino acid positions 53 to 55 (“CDR2”), and amino acidpositions 96 to 101 (“CDR3”). Using the Kabat numbering system ofnumbering amino acid residues in the VH chain region and VL chainregion, Chothia CDRs within an antibody light chain molecule aretypically present at amino acid positions 26 to 33 (CDR1), amino acidpositions 50 to 52 (CDR2), and amino acid positions 91 to 96 (CDR3).

In a specific embodiment, the position of a CDR along the VH and/or VLregion of an antibody described herein may vary by one, two, three orfour amino acid positions so long as immunospecific binding to KIT(e.g., the D4 region of human KIT) is maintained (e.g., substantiallymaintained, for example, at least 50%, at least 60%, at least 70%, atleast 80%, at least 90%, at least 95%). For example, in one embodiment,the position defining a CDR of an antibody described herein may vary byshifting the N-terminal and/or C-terminal boundary of the CDR by one,two, three, or four, amino acids, relative to the CDR position depictedin FIGS. 3A-31, so long as immunospecific binding to KIT (e.g., the D4region) is maintained (e.g., substantially maintained, for example, atleast 50%, at least 60%, at least 70%, at least 80%, at least 90%, atleast 95%).

In specific aspects, provided herein is an antibody comprising anantibody light chain and heavy chain, e.g., a separate light chain andheavy chain. With respect to the light chain, in a specific embodiment,the light chain of an antibody described herein is a kappa light chain.In another specific embodiment, the light chain of an antibody describedherein is a lambda light chain. In yet another specific embodiment, thelight chain of an antibody described herein is a human kappa light chainor a human lambda light chain. In a particular embodiment, an antibodydescribed herein, which immunospecifically binds to a KIT polypeptide(e.g., a KIT polypeptide comprising a D4 region of KIT, for examplehuman KIT (e.g., SEQ ID NO: 15)) comprises a light chain wherein theamino acid sequence of the VL chain region comprises any amino acidsequence described herein (e.g., SEQ ID NO: 7, 8, 9, or 10), and whereinthe constant region of the light chain comprises the amino acid sequenceof a human kappa light chain constant region. Non-limiting examples ofhuman light chain constant region sequences have been described in theart, e.g., see U.S. Pat. No. 5,693,780 and Kabat et al. (1991) Sequencesof Proteins of Immunological Interest, Fifth Edition, U.S. Department ofHealth and Human Services, NIH Publication No. 91-3242.

With respect to the heavy chain, in a specific embodiment, the heavychain of an antibody described herein can be an alpha (α), delta (δ),epsilon (ε), gamma (γ) or mu (μ) heavy chain. In another specificembodiment, the heavy chain of an antibody described can comprise ahuman alpha (α), delta (δ), epsilon (ε), gamma (γ) or mu (μ) heavychain. In a particular embodiment, an antibody described herein, whichimmunospecifically binds to a KIT polypeptide (e.g., a KIT polypeptidecomprising a KIT polypeptide comprising a D4 region of KIT, for examplehuman KIT (e.g., SEQ ID NO: 15)), comprises a heavy chain wherein theamino acid sequence of the VH chain region can comprise any amino acidsequence described herein (e.g., any of SEQ ID NOs: 2-6), and whereinthe constant region of the heavy chain comprises the amino acid sequenceof a human gamma (γ) heavy chain constant region. Non-limiting examplesof human heavy chain constant region sequences have been described inthe art, e.g., see U.S. Pat. No. 5,693,780 and Kabat et al. (1991)Sequences of Proteins of Immunological Interest, Fifth Edition, U.S.Department of Health and Human Services, NIH Publication No. 91-3242.

In a specific embodiment, an antibody described herein, whichimmunospecifically binds to a KIT polypeptide (e.g., a D4 region of KIT,for example human KIT) comprises a VL chain region and a VH chain regioncomprising any amino acid sequences described herein, and wherein theconstant regions comprise the amino acid sequences of the constantregions of an IgG, IgE, IgM, IgD, IgA or IgY immunoglobulin molecule, ora human IgG, IgE, IgM, IgD, IgA or IgY immunoglobulin molecule. Inanother specific embodiment, an antibody described herein, whichimmunospecifically binds to a KIT polypeptide (e.g., a D4 region of KIT,for example human KIT) comprises a VL chain region and a VH chain regioncomprising any amino acid sequences described herein, and wherein theconstant regions comprise the amino acid sequences of the constantregions of an IgG, IgE, IgM, IgD, IgA or IgY immunoglobulin molecule,any class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2), or any subclass(e.g., IgG2a and IgG2b) of immunoglobulin molecule. In a particularembodiment, the constant regions comprise the amino acid sequences ofthe constant regions of a human IgG, IgE, IgM, IgD, IgA or IgYimmunoglobulin molecule, any class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1and IgA2), or any subclass (e.g., IgG2a and IgG2b) of immunoglobulinmolecule.

In yet another specific embodiment, an antibody described herein, whichimmunospecifically binds to a KIT polypeptide (e.g., a D4 region of KIT,for example human KIT), comprises a VL chain region and a VH chainregion comprising any amino acid sequences described herein (e.g., anyone of SEQ ID NOs: 2-6 and/or any one of SEQ ID NOs: 7-10), and whereinthe constant regions comprise the amino acid sequences of the constantregions of a human IgG1 or human IgG4. In a particular embodiment, anantibody described herein, which immunospecifically binds to a KITpolypeptide (e.g., a D4 region of KIT, for example human KIT) comprisesa VL chain region and a VH chain region comprising any amino acidsequences described herein, and wherein the constant regions comprisethe amino acid sequences of the constant region of a human IgG1.

In specific embodiments, an antibody described herein, whichimmunospecifically bind to a KIT polypeptide, e.g., a human KITpolypeptide, for example, a D4 region of KIT (e.g., human KIT, forexample SEQ ID NO: 15), comprises framework regions (e.g., frameworkregions of the VL domain and/or VH domain) that are human frameworkregions or derived from human framework regions. Non-limiting examplesof human framework regions are described in the art, e.g., see Kabat etal. (1991) Sequences of Proteins of Immunological Interest, FifthEdition, U.S. Department of Health and Human Services, NIH PublicationNo. 91-3242). In a certain embodiment, an antibody described hereincomprises framework regions (e.g., framework regions of the VL domainand/or VH domain) that are primate (e.g., non-human primate) frameworkregions or derived from primate (e.g., non-human primate) frameworkregions.

In certain examples, an antibody described herein comprises frameworkregions (e.g., framework regions of the VL domain and/or VH domain) thatare not primate (e.g., non-human primate, for example, ape such as OldWorld ape) framework regions or derived from primate (e.g., non-humanprimate) framework regions.

In certain examples, with respect to any of these antibodies describedherein, the VL chain region does not comprise non-human primate (e.g.,ape such as Old World ape) framework regions or is derived fromnon-human primate (e.g., ape such as Old World ape) framework regions.In certain other embodiments, the VH chain region does not comprisenon-human primate (e.g., ape such as Old World ape) framework regions oris derived from non-human primate (e.g., ape such as Old World ape)framework regions.

Non-limiting examples of non-human primate framework regions includethose from Old World apes, e.g., Pan troglodytes, Pan paniscus orGorilla gorilla; chimpanzee Pan troglodytes; Old World monkey such asOld World monkey from the genus Macaca; and cynomolgus monkey Macacacynomolgus. Non-limiting examples of non-human primate frameworksequences are described in U.S. Patent Application Publication No. US2005/0208625.

In certain aspects, also provided herein are antibodies, whichimmunospecifically binds to a KIT polypeptide (e.g., a D4 region of KIT,for example human KIT), comprising one or more amino acid residuesubstitutions, e.g., in the VL chain region or VH chain region, forexample, the CDRs or FRs. In specific embodiments, none of the aminoacid residue substitutions are located within the CDRs. In specificembodiments, all of the amino acid substitutions are in the FRs (see,e.g., Tables 5A-6B). In a certain embodiment, an amino acid substitutionis a conservative amino acid substitution.

As used herein, a “conservative amino acid substitution” is one in whichthe amino acid residue is replaced with an amino acid residue having aside chain with a similar charge. Families of amino acid residues havingside chains with similar charges have been defined in the art. Thesefamilies include amino acids with basic side chains (e.g., lysine,arginine, histidine), acidic side chains (e.g., aspartic acid, glutamicacid), uncharged polar side chains (e.g., glycine, asparagine,glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains(e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine,methionine, tryptophan), beta-branched side chains (e.g., threonine,valine, isoleucine) and aromatic side chains (e.g., tyrosine,phenylalanine, tryptophan, histidine).

In particular embodiments, the glycosylation of antibodies describedherein is modified. For example, an aglycoslated antibody can be made(i.e., the antibody lacks glycosylation) or an antibody comprising amutation or substitution at one or more glycosylation sites to eliminateglycosylation at the one or more glycosylation sites can be made.Glycosylation can be altered to, for example, increase the affinity ofthe antibody for a target antigen (e.g., human KIT, for example, a D4region of human KIT). Such carbohydrate modifications can beaccomplished by, for example, altering one or more sites ofglycosylation within the antibody sequence. For example, one or moreamino acid substitutions can be made that result in elimination of oneor more variable region (e.g., VL and/or VH CDRs or VL and/or VH FRs)glycosylation sites to thereby eliminate glycosylation at that site.Such aglycosylation can increase the affinity of the antibody forantigen (e.g., human KIT, for example, a D4 region of human KIT). Suchan approach is described in further detail in U.S. Pat. Nos. 5,714,350and 6,350,861.

Glycosylation can occur via N-linked (or asparagine-linked)glycosylation or O-linked glycosylation. N-linked glycosylation involvescarbohydrate modification at the side-chain NH₂ group of an asparagineamino acid in a polypeptide. O-linked glycosylation involvescarbohydrate modification at the hydroxyl group on the side chain of aserine, threonine, or hydroxylysine amino acid.

In specific embodiments, an asparagine (N) residue within a VH (e.g.,SEQ ID NO: 2, 3, 4, 5, or 6) or VL region (e.g., SEQ ID NO: 7, 8, 9, or10) of an antibody described herein is substituted with a serine (S) oranother amino acid (e.g., alanine, glycine, glutamine, threonine,tyrosine, cysteine). In other specific embodiments, an asparagine (N)residue within a VH CDR (e.g., VH CDR1, VH CDR2, and/or VH CDR3comprising the sequences of SEQ ID NOs: 16-18, respectively) and/or a VLCDR (e.g., VL CDR1, VL CDR2, and/or VL CDR3 comprising the sequences ofSEQ ID NOs: 19-21, respectively) of an antibody described herein issubstituted with a serine (S) or another amino acid (e.g., alanine,glycine, glutamine, threonine, tyrosine, cysteine). In other specificembodiments, an asparagine (N) residue within a VH FR (e.g., VH FR1, VHFR2, VH FR3 and/or VH FR4 as set forth in Tables 5A, 5C, and 6B) and/ora VL FR (e.g., VL FR1, VL FR2, VL FR3, and/or VL FR4 as set forth inTable 5B, 5D, and 6A) of an antibody described herein is substitutedwith a serine (S) or another amino acid (e.g., alanine, glycine,glutamine, threonine, tyrosine, cysteine).

In certain embodiments, aglycosylated antibodies can be produced inbacterial cells which lack the necessary glycosylation machinery. Cellswith altered glycosylation machinery have been described in the art andcan be used as host cells in which to express recombinant antibodiesdescribed herein to thereby produce an antibody with alteredglycosylation. See, for example, Shields, R. L. et al. (2002) J. Biol.Chem. 277:26733-26740; Umana et al. (1999) Nat. Biotech. 17:176-1, aswell as, European Patent No: EP 1,176,195; PCT Publications WO03/035835; WO 99/54342.

In certain embodiments, one or more modifications can be made to the Fcregion of an antibody described here, generally, to alter one or morefunctional properties of the antibody, such as serum half-life,complement fixation, Fc receptor binding, and/or antibody-dependentcellular cytotoxicity. These modifications are described, for example,in International Patent Application Publication No. WO 2008/153926 A2.

In specific embodiments, an asparagine (N) residue within the constantregion of a heavy chain and/or the constant region of a light region ofan antibody described herein is substituted with a serine (S) or anotheramino acid (e.g., alanine, glycine, glutamine, threonine, tyrosine,cysteine).

In specific embodiments, an asparagine (N) residue within a heavy chainand/or a light region of an antibody described herein is substitutedwith a serine (S) or another amino acid (e.g., alanine, glycine,glutamine, threonine, tyrosine, cysteine).

Provided herein are antibodies that immunospecifically bind to KITantigen and that can modulate KIT activity. In certain embodiments, anantibody provided herein immunospecifically binds to a KIT polypeptide,e.g., a human KIT polypeptide, and inhibits a KIT activity. KIT activitycan relate to any activity of KIT known or described in the art, e.g.,KIT receptor dimerization, KIT receptor phosphorylation (tyrosinephosphorylation), signaling downstream of the KIT receptor (e.g., AKT,MAPK/ERK, Ras, Stat1, Stat3, or Stat5 signaling), KIT ligand (e.g., SCF)induced transcriptional regulation (e.g., SCF-induced transcriptionalactivation of c-Myc), induction or enhancement of cell proliferation, orcell survival. KIT activity or KIT function are used interchangeablyherein. In certain aspects, KIT activity is induced by KIT ligand (e.g.,SCF) binding to KIT receptor. In particular aspects, KIT activity can beinduced or enhanced by gain-of-function mutations which can result, forexample, in dimerization and constitutively active KIT signaling (see,e.g., Mol et al., J. Biol. Chem., 2003, 278:31461-31464; Hirota et al.,J. Pathology, 2001, 193:505-510). Such gain-of-function can allow forKIT receptor dimerization and KIT signaling to occur in the absence ofKIT ligand (e.g., SCF) binding to KIT receptor. In certain embodiments,an increase in KIT activity or signaling can occur, in the absence ofKIT ligand (e.g., SCF) binding KIT receptor, due to high (oroverexpression) expression of KIT receptors. High or overexpression ofKIT in a cell refers to an expression level which is at least about 10%,20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% more than the expressionlevel of a reference cell known to have normal KIT expression or KITactivity or more than the average expression level of KIT in apopulation of cells or samples known to have normal KIT expression orKIT activity. Expression levels of KIT can be assessed by methodsdescribed herein or known to one of skill in the art (e.g., Westernblotting or immunohistochemistry). In particular embodiments, KITactivity that is higher than normal KIT activity can lead to cellulartransformation, neoplasia, and tumorogenesis. In particular embodiments,KIT activity that is higher than normal KIT activity can lead to otherKIT-associated disorders or diseases.

In certain embodiments, an anti-KIT antibody described herein does notblock or inhibit binding of KIT ligand (e.g., SCF) to KIT receptor. Incertain embodiments, an anti-KIT antibody described herein onlynegligibly (e.g., less than about 2% or 3%) inhibits or reduces bindingof KIT ligand (e.g., SCF) to KIT receptor. In certain embodiments, ananti-KIT antibody described herein does not induce or enhancedissociation of KIT ligand (e.g., SCF) from the KIT receptor. In certainembodiments, an anti-KIT antibody described herein only negligibly(e.g., less than about 2% or 3%) induces or enhances dissociation of KITligand (e.g., SCF) from the KIT receptor.

In certain embodiments, an anti-KIT antibody described herein does notblock or inhibit KIT receptor dimerization. In certain embodiments, ananti-KIT antibody described herein only negligibly (e.g., less thanabout 2% or 3% or within a standard of error or deviation) inhibits orreduces KIT receptor dimerization. In certain embodiments, an anti-KITantibody described herein does not induce or enhance KIT receptor dimerdissociation. In certain embodiments, an anti-KIT antibody describedherein only negligibly (e.g., less than about 2% or 3% or within astandard of error or deviation) induces or enhances KIT receptor dimerdissociation. In a particular embodiment, an anti-KIT antibody describedherein can specifically bind to a KIT receptor dimer and do not block orinhibit KIT receptor dimerization. In a particular embodiment, ananti-KIT antibody described herein can specifically bind to a KITreceptor monomer and do not block or inhibit KIT receptor dimerization.

In certain aspects, as an inhibitor of KIT activity, an antibodydescribed herein can block or inhibit (e.g., partially inhibit)dimerization of KIT. Generally, KIT receptor dimerization is inducedwhen KIT ligand binds to KIT. Thus, in specific embodiments, antibodiesdescribed herein specifically bind to KIT and block or inhibit (e.g.,partially inhibit) dimerization of KIT receptors by at least about 5%,10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%,80%, 85%, 90%, 95%, 98%, or 99% as assessed by methods described hereinor known to one of skill in the art, e.g., immunoprecipitation assay,relative to dimerization of KIT receptors in the presence of KIT ligandstimulation without any antibody or with an unrelated antibody (e.g., anantibody that does not immunospecifically bind to KIT). In a specificembodiment, antibodies described herein specifically bind to KIT andpartially inhibit dimerization of KIT receptors by about 25% to 75%.Blocking or inhibition (e.g., partial inhibition) of dimerization of KITreceptors by antibodies described herein can be assessed in thepresences of KIT ligand stimulation. For example, cells expressing KITare contacted with KIT ligand in the presence or absence of anti-KITantibodies described herein, and the level of KIT receptor dimerizationis determined. In certain embodiments, KIT ligand induced KIT receptordimerization in the absence of anti-KIT antibody is at least about 1fold, 1.2 fold, 1.3 fold, 1.4 fold, 1.5 fold, 2 fold, 2.5 fold, 3 fold,3.5 fold, 4 fold, 4.5 fold, 5 fold, 6 fold, 7 fold, 8 fold, 9 fold, 10fold, 15 fold, 20 fold, 30 fold, 40 fold, 50 fold, 60 fold, 70 fold, 80fold, 90 fold, or 100 fold higher than KIT receptor dimerization in thepresence of anti-KIT antibody as assessed by methods described herein orknown to one of skill in the art (e.g., immunoprecipitation assays).Tyrosine phosphorylation of one or more residues in the cytoplasmicdomain of KIT can be an indicator of KIT receptor dimerization.

In certain embodiments, an antibody described herein can inhibit (e.g.,partially inhibit) KIT activity by at least about 10%, 15%, 20%, 25%,30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%,98%, or 99% as assessed by methods described herein and/or known to oneof skill in the art, relative to KIT activity in the presence of KITligand stimulation without any antibody or with an unrelated antibody(e.g., an antibody that does not immunospecifically bind to KIT). Incertain embodiments, an antibody described herein can inhibit (e.g.,partially inhibit) KIT activity by at least about 25% to about 65% asassessed by methods described herein and/or known to one of skill in theart, relative to KIT activity in the presence of KIT ligand stimulationwithout any antibody or with an unrelated antibody (e.g., an antibodythat does not immunospecifically bind to KIT). Non-limiting examples ofKIT activity can include KIT receptor phosphorylation, KIT receptorsignaling, KIT ligand (e.g., SCF) mediated cell proliferation, KITligand (e.g., SCF) mediated cell survival, and transcriptionalactivation of a KIT target gene (e.g., c-Myc).

As an inhibitor of KIT activity, an antibody described herein (or anantigen-binding fragment thereof, or a conjugate thereof) can block(e.g., partially block) or inhibit (e.g., partially inhibit)phosphorylation of KIT, specifically tyrosine phosphorylation of one ormore residues in the cytoplasmic domain of KIT. Generally, KIT receptordimerization and phosphorylation is induced when KIT ligand binds toKIT. However, in certain aspects, KIT receptor dimerization and/orphosphorylation can occur independently of KIT ligand binding to KITreceptor. For example KIT receptor dimerization and/or phosphorylationcan occur due to gain-of-function mutations or overexpression of KIT.

Non-limiting examples of tyrosine residues in the cytoplasmic domain ofmurine KIT that can be phosphorylated, e.g., upon ligand stimulation,include 544, 546, 552, 567, 569, 577, 608, 645, 671, 674, 702, 719, 728,745, 772, 821, 844, 853, 868, 878, 898, and 934 (see Ueda et al., Blood,2002, 99:3342-3349). The corresponding tyrosine residues in thecytoplasmic domain of human KIT can be readily determined. Non-limitingexamples of tyrosine residues in the cytoplasmic domain of human KIT(e.g., GenBank Accession No. P10721) that can be phosphorylated, e.g.,upon ligand stimulation, include residues 568, 570, 703, 721, 730, 747,823, 900, and 936. In a specific embodiment, an anti-KIT antibodydescribed herein can inhibit receptor phosphorylation at tyrosineresidue 719 of murine KIT. In another specific embodiment, an anti-KITantibody described herein can inhibit receptor phosphorylation attyrosine residue 703 or 721 of human KIT.

Thus, in specific embodiments, antibodies described herein (or anantigen-binding fragment thereof, or a conjugate thereof) specificallybind to KIT and block or inhibit tyrosine phosphorylation in thecytoplasmic domain of KIT by at least about 10%, 15%, 20%, 25%, 30%,35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or99% as assessed by methods described herein or known to one of skill inthe art, e.g., ELISA assay as described in section 6 or immunoblottingassay, relative to phosphorylation in the presence of KIT ligandstimulation without any antibody or with an unrelated antibody (e.g., anantibody that does not immunospecifically bind to KIT). In particularembodiments, antibodies described herein specifically bind to KIT andblock or inhibit tyrosine phosphorylation in the cytoplasmic domain ofKIT by at least about 25%, optionally to about 65% or 75%, as assessedby methods described herein or known to one of skill in the art, e.g.,ELISA assay as described in section 6 or immunoblotting assay. Incertain embodiments, antibodies described herein specifically bind toKIT and block or inhibit tyrosine phosphorylation of the cytoplasmicdomain of KIT by at least about 25% to about 80% as assessed by methodsdescribed herein or known to one of skill in the art, e.g., ELISA assayas described in section 6 or immunoblotting assay. In specificembodiments, antibodies described herein specifically bind to KIT andblock or inhibit tyrosine phosphorylation of the cytoplasmic domain ofKIT with an IC₅₀ of less than about 600 pM, or less than about 550 pM,or less than about 500 pM, or less than about 400 pM or less than about300 pM as assessed by methods described herein (e.g., phosphorylationinhibition assay with CHO cells expressing wild-type KIT as described inSection 6 below) or known to one of skill in the art. In specificembodiments, antibodies described herein specifically bind to KIT andblock or inhibit tyrosine phosphorylation of the cytoplasmic domain ofKIT with an IC₅₀ of less than about 600 pM. In specific embodiments,antibodies described herein specifically bind to KIT and block orinhibit tyrosine phosphorylation of the cytoplasmic domain of KIT withan IC₅₀ of less than about 550 pM. In specific embodiments, antibodiesdescribed herein specifically bind to KIT and block or inhibit tyrosinephosphorylation of the cytoplasmic domain of KIT with an IC₅₀ in therange of about 100 pM to about 500 pM, about 25 pM to about 550 pM, orabout 40 pM to about 600 pM, or about 50 pM to about 350 pM. Forexample, an IC₅₀ for inhibition of tyrosine phosphorylation can bedetermined by assaying lysates from cells, e.g., CHO cells,recombinantly expressing KIT, in ELISA which detects tyrosinephosphorylation, for example, as described in Section 6 below. Incertain embodiments, cells, e.g., CHO cells, recombinantly expressingKIT, are sorted, e.g., sorted to select for cells highly expressing KIT,prior to use in the phosphorylation inhibition assays. In someembodiments, the cells are not sorted prior to use in thephosphorylation inhibition assays.

In specific embodiments, antibodies described herein (or anantigen-binding fragment thereof, or a conjugate thereof) specificallybind to KIT and reduce tyrosine phosphorylation of the cytoplasmicdomain of KIT by at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%,50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% asassessed by methods described herein or known to one of skill in theart, e.g., ELISA assay as described in section 6 or immunoblottingassay, relative to phosphorylation in the presence of KIT ligandstimulation without any antibody or with an unrelated antibody (e.g., anantibody that does not immunospecifically bind to KIT). In specificembodiments, antibodies described herein (or an antigen-binding fragmentthereof, or a conjugate thereof) specifically bind to KIT and reducetyrosine phosphorylation of the cytoplasmic domain of KIT by at leastabout 25% or 35%, optionally to about 75% as assessed by methodsdescribed herein or known to one of skill in the art, e.g., ELISA assayas described in section 6 or immunoblotting assay, relative tophosphorylation in the presence of KIT ligand stimulation without anyantibody or with an unrelated antibody (e.g., an antibody that does notimmunospecifically bind to KIT).

In specific embodiments, antibodies described herein specifically bindto KIT and block or inhibit phosphorylation of one or more tyrosineresidues in the cytoplasmic domain of KIT by at least about 10%, 15%,20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%,90%, 95%, 98%, or 99% as assessed by methods described herein or knownto one of skill in the art, e.g., immunoblotting assay, relative tophosphorylation in the presence of KIT ligand stimulation without anyantibody or with an unrelated antibody (e.g., an antibody that does notimmunospecifically bind to KIT). In specific embodiments, blocking orinhibition (e.g., partial inhibition) of phosphorylation of one or moretyrosine residues of the cytoplasmic domain of KIT by antibodiesdescribed herein can be assessed upon KIT ligand stimulation. Forexample, cells expressing KIT are contacted with KIT ligand in thepresence or absence of anti-KIT antibodies described herein, and thelevel of phosphorylation of one or more tyrosine residues in thecytoplasmic domain of KIT can be determined. In certain embodiments, KITligand induced phosphorylation of one or more tyrosine residues of thecytoplasmic domain of KIT the absence of anti-KIT antibody is at leastabout 1 fold, 1.2 fold, 1.3 fold, 1.4 fold, 1.5 fold, 2 fold, 2.5 fold,3 fold, 3.5 fold, 4 fold, 4.5 fold, 5 fold, 6 fold, 7 fold, 8 fold, 9fold, 10 fold, 15 fold, 20 fold, 30 fold, 40 fold, 50 fold, 60 fold, 70fold, 80 fold, 90 fold, or 100 fold higher than KIT ligand inducedphosphorylation of one or more tyrosine residues of the cytoplasmicdomain of KIT in the presence of anti-KIT antibody, as assessed bymethods described herein or known to one of skill in the art (e.g.,immunoblotting assays), relative to phosphorylation in the presence ofKIT ligand stimulation without any antibody or with an unrelatedantibody (e.g., an antibody that does not immunospecifically bind toKIT).

In specific embodiments, antibodies described herein (or anantigen-binding fragment thereof, or a conjugate thereof) specificallybind to KIT and induce or enhance KIT receptor internalization by atleast about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%,65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% as assessed by methodsdescribed herein or known to one of skill in the art, relative tointernalization in the presence of an unrelated antibody (e.g., anantibody that does not immunospecifically bind to KIT). In specificembodiments, antibodies described herein (or an antigen-binding fragmentthereof, or a conjugate thereof) specifically bind to KIT and induce orenhance KIT receptor internalization by at least about 25% or 35%,optionally to about 75%, as assessed by methods described herein orknown to one of skill in the art, relative to internalization in thepresence of an unrelated antibody (e.g., an antibody that does notimmunospecifically bind to KIT). In specific embodiments, antibodiesdescribed herein specifically bind to KIT and induce or enhance KITreceptor internalization by at least about 1 fold, 1.2 fold, 1.3 fold,1.4 fold, 1.5 fold, 2 fold, 2.5 fold, 3 fold, 3.5 fold, 4 fold, 4.5fold, 5 fold, 6 fold, 7 fold, 8 fold, 9 fold, 10 fold, 15 fold, 20 fold,30 fold, 40 fold, 50 fold, 60 fold, 70 fold, 80 fold, 90 fold, or 100fold as assessed by methods described herein or known to one of skill inthe art, relative to internalization in the presence of an unrelatedantibody (e.g., an antibody that does not immunospecifically bind toKIT). Techniques for the quantitation or visualization of cell surfacereceptors are well known in the art and include a variety of fluorescentand radioactive techniques. For example, one method involves incubatingthe cells with a radiolabeled anti-receptor antibody. Alternatively, thenatural ligand of the receptor can be conjugated to a fluorescentmolecule or radioactive-label and incubated with the cells. Additionalreceptor internalization assays are well known in the art and aredescribed in, for example, Jimenez et al., Biochemical Pharmacology,1999, 57:1125-1131; Bernhagen et al., Nature Medicine, 2007, 13:587-596;and Conway et al., J. Cell Physiol., 2001, 189:341-55.

In specific embodiments, antibodies described herein specifically bindto KIT and induce or enhance KIT receptor turnover by at least about 5%,10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%,80%, 85%, 90%, 95%, 98%, or 99% as assessed by methods described hereinor known to one of skill in the art (e.g., pulse-chase assay), relativeto turnover in the presence of an unrelated antibody (e.g., an antibodythat does not immunospecifically bind to KIT). In specific embodiments,antibodies described herein (or an antigen-binding fragment thereof, ora conjugate thereof) specifically bind to KIT and induce or enhance KITreceptor turnover by at least about 25% or 35%, optionally to about 75%,as assessed by methods described herein or known to one of skill in theart (e.g., pulse-chase assay), relative to turnover in the presence ofan unrelated antibody (e.g., an antibody that does notimmunospecifically bind to KIT). In specific embodiments, antibodiesdescribed herein specifically bind to KIT and induce or enhance KITreceptor turnover by at least about 1 fold, 1.2 fold, 1.3 fold, 1.4fold, 1.5 fold, 2 fold, 2.5 fold, 3 fold, 3.5 fold, 4 fold, 4.5 fold, 5fold, 6 fold, 7 fold, 8 fold, 9 fold, 10 fold, 15 fold, 20 fold, 30fold, 40 fold, 50 fold, 60 fold, 70 fold, 80 fold, 90 fold, or 100 foldas assessed by methods described herein or known to one of skill in theart (e.g., pulse-chase assay), relative to turnover in the presence ofan unrelated antibody (e.g., an antibody that does notimmunospecifically bind to KIT). Methods for the determining receptorturnover are well known in the art. For example, cells expressing KITcan be pulse-labeled using ³⁵S-EXPRESS Protein Labeling mix (NEG772, NENLife Science Products), washed and chased with unlabeled medium for aperiod of time before protein lysates from the labeled cells areimmunoprecipitated using an anti-KIT antibody and resolved by SDS-PAGEand visualized (e.g., exposed to a Phospholmager screen (MolecularDynamics), scanned using the Typhoon8600 scanner (Amersham), andanalyzed using ImageQuant software (Molecular Dynamics)) (see, e.g.,Chan et al., Development, 2004, 131:5551-5560).

In specific embodiments, antibodies described herein specifically bindto KIT and induce or enhance KIT receptor degradation by at least about5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%,75%, 80%, 85%, 90%, 95%, 98%, or 99% as assessed by methods describedherein or known to one of skill in the art (e.g., pulse-chase assays),relative to degradation in the presence of an unrelated antibody (e.g.,an antibody that does not immunospecifically bind to KIT). In specificembodiments, antibodies described herein specifically bind to KIT andinduce or enhance KIT receptor degradation by at least about 25% or 35%,optionally to about 75%, as assessed by methods described herein orknown to one of skill in the art (e.g., pulse-chase assays), relative todegradation in the presence of an unrelated antibody (e.g., an antibodythat does not immunospecifically bind to KIT). In specific embodiments,antibodies described herein specifically bind to KIT and induce orenhance KIT receptor degradation by at least about 1 fold, 1.2 fold, 1.3fold, 1.4 fold, 1.5 fold, 2 fold, 2.5 fold, 3 fold, 3.5 fold, 4 fold,4.5 fold, 5 fold, 6 fold, 7 fold, 8 fold, 9 fold, 10 fold, 15 fold, 20fold, 30 fold, 40 fold, 50 fold, 60 fold, 70 fold, 80 fold, 90 fold, or100 fold as assessed by methods described herein or known to one ofskill in the art (e.g., pulse-chase assays), relative to degradation inthe presence of an unrelated antibody (e.g., an antibody that does notimmunospecifically bind to KIT). Techniques for quantitating ormonitoring ubiquitination and/or degradation (e.g., kinetics or rate ofdegradation) of cell surface receptors are well known in the art andinvolve a variety of fluorescent and radioactive techniques (see, e.g.,International Patent Application Publication No. WO 2008/153926 A2). Forexample, pulse chase experiments or experiments using radiolabeledligands such as ¹²⁵I-SCF can be carried out to quantitatively measuredegradation of KIT.

Moreover, signaling events downstream of KIT receptor phosphorylationcan serve as indicators of KIT activity. For example, KIT ligand (e.g.,SCF) binding to its receptor KIT stimulates several distinct signalingpathways, including for example members of Src family kinases,phosphatidylinositol (PI) 3-kinases, and Ras mitogen-activated proteinkinase (MAPK) (see Munugalavadla et al., Mol. Cell. Biol., 2005,25:6747-6759). Phosphorylated tyrosines in the cytoplasmic domain of KITcan provide for binding sites for SH2 domain-containing proteins, whichinclude, but are not limited to, proteins of the p21Ras-mitogenactivated protein kinase (MAPK) pathway, the p85 subunit of PI 3-kinase,phospholipase C-gamma₁, the Grb2 adaptor protein, the Src family kinases(SFKs), Cbl, CRKL, p62Dok-1, SHP1, and SHP2 (see Ueda et al., Blood,2002, 99:3342-3349).

Thus, in certain aspects, anti-KIT antibodies described herein which actas inhibitors of KIT activity can inhibit signaling of a member of theSrc family kinases, PI 3-kinases, or Ras-MAPK. In particularembodiments, anti-KIT antibodies described herein which act asinhibitors of KIT activity can inhibit binding (or inhibit interaction),to the cytoplasmic domain of KIT, of one or more SH2 domain-containingproteins, such as proteins of the p21Ras-MAPK pathway, the p85 subunitof PI 3-kinase, phospholipase C-gamma1, the Grb2 adaptor protein, amember of the SFK, Cbl, CRKL, p62Dok-1, SHP1, and SHP2. In certainembodiments, anti-KIT antibodies described herein which act asinhibitors of KIT activity can inhibit activation by KIT of one or moreSH2 domain-containing proteins, such as proteins of the p21Ras-MAPKpathway, the p85 subunit of PI 3-kinase, phospholipase C-gamma1, theGrb2 adaptor protein, a member of the SFK, Cbl, CRKL, p62Dok-1, SHP1,and SHP2.

In particular embodiments, anti-KIT antibodies described herein whichact as inhibitors of KIT activity can inhibit downstream signaling suchas phosphorylation of MAPK, phosphorylation of AKT, or phosphorylationof Stat1, Stat3, or Stat5. Thus, in certain embodiments, an anti-KITantibody described herein can inhibit or reduce phosphorylation of MAPK(e.g., KIT ligand (e.g., SCF) induced phosphorylation of MAPK) by atleast about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%,65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% as assessed by methodsdescribed herein or known to one of skill in the art, e.g., Western blotor ELISA assay as described in section 6 or immunoblotting assay,relative to phosphorylation in the presence of KIT ligand stimulationwithout any antibody or with an unrelated antibody (e.g., an antibodythat does not immunospecifically bind to KIT). In certain embodiments,an anti-KIT antibody described herein can inhibit or reducephosphorylation of AKT (e.g., KIT ligand (e.g., SCF) inducedphosphorylation of AKT) by at least about 5%, 10%, 15%, 20%, 25%, 30%,35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or99% as assessed by methods described herein or known to one of skill inthe art, e.g., Western blot or ELISA assay as described in section 6 orimmunoblotting assay, relative to phosphorylation in the presence of KITligand stimulation without any antibody or with an unrelated antibody(e.g., an antibody that does not immunospecifically bind to KIT). Inparticular embodiments, an anti-KIT antibody described herein caninhibit or reduce phosphorylation of Stat3 (e.g., KIT ligand (e.g., SCF)induced phosphorylation of Stat3) by at least about 5%, 10%, 15%, 20%,25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%,95%, 98%, or 99% as assessed by methods described herein or known to oneof skill in the art, e.g., Western blot or ELISA assay as described insection 6 or immunoblotting assay, relative to phosphorylation in thepresence of KIT ligand stimulation without any antibody or with anunrelated antibody (e.g., an antibody that does not immunospecificallybind to KIT). In particular embodiments, an anti-KIT antibody describedherein can inhibit or reduce phosphorylation of Stat1 or Stat5 (e.g.,KIT ligand (e.g., SCF) induced phosphorylation) by at least about 5%,10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%,80%, 85%, 90%, 95%, 98%, or 99% as assessed by methods described hereinor known to one of skill in the art, e.g., Western blot or ELISA assayas described in section 6 or immunoblotting assay, relative tophosphorylation in the presence of KIT ligand stimulation without anyantibody or with an unrelated antibody (e.g., an antibody that does notimmunospecifically bind to KIT).

In certain aspects, an anti-KIT antibody described herein which can actas an inhibitor of KIT activity or activity can inhibit cellularproliferation of cells (e.g., cancer cells such as TF-1 cells) thatexpress KIT and that respond to KIT signaling (e.g., cells thatproliferate in response to KIT ligand stimulation and KIT signaling).Cell proliferation assays are described in the art and can be readilycarried out by one of skill in the art. For example, cell proliferationcan be assayed by measuring Bromodeoxyuridine (BrdU) incorporation (see,e.g., Hoshino et al., 1986, Int. J. Cancer 38, 369; Campana et al.,1988, J. Immunol. Meth. 107:79) or (3H) thymidine incorporation (see,e.g., Blechman et al., Cell, 1995, 80:103-113; Chen, J., 1996, Oncogene13:1395-403; Jeoung, J., 1995, J. Biol. Chem. 270:18367 73), by directcell count at various time intervals (e.g., 12-hour or 24-hourintervals), or by detecting changes in transcription, translation oractivity of known genes such as proto-oncogenes (e.g., fos, myc) or cellcycle markers (Rb, cdc2, cyclin A, D1, D2, D3, E, etc). The levels ofsuch protein and mRNA and activity can be determined by any method wellknown in the art. For example, protein can be quantitated by knownimmunodiagnostic methods such as ELISA, Western blotting orimmunoprecipitation using antibodies, including commercially availableantibodies. mRNA can be quantitated using methods that are well knownand routine in the art, for example, using northern analysis, RNaseprotection, or polymerase chain reaction in connection with reversetranscription.

In specific embodiments, antibodies described herein specifically bindto KIT and inhibit cell proliferation by at least about 5%, 10%, 15%,20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%,90%, 95%, 98%, or 99% as assessed by methods described herein or knownto one of skill in the art (e.g., BrdU incorporation assay). In specificembodiments, antibodies described herein specifically bind to KIT andinhibit cell proliferation by at least about 1 fold, 1.2 fold, 1.3 fold,1.4 fold, 1.5 fold, 2 fold, 2.5 fold, 3 fold, 3.5 fold, 4 fold, 4.5fold, 5 fold, 6 fold, 7 fold, 8 fold, 9 fold, 10 fold, 15 fold, 20 fold,30 fold, 40 fold, 50 fold, 60 fold, 70 fold, 80 fold, 90 fold, or 100fold as assessed by methods described herein or known to one of skill inthe art (e.g., BrdU incorporation assay).

In certain aspects, an anti-KIT antibody described herein, which can actas an inhibitor of KIT activity, can reduce or inhibit survival of cellsthat express KIT and that respond to KIT signaling (e.g., cells thatproliferate in response to KIT ligand stimulation and KIT signaling).Cell survival assays are described in the art and can be readily carriedout by one of skill in the art. For example, cell viability can beassessed by using trypan-blue staining or other cell death or viabilitymarkers known in the art. In a specific embodiment, the level ofcellular ATP is measured to determined cell viability. In specificembodiments, cell viability is measured in three-day and seven-dayperiods using an assay standard in the art, such as the CellTiter-GloAssay Kit (Promega) which measures levels of intracellular ATP. Areduction in cellular ATP is indicative of a cytotoxic effect. Inanother specific embodiment, cell viability can be measured in theneutral red uptake assay. In other embodiments, visual observation formorphological changes can include enlargement, granularity, cells withragged edges, a filmy appearance, rounding, detachment from the surfaceof the well, or other changes. These changes are given a designation ofT (100% toxic), PVH (partially toxic-very heavy-80%), PH (partiallytoxic-heavy-60%), P (partially toxic-40%), Ps (partiallytoxic-slight-20%), or 0 (no toxicity-0%), conforming to the degree ofcytotoxicity seen. A 50% cell inhibitory (cytotoxic) concentration(IC₅₀) is determined by regression analysis of these data.

In specific embodiments, antibodies described herein specifically bindto KIT and inhibit (e.g, partially inhibit) cell (e.g., cancer cell)survival by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%,50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% asassessed by methods described herein or known to one of skill in the art(e.g., trypan blue exclusion assay). In specific embodiments, antibodiesdescribed herein specifically bind to KIT and inhibit cell (e.g., cancercell) survival by at least about 1 fold, 1.2 fold, 1.3 fold, 1.4 fold,1.5 fold, 2 fold, 2.5 fold, 3 fold, 3.5 fold, 4 fold, 4.5 fold, 5 fold,6 fold, 7 fold, 8 fold, 9 fold, 10 fold, 15 fold, 20 fold, 30 fold, 40fold, 50 fold, 60 fold, 70 fold, 80 fold, 90 fold, or 100 fold asassessed by methods described herein or known to one of skill in the art(e.g., trypan blue assay).

In certain aspects, an anti-KIT antibody described herein, which can actas an inhibitor of KIT activity, is capable of inducing apoptosis (i.e.,programmed cell death) of cells (e.g., cancer cells, such as MO7E cells)that express KIT and that respond to KIT signaling (e.g., cells thatproliferate in response to KIT ligand stimulation and KIT signaling).Apoptosis is described in the art and can be readily carried out by oneof skill in the art. For example, flow cytometry can be used to detectactivated caspase 3, an apoptosis-mediating enzyme, in cells undergoingapoptosis, or Western blotting can be used to detect cleavage ofpoly(ADP-ribose) polymerase (PARP) (see, e.g., Smolich et al., Blood,2001, 97:1413-1421). Cleavage of PARP is an indicator of apoptosis. Inspecific embodiments, antibodies described herein specifically bind toKIT and induce or enhance apoptosis by at least about 5%, 10%, 15%, 20%,25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%,95%, 98%, or 99% as assessed by methods described herein or known to oneof skill in the art (e.g., flow cytometry to detect activated caspase3). In specific embodiments, antibodies described herein specificallybind to KIT and induce or enhance apoptosis by at least about 1 fold,1.2 fold, 1.3 fold, 1.4 fold, 1.5 fold, 2 fold, 2.5 fold, 3 fold, 3.5fold, 4 fold, 4.5 fold, 5 fold, 6 fold, 7 fold, 8 fold, 9 fold, 10 fold,15 fold, 20 fold, 30 fold, 40 fold, 50 fold, 60 fold, 70 fold, 80 fold,90 fold, or 100 fold as assessed by methods described herein or known toone of skill in the art (e.g., flow cytometry to detect activatedcaspase 3).

In certain aspects, an anti-KIT antibody described herein, which can actas an inhibitor of KIT activity, is capable of inhibiting or decreasinganchorage independent cell growth (e.g., colony formation) by cells(e.g., H526 cells or CHO cells expressing exogenous KIT) that expressKIT and that respond to KIT signaling (e.g., cells that proliferate inresponse to KIT ligand stimulation and KIT signaling), as measured bymethods commonly known in the art, e.g., soft agar assay. In specificembodiments, antibodies described herein (or an antigen-binding fragmentthereof, or a conjugate thereof) specifically bind to KIT and inhibit ordecrease anchorage independent cell growth by at least about 5%, 10%,15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%,85%, 90%, 95%, 98%, or 99% as assessed by methods described herein orknown to one of skill in the art (e.g., soft agar assay). In specificembodiments, antibodies described herein (or an antigen-binding fragmentthereof, or a conjugate thereof) specifically bind to KIT and inhibit ordecrease anchorage independent cell growth by at least about 25% or 35%,optionally to about 75%, as assessed by methods described herein orknown to one of skill in the art (e.g., soft agar assay). In specificembodiments, antibodies described herein specifically bind to KIT andinhibit or decrease anchorage independent cell growth by at least about1 fold, 1.2 fold, 1.3 fold, 1.4 fold, 1.5 fold, 2 fold, 2.5 fold, 3fold, 3.5 fold, 4 fold, 4.5 fold, 5 fold, 6 fold, 7 fold, 8 fold, 9fold, 10 fold, 15 fold, 20 fold, 30 fold, 40 fold, 50 fold, 60 fold, 70fold, 80 fold, 90 fold, or 100 fold as assessed by methods describedherein or known to one of skill in the art (e.g., soft agar assay).

Cells and cell lines which are appropriate for use in the assaysdescribed herein relating to KIT activity are readily available (e.g.,ATCC) or can be readily identified using methods known in the art. Forexample, cells and/or cell lines that express KIT endogenously or thatpossess KIT signaling or activity are known to one of skill in the art.In certain embodiments, cells or cell lines that are appropriate for usein the assays described herein can express KIT, either endogenously orrecombinantly. In particular embodiments, cells or cell lines for use incell proliferation assays can express KIT, endogenously orrecombinantly, and proliferate or increase proliferation in response toKIT ligand (e.g., SCF) stimulation. Cells or cell lines for use in cellviability assays can express KIT, endogenously or recombinantly, andexert changes in cell viability in response to KIT ligand (e.g., SCF)stimulation. Cells or cell lines for use in apoptosis assays can expressKIT, endogenously or recombinantly, and exert changes in apoptosis inresponse to KIT ligand (e.g., SCF) stimulation.

Non-limiting examples of cells that can be used in the methods andassays described herein include primary cells, cancer cells, transformedcells, stem cells, mast cells, primordial germ cells, oocytes,spermatocytes, embryonic stem cells, hematopoietic cells,erythroleukemia cells (e.g., F36P and TF-1 cell lines), human myeloidleukemia cell lines, such as MO7E cells; gastrointestinal stromal tumorcell lines such as ST-882, GIST-T1, GIST48, GIST48B, GIST430, andGIST882; neuroblastoma cell lines such as SK-N-SH, SK-SY5Y, H-EP1,SK-N-BE(2), SK-N-BE(ZkM17), SK-N-BE(2)C, LA-N-1, or LA-N-1-5s; Ewing'ssarcoma cell lines such as TC71, TC32, RD-ES, 5838, A4573, EWS-925,NCI-EWS-94, and NCI-EWS-95; and small cell lung carcinoma cell linessuch as H526, ECC12, TMK1, MKN7, GCIY, and HGC27.

Alternatively, cells and cell lines that express KIT, e.g., human KIT,can routinely be generated recombinantly. Non-limiting examples of cellsthat can be engineered to express KIT recombinantly include COS cells,HEK 293 cells, CHO cells, fibroblasts (e.g., human fibroblasts) such asNIH3T3 cells, and MEFS. In a specific embodiment, cells for use in themethods described herein are CHO cells, for example CHO cells from theCHO GS System™ (Lonza). In a particular embodiment, these engineeredcells exogenously expressing full-length human KIT (e.g., SEQ ID NO: 1).

In certain aspects, an anti-KIT antibody described herein, which can actas an inhibitor of KIT activity, is capable of inhibiting tumor growthor inducing tumor regression in mouse model studies. For example, tumorcell lines can be introduced into nude mice, and the mice can beadministered with anti-KIT antibodies described herein one or moretimes, and tumor progression of the injected tumor cells can bemonitored over a period of weeks and/or months. In some cases,administration of anti-KIT antibodies to the nude mice can occur priorto introduction of the tumor cell lines. Any appropriate tumor cell line(e.g., tumor cell line expressing KIT) can be used in the mousexenograft models described herein. Non-limiting examples of tumor celllines for use in these xenograft mouse models include megakaryoblasticleukemia cell lines such as MO7e; gastrointestinal stromal tumor celllines such as ST-882, GIST-T1, GIST430, GIST48, GIST48B and GIST882;human erythroleukemic cell lines such as HEL and TF-1; humanpromyelocytic leukemia cell line, HL60; neuroblastoma cell lines such asSK-N-SH, SK-SY5Y, H-EP1, SK-N-BE(2), SK-N-BE(ZkM17), SK-N-BE(2)C,LA-N-1, or LA-N-1-5s; Ewing's sarcoma cell lines such as TC71, TC32,RD-ES, 5838, A4573, EWS-925, NCI-EWS-94, and NCI-EWS-95; and small celllung carcinoma cell lines such as H526, DMS153, DMS79, ECC12, TMK1,MKN7, GCIY, and HGC27. In a specific embodiments, a tumor cell line foruse in a xenograft mouse model is the GIST882, GIST430, GIST48, GIST48B,HEL, HL60, H526, DMS153, or DMS79 cell line. In certain embodiments,suitable cell lines for use in xenograft tumor models can be generatedby recombinantly expressing KIT in cell. In specific embodiments,antibodies described herein (or an antigen-binding fragment thereof, ora conjugate thereof) specifically bind to KIT and inhibit tumor grow orinduce tumor regression in a mouse model by at least about 5%, 10%, 15%,20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%,90%, 95%, 98%, or 99% as assessed by methods described herein or knownto one of skill in the art. In specific embodiments, antibodiesdescribed herein (or an antigen-binding fragment thereof, or a conjugatethereof) specifically bind to KIT and inhibit tumor grow or induce tumorregression in a mouse model by at least about 25% or 35%, optionally toabout 75%, as assessed by methods described herein or known to one ofskill in the art. In specific embodiments, antibodies described hereinspecifically bind to KIT and inhibit tumor grow or induce tumorregression in a mouse model by at least about 1 fold, 1.2 fold, 1.3fold, 1.4 fold, 1.5 fold, 2 fold, 2.5 fold, 3 fold, 3.5 fold, 4 fold,4.5 fold, 5 fold, 6 fold, 7 fold, 8 fold, 9 fold, 10 fold, 15 fold, 20fold, 30 fold, 40 fold, 50 fold, 60 fold, 70 fold, 80 fold, 90 fold, or100 fold as assessed by methods described herein or known to one ofskill in the art. Determining tumor growth inhibition or tumorregression can be assessed by monitoring tumor size over a period oftime, such as by physical measurement of palpable tumors, or othervisual detection methods. For example, tumor cell lines can be generatedto recombinantly express a visualization agent, such as greenfluorescent protein (GFP) or luciferase, then in vivo visualization ofGFP can be carried out by microscopy, and in vivo visualization ofluciferase can be carried out by administering luciferase substrate tothe xenograft mice and detecting luminescent due to the luciferaseenzyme processing the luciferase substrate. The degree or level ofdetection of GFP or luciferase correlates to the size of the tumor inthe xenograft mice.

In certain aspects, anti-KIT antibodies described herein bindspecifically to KIT antigen and can increase survival of animals intumor xenograft models. In specific embodiments, antibodies describedherein (or an antigen-binding fragment thereof, or a conjugate thereof)specifically bind to KIT and increase survival of mice in tumorxenograft models by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%,40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%as assessed by methods described herein or known to one of skill in theart. In specific embodiments, antibodies described herein (or anantigen-binding fragment thereof, or a conjugate thereof) specificallybind to KIT and increase survival of mice in tumor xenograft models byat least about 25% or 35%, optionally to about 75%, as assessed bymethods described herein or known to one of skill in the art. Inspecific embodiments, antibodies described herein specifically bind toKIT and increase survival of mice in tumor xenograft models by at leastabout 1 fold, 1.2 fold, 1.3 fold, 1.4 fold, 1.5 fold, 2 fold, 2.5 fold,3 fold, 3.5 fold, 4 fold, 4.5 fold, 5 fold, 6 fold, 7 fold, 8 fold, 9fold, 10 fold, 15 fold, 20 fold, 30 fold, 40 fold, 50 fold, 60 fold, 70fold, 80 fold, 90 fold, or 100 fold as assessed by methods describedherein or known to one of skill in the art. Survival can be determinedby plotting a survival curve of number of surviving mice against time(e.g., days or weeks) after tumor cell line injection.

Provided herein are antibodies that immunospecifically bind a KITpolypeptide, e.g., a human KIT polypeptide, e.g., a D4 region of KIT,for example, human KIT, with a particular affinity.

“Affinity” of an antibody described herein for an epitope (e.g., KITepitope) is a term well understood in the art and refers to the extent,or strength, of binding of an antibody to an epitope. Affinity can bemeasured and/or expressed in a number of ways known in the art,including, but not limited to, equilibrium dissociation constant (K_(D)or K_(d)), apparent equilibrium dissociation constant (K_(D)′ orK_(d)′), and IC₅₀ (amount needed to effect 50% inhibition in acompetition assay). It is understood that, for purposes describedherein, an affinity is an average affinity for a given population ofantibodies which bind to an epitope. Values of K_(D)′ described hereinin terms of milligram (mg) Ig per mL or mg/mL indicate mg Ig per mL ofserum, although plasma can be used. When antibody affinity is used as abasis for administration of the treatment methods described herein, orselection for the treatment methods described herein, antibody affinitycan be measured before and/or during treatment, and the values obtainedcan be used by a clinician in assessing whether a human patient is anappropriate candidate for treatment.

In specific aspects, provided herein are antibodies (or antigen-bindingfragments thereof, or conjugates thereof) that have a high bindingaffinity (e.g., antibodies having a K_(D) of less than 250 nM, 100 nM,50 nM, 10 nM, 1 nM, 500 pM, 200 pM, 100 pM, or 50 pM) for a KIT antigen,preferably a human KIT antigen, in particular the D4/D5 region of ahuman KIT.

In specific embodiments, an antibody described herein (or anantigen-binding fragment thereof, or a conjugate thereof)immunospecifically binds to a KIT antigen (e.g., a D4/D5 region of KIT,for example human KIT), and has a dissociation constant (K_(D)) of lessthan 500,000 pM (500 nM), less than 100,000 pM (100 nM), less than50,000 pM (50 nM), less than 10,000 pM (10 nM), less than 3,000 pM (3nM), less than 2,500 pM (2.5 nM), less than 2,000 pM, less than 1,500pM, less than 1,000 pM, less than 750 pM, less than 500 pM, less than250 pM, less than 200 pM, less than 150 pM, less than 100 pM, less than75 pM as assessed using an assay described herein or known to one ofskill in the art (e.g., a Biacore™ assay) (Biacore™ International AB,Uppsala, Sweden). In a specific embodiment, an antibody described herein(or an antigen-binding fragment thereof, or a conjugate thereof)immunospecifically binds to a KIT antigen (e.g., a D4/D5 region of KIT,for example human KIT), and has a K_(D) in the range of from 25 to100,000 pM, 25 to 75,000 pM, 25 to 50,000 pM, 25 to 40,000 pM, 25 to30,000 pM, 25 to 20,000 pM, 25 to 10,000 pM, 25 to 1,000 pM, 25 to 500pM, 25 to 250 pM, 25 to 100 pM, or 25 to 50 pM as assessed using methodsdescribed herein or known to one of skill in the art (e.g., a Biacore™assay, assay using KinExA 3000 instrument). In a particular embodiment,an antibody described herein (or an antigen-binding fragment thereof, ora conjugate thereof) immunospecifically binds to a KIT antigen (e.g., aD4 region of KIT, for example human KIT), and has a K_(D) of about 100pM to about 250 nM, or any value in between, as assessed using methodsdescribed herein or known to one of skill in the art (e.g., a Biacore™assay, assay using KinExA 3000 instrument).

In specific embodiments, an anti-KIT antibody (or an antigen-bindingfragment thereof, or a conjugate thereof) immunospecifically binds to aKIT antigen (e.g., a D4 region of KIT, for example human KIT), and has aconcentration at 50% binding to antigen of less than 3000 pM (3 nM),less than 2500 pM (2.5 nM), less than 2000 pM, less than 1500 pM, lessthan 1000 pM, less than 750 pM, less than 500 pM, less than 250 pM, lessthan 200 pM, less than 150 pM, less than 100 pM, less than 75 pM asassessed using an assay described herein or known to one of skill in theart (e.g., solid phase ELISA as described in section 6). In a specificembodiment, an antibody described herein (or an antigen-binding fragmentthereof, or a conjugate thereof) immunospecifically binds to a KITantigen (e.g., a D4 region of KIT, for example human KIT), and has aconcentration at 50% binding to antigen in the range of from 25 to500,000 pM (500 nM), 25 to 250,000 pM (250 nM), 25 to 100,000 pM (100nM), 25 to 75,000 pM (75 nM), 25 to 50,000 pM (50 nM), 25 to 40,000 pM(40 nM), 25 to 30,000 pM (30 nM), 25 to 20,000 pM (20 nM), 25 to 10,000pM (10 nM), 25 to 1,000 pM (1 nM), 25 to 500 pM, 25 to 250 pM, 25 to 100pM, or 25 to 50 pM as assessed using methods described herein or knownto one of skill in the art (e.g., solid phase ELISA as described insection 6). In a particular embodiment, an antibody described herein (oran antigen-binding fragment thereof, or a conjugate thereof)immunospecifically binds to a KIT antigen (e.g., a D4 region of KIT, forexample human KIT), and has a concentration at 50% binding to antigen ofabout 1 nM to about 25 nM, or any value in between, as assessed usingmethods described herein or known to one of skill in the art (e.g.,solid phase ELISA as described in section 6). In a particularembodiment, an antibody described herein (or an antigen-binding fragmentthereof, or a conjugate thereof) immunospecifically binds to a KITantigen (e.g., a D4 region of KIT, for example human KIT), and has aconcentration at 50% binding to antigen of about 50 pM to about 500 pM,or any value in between, as assessed using methods described herein orknown to one of skill in the art (e.g., solid phase ELISA as describedin section 6). In a particular embodiment, an antibody described herein(or an antigen-binding fragment thereof, or a conjugate thereof)immunospecifically binds to KIT antigen (e.g., a D4 region of KIT, forexample human KIT), and has a concentration at 50% binding of about 0.5nM, 0.25 nM, 0.1 nM, 1 nM, 1.5 nM, 2 nM, 2.5 nM, 3 nM, 3.5 nM, 4 nM, 4.5nM, 5 nM, 5.5 nM, 6 nM, 6.5 nM, 7 nM, 8 nM, 9 nM, 10 nM, 11 nM, 12 nM,13 nM, 14 nM, 15 nM, 16 nM, 17 nM, 18 nM, 19 nM, 20 nM, 30 nM, 40 nM, 50nM, 60 nM, 70 nM, 80 nM, 90 nM, 100 nM, 150 nM, 200 nM, 250 nM, 300 nM,350 nM, 400 nM, or 500 nM, or less, as assessed using methods describedherein or known to one of skill in the art (e.g., solid phase ELISA asdescribed in section 6). In a particular embodiment, antibodiesdescribed herein immunospecifically bind to KIT antigen (e.g., a D4region of KIT, for example human KIT), and have a concentration at 50%binding from about 100 pM to about 10 nM, as assessed using methodsdescribed herein or known to one of skill in the art (e.g., ELISA, assayusing KinExA 3000 instrument, or Biacore™ assay).

Methods for determining affinity of an antibody to its target antigenare readily available and described in the art. For example, theaffinities and binding properties of an antibody for its target antigen,can be determined by a variety of in vitro assay methods (biochemical orimmunological based assays) known in the art such as equilibrium methods(e.g., enzyme-linked immunoabsorbent assay (ELISA), or radioimmunoassay(RIA)), or kinetics (e.g., Biacore™ analysis), and other methods such asindirect binding assays, competitive inhibition assays, fluorescenceresonance energy transfer (FRET), immunoprecipitation, gelelectrophoresis and chromatography (e.g., gel filtration). These andother methods can utilize a label on one or more of the components beingexamined and/or employ a variety of detection methods including but notlimited to chromogenic, fluorescent, luminescent, or isotopic labels. Incertain embodiments, use of labels is not necessary, e.g., Biacore™systems utilize the natural phenomenon of surface plasmon resonance(SPR) to deliver data in real time, without the use of labels. Adetailed description of binding affinities and kinetics can be found inPaul, W. E., ed., Fundamental Immunology, 4th Ed. (Lippincott-Raven,Philadelphia 1999), which focuses on antibody-immunogen interactions.

In certain aspects, the affinity of an antibody described herein for aKIT antigen, e.g., human KIT, for example a D4 region of KIT (e.g.,human KIT), can be characterized indirectly using cell-based assays. Forexample, cells expressing KIT on their cell membrane surface can becontacted with anti-KIT antibodies, and cellular activities downstreamof KIT can be determined using assays known in the art. For examples,phosphorylation of the cytoplasmic domain of KIT can be determined byimmunoblotting (or Western blotting) following contacting the cells withan anti-KIT antibody; cellular extracts are obtained and processed forimmunoblotting (e.g., subjecting the cellular extracts to sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferringthe proteins separated on the gel to a membrane (e.g., nitrocellulose orpolyvinylidene fluoride (PVDF)) with an antibody that specifically bindsto a phosphorylated tyrosine in the cytoplasmic domain of KIT, but doesnot bind an unphosphorylated tyrosine.

In certain embodiments, an anti-KIT antibody described hereinspecifically binds to a KIT antigen, e.g., human KIT, for example a D4region of KIT (e.g., human KIT), and induces or enhances dimerizationand phosphorylation of KIT, in the presence or absence of the KIT ligandSCF. In some embodiments, an anti-KIT antibody described herein caninhibit or decrease KIT ligand, e.g., SCF, binding to KIT (i.e., ananti-KIT antibody can compete with a KIT ligand, e.g., SCF, for bindingto KIT). In such case, cells can be contacted with an anti-KIT antibodyand a KIT ligand, and the degree of inhibition of KIT phosphorylationcan be determined as an indication of the degree of the anti-KITantibody competing with the KIT ligand for binding to KIT.

Antibodies include, but are not limited to, monoclonal antibodies,recombinantly produced antibodies, multispecific antibodies (includingbi-specific antibodies), human antibodies, humanized antibodies,chimeric antibodies, synthetic antibodies, tetrameric antibodiescomprising two heavy chain and two light chain molecule, an antibodylight chain monomer, an antibody heavy chain monomer, an antibody lightchain dimer, an antibody heavy chain dimer, an antibody lightchain-antibody heavy chain pair, intrabodies, heteroconjugateantibodies, single domain antibodies, monovalent antibodies, singlechain antibodies or single-chain Fvs (scFv) (e.g., includingmonospecific, bispecific, etc.), camelized antibodies, affybodies, Fabfragments, F(ab′) fragments, disulfide-linked Fvs (sdFv), anti-idiotypic(anti-Id) antibodies (including, e.g., anti-anti-Id antibodies), andepitope-binding fragments of any of the above. In certain embodiments,antibodies described herein refer to polyclonal antibody populations.Antibodies can be of any type (e.g., IgG, IgE, IgM, IgD, IgA or IgY),any class, (e.g., IgG₁, IgG₂, IgG₃, IgG₄, IgA₁ or IgA₂), or any subclass(e.g., IgG2a or IgG2b) of immunoglobulin molecule. In certainembodiments, antibodies described herein are IgG antibodies, or a class(e.g., human IgG₁ or IgG₄) or subclass thereof. In specific embodiments,a monoclonal antibody is an antibody produced by a single hybridoma orother cell, wherein the antibody immunospecifically binds to a D4 regionof human KIT epitope as determined, e.g., by ELISA or otherantigen-binding or competitive binding assay known in the art or in theExamples provided herein. The term “monoclonal” is not limited to anyparticular method for making the antibody.

In a particular embodiment, an antibody provided herein is a Fabfragment that immunospecifically binds to a KIT polypeptide, such as theD4 region of KIT. In a specific embodiment, antibodies described hereinare monoclonal antibodies or isolated monoclonal antibodies. In anotherspecific embodiment, an antibody described herein is a humanizedmonoclonal antibody. In a particular embodiment, an antibody describedherein is a recombinant antibody, for example, a recombinant humanantibody, recombinant humanized antibody or a recombinant monoclonalantibody. In certain embodiments, an antibody described herein containsnon-human amino acid sequences, e.g., non-human CDRs or non-human (e.g.,non-human primate) framework residues.

In particular embodiments provided herein, recombinant antibodies can beisolated, prepared, expressed, or created by recombinant means, such asantibodies expressed using a recombinant expression vector transfectedinto a host cell, antibodies isolated from a recombinant, combinatorialantibody library, or antibodies prepared, expressed, created or isolatedby any other means that involves creation, e.g., via synthesis, geneticengineering of DNA sequences that encode human immunoglobulin sequences,or splicing of sequences that encode human immunoglobulins, e.g., humanimmunoglobulin gene sequences, to other such sequences. In certainembodiments, the amino acid sequences of such recombinant antibodieshave been modified such thus the amino acid sequences of suchantibodies, e.g., VH and/or VL regions, are sequences that do notnaturally exist within an organism's antibody germline repertoire invivo, for example a murine or human germline repertoire. In a particularembodidment, a recombinant antibody can be obtained by assemblingseveral sequence fragments that naturally exist in an organism (e.g.,primate, such as human) into a composite sequence of a recombinantantibody, wherein the composite sequence does not naturally exist withinan organism (e.g., primate such as human).

Antibodies provided herein include immunoglobulin molecules of any type(e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3,IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecule. In aspecific embodiment, an antibody provided herein is an IgG antibody(e.g., human IgG antibody), or a class (e.g., human IgG1 or IgG4) orsubclass thereof. In another specific embodiment, an antibody describedherein is an IgG1 (e.g., human IgG1 (isotype a, z, or f)) or IgG4antibody. In certain embodiments, an antibody described herein is awhole or entire antibody, e.g., a whole or entire humanized, human, orcomposite human antibody.

Antibodies provided herein can include antibody fragments that retainthe ability to specifically bind to an antigen, e.g., KIT epitope (e.g.,a KIT epitope within a KIT polypeptide containing a D4 region of humanKIT). In a specific embodiment, fragments include Fab fragments (anantibody fragment that contains the antigen-binding domain and comprisesa light chain and part of a heavy chain (i.e., the VH and CH1 domains ofa heavy chain) bridged by a disulfide bond); Fab′ (an antibody fragmentcontaining a single antigen-binding domain comprising an Fab and anadditional portion of the heavy chain through the hinge region); F(ab′)₂(two Fab′ molecules joined by interchain disulfide bonds in the hingeregions of the heavy chains; the Fab′ molecules can be directed towardthe same or different epitopes); a bispecific Fab (a Fab molecule havingtwo antigen binding domains, each of which can be directed to adifferent epitope); a single chain Fab chain comprising a variableregion, also known as a sFv (the variable, antigen-binding determinativeregion of a single light and heavy chain of an antibody linked togetherby a chain of 10-25 amino acids); a disulfide-linked Fv, or dsFv (thevariable, antigen-binding determinative region of a single light andheavy chain of an antibody linked together by a disulfide bond); acamelized VH (the variable, antigen-binding determinative region of asingle heavy chain of an antibody in which some amino acids at the VHinterface are those found in the heavy chain of naturally occurringcamel antibodies); a bispecific sFv (a sFv or a dsFv molecule having twoantigen-binding domains, each of which can be directed to a differentepitope); a diabody (a dimerized sFv formed when the VH domain of afirst sFv assembles with the VL domain of a second sFv and the VL domainof the first sFv assembles with the VH domain of the second sFv; the twoantigen-binding regions of the diabody can be directed towards the sameor different epitopes); and a triabody (a trimerized sFv, formed in amanner similar to a diabody, but in which three antigen-binding domainsare created in a single complex; the three antigen binding domains canbe directed towards the same or different epitopes). Antibodies providedherein can also include one or more CDR sequences of an antibody. TheCDR sequences can be linked together on a scaffold when two or more CDRsequences are present. In certain embodiments, an antibody comprises asingle-chain Fv (“scFv”). scFvs are antibody fragments comprising the VHand VL domains of an antibody, wherein these domains are present in asingle polypeptide chain. Generally, the scFv polypeptide furthercomprises a polypeptide linker between the VH and VL domains whichenables the scFv to form the desired structure for antigen binding. Fora review of scFvs, see Pluckthun in The Pharmacology of MonoclonalAntibodies, vol. 113, Rosenburg and Moore eds. Springer-Verlag, NewYork, pp. 269-315 (1994). Without being bound by any particulartheories, Fv molecules can be able to penetrate tissues because of theirsmall size. A whole antibody can be enzymatically cleaved by pepsin toproduce a F(ab′)₂ fragment, or can be enzymatically cleaved by papain toproduce two Fab fragments.

In certain embodiments, antibodies described herein are human, compositehuman, or humanized monoclonal antibodies. In a particular embodiment,an antibody described herein is an engineered antibody, for example,antibody produced by recombinant methods. In a specific embodiment, anantibody described herein is a humanized antibody comprising one or morenon-human (e.g., rodent or murine) CDRs and one or more human frameworkregions (FR), and optionally human heavy chain constant region and/orlight chain constant region. In a specific embodiment, an antibodydescribed herein comprises one or more primate (or non-human primate)framework regions. In a specific embodiment, an antibody describedherein does not comprise non-human primate framework regions.

Antibodies provided herein can include antibodies comprising chemicalmodifications, for example, antibodies which have been chemicallymodified, e.g., by covalent attachment of any type of molecule to theantibody. For example, but not by way of limitation, an anti-KITantibody can be glycosylated, acetylated, pegylated, phosphorylated, oramidated, can be derivitized via protective/blocking groups, or canfurther comprise a cellular ligand and or other protein or peptide, etc.For example, an antibody provided herein can be chemically modified,e.g., by glycosylation, acetylation, pegylation, phosphorylation,amidation, derivatization by known protecting/blocking groups,proteolytic cleavage, linkage to a cellular ligand or other protein,etc. Further, an anti-KIT antibody described herein can contain one ormore non-classical amino acids.

In a particular embodiment, provided herein is an anti-KIT antibodywhich has been modified in a manner suitable for large scalemanufacturing, e.g., the manufacturing platform of Lonza (Basel,Switzerland). For example, the BI-HEX® technology platform (BoehringerIngleheim, Germany) can be used to adapt the anti-KIT antibodiesdescribed herein for suitable large scale manufacturing in recombinantmammalian cell expression systems. Such adaptation can involve cloningpolynucleotide sequences encoding the necessary domains of an anti-KITantibody, such as one or more CDRs or FRs, into a suitable expressionvector which also contains polynucleotide sequences encoding suitableconstant regions, so that an entire antibody is produced. Thepolynucleotide sequences provided by the expression vectors arenucleotide sequences which can be optimized to maximize antibody yieldand stability for cell culture manufacturing conditions and purificationprocesses.

5.1.1. Conjugates

In some embodiments, provided herein are antibodies (e.g., human orhumanized antibodies), or antigen-binding fragments thereof, conjugatedor recombinantly fused to a diagnostic, detectable or therapeutic agentor any other molecule. The conjugated or recombinantly fused antibodiescan be useful, e.g., for monitoring or prognosing the onset,development, progression and/or severity of a KIT-associated disorder ordisease, for example, as part of a clinical testing procedure, such asdetermining the efficacy of a particular therapy. The conjugated orrecombinantly fused antibodies can be useful, e.g., for treating ormanaging a KIT-associated disorder (e.g., cancer), or for treating ormanaging effects of a KIT-associated disorder (e.g., cancer). Antibodiesdescribed herein can also be conjugated to a molecule (e.g.,polyethylene glycol) which can affect one or more biological and/ormolecular properties of the antibodies, for example, stability (e.g., inserum), half-life, solubility, and antigenicity.

In a particular aspect, provided herein is a conjugate comprising anagent (e.g., therapeutic agent) linked to an antibody described herein(or an antigen-binding fragment thereof), which antibodyimmunospecifically binds to a D4 region of human KIT (e.g., SEQ ID NO:15). In a specific embodiment, a conjugated antibody specifically bindsa D4 region of KIT (e.g., human KIT), and comprises an antibodycomprising the CDRs set forth in Table 1, or Table 2, or Table 3. In aspecific embodiment, a conjugated antibody specifically binds a D4region of KIT (e.g., human KIT) and comprises a VL chain regioncomprising VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequenceof SEQ ID NO: 19, 20, and 21, respectively, and/or a VH chain regioncomprising VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequenceof SEQ ID NO: 16, 17, and 18, respectively. In a specific embodiment, aconjugated antibody specifically binds a D4 region of KIT (e.g., humanKIT), and comprises any one of antibodies Hum1-Hum20. In a specificembodiment, a conjugated antibody provided herein specifically binds aD4 region of KIT (e.g., human KIT), and comprises an antibody comprisinga VL and/or VH comprising CDRs selected from Table 1, or Table 2, orTable 3, and FRs selected from Tables 5A-5D. In a specific embodiment, aconjugated antibody provided herein specifically binds a D4 region ofKIT (e.g., human KIT), and comprises an antibody comprising a VLcomprising SEQ ID NO: 12 and/or VH comprising SEQ ID NO: 11. In oneembodiment, an antibody that is conjugated is one that binds a D4 regionof human KIT with an affinity, for example, an EC50 of about 200 pM orless. In another embodiment, an antibody that is conjugated is one thatinhibits a biological activity of KIT. In specific embodiments, aconjugate comprises an antibody described herein and a molecule (e.g.,therapeutic or drug moiety), wherein the antibody is linked directly tothe molecule, or by way of one or more linkers. In certain embodiments,an antibody is covalently conjugated to a molecule. In a particularembodiment, an antibody is noncovalently conjugated to a molecule. Inspecific embodiments, an antibody described herein, e.g., an antibodyconjugated to an agent, binds to wild-type human KIT. In certainembodiments, an antibody described herein, e.g., antibody conjugated toan agent, binds to an extracellular domain of human KIT comprising amutation, for example a somatic mutation associated with cancer (e.g.,GIST), such as a mutation in exon 9 of human KIT wherein the Ala and Tyrresidues at positions 502 and 503 are duplicated.

Such diagnosis and detection can be accomplished, for example, bycoupling the antibody to detectable molecules or substances including,but not limited to, various enzymes, such as, but not limited to,horseradish peroxidase, alkaline phosphatase, beta-galactosidase, oracetylcholinesterase; prosthetic groups, such as, but not limited to,streptavidin/biotin and avidin/biotin; fluorescent materials, such as,but not limited to, umbelliferone, fluorescein, fluoresceinisothiocynate, rhodamine, dichlorotriazinylamine fluorescein, dansylchloride or phycoerythrin; luminescent materials, such as, but notlimited to, luminol; bioluminescent materials, such as but not limitedto, luciferase, luciferin, and aequorin; radioactive materials, such asbut not limited to iodine (¹³¹I, ¹²⁵I, ¹²³I, carbon (¹⁴C), sulfur (³⁵S),tritium (³H), indium (¹¹⁵In, ¹¹³In, ¹¹²In, and ¹¹¹In), technetium(⁹⁹Tc), thallium (²⁰¹Ti), gallium (⁶⁸Ga, ⁶⁷Ga), palladium (¹⁰³Pd),molybdenum (⁹⁹Mo), xenon (¹³³Xe), fluorine (¹⁸F), ¹⁵³Sm, ¹⁷⁷Lu, ¹⁵⁹Gd,¹⁴⁹Pm, ¹⁴⁰La, ¹⁷⁵Yb, ¹⁶⁶Ho, ⁹⁰Y, ⁴⁷Sc, ¹⁸⁶Re, ¹⁸⁸Re, ¹⁴²Pr, ¹⁰⁵Rh, ⁹⁷Ru,⁶⁸Ge, ⁵⁷Co, ⁶⁵Zn, ⁸⁵Sr, ³²P, ¹⁵³Gd, ¹⁶⁹Yb, ⁵¹Cr, ⁵⁴Mn, ⁷⁵Se, ¹¹³Sn, and¹¹⁷Sn; and positron emitting metals using various positron emissiontomographies, and non-radioactive paramagnetic metal ions.

Provided are antibodies described herein, or antigen-binding fragmentsthereof, conjugated or recombinantly fused to a therapeutic moiety (orone or more therapeutic moieties) and uses of such antibodies. Theantibody can be conjugated or recombinantly fused to a therapeuticmoiety, such as a cytotoxin, e.g., a cytostatic or cytocidal agent, atherapeutic agent or a radioactive metal ion, e.g., alpha-emitters. Acytotoxin or cytotoxic agent includes any agent that is detrimental tocells. Therapeutic moieties include, but are not limited to, auristatinor a derivative thereof, e.g., monomethyl auristatin E (MMAE),monomethyl auristatin F (MMAF), auristatin PYE, and auristatin E (AE)(see, e.g., U.S. Pat. No. 7,662,387 and U.S. Pat. ApplicationPublication Nos. 2008/0300192 and 2008/0025989, each of which isincorporated herein by reference); a microtubule-disrupting agent, e.g.,maytansine or a derivative thereof, e.g., maytansinoid DM1 (see, e.g.,U.S. Pat. Nos. 7,851,432, 7,575,748, and 5,416,064, each of which isincorporated herein by reference); a prodrug, e.g., a prodrug of aCC-1065 (rachelmycin) analogue; antimetabolites (e.g., methotrexate,6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracildecarbazine); alkylating agents (e.g., mechlorethamine, thioepachlorambucil, melphalan, carmustine (BCNU) and lomustine (CCNU),cyclothosphamide, busulfan, dibromomannitol, streptozotocin, mitomycinC, and cisdichlorodiamine platinum (II) (DDP), and cisplatin);minor-groove-binding alkylating agent; anthracyclines (e.g.,daunorubicin (formerly daunomycin) and doxorubicin); antibiotics (e.g.,d actinomycin (formerly actinomycin), bleomycin, mithramycin, andanthramycin (AMC)); Auristatin molecules (e.g., auristatin PHE,bryostatin 1, and solastatin 10; see Woyke et al., Antimicrob. AgentsChemother. 46:3802-8 (2002), Woyke et al., Antimicrob. Agents Chemother.45:3580-4 (2001), Mohammad et al., Anticancer Drugs 12:735-40 (2001),Wall et al., Biochem. Biophys. Res. Commun. 266:76-80 (1999), Mohammadet al., Int. J. Oncol. 15:367-72 (1999), all of which are incorporatedherein by reference); hormones (e.g., glucocorticoids, progestins,androgens, and estrogens), DNA-repair enzyme inhibitors (e.g., etoposideor topotecan), kinase inhibitors (e.g., compound ST1571, imatinibmesylate (Kantarjian et al., Clin Cancer Res. 8(7):2167-76 (2002));cytotoxic agents (e.g., paclitaxel, cytochalasin B, gramicidin D,ethidium bromide, emetine, mitomycin, etoposide, tenoposide,vincristine, vinblastine, colchicin, doxorubicin, daunorubicin,dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D,1-dehydrotestosterone, glucorticoids, procaine, tetracaine, lidocaine,propranolol, and puromycin and analogs or homologs thereof and thosecompounds disclosed in U.S. Pat. Nos. 6,245,759, 6,399,633, 6,383,790,6,335,156, 6,271,242, 6,242,196, 6,218,410, 6,218,372, 6,057,300,6,034,053, 5,985,877, 5,958,769, 5,925,376, 5,922,844, 5,911,995,5,872,223, 5,863,904, 5,840,745, 5,728,868, 5,648,239, 5,587,459, eachof which is incorporated herein by reference with respect to suchcompound disclosure); farnesyl transferase inhibitors (e.g., R115777,BMS-214662, and those disclosed by, for example, U.S. Pat. Nos.6,458,935, 6,451,812, 6,440,974, 6,436,960, 6,432,959, 6,420,387,6,414,145, 6,410,541, 6,410,539, 6,403,581, 6,399,615, 6,387,905,6,372,747, 6,369,034, 6,362,188, 6,342,765, 6,342,487, 6,300,501,6,268,363, 6,265,422, 6,248,756, 6,239,140, 6,232,338, 6,228,865,6,228,856, 6,225,322, 6,218,406, 6,211,193, 6,187,786, 6,169,096,6,159,984, 6,143,766, 6,133,303, 6,127,366, 6,124,465, 6,124,295,6,103,723, 6,093,737, 6,090,948, 6,080,870, 6,077,853, 6,071,935,6,066,738, 6,063,930, 6,054,466, 6,051,582, 6,051,574, and 6,040,305,each of which is incorporated herein by reference with respect to suchinhibitor disclosure); topoisomerase inhibitors (e.g., camptothecin;irinotecan; SN-38; topotecan; 9-aminocamptothecin; GG-211 (GI 147211);DX-8951f; IST-622; rubitecan; pyrazoloacridine; XR-5000; saintopin;UCE6; UCE1022; TAN-1518A; TAN 1518B; KT6006; KT6528; ED-110; NB-506;ED-110; NB-506; and rebeccamycin); bulgarein; DNA minor groove binderssuch as Hoescht dye 33342 and Hoechst dye 33258; nitidine; fagaronine;epiberberine; coralyne; beta-lapachone; BC-4-1; bisphosphonates (e.g.,alendronate, cimadronte, clodronate, tiludronate, etidronate,ibandronate, neridronate, olpandronate, risedronate, piridronate,pamidronate, zolendronate) HMG-CoA reductase inhibitors, (e.g.,lovastatin, simvastatin, atorvastatin, pravastatin, fluvastatin, statin,cerivastatin, lescol, lupitor, rosuvastatin and atorvastatin); antisenseoligonucleotides (e.g., those disclosed in the U.S. Pat. Nos. 6,277,832,5,998,596, 5,885,834, 5,734,033, and 5,618,709, each of which isincorporated herein by reference with respect to such oligonucleotides);adenosine deaminase inhibitors (e.g., Fludarabine phosphate and2-Chlorodeoxyadenosine); ibritumomab tiuxetan (Zevalin®); tositumomab(Bexxar®)) and pharmaceutically acceptable salts, solvates, clathrates,and prodrugs thereof. In one embodiment, an antibody that is conjugatedto such therapeutic/drug moiety is one that binds a D4 region of humanKIT with an affinity of less than about 200 pM. In another embodiment,an antibody that is conjugated to such therapeutic/drug moiety is onethat inhibits a biological activity of KIT. In a specific embodiment, anantibody that is conjugated to such therapeutic/drug moiety is one thatcomprises the CDRs set forth in Table 1 (e.g., VL CDR1, VL CDR2, and VLCDR3 having the amino acid sequence of SEQ ID NO: 19, 20, and 21,respectively, and/or a VH chain region comprising VH CDR1, VH CDR2, andVH CDR3 having the amino acid sequence of SEQ ID NO: 16, 17, and 18,respectively), or Table 2, or Table 3. In a specific embodiment, anantibody that is conjugated to such therapeutic/drug moiety is one thatcomprises a VL comprising SEQ ID NO: 7, 8, 9, 10, or 12 or a sequenceset forth in Tables 5B and 5D, and/or VH comprising SEQ ID NO: 2, 3, 4,5, 6, or 11 or a sequence set forth in Tables 5A and 5C.

In particular embodiments, a therapeutic moiety or drug moiety is anantitubulin drug, such as an auristatin or a derivative thereof.Non-limiting examples of auristatins include monomethyl auristatin E(MMAE), monomethyl auristatin F (MMAF), auristatin PYE, and auristatin E(AE) (see, e.g., U.S. Pat. No. 7,662,387 and U.S. Pat. ApplicationPublication Nos. 2008/0300192 and 2008/0025989, each of which isincorporated herein by reference). In certain embodiments, a therapeuticmoiety or drug moiety is a microtubule-disrupting agent such asmaytansine or a derivative thereof, e.g., maytansinoid DM1 or DM4 (see,e.g., U.S. Pat. Nos. 7,851,432, 7,575,748, and 5,416,064, each of whichis incorporated herein by reference). In certain embodiments, atherapeutic moiety or drug moiety is a prodrug, e.g., a prodrug of aCC-1065 (rachelmycin) analogue (see, e.g., U.S. Patent ApplicationPublication No. 2008/0279868, and PCT International Patent ApplicationPublication Nos. WO 2009/017394, WO 2010/062171, and WO 2007/089149,each of which is incorporated herein by reference). In one embodiment,an antibody that is conjugated to such therapeutic/drug moiety is onethat binds a D4 region of human KIT with an affinity of less than about200 pM. In another embodiment, an antibody that is conjugated to suchtherapeutic/drug moiety is one that inhibits a biological activity ofKIT. In a specific embodiment, an antibody (e.g., human or humanizedantibody) that is conjugated to such therapeutic/drug moiety is one thatcomprises the CDRs set forth in Table 1 (e.g., VL CDR1, VL CDR2, and VLCDR3 having the amino acid sequence of SEQ ID NO: 19, 20, and 21,respectively, and/or a VH chain region comprising VH CDR1, VH CDR2, andVH CDR3 having the amino acid sequence of SEQ ID NO: 16, 17, and 18,respectively), or Table 2, or Table 3. In a specific embodiment, anantibody (e.g., human or humanized antibody) that is conjugated to suchtherapeutic/drug moiety is one that comprises a VL comprising SEQ ID NO:7, 8, 9, 10, or 12 or a sequence set forth in Tables 5B and 5D, and/orVH comprising SEQ ID NO: 2, 3, 4, 5, 6, or 11 or a sequence set forth inTables 5A and 5C.

In a specific embodiment, the antibody and therapeutic/drug agent areconjugated by way of one or more linkers. In another specificembodiment, the antibody and therapeutic/drug agent are conjugateddirectly.

In specific embodiments, non-limiting examples of therapeutic moietiesor drug moieties for conjugation to an antibody described herein includecalicheamicins (e.g., LL-E33288 complex, for example,gamma-calicheamicin, see, e.g., U.S. Pat. No. 4,970,198) and derivativesthereof (e.g., gamma calicheamicin hydrazide derivatives), ozogamicins,duocarmycins and derivatives thereof (e.g., CC-1065 (NSC 298223), or anachiral analogue of duocarmycin (for example AS-1-145 or centanamycin)),taxanes and derivatives thereof, and enediynes and derivatives thereof(See, e.g., PCT International Patent Application Publication Nos. WO2009/017394, WO 2010/062171, WO 2007/089149, WO 2011/021146, WO2008/150261, WO 2006/031653, WO 2005/089809, WO 2005/089807, and WO2005/089808, each of which is incorporated by reference herein in itsentirety). In a specific embodiment, an antibody that is conjugated tosuch therapeutic/drug moiety is one that comprises the CDRs set forth inTable 1 (e.g., VL CDR1, VL CDR2, and VL CDR3 having the amino acidsequence of SEQ ID NO: 20, 21, and 22, respectively, and/or a VH chainregion comprising VH CDR1, VH CDR2, and VH CDR3 having the amino acidsequence of SEQ ID NO: 23, 24, and 25, respectively). In a specificembodiment, an antibody that is conjugated to such therapeutic/drugmoiety is one that comprises a VL comprising SEQ ID NO: 7, 8, 9, 10, or12 or a sequence set forth in Tables 5B and 5D, and/or VH comprising SEQID NO: 2, 3, 4, 5, 6, or 11 or a sequence set forth in Tables 5A and 5C.In a specific embodiment, the antibody and therapeutic agent areconjugated by way of one or more linkers. In another specificembodiment, the antibody and therapeutic agent are conjugated directly.

Non-limiting examples of calicheamicins suitable for conjugation to anantibody described herein are disclosed, for example, in U.S. Pat. Nos.4,671,958; 5,053,394; 5,037,651; 5,079,233; and 5,108,912; and PCTInternational Patent Application Publication Nos. WO 2011/021146, WO2008/150261, WO 2006/031653, WO 2005/089809, WO 2005/089807, and WO2005/089808; each of which is incorporated herein by reference for suchcalicheamcin disclosure. In particular embodiments, these compounds maycontain a methyltrisulfide that reacts with appropriate thiols to formdisulfides, and at the same time introduces a functional group such as ahydrazide or other functional group that may be useful for conjugatingcalicheamicin to an antibody described herein. In certain embodiments,stabilizing the disulfide bond that is present in calicheamicinconjugates by adding dimethyl substituents may yield an improvedantibody/drug conjugate. In specific embodiments, the calicheamicinderivative is N-acetyl gamma calicheamicin dimethyl hydrazide, orNAc-gamma DMH (CL-184,538), as one of the optimized derivatives forconjugation. Disulfide analogs of calicheamicin which can be conjugatedto an antibody described herein are described, for example, in U.S. Pat.Nos. 5,606,040 and 5,770,710, each of which is incorporated herein byreference for such compound disclosure. In a certain embodiment, amoiety (e.g., calicheamicin or a derivative thereof) is conjugated to anantibody by a linker. In a particular embodiment, a moiety (e.g.,calicheamicin or a derivative thereof) is hydrolyzed from theantibody-drug conjugate at the linker. In one embodiment, a moiety(e.g., calicheamicin or a derivative thereof) is hydrolyzed from anantibody conjugate at the linker between about a pH of 3.0 and pH 4.0for 1-24 hours at a temperature from 20 to 50° C., preferably 37° C.

In specific embodiments, non-limiting examples of therapeutic moietiesor drug moieties for conjugation to an antibody described herein includepyrrolobenzodiazepines (PBDs) and derivatives thereof, for example, PBDdimers (e.g., SJG-136 or SG2000), C2-unsaturated PBD dimers,pyrrolobenzodiazepine dimers bearing C2 aryl substitutions (e.g.,SG2285), PBD dimer pro-drug that is activated by hydrolysis (e.g.,SG2285), and polypyrrole-PBD (e.g., SG2274) (see, e.g., PCTInternational Patent Application Publication Nos. WO 2000/012507, WO2007/039752, WO 2005/110423, WO 2005/085251, and WO 2005/040170, andU.S. Pat. No. 7,612,062, each of which is incorporated herein byreference for such compound disclosure). In a specific embodiment, anantibody that is conjugated to such therapeutic/drug moiety is one thatcomprises the CDRs set forth in Table 1 (e.g., VL CDR1, VL CDR2, and VLCDR3 having the amino acid sequence of SEQ ID NO: 19, 20, and 21,respectively, and/or a VH chain region comprising VH CDR1, VH CDR2, andVH CDR3 having the amino acid sequence of SEQ ID NO: 16, 17, and 18,respectively), or Table 2, or Table 3. In a specific embodiment, anantibody that is conjugated to such therapeutic/drug moiety is one thatcomprises a VL comprising SEQ ID NO: 7, 8, 9, 10, or 12 or a sequenceset forth in Tables 5B and 5D, and/or VH comprising SEQ ID NO: 2, 3, 4,5, 6, or 11 or a sequence set forth in Tables 5A and 5C. In a specificembodiment, the antibody and therapeutic agent is conjugated by way ofone or more linkers.

Further, an antibody described herein can be conjugated or recombinantlyfused to a therapeutic moiety or drug moiety that modifies a givenbiological response. Therapeutic moieties or drug moieties are not to beconstrued as limited to classical chemical therapeutic agents. Forexample, the drug moiety can be a protein, peptide, or polypeptidepossessing a desired biological activity. Such proteins can include, forexample, a toxin such as abrin, ricin A, pseudomonas exotoxin, choleratoxin, or diphtheria toxin; a protein such as tumor necrosis factor,γ-interferon, α-interferon, nerve growth factor, platelet derived growthfactor, tissue plasminogen activator, an apoptotic agent, e.g., TNF-γ,TNF-γ, AIM I (see, International Publication No. WO 97/33899), AIM II(see, International Publication No. WO 97/34911), Fas Ligand (Takahashiet al., 1994, J. Immunol., 6:1567-1574), and VEGF (see, InternationalPublication No. WO 99/23105), an anti-angiogenic agent, e.g.,angiostatin, endostatin or a component of the coagulation pathway (e.g.,tissue factor); or, a biological response modifier such as, for example,a lymphokine (e.g., interferon gamma, interleukin-1 (“IL-1”),interleukin-2 (“IL-2”), interleukin-5 (“IL-5”), interleukin-6 (“IL-6”),interleukin-7 (“IL-7”), interleukin 9 (“IL-9”), interleukin-10(“IL-10”), interleukin-12 (“IL-12”), interleukin-15 (“IL-15”),interleukin-23 (“IL-23”), granulocyte macrophage colony stimulatingfactor (“GM-CSF”), and granulocyte colony stimulating factor (“G-CSF”)),or a growth factor (e.g., growth hormone (“GH”)), or a coagulation agent(e.g., calcium, vitamin K, tissue factors, such as but not limited to,Hageman factor (factor XII), high-molecular-weight kininogen (HMWK),prekallikrein (PK), coagulation proteins-factors II (prothrombin),factor V, XIIa, VIII, XIIIa, XI, XIa, IX, IXa, X, phospholipid, andfibrin monomer).

Provided herein are antibodies recombinantly fused or chemicallyconjugated (covalent or non-covalent conjugations) to a heterologousprotein or polypeptide (or fragment thereof, preferably to a polypeptideof about 10, about 20, about 30, about 40, about 50, about 60, about 70,about 80, about 90 or about 100 amino acids) to generate fusionproteins. In particular, provided herein are fusion proteins comprisingan antigen-binding fragment of an antibody described herein (e.g., a Fabfragment, Fd fragment, Fv fragment, F(ab)₂ fragment, a VH domain, a VHCDR, a VL domain or a VL CDR) and a heterologous protein, polypeptide,or peptide. In one embodiment, the heterologous protein, polypeptide, orpeptide that the antibody is fused to is useful for targeting theantibody to a particular cell type, such as a cell that expresses KIT.For example, an antibody that immunospecifically binds to a cell surfacereceptor expressed by a particular cell type (e.g., an immune cell) canbe fused or conjugated to a modified antibody described herein. Inspecific embodiments, the heterologous protein or polypeptide (orfragment thereof) binds to a second target (e.g., a target other thanKIT) (see, e.g., PCT International Patent Application Publication No. WO2009/088805 and U.S. Patent Application Publication No. US2009/0148905).

Provided herein is a conjugated or fusion protein comprising anyantibody described herein, or an antigen-binding fragment thereof, and aheterologous polypeptide (e.g., a polypeptide other than KIT). In oneembodiment, a conjugated or fusion protein described herein comprises ananti-KIT antibody described herein, and a heterologous polypeptide. Inanother embodiment, a conjugated or fusion protein provided hereincomprises an antigen-binding fragment of an anti-KIT antibody describedherein, and a heterologous polypeptide. In another embodiment, aconjugated or fusion protein described herein comprises a VH domainhaving the amino acid sequence of any one of the VH domains of ananti-KIT antibody described herein, and/or a VL domain having the aminoacid sequence of any one of the VL domains of an anti-KIT antibodydescribed herein, and a heterologous polypeptide. In another embodiment,a conjugated or fusion protein described herein comprises one or more VHCDRs having the amino acid sequence of any one of SEQ ID NO: 16, 17, and18 (see, e.g., Table 1), or the amino acid sequence of any one of theCDRs set forth in Table 2 or 3, and a heterologous polypeptide. Inanother embodiment, a conjugated or fusion protein comprises one or moreVL CDRs having the amino acid sequence of any one of the VL CDRs of ananti-KIT antibody described herein (e.g., VL CDRs in Table 1, SEQ IDNOs: 19, 20, and 21, or VL CDRs of Table 2 or Table 3), and aheterologous polypeptide. In another embodiment, a conjugated or fusionprotein described herein comprises at least one VH domain and at leastone VL domain of an anti-KIT antibody described herein, and aheterologous polypeptide. In another embodiment, a conjugated or fusionprotein described herein comprises at least one VH domain and at least aVL domain comprising SEQ ID NO: 7, 8, 9, 10, or 12 or a sequence setforth in Tables 5B and 5D, and/or VH domain comprising SEQ ID NO: 2, 3,4, 5, 6, or 11 or a sequence set forth in Tables 5A and 5C, and aheterologous polypeptide. In yet another embodiment, a conjugated orfusion protein described herein comprises at least one VH CDR and atleast one VL CDR of an anti-KIT antibody described herein (e.g., VL CDRsand VH CDRs in Table 1 or Table 2 or Table 3), and a heterologouspolypeptide.

In addition, an antibody described herein can be conjugated totherapeutic moieties such as a radioactive metal ion, such asalpha-emitters such as ²¹³Bi or macrocyclic chelators useful forconjugating radiometal ions, including but not limited to, ¹³¹In, ¹³¹Lu,¹³¹Y, ¹³¹Ho, ¹³¹Sm, to polypeptides. In certain embodiments, themacrocyclic chelator is1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid (DOTA) whichcan be attached to the antibody via a linker molecule. Such linkermolecules are commonly known in the art and described in Denardo et al.,1998, Clin Cancer Res. 4(10):2483-90; Peterson et al., 1999, Bioconjug.Chem. 10(4):553-7; and Zimmerman et al., 1999, Nucl. Med. Biol.26(8):943-50, each incorporated by reference in their entireties.

In certain embodiments, an antibody described herein, or anantigen-binding fragment thereof, is conjugated to one or more molecules(e.g., therapeutic or drug moiety) directly or indirectly via one ormore linker molecules. In particular embodiments, a linker is anenzyme-cleavable linker or a disulfide linker. In a specific embodiment,the cleavable linker is cleavable via an enzyme such an aminopeptidase,an aminoesterase, a dipeptidyl carboxy peptidase, or a protease of theblood clotting cascade. In particular embodiments, a linker comprises 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 20 amino acidresidues. In certain embodiments, a linker consists of 1 to 10 aminoacid residues, 1 to 15 amino acid residues, 5 to 20 amino acid residues,10 to 25 amino acid residues, 10 to 30 amino acid residues, or 10 to 50amino acid residues.

In certain embodiments, a moiety is conjugated to an antibody by one ormore linkers. In a particular embodiment, a moiety is hydrolyzed fromthe antibody-drug conjugate at the linker. In one embodiment, a moietyis hydrolyzed from the antibody conjugate at the linker between about apH of 3.0 and pH 4.0 for about 1-24 hours, and at a temperature fromabout 20 to 50° C., preferably 37° C. In a specific embodiment, a linkeris stable in the blood stream but releases the conjugated moiety once itis inside the targeted cells. In certain embodiments, a moiety isconjugated to an antibody described herein via one or moretriazole-containing linkers (see, e.g., International Patent ApplicationPublication No. WO 2007/018431, which is incorporated herein byreference). Non-limiting examples of linkers and spacers forincorporation into antibody-drug conjugates described herein aredisclosed in PCT International Patent Application Publication Nos. WO2007/018431, WO 2004/043493, and WO 2002/083180.

Moreover, antibodies described herein can be fused to marker sequences,such as a peptide to facilitate purification. In preferred embodiments,the marker amino acid sequence is a hexa-histidine peptide, such as thetag provided in a pQE vector (QIAGEN, Inc.), among others, many of whichare commercially available. As described in Gentz et al., 1989, Proc.Natl. Acad. Sci. USA 86:821-824, for instance, hexa-histidine providesfor convenient purification of the fusion protein. Other peptide tagsuseful for purification include, but are not limited to, thehemagglutinin (“HA”) tag, which corresponds to an epitope derived fromthe influenza hemagglutinin protein (Wilson et al., 1984, Cell 37:767),and the “FLAG” tag.

Methods for fusing or conjugating therapeutic moieties (includingpolypeptides) to antibodies are well known, see, e.g., Arnon et al.,“Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy”,in Monoclonal Antibodies And Cancer Therapy, Reisfeld et al. (eds.), pp.243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., “Antibodies For DrugDelivery”, in Controlled Drug Delivery (2nd Ed.), Robinson et al.(eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, “AntibodyCarriers Of Cytotoxic Agents In Cancer Therapy: A Review”, in MonoclonalAntibodies 84: Biological And Clinical Applications, Pinchera et al.(eds.), pp. 475-506 (1985); “Analysis, Results, And Future ProspectiveOf The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy”, inMonoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al.(eds.), pp. 303-16 (Academic Press 1985), Thorpe et al., 1982, Immunol.Rev. 62:119-58; U.S. Pat. Nos. 5,336,603, 5,622,929, 5,359,046,5,349,053, 5,447,851, 5,723,125, 5,783,181, 5,908,626, 5,844,095, and5,112,946; EP 307,434; EP 367,166; EP 394,827; PCT publications WO91/06570, WO 96/04388, WO 96/22024, WO 97/34631, and WO 99/04813;Ashkenazi et al., Proc. Natl. Acad. Sci. USA, 88: 10535-10539, 1991;Traunecker et al., Nature, 331:84-86, 1988; Zheng et al., J. Immunol.,154:5590-5600, 1995; Vil et al., Proc. Natl. Acad. Sci. USA,89:11337-11341, 1992, which are incorporated herein by reference intheir entireties.

Fusion proteins can be generated, for example, through the techniques ofgene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling(collectively referred to as “DNA shuffling”). DNA shuffling can beemployed to alter the activities of antibodies described herein (e.g.,antibodies with higher affinities and lower dissociation rates). See,generally, U.S. Pat. Nos. 5,605,793, 5,811,238, 5,830,721, 5,834,252,and 5,837,458; Patten et al., 1997, Curr. Opinion Biotechnol. 8:724-33;Harayama, 1998, Trends Biotechnol. 16(2):76-82; Hansson et al., 1999, J.Mol. Biol. 287:265-76; and Lorenzo and Blasco, 1998, Biotechniques24(2):308-313 (each of these patents and publications is herebyincorporated by reference). Antibodies, or the encoded antibodies, canbe altered by being subjected to random mutagenesis by error-prone PCR,random nucleotide insertion or other methods prior to recombination. Apolynucleotide encoding an antibody described herein can be recombinedwith one or more components, motifs, sections, parts, domains,fragments, etc. of one or more heterologous molecules.

An antibody described herein can also be conjugated to a second antibodyto form an antibody heteroconjugate as described in U.S. Pat. No.4,676,980, which is incorporated herein by reference.

The therapeutic moiety or drug conjugated or recombinantly fused to anantibody described herein that immunospecifically binds to a KIT antigencan be chosen to achieve the desired prophylactic or therapeuticeffect(s), e.g., reducing tumor size or burden, reducing cancer cellgrowth or proliferation, or inducing death of cancer cells. In certainembodiments, the antibody is a modified antibody. A clinician or othermedical personnel should consider the following when deciding on whichtherapeutic moiety or drug to conjugate or recombinantly fuse to anantibody described herein: the nature of the disease, the severity ofthe disease, and the condition of the subject.

Antibodies described herein can also be attached to solid supports,which are particularly useful for immunoassays or purification of thetarget antigen. Such solid supports include, but are not limited to,glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chlorideor polypropylene.

In a certain aspect, an antibody described herein or an antigen-bindingfragment thereof is an extracellular drug conjugate (ECD) comprising anantibody linked to a drug, optionally by a linker (see, e.g., PCTInternational Patent Application Publication No. WO 2011/031870). Thedrug can act outside of the cell, and thus internalization of theconjugate is not required. After an ECD binds a target cell, the drugsends a signal into the cell.

In one embodiment, the linker of the ECD is a non-cleavable linker.Examples of non-cleavable linkers include linkers that containpolyethylene glycol chains or polyethylene chains that are not acid orbase sensitive (such as hydrazone containing linkers), are not sensitiveto reducing or oxidizing agents (such as those containing disulfidelinkages), and are not sensitive to enzymes that may be found in cellsor circulatory system. Specific examples of non-cleavable linkersinclude SMCC linker (US Patent Application 20090202536). Forillustrative purposes, examples of cleavable linkers include linkersthat contain non-hindered glutathione sensitive disulfides, esters,peptide sequences sensitive to the peptidases such as cathepsin orplasmin, pH sensitive hydrazones (see Bioconjugate Chem., 2010, 21 (1),pp 5-13) and non-hindered disulfide linker SPP (US Patent Application20090202536).

In certain aspects, an ECD comprises a drug or agent that is a cardiacglycoside, for example, proscillaridin or a sugar-enhancedproscillaridin. In one embodiment, the agent is composed from a cardiacglycoside which is void a sugar. In various embodiments, the cardiacglycoside is a compound identified in PCT Pub. No. WO 2010/017480(PCT/US2009/053159).

5.2 Polynucleotides

In certain aspects, provided herein are polynucleotides comprising anucleotide sequence encoding an antibody (e.g., human or humanizedantibody) described herein or a fragment thereof (e.g., a variable lightchain region and/or variable heavy chain region) that immunospecificallybinds to a KIT antigen, and vectors, e.g., vectors comprising suchpolynucleotides for recombinant expression in host cells (e.g., E. coliand mammalian cells). Provided herein are polynucleotides comprisingnucleotide sequences encoding any of the antibodies provided herein, aswell as vectors comprising such polynucleotide sequences, e.g.,expression vectors for their efficient expression in host cells, e.g.,mammalian cells. Also provided herein are polynucleotides encoding KITantigens (e.g., SEQ ID NO: 14 or 15) for generating anti-KIT antibodiesdescribed herein.

As used herein, an “isolated” polynucleotide or nucleic acid molecule isone which is separated from other nucleic acid molecules which arepresent in the natural source (e.g., in a human) of the nucleic acidmolecule. Moreover, an “isolated” nucleic acid molecule, such as a cDNAmolecule, can be substantially free of other cellular material, orculture medium when produced by recombinant techniques, or substantiallyfree of chemical precursors or other chemicals when chemicallysynthesized. For example, the language “substantially free” includespreparations of polynucleotide or nucleic acid molecule having less thanabout 15%, 10%, 5%, 2%, 1%, 0.5%, or 0.1% (in particular less than about10%) of other material, e.g., cellular material, culture medium, othernucleic acid molecules, chemical precursors and/or other chemicals. In aspecific embodiment, a nucleic acid molecule(s) encoding an antibodydescribed herein is isolated or purified.

In particular aspects, provided herein are polynucleotides comprisingnucleotide sequences encoding antibodies (e.g., a humanized antibody) orantigen-binding fragments thereof, which immunospecifically bind to aKIT polypeptide (e.g., the D4 region of KIT, for example, human KIT) andcomprises an amino acid sequence as described herein, as well asantibodies which compete with such antibodies for binding to a KITpolypeptide (e.g., in a dose-dependent manner), or which binds to thesame epitope as that of such antibodies.

In certain aspects, provided herein are polynucleotides comprising anucleotide sequence encoding the light chain or heavy chain of anantibody described herein. The polynucleotides can comprise nucleotidesequences encoding a light chain comprising the VL FRs and CDRs ofantibodies described herein (see, e.g., Tables 1 and 5B). Thepolynucleotides can comprise nucleotide sequences encoding a heavy chaincomprising the VH FRs and CDRs of antibodies described herein (see,e.g., Tables 1 and 5A). In specific embodiments, a polynucleotidedescribed herein encodes a VL chain region comprising the amino acidsequence of SEQ ID NO: 7, 8, 9 or 10. In specific embodiments, apolynucleotide described herein encodes a VH chain region comprising theamino acid sequence of any one of SEQ ID NOs: 2-6.

In particular embodiments, a polynucleotide described herein encodes aVL chain region, wherein the polynucleotide comprises the nucleic acidsequence of SEQ ID NO: 27, 28, 29, or 30. In particular embodiments, apolynucleotide described herein encodes a VH chain region, wherein thepolynucleotide comprises the nucleic acid sequence of SEQ ID NO: 22, 23,24, 25, or 26. In particular embodiments, a polynucleotide encodes anantibody described herein, wherein the polynucleotide comprises thenucleic acid sequence of SEQ ID NO: 28 encoding a L2 VL chain region andthe nucleic acid sequence of SEQ ID NO: 24 encoding a H3 VH chainregion. In particular embodiments, one or more polynucleotides comprisethe nucleic acid sequence of SEQ ID NO: 28 encoding a VL chain regionand the nucleic acid sequence of SEQ ID NO: 24 encoding a VH chainregion. In particular embodiments, a polynucleotide encodes an antibodydescribed herein, wherein the polynucleotide comprises the nucleic acidsequence of SEQ ID NO: 27 encoding a L1 VL chain region and the nucleicacid sequence of SEQ ID NO: 25 encoding a H4 VH chain region. Inparticular embodiments, one or more polynucleotides comprise the nucleicacid sequence of SEQ ID NO: 27 encoding a VL chain region and thenucleic acid sequence of SEQ ID NO: 25 encoding a VH chain region. Inparticular embodiments, a polynucleotide described herein encodes a VLchain region, wherein the polynucleotide comprises a nucleic acidsequence that is at least 80%, at least 85%, at least 90%, at least 95%,or at least 98% identical to the nucleic acid sequence of SEQ ID NO: 27,28, 29, or 30. In particular embodiments, a polynucleotide describedherein encodes a VH chain region, wherein the polynucleotide comprises anucleic acid sequence that is at least 80%, at least 85%, at least 90%,at least 95%, or at least 98% identical to the nucleic acid sequence ofSEQ ID NO: 22, 23, 24, 25, or 26.

In particular embodiments, provided herein are polynucleotidescomprising a nucleotide sequence encoding an anti-KIT antibodycomprising a VL chain region, e.g., containingFR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, comprising an amino acid sequencesdescribed herein (e.g., see Tables 1, 5A-5B, and 6A-6B). In specificembodiments, provided herein are polynucleotides comprising a nucleotidesequence encoding an anti-KIT antibody comprising a VH chain region,e.g., containing FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, comprising an aminoacid sequence described herein (e.g., see Tables 1, 5A-5B, and 6A-6B).

In certain embodiments, a polynucleotide described herein comprises anucleotide sequence encoding an antibody provided herein comprising avariable light (VL) chain region comprising an amino acid describedherein (e.g., see FIGS. 3A-31), wherein the antibody immunospecificallybinds to a KIT polypeptide, e.g., a human KIT polypeptide, for example,a D4 region of KIT (e.g., human KIT), for example SEQ ID NO: 15.

In certain embodiments, a polynucleotide described herein comprises anucleotide sequence encoding an antibody provided herein comprising avariable heavy (VH) chain region comprising an amino acid sequencedescribed herein (e.g., see FIGS. 3A-31), wherein the antibodyimmunospecifically binds to a KIT polypeptide, e.g., a human KITpolypeptide, for example, a D4 region of KIT (e.g., human KIT), forexample SEQ ID NO: 15.

In certain aspects, a polynucleotide comprises a nucleotide sequenceencoding an antibody (e.g., human or humanized antibody) describedherein comprising a VL chain region comprising one or more VL FRs havingthe amino acid sequence described herein (e.g., see Tables 5B and 5D),wherein the antibody immunospecifically binds to a KIT polypeptide,e.g., a human KIT polypeptide, for example, a D4 region of KIT (e.g.,human KIT), for example SEQ ID NO: 15. In certain aspects, apolynucleotide comprises a nucleotide sequence encoding an antibodydescribed herein comprising a VH chain region comprising one or more VHFRs having the amino acid sequence described herein (e.g., see Tables 5Aand 5C), wherein the antibody immunospecifically binds to a KITpolypeptide, e.g., a human KIT polypeptide, for example, a D4 region ofKIT (e.g., human KIT), for example SEQ ID NO: 15.

In specific embodiments, a polynucleotide provided herein comprises anucleotide sequence encoding an antibody (e.g., human or humanizedantibody) described herein comprising: framework regions (e.g.,framework regions of the VL domain and VH domain) that are humanframework regions, wherein the antibody immunospecifically binds to aKIT polypeptide, e.g., a human KIT polypeptide, for example, a D4 regionof KIT (e.g., human KIT, for example SEQ ID NO: 15).

In specific aspects, provided herein is a polynucleotide comprising anucleotide sequence encoding an antibody comprising a light chain and aheavy chain, e.g., a separate light chain and heavy chain. With respectto the light chain, in a specific embodiment, a polynucleotide providedherein comprises a nucleotide sequence encoding a kappa light chain. Inanother specific embodiment, a polynucleotide provided herein comprisesa nucleotide sequence encoding a lambda light chain. In yet anotherspecific embodiment, a polynucleotide provided herein comprises anucleotide sequence encoding an antibody described herein comprising ahuman kappa light chain or a human lambda light chain. In a particularembodiment, a polynucleotide provided herein comprises a nucleotidesequence encoding an antibody described herein, which immunospecificallybinds to a KIT polypeptide (e.g., a KIT polypeptide comprising a D4region of KIT, for example human KIT (e.g., SEQ ID NO: 15)), wherein theantibody comprises a light chain, and wherein the amino acid sequence ofthe VL chain region can comprise any amino acid sequence describedherein (e.g., SEQ ID NO: 7, 8, 9, or 10 or 12), and wherein the constantregion of the light chain comprises the amino acid sequence of a humankappa light chain constant region. In a particular embodiment, the lightchain comprises the amino acid sequence of SEQ ID NO: 12. In anotherparticular embodiment, a polynucleotide provided herein comprises anucleotide sequence encoding an antibody described herein, whichimmunospecifically binds to a KIT polypeptide (e.g., a KIT polypeptidecomprising a KIT polypeptide comprising a D4 region of KIT, for examplehuman KIT (e.g., SEQ ID NO: 15)), and comprises a light chain, whereinthe amino acid sequence of the VL chain region can comprises any aminoacid sequence described herein (e.g., SEQ ID NO: 7, 8, 9, or 10 or 12),and wherein the constant region of the light chain comprises the aminoacid sequence of a human lambda light chain constant region. Forexample, human constant region sequences can be those described in U.S.Pat. No. 5,693,780.

In a particular embodiment, a polynucleotide provided herein comprises anucleotide sequence encoding an antibody described herein, whichimmunospecifically binds to a KIT polypeptide (e.g., a KIT polypeptidecomprising a KIT polypeptide comprising a D4 region of KIT, for examplehuman KIT (e.g., SEQ ID NO: 15)), wherein the antibody comprises a heavychain, wherein the amino acid sequence of the VH chain region cancomprise any amino acid sequence described herein (e.g., SEQ ID NO: 2,3, 4, 5, or 6 or 11), and wherein the constant region of the heavy chaincomprises the amino acid sequence of a human gamma (γ) heavy chainconstant region.

In yet another specific embodiment, a polynucleotide provided hereincomprises a nucleotide sequence encoding an antibody described herein(or an antigen-binding fragment thereof), which immunospecifically bindsto a KIT polypeptide (e.g., a D4 region of KIT, for example human KIT),wherein the antibody comprises a VL chain region and a VH chain regioncomprising any amino acid sequences described herein, and wherein theconstant regions comprise the amino acid sequences of the constantregions of a human IgG1 (e.g., isotype a, z, or f) or human IgG4.

In a specific embodiment, provided herein are polynucleotides comprisinga nucleotide sequence encoding an anti-KIT antibody, or anantigen-binding fragment or domain thereof, designated herein, see,e.g., Tables 1-6B and FIGS. 3A-3I, for example antibody Hum1-Hum20.

Also provided herein are polynucleotides encoding an anti-KIT antibodyor a fragment thereof that are optimized, e.g., by codon/RNAoptimization, replacement with heterologous signal sequences, andelimination of mRNA instability elements. Methods to generate optimizednucleic acids encoding an anti-KIT antibody or a fragment thereof (e.g.,light chain, heavy chain, VH domain, or VL domain) for recombinantexpression by introducing codon changes and/or eliminating inhibitoryregions in the mRNA can be carried out by adapting the optimizationmethods described in, e.g., U.S. Pat. Nos. 5,965,726; 6,174,666;6,291,664; 6,414,132; and 6,794,498, accordingly. For example, potentialsplice sites and instability elements (e.g., A/T or A/U rich elements)within the RNA can be mutated without altering the amino acids encodedby the nucleic acid sequences to increase stability of the RNA forrecombinant expression. The alterations utilize the degeneracy of thegenetic code, e.g., using an alternative codon for an identical aminoacid. In some embodiments, it can be desirable to alter one or morecodons to encode a conservative mutation, e.g., a similar amino acidwith similar chemical structure and properties and/or function as theoriginal amino acid. Such methods can increase expression of an anti-KITantibody or fragment thereof by at least 1 fold, 2 fold, 3 fold, 4 fold,5 fold, 10 fold, 20 fold, 30 fold, 40 fold, 50 fold, 60 fold, 70 fold,80 fold, 90 fold, or 100 fold or more relative to the expression of ananti-KIT antibody encoded by polynucleotides that have not beenoptimized.

In certain embodiments, an optimized polynucleotide sequence encoding ananti-KIT antibody described herein or a fragment thereof (e.g., VLdomain and/or VH domain) can hybridize to an antisense (e.g.,complementary) polynucleotide of an unoptimized polynucleotide sequenceencoding an anti-KIT antibody described herein or a fragment thereof(e.g., VL domain and/or VH domain). In specific embodiments, anoptimized nucleotide sequence encoding an anti-KIT antibody describedherein or a fragment hybridizes under high stringency conditions toantisense polynucleotide of an unoptimized polynucleotide sequenceencoding an anti-KIT antibody described herein or a fragment thereof. Ina specific embodiment, an optimized nucleotide sequence encoding ananti-KIT antibody described herein or a fragment thereof hybridizesunder high stringency, intermediate or lower stringency hybridizationconditions to an antisense polynucleotide of an unoptimized nucleotidesequence encoding an anti-KIT antibody described herein or a fragmentthereof. Information regarding hybridization conditions have beendescribed, see, e.g., U.S. Patent Application Publication No. US2005/0048549 (e.g., paragraphs 72-73), which is incorporated herein byreference.

In certain embodiments, an optimized polynucleotide sequence encoding aVL region of an antibody described herein is at least 75%, at least 80%,at least 85%, at least 90%, at least 95%, at least 98% identical to thenucleotide sequence of SEQ ID NO: 27, 28, 29, or 30. In certainembodiments, an optimized polynucleotide sequence encoding a VH regionof an antibody described herein is at least 75%, at least 80%, at least85%, at least 90%, at least 95%, at least 98% identical to thenucleotide sequence of SEQ ID NO: 22, 23, 24, 25, or 26.

The polynucleotides can be obtained, and the nucleotide sequence of thepolynucleotides determined, by any method known in the art. Nucleotidesequences encoding antibodies described herein, e.g., antibodiesdescribed in Tables 1-6B and FIGS. 3A-3I, and modified versions of theseantibodies can be determined using methods well known in the art, i.e.,nucleotide codons known to encode particular amino acids are assembledin such a way to generate a nucleic acid that encodes the antibody. Sucha polynucleotide encoding the antibody can be assembled from chemicallysynthesized oligonucleotides (e.g., as described in Kutmeier et al.,1994, BioTechniques 17:242), which, briefly, involves the synthesis ofoverlapping oligonucleotides containing portions of the sequenceencoding the antibody, annealing and ligating of those oligonucleotides,and then amplification of the ligated oligonucleotides by PCR.

Alternatively, a polynucleotide encoding an antibody described hereincan be generated from nucleic acid from a suitable source (e.g., ahybridoma) using methods well known in the art (e.g., PCR and othermolecular cloning methods). For example, PCR amplification usingsynthetic primers hybridizable to the 3′ and 5′ ends of a known sequencecan be performed using genomic DNA obtained from hybridoma cellsproducing the antibody of interest. Such PCR amplification methods canbe used to obtain nucleic acids comprising the sequence encoding thelight chain and/or heavy chain of an antibody. Such PCR amplificationmethods can be used to obtain nucleic acids comprising the sequenceencoding the variable light chain region and/or the variable heavy chainregion of an antibody. The amplified nucleic acids can be cloned intovectors for expression in host cells and for further cloning, forexample, to generate chimeric and humanized antibodies.

If a clone containing a nucleic acid encoding a particular antibody isnot available, but the sequence of the antibody molecule is known, anucleic acid encoding the immunoglobulin can be chemically synthesizedor obtained from a suitable source (e.g., an antibody cDNA library or acDNA library generated from, or nucleic acid, preferably poly A+RNA,isolated from, any tissue or cells expressing the antibody, such ashybridoma cells selected to express an antibody described herein) by PCRamplification using synthetic primers hybridizable to the 3′ and 5′ endsof the sequence or by cloning using an oligonucleotide probe specificfor the particular gene sequence to identify, e.g., a cDNA clone from acDNA library that encodes the antibody. Amplified nucleic acidsgenerated by PCR can then be cloned into replicable cloning vectorsusing any method well known in the art.

DNA encoding anti-KIT antibodies described herein can be readilyisolated and sequenced using conventional procedures (e.g., by usingoligonucleotide probes that are capable of binding specifically to genesencoding the heavy and light chains of the anti-KIT antibodies).Hybridoma cells can serve as a source of such DNA. Once isolated, theDNA can be placed into expression vectors, which are then transfectedinto host cells such as E. coli cells, simian COS cells, Chinese hamsterovary (CHO) cells (e.g., CHO cells from the CHO GS System™ (Lonza)), ormyeloma cells that do not otherwise produce immunoglobulin protein, toobtain the synthesis of anti-KIT antibodies in the recombinant hostcells.

To generate whole antibodies, PCR primers including VH or VL nucleotidesequences, a restriction site, and a flanking sequence to protect therestriction site can be used to amplify the VH or VL sequences in scFvclones. Utilizing cloning techniques known to those of skill in the art,the PCR amplified VH domains can be cloned into vectors expressing aheavy chain constant region, e.g., the human gamma 4 constant region,and the PCR amplified VL domains can be cloned into vectors expressing alight chain constant region, e.g., human kappa or lambda constantregions. In certain embodiments, the vectors for expressing the VH or VLdomains comprise an EF-1α promoter, a secretion signal, a cloning sitefor the variable domain, constant domains, and a selection marker suchas neomycin. The VH and VL domains can also be cloned into one vectorexpressing the necessary constant regions. The heavy chain conversionvectors and light chain conversion vectors are then co-transfected intocell lines to generate stable or transient cell lines that expressfull-length antibodies, e.g., IgG, using techniques known to those ofskill in the art.

The DNA also can be modified, for example, by substituting the codingsequence for human heavy and light chain constant domains in place ofthe murine sequences, or by covalently joining to the immunoglobulincoding sequence all or part of the coding sequence for anon-immunoglobulin polypeptide.

Also provided are polynucleotides that hybridize under high stringency,intermediate or lower stringency hybridization conditions topolynucleotides that encode an antibody described herein. In specificembodiments, polynucleotides described herein hybridize under highstringency, intermediate or lower stringency hybridization conditions topolynucleotides encoding a VH chain region (e.g., SEQ ID NO: 2, 3, 4, 5,or 6) and/or VL chain region (e.g., SEQ ID NO: 7, 8, 9, or 10) providedherein. In specific embodiments, polynucleotides described hereinhybridize under high stringency or intermediate stringency hybridizationconditions to polynucleotides which are complements to polynucleotidesencoding a VH chain region (e.g., SEQ ID NO: 3 or 5) and/or VL chainregion (e.g., a SEQ ID NO: 2) provided herein.

In specific embodiments, polynucleotides described herein hybridizeunder high stringency, intermediate or lower stringency hybridizationconditions to polynucleotides which are complements to a polynucleotidecomprising SEQ ID NO: 27, 28, 29, or 30 encoding a VL domain. Inspecific embodiments, polynucleotides described herein hybridize underhigh stringency or intermediate stringency hybridization conditions topolynucleotides which are complements to a polynucleotide comprising SEQID NO: 22, 23, 24, 25, or 26 encoding a VH domain.

Hybridization conditions have been described in the art and are known toone of skill in the art. For example, hybridization under stringentconditions can involve hybridization to filter-bound DNA in 6× sodiumchloride/sodium citrate (SSC) at about 45° C. followed by one or morewashes in 0.2×SSC/0.1% SDS at about 50-65° C.; hybridization underhighly stringent conditions can involve hybridization to filter-boundnucleic acid in 6×SSC at about 45° C. followed by one or more washes in0.1×SSC/0.2% SDS at about 68° C. Hybridization under other stringenthybridization conditions are known to those of skill in the art and havebeen described, see, for example, Ausubel, F. M. et al., eds., 1989,Current Protocols in Molecular Biology, Vol. I, Green PublishingAssociates, Inc. and John Wiley & Sons, Inc., New York at pages6.3.1-6.3.6 and 2.10.3.

5.3 Host Cells and Recombinant Expression of Antibodies

In certain aspects, provided herein are host cells recombinantlyexpressing the antibodies described herein (or an antigen-bindingfragment thereof) and related expression vectors. Provided herein arevectors (e.g., expression vectors) comprising polynucleotides comprisingnucleotide sequences encoding anti-KIT antibodies or a fragment forrecombinant expression in host cells, preferably in mammalian cells.Also provided herein are host cells comprising such vectors forrecombinantly expressing anti-KIT antibodies described herein (e.g.,human or humanized antibody). In a particular aspect, provided hereinare methods for producing an antibody described herein, comprisingexpressing such antibody from a host cell.

Recombinant expression of an antibody described herein (e.g., afull-length antibody, heavy and/or light chain of an antibody, or asingle chain antibody described herein) that immunospecifically binds toa KIT antigen involves construction of an expression vector containing apolynucleotide that encodes the antibody. Once a polynucleotide encodingan antibody molecule, heavy and/or light chain of an antibody, orfragment thereof (preferably, but not necessarily, containing the heavyand/or light chain variable domain) described herein has been obtained,the vector for the production of the antibody molecule can be producedby recombinant DNA technology using techniques well-known in the art.Thus, methods for preparing a protein by expressing a polynucleotidecontaining an antibody encoding nucleotide sequence are describedherein. Methods which are well known to those skilled in the art can beused to construct expression vectors containing antibody codingsequences and appropriate transcriptional and translational controlsignals. These methods include, for example, in vitro recombinant DNAtechniques, synthetic techniques, and in vivo genetic recombination.Also provided are replicable vectors comprising a nucleotide sequenceencoding an antibody molecule described herein, a heavy or light chainof an antibody, a heavy or light chain variable domain of an antibody ora fragment thereof, or a heavy or light chain CDR, operably linked to apromoter. Such vectors can, for example, include the nucleotide sequenceencoding the constant region of the antibody molecule (see, e.g.,International Publication Nos. WO 86/05807 and WO 89/01036; and U.S.Pat. No. 5,122,464) and the variable domain of the antibody can becloned into such a vector for expression of the entire heavy, the entirelight chain, or both the entire heavy and light chains.

An expression vector can be transferred to a cell (e.g., host cell) byconventional techniques and the resulting cells can then be cultured byconventional techniques to produce an antibody described herein or afragment thereof. Thus, provided herein are host cells containing apolynucleotide encoding an antibody described herein or fragmentsthereof, or a heavy or light chain thereof, or fragment thereof, or asingle chain antibody described herein, operably linked to a promoterfor expression of such sequences in the host cell. In certainembodiments, for the expression of double-chained antibodies, vectorsencoding both the heavy and light chains, individually, can beco-expressed in the host cell for expression of the entireimmunoglobulin molecule, as detailed below. In certain embodiments, ahost cell contains a vector comprising a polynucleotide encoding boththe heavy chain and light chain of an antibody described herein, or afragment thereof. In specific embodiments, a host cell contains twodifferent vectors, a first vector comprising a polynucleotide encoding aheavy chain of an antibody described herein, or a fragment thereof, anda second vector comprising a polynucleotide encoding a light chain of anantibody described herein, or a fragment thereof. In other embodiments,a first host cell comprises a first vector comprising a polynucleotideencoding a heavy chain of an antibody described herein, or a fragmentthereof, and a second host cell comprises a second vector comprising apolynucleotide encoding a light chain of an antibody described herein.

A variety of host-expression vector systems can be utilized to expressantibody molecules described herein (see, e.g., U.S. Pat. No.5,807,715). Such host-expression systems represent vehicles by which thecoding sequences of interest can be produced and subsequently purified,but also represent cells which can, when transformed or transfected withthe appropriate nucleotide coding sequences, express an antibodymolecule described herein in situ. These include but are not limited tomicroorganisms such as bacteria (e.g., E. coli and B. subtilis)transformed with recombinant bacteriophage DNA, plasmid DNA or cosmidDNA expression vectors containing antibody coding sequences; yeast(e.g., Saccharomyces Pichia) transformed with recombinant yeastexpression vectors containing antibody coding sequences; insect cellsystems infected with recombinant virus expression vectors (e.g.,baculovirus) containing antibody coding sequences; plant cell systems(e.g., green algae such as Chlamydomonas reinhardtii) infected withrecombinant virus expression vectors (e.g., cauliflower mosaic virus,CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmidexpression vectors (e.g., Ti plasmid) containing antibody codingsequences; or mammalian cell systems (e.g., COS, CHO, BHK, MDCK, HEK293, NS0, PER.C6, VERO, CRL7O3O, HsS78Bst, HeLa, and NIH 3T3 cells)harboring recombinant expression constructs containing promoters derivedfrom the genome of mammalian cells (e.g., metallothionein promoter) orfrom mammalian viruses (e.g., the adenovirus late promoter; the vacciniavirus 7.5K promoter). In a specific embodiment, cells for expressingantibodies described herein (e.g., Hum1-Hum20) or an antigen-bindingfragment thereof are CHO cells, for example CHO cells from the CHO GSSystem™ (Lonza). In a specific embodiment, a mammalian expression vectoris pOptiVEC™ or pcDNA3.3. Preferably, bacterial cells such asEscherichia coli, and more preferably, eukaryotic cells, especially forthe expression of whole recombinant antibody molecule, are used for theexpression of a recombinant antibody molecule. For example, mammaliancells such as Chinese hamster ovary (CHO) cells, in conjunction with avector such as the major intermediate early gene promoter element fromhuman cytomegalovirus is an effective expression system for antibodies(Foecking et al., 1986, Gene 45:101; and Cockett et al., 1990,Bio/Technology 8:2). In certain embodiments, antibodies described hereinare produced by CHO cells or NS0 cells. In a specific embodiment, theexpression of nucleotide sequences encoding antibodies described hereinwhich immunospecifically bind to a KIT antigen is regulated by aconstitutive promoter, inducible promoter or tissue specific promoter.

In bacterial systems, a number of expression vectors can beadvantageously selected depending upon the use intended for the antibodymolecule being expressed. For example, when a large quantity of such anantibody is to be produced, for the generation of pharmaceuticalcompositions of an antibody molecule, vectors which direct theexpression of high levels of fusion protein products that are readilypurified can be desirable. Such vectors include, but are not limited to,the E. coli expression vector pUR278 (Ruther et al., 1983, EMBO12:1791), in which the antibody coding sequence can be ligatedindividually into the vector in frame with the lac Z coding region sothat a fusion protein is produced; pIN vectors (Inouye & Inouye, 1985,Nucleic Acids Res. 13:3101-3109; Van Heeke & Schuster, 1989, J. Biol.Chem. 24:5503-5509); and the like. pGEX vectors can also be used toexpress foreign polypeptides as fusion proteins with glutathione5-transferase (GST). In general, such fusion proteins are soluble andcan easily be purified from lysed cells by adsorption and binding tomatrix glutathione agarose beads followed by elution in the presence offree glutathione. The pGEX vectors are designed to include thrombin orfactor Xa protease cleavage sites so that the cloned target gene productcan be released from the GST moiety.

In an insect system, Autographa californica nuclear polyhedrosis virus(AcNPV) is used as a vector to express foreign genes. The virus grows inSpodoptera frupperda cells. The antibody coding sequence can be clonedindividually into non-essential regions (for example the polyhedringene) of the virus and placed under control of an AcNPV promoter (forexample the polyhedrin promoter).

In mammalian host cells, a number of viral-based expression systems canbe utilized. In cases where an adenovirus is used as an expressionvector, the antibody coding sequence of interest can be ligated to anadenovirus transcription/translation control complex, e.g., the latepromoter and tripartite leader sequence. This chimeric gene can then beinserted in the adenovirus genome by in vitro or in vivo recombination.Insertion in a non-essential region of the viral genome (e.g., region E1or E3) will result in a recombinant virus that is viable and capable ofexpressing the antibody molecule in infected hosts (e.g., see Logan &Shenk, 1984, Proc. Natl. Acad. Sci. USA 8 1:355-359). Specificinitiation signals can also be required for efficient translation ofinserted antibody coding sequences. These signals include the ATGinitiation codon and adjacent sequences. Furthermore, the initiationcodon must be in phase with the reading frame of the desired codingsequence to ensure translation of the entire insert. These exogenoustranslational control signals and initiation codons can be of a varietyof origins, both natural and synthetic. The efficiency of expression canbe enhanced by the inclusion of appropriate transcription enhancerelements, transcription terminators, etc. (see, e.g., Bittner et al.,1987, Methods in Enzymol. 153:51-544).

In addition, a host cell strain can be chosen which modulates theexpression of the inserted sequences, or modifies and processes the geneproduct in the specific fashion desired. Such modifications (e.g.,glycosylation) and processing (e.g., cleavage) of protein products canbe important for the function of the protein. Different host cells havecharacteristic and specific mechanisms for the post-translationalprocessing and modification of proteins and gene products. Appropriatecell lines or host systems can be chosen to ensure the correctmodification and processing of the foreign protein expressed. To thisend, eukaryotic host cells which possess the cellular machinery forproper processing of the primary transcript, glycosylation, andphosphorylation of the gene product can be used. Such mammalian hostcells include but are not limited to CHO, VERO, BHK, Hela, COS, MDCK,HEK 293, NIH 3T3, W138, BT483, Hs578T, HTB2, BT2O and T47D, NS0 (amurine myeloma cell line that does not endogenously produce anyimmunoglobulin chains), CRL7O3O and HsS78Bst cells. In certainembodiments, humanized monoclonal anti-KIT antibodies described hereinare produced in mammalian cells, such as CHO cells.

For long-term, high-yield production of recombinant proteins, stableexpression is preferred. For example, cell lines which stably expressthe antibody molecule can be engineered. Rather than using expressionvectors which contain viral origins of replication, host cells can betransformed with DNA controlled by appropriate expression controlelements (e.g., promoter, enhancer, sequences, transcriptionterminators, polyadenylation sites, etc.), and a selectable marker.Following the introduction of the foreign DNA, engineered cells can beallowed to grow for 1-2 days in an enriched media, and then are switchedto a selective media. The selectable marker in the recombinant plasmidconfers resistance to the selection and allows cells to stably integratethe plasmid into their chromosomes and grow to form foci which in turncan be cloned and expanded into cell lines. This method canadvantageously be used to engineer cell lines which express the antibodymolecule. Such engineered cell lines can be particularly useful inscreening and evaluation of compositions that interact directly orindirectly with the antibody molecule.

A number of selection systems can be used, including but not limited to,the herpes simplex virus thymidine kinase (Wigler et al., 1977, Cell11:223), hypoxanthineguanine phosphoribosyltransferase (Szybalska &Szybalski, 1992, Proc. Natl. Acad. Sci. USA 48:202), and adeninephosphoribosyltransferase (Lowy et al., 1980, Cell 22:8-17) genes can beemployed in tk-, hgprt- or aprt-cells, respectively. Also,antimetabolite resistance can be used as the basis of selection for thefollowing genes: dhfr, which confers resistance to methotrexate (Wigleret al., 1980, Natl. Acad. Sci. USA 77:357; O'Hare et al., 1981, Proc.Natl. Acad. Sci. USA 78:1527); gpt, which confers resistance tomycophenolic acid (Mulligan & Berg, 1981, Proc. Natl. Acad. Sci. USA78:2072); neo, which confers resistance to the aminoglycoside G-418 (Wuand Wu, 1991, Biotherapy 3:87-95; Tolstoshev, 1993, Ann. Rev. Pharmacol.Toxicol. 32:573-596; Mulligan, 1993, Science 260:926-932; and Morgan andAnderson, 1993, Ann. Rev. Biochem. 62:191-217; May, 1993, TIB TECH11(5):155-2 15); and hygro, which confers resistance to hygromycin(Santerre et al., 1984, Gene 30:147). Methods commonly known in the artof recombinant DNA technology can be routinely applied to select thedesired recombinant clone, and such methods are described, for example,in Ausubel et al. (eds.), Current Protocols in Molecular Biology, JohnWiley & Sons, NY (1993); Kriegler, Gene Transfer and Expression, ALaboratory Manual, Stockton Press, NY (1990); and in Chapters 12 and 13,Dracopoli et al. (eds.), Current Protocols in Human Genetics, John Wiley& Sons, NY (1994); Colberre-Garapin et al., 1981, J. Mol. Biol. 150:1,which are incorporated by reference herein in their entireties.

The expression levels of an antibody molecule can be increased by vectoramplification (for a review, see Bebbington and Hentschel, The use ofvectors based on gene amplification for the expression of cloned genesin mammalian cells in DNA cloning, Vol. 3 (Academic Press, New York,1987)). When a marker in the vector system expressing antibody isamplifiable, increase in the level of inhibitor present in culture ofhost cell will increase the number of copies of the marker gene. Sincethe amplified region is associated with the antibody gene, production ofthe antibody will also increase (Crouse et al., 1983, Mol. Cell. Biol.3:257).

The host cell can be co-transfected with two or more expression vectorsdescribed herein, the first vector encoding a heavy chain derivedpolypeptide and the second vector encoding a light chain derivedpolypeptide. The two vectors can contain identical selectable markerswhich enable equal expression of heavy and light chain polypeptides. Thehost cells can be co-transfected with different amounts of the two ormore expression vectors. For example, host cells can be transfected withany one of the following ratios of a first expression vector and asecond expression vector: 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9,1:10, 1:12, 1:15, 1:20, 1:25, 1:30, 1:35, 1:40, 1:45, or 1:50.

Alternatively, a single vector can be used which encodes, and is capableof expressing, both heavy and light chain polypeptides. In suchsituations, the light chain should be placed before the heavy chain toavoid an excess of toxic free heavy chain (Proudfoot, 1986, Nature322:52; and Kohler, 1980, Proc. Natl. Acad. Sci. USA 77:2197-2199). Thecoding sequences for the heavy and light chains can comprise cDNA orgenomic DNA. The expression vector can be monocistronic ormulticistronic. A multicistronic nucleic acid construct can encode 2, 3,4, 5, 6, 7, 8, 9, 10 or more, or in the range of 2-5, 5-10 or 10-20genes/nucleotide sequences. For example, a bicistronic nucleic acidconstruct can comprise in the following order a promoter, a first gene(e.g., heavy chain of an antibody described herein), and a second geneand (e.g., light chain of an antibody described herein). In such anexpression vector, the transcription of both genes can be driven by thepromoter, whereas the translation of the mRNA from the first gene can beby a cap-dependent scanning mechanism and the translation of the mRNAfrom the second gene can be by a cap-independent mechanism, e.g., by anIRES.

Once an antibody molecule described herein has been produced byrecombinant expression, it can be purified by any method known in theart for purification of an immunoglobulin molecule, for example, bychromatography (e.g., ion exchange, affinity, particularly by affinityfor the specific antigen after Protein A, and sizing columnchromatography), centrifugation, differential solubility, or by anyother standard technique for the purification of proteins. Further, theantibodies described herein can be fused to heterologous polypeptidesequences described herein or otherwise known in the art to facilitatepurification.

In specific embodiments, an antibody described herein is isolated orpurified. Generally, an isolated antibody is one that is substantiallyfree of other antibodies with different antigenic specificities than theisolated antibody. For example, in a particular embodiment, apreparation of an antibody described herein is substantially free ofcellular material and/or chemical precursors. The language“substantially free of cellular material” includes preparations of anantibody in which the antibody is separated from cellular components ofthe cells from which it is isolated or recombinantly produced. Thus, anantibody that is substantially free of cellular material includespreparations of antibody having less than about 30%, 20%, 10%, 5%, 2%,1%, 0.5%, or 0.1% (by dry weight) of heterologous protein (also referredto herein as a “contaminating protein”) and/or variants of an antibody,for example, different post-translational modified forms of an antibodyor other different versions of an antibody (e.g., antibody fragments).When the antibody is recombinantly produced, it is also generallysubstantially free of culture medium, i.e., culture medium representsless than about 20%, 10%, 2%, 1%, 0.5%, or 0.1% of the volume of theprotein preparation. When the antibody is produced by chemicalsynthesis, it is generally substantially free of chemical precursors orother chemicals, i.e., it is separated from chemical precursors or otherchemicals which are involved in the synthesis of the protein.Accordingly, such preparations of the antibody have less than about 30%,20%, 10%, or 5% (by dry weight) of chemical precursors or compoundsother than the antibody of interest. In a specific embodiment,antibodies described herein are isolated or purified.

5.4 Methods of Producing Antibodies

Antibodies (e.g., human or humanized antibodies) described herein (or anantigen-binding fragment thereof) that immunospecifically bind to a KITantigen can be produced by any method known in the art for the synthesisof antibodies, for example, by chemical synthesis or by recombinantexpression techniques. The methods described herein employs, unlessotherwise indicated, conventional techniques in molecular biology,microbiology, genetic analysis, recombinant DNA, organic chemistry,biochemistry, PCR, oligonucleotide synthesis and modification, nucleicacid hybridization, and related fields within the skill of the art.These techniques are described in the references cited herein and arefully explained in the literature. See, e.g., Maniatis et al. (1982)Molecular Cloning: A Laboratory Manual, Cold Spring Harbor LaboratoryPress; Sambrook et al. (1989), Molecular Cloning: A Laboratory Manual,Second Edition, Cold Spring Harbor Laboratory Press; Sambrook et al.(2001) Molecular Cloning: A Laboratory Manual, Cold Spring HarborLaboratory Press, Cold Spring Harbor, N.Y.; Ausubel et al., CurrentProtocols in Molecular Biology, John Wiley & Sons (1987 and annualupdates); Current Protocols in Immunology, John Wiley & Sons (1987 andannual updates) Gait (ed.) (1984) Oligonucleotide Synthesis: A PracticalApproach, IRL Press; Eckstein (ed.) (1991) Oligonucleotides andAnalogues: A Practical Approach, IRL Press; Birren et al. (eds.) (1999)Genome Analysis: A Laboratory Manual, Cold Spring Harbor LaboratoryPress.

For example, humanized antibodies can be produced using a variety oftechniques known in the art, including but not limited to, CDR-grafting(European Patent No. EP 239,400; International publication No. WO91/09967; and U.S. Pat. Nos. 5,225,539, 5,530,101, and 5,585,089),veneering or resurfacing (European Patent Nos. EP 592,106 and EP519,596; Padlan, 1991, Molecular Immunology 28(4/5):489-498; Studnickaet al., 1994, Protein Engineering 7(6):805-814; and Roguska et al.,1994, PNAS 91:969-973), chain shuffling (U.S. Pat. No. 5,565,332), andtechniques disclosed in, e.g., U.S. Pat. Nos. 6,407,213, 5,766,886, WO9317105, Tan et al., J. Immunol. 169:1119 25 (2002), Caldas et al.,Protein Eng. 13(5):353-60 (2000), Morea et al., Methods 20(3):267 79(2000), Baca et al., J. Biol. Chem. 272(16):10678-84 (1997), Roguska etal., Protein Eng. 9(10):895 904 (1996), Couto et al., Cancer Res. 55 (23Supp):5973s-5977s (1995), Couto et al., Cancer Res. 55(8):1717-22(1995), Sandhu J S, Gene 150(2):409-10 (1994), and Pedersen et al., J.Mol. Biol. 235(3):959-73 (1994). See also U.S. Patent Pub. No. US2005/0042664 A1 (Feb. 24, 2005), which is incorporated herein byreference.

In specific aspects, a humanized antibody is capable of binding to apredetermined antigen and which comprises a framework region havingsubstantially the amino acid sequence of a human immunoglobulin and CDRshaving substantially the amino acid sequence of a non-humanimmunoglobulin (e.g., a murine immunoglobulin). In particularembodiments, a humanized antibody also comprises at least a portion ofan immunoglobulin constant region (Fc), typically that of a humanimmunoglobulin. The antibody also can include the CHL hinge, CH2, CH3,and CH4 regions of the heavy chain. A humanized antibody can be selectedfrom any class of immunoglobulins, including IgM, IgG, IgD, IgA and IgE,and any isotype, including IgG₁, IgG₂, IgG₃ and IgG₄.

Monoclonal antibodies can be prepared using a wide variety of techniquesknown in the art including the use of hybridoma, recombinant, and phagedisplay technologies, or a combination thereof. For example, monoclonalantibodies can be produced using hybridoma techniques including thoseknown in the art and taught, for example, in Harlow et al., Antibodies:A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd ed.1988); Hammerling et al., in: Monoclonal Antibodies and T-CellHybridomas 563 681 (Elsevier, N.Y., 1981). The term “monoclonalantibody” as used herein is not limited to antibodies produced throughhybridoma technology. For example, monoclonal antibodies can be producedby recombinant techonology, e.g., recombinant monoclonal antibodiesexpressed by a host cell, such as a mammalian host cell.

Methods for producing and screening for specific antibodies usinghybridoma technology are routine and well known in the art. For example,in the hybridoma method, a mouse or other appropriate host animal, suchas a sheep, goat, rabbit, rat, hamster or macaque monkey, is immunizedto elicit lymphocytes that produce or are capable of producingantibodies that will specifically bind to the protein (e.g., D4 regionof human KIT) used for immunization. Alternatively, lymphocytes may beimmunized in vitro. Lymphocytes then are fused with myeloma cells usinga suitable fusing agent, such as polyethylene glycol, to form ahybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice,pp. 59-103 (Academic Press, 1986)). Additionally, a RIMMS (repetitiveimmunization multiple sites) technique can be used to immunize an animal(Kilptrack et al., 1997 Hybridoma 16:381-9, which is incorporated hereinby reference).

Non-limiting examples of myeloma cell lines include murine myelomalines, such as those derived from MOPC-21 and MPC-11 mouse tumorsavailable from the Salk Institute Cell Distribution Center, San Diego,Calif., USA, and SP-2 or X63-Ag8.653 cells available from the AmericanType Culture Collection, Rockville, Md., USA. Human myeloma andmouse-human heteromyeloma cell lines also have been described for theproduction of human monoclonal antibodies (Kozbor, J. Immunol., 133:3001(1984); Brodeur et al., Monoclonal Antibody Production Techniques andApplications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987)).

Antibodies described herein include antibody fragments which recognizespecific KIT antigens and can be generated by any technique known tothose of skill in the art. For example, Fab and F(ab′)₂ fragmentsdescribed herein can be produced by proteolytic cleavage ofimmunoglobulin molecules, using enzymes such as papain (to produce Fabfragments) or pepsin (to produce F(ab′)₂ fragments). A Fab fragmentcorresponds to one of the two identical arms of an antibody molecule andcontains the complete light chain paired with the VH and CH1 domains ofthe heavy chain. A F(ab′)₂ fragment contains the two antigen-bindingarms of an antibody molecule linked by disulfide bonds in the hingeregion.

In one aspect, to generate whole antibodies, PCR primers including VH orVL nucleotide sequences, a restriction site, and a flanking sequence toprotect the restriction site can be used to amplify the VH or VLsequences from a template, e.g., scFv clones. Utilizing cloningtechniques known to those of skill in the art, the PCR amplified VHdomains can be cloned into vectors expressing a VH constant region, andthe PCR amplified VL domains can be cloned into vectors expressing a VLconstant region, e.g., human kappa or lambda constant regions. The VHand VL domains can also be cloned into one vector expressing thenecessary constant regions. The heavy chain conversion vectors and lightchain conversion vectors are then co-transfected into cell lines togenerate stable or transient cell lines that express full-lengthantibodies, e.g., IgG, using techniques known to those of skill in theart.

Single domain antibodies, for example, antibodies lacking the lightchains, can be produced by methods well-known in the art. See Riechmannet al., 1999, J. Immunol. 231:25-38; Nuttall et al., 2000, Curr. Pharm.Biotechnol. 1(3):253-263; Muylderman, 2001, J. Biotechnol. 74(4):277302;U.S. Pat. No. 6,005,079; and International Publication Nos. WO 94/04678,WO 94/25591, and WO 01/44301.

In certain aspects, antibodies described herein, such as heteroconjugateantibodies, single chain antibodies, and bispecific antibodies, can beproduced through recombinant technology known in the art. For example,mammalian host cells comprising vectors expressing an antibody describedherein are cultured under conditions suitable for antibody production.

Further, antibodies that immunospecifically bind to a KIT antigen can,in turn, be utilized to generate anti-idiotype antibodies that “mimic”an antigen using techniques well known to those skilled in the art.(See, e.g., Greenspan & Bona, 1989, FASEB J. 7(5):437-444; andNissinoff, 1991, J. Immunol. 147(8):2429-2438).

5.5 Pharmaceutical Compositions and Kits

Provided herein are compositions, pharmaceutical compositions, and kitscomprising one or more antibodies (e.g., humanized antibodies) describedherein, or antigen-binding fragments thereof, or conjugates thereof. Inparticular aspects, compositions described herein can be for in vitro,in vivo, or ex vivo uses. In specific embodiments, provided herein is apharmaceutical composition comprising an antibody (e.g., a humanizedantibody) described herein (or an antigen-binding fragment thereof) anda pharmaceutically acceptable carrier or excipient.

As used herein, the term “pharmaceutically acceptable” means beingapproved by a regulatory agency of the Federal or a state government, orlisted in the U.S. Pharmacopeia, European Pharmacopeia or othergenerally recognized Pharmacopeia for use in animals, and moreparticularly in humans.

Therapeutic formulations containing one or more antibodies (e.g.,humanized antibodies) provided herein can be prepared for storage bymixing the antibody having the desired degree of purity with optionalphysiologically acceptable carriers, excipients or stabilizers(Remington's Pharmaceutical Sciences (1990) Mack Publishing Co., Easton,Pa.; Remington: The Science and Practice of Pharmacy, 21st ed. (2006)Lippincott Williams & Wilkins, Baltimore, Md.), in the form oflyophilized formulations or aqueous solutions. Acceptable carriers,excipients, or stabilizers are nontoxic to recipients at the dosages andconcentrations employed, and include buffers such as phosphate, citrate,and other organic acids; and/or non-ionic surfactants such as TWEEN™,PLURONICS™ or polyethylene glycol (PEG).

Formulations, such as those described herein, can also contain more thanone active compounds (for example, molecules, e.g., antibody orantibodies described herein) as necessary for the particular indicationbeing treated. In certain embodiments, formulations comprise an antibodyprovided herein and one or more active compounds with complementaryactivities that do not adversely affect each other. Such molecules aresuitably present in combination in amounts that are effective for thepurpose intended. For example, an antibody described herein can becombined with one or more other therapeutic agents (e.g., a tyrosinekinase inhibitor such as imatinib mesylated or sunitinib, or a histonedeacetylase inhibitor such as vorinostat). Such combination therapy canbe administered to the patient serially or simultaneously or insequence.

The formulations to be used for in vivo administration can be sterile.This is readily accomplished by filtration through, e.g., sterilefiltration membranes.

In specific aspects, the pharmaceutical compositions provided hereincontain therapeutically effective amounts of one or more of theantibodies (e.g., humanized antibodies) provided herein, and optionallyone or more additional prophylactic of therapeutic agents, in apharmaceutically acceptable carrier. Such pharmaceutical compositionsare useful in the prevention, treatment, management or amelioration of aKIT-associated disorder or disease, such as cancer (e.g., GIST) or aninflammatory bowl disease, or one or more of the symptoms thereof.

Pharmaceutical carriers suitable for administration of the antibodiesprovided herein include any such carriers known to those skilled in theart to be suitable for the particular mode of administration.

In addition, the antibodies described herein can be formulated as thesole pharmaceutically active ingredient in the composition or can becombined with other active ingredients (such as one or more otherprophylactic or therapeutic agents).

The compositions can contain one or more antibodies provided herein. Inone embodiment, the antibodies are formulated into suitablepharmaceutical preparations, such as solutions, suspensions, tablets,dispersible tablets, pills, capsules, powders, sustained releaseformulations or elixirs, for oral administration or in sterile solutionsor suspensions for parenteral administration, as well as transdermalpatch preparation and dry powder inhalers.

In the compositions, one or more antibodies provided herein (orconjugates thereof) is (are) mixed with a suitable pharmaceuticalcarrier. The concentrations of the antibody or antibodies in thecompositions can, for example, be effective for delivery of an amount,upon administration, that treats, prevents, or ameliorates aKIT-associated disorder or disease or a symptom thereof. In particularembodiments, concentrations of an antibody-drug conjugate orantibody-drug conjugates in the compositions can, for example, beeffective for delivery of an amount of a drug(s), upon administration,that treats, prevents, or ameliorates a KIT-associated disorder ordisease or a symptom thereof.

In one embodiment, the compositions are formulated for single dosageadministration. To formulate a composition, the weight fraction ofcompound is dissolved, suspended, dispersed or otherwise mixed in aselected carrier at an effective concentration such that the treatedcondition is relieved, prevented, or one or more symptoms areameliorated.

In certain aspects, an antibody (e.g., a humanized antibody) providedherein (or an antibody-drug conjugate thereof) is included in thepharmaceutically acceptable carrier in an effective amount sufficient toexert a therapeutically useful effect in the absence of, or with minimalor negligible, undesirable side effects on the patient treated. Atherapeutically effective concentration can be determined empirically bytesting the compounds in in vitro and in vivo systems using routinemethods and then extrapolated therefrom for dosages for humans.

The concentration of antibody in the pharmaceutical composition willdepend on, e.g., the physicochemical characteristics of the antibody,the dosage schedule, and amount administered as well as other factorsknown to those of skill in the art. In certain aspects, theconcentration of antibody-drug conjugate in the pharmaceuticalcomposition will depend on, e.g., the physicochemical characteristics ofthe antibody and/or the drug, the dosage schedule, and amountadministered as well as other factors known to those of skill in theart.

In one embodiment, a therapeutically effective dosage produces a serumconcentration of antibody of from about 0.1 ng/ml to about 50-100 μg/ml.The pharmaceutical compositions, in another embodiment, provide a dosageof from about 0.001 mg to about 2000 mg of antibody per kilogram of bodyweight for administration over a period of time, e.g., every day, everyweek, every 2 weeks, or every 3 weeks. Pharmaceutical dosage unit formscan be prepared to provide from about 0.01 mg to about 2000 mg, and inone embodiment from about 10 mg to about 500 mg of the antibody and/or acombination of other optional essential ingredients per dosage unitform.

In a particular embodiment, an antibody-drug conjugate described hereinis administered at an effective dosage of about 1 to 100 mg ofantibody-drug conjugate per kilogram of body weight for administrationover a period of time, e.g., every day, every week, every 2 weeks, orevery 3 weeks.

The antibody can be administered at once, or can be divided into anumber of smaller doses to be administered at intervals of time. It isunderstood that the precise dosage and duration of treatment is afunction of the disease being treated and can be determined empiricallyusing known testing protocols or by extrapolation from in vivo or invitro test data. It is to be noted that concentrations and dosage valuescan also vary with the severity of the condition to be alleviated. It isto be further understood that for any particular subject, specificdosage regimens can be adjusted over time according to the individualneed and the professional judgment of the person administering orsupervising the administration of the compositions, and that theconcentration ranges set forth herein are exemplary only and are notintended to limit the scope or practice of the claimed compositions.

Upon mixing or addition of the antibody, the resulting mixture can be asolution, suspension, emulsion or the like. The form of the resultingmixture depends upon a number of factors, including the intended mode ofadministration and the solubility of the compound in the selectedcarrier or vehicle. The effective concentration is sufficient forameliorating the symptoms of the disease, disorder or condition treatedand can be empirically determined.

The pharmaceutical compositions are provided for administration tohumans and animals in unit dosage forms, such as sterile parenteral(e.g., intravenous) solutions or suspensions containing suitablequantities of the compounds or pharmaceutically acceptable derivativesthereof. Pharmaceutical compositions are also provided foradministration to humans and animals in unit dosage form, such astablets, capsules, pills, powders, granules, and oral solutions orsuspensions, and oil-water emulsions containing suitable quantities ofthe compounds or pharmaceutically acceptable derivatives thereof. Theantibody is, in one embodiment, formulated and administered inunit-dosage forms or multiple-dosage forms. Unit-dose forms as usedherein refers to physically discrete units suitable for human and animalsubjects and packaged individually as is known in the art. Eachunit-dose contains a predetermined quantity of the antibody sufficientto produce the desired therapeutic effect, in association with therequired pharmaceutical carrier, vehicle or diluent. Examples ofunit-dose forms include ampoules and syringes and individually packagedtablets or capsules. Unit-dose forms can be administered in fractions ormultiples thereof. A multiple-dose form is a plurality of identicalunit-dosage forms packaged in a single container to be administered insegregated unit-dose form. Examples of multiple-dose forms includevials, bottles of tablets or capsules or bottles of pints or gallons.Hence, multiple dose form is a multiple of unit-doses which are notsegregated in packaging.

In certain embodiments, one or more anti-KIT antibodies described hereinare in a liquid pharmaceutical formulation. Liquid pharmaceuticallyadministrable compositions can, for example, be prepared by dissolving,dispersing, or otherwise mixing an active compound as defined above andoptional pharmaceutical adjuvants in a carrier, such as, for example,water, saline, aqueous dextrose, glycerol, glycols, ethanol, and thelike, to thereby form a solution or suspension. If desired, thepharmaceutical composition to be administered can also contain minoramounts of nontoxic auxiliary substances such as wetting agents,emulsifying agents, solubilizing agents, and pH buffering agents and thelike.

Actual methods of preparing such dosage forms are known, or will beapparent, to those skilled in this art; for example, see, e.g.,Remington's Pharmaceutical Sciences (1990) Mack Publishing Co., Easton,Pa.; Remington: The Science and Practice of Pharmacy, 21st ed. (2006)Lippincott Williams & Wilkins, Baltimore, Md.

Dosage forms or compositions containing antibody in the range of 0.005%to 100% with the balance made up from non-toxic carrier can be prepared.Methods for preparation of these compositions are known to those skilledin the art.

Parenteral administration, in one embodiment, is characterized byinjection, either subcutaneously, intramuscularly or intravenously isalso contemplated herein. Injectables can be prepared in conventionalforms, either as liquid solutions or suspensions, solid forms suitablefor solution or suspension in liquid prior to injection, or asemulsions. The injectables, solutions and emulsions also contain one ormore excipients. Suitable excipients are, for example, water, saline,dextrose, glycerol or ethanol. In addition, if desired, thepharmaceutical compositions to be administered can also contain minoramounts of non-toxic auxiliary substances such as wetting or emulsifyingagents, pH buffering agents, stabilizers, solubility enhancers, andother such agents. Other routes of administration may include, entericadministration, intracerebral administration, nasal administration,intraarterial administration, intracardiac administration, intraosseousinfusion, intrathecal administration, and intraperitonealadministration.

Preparations for parenteral administration include sterile solutionsready for injection, sterile dry soluble products, such as lyophilizedpowders, ready to be combined with a solvent just prior to use,including hypodermic tablets, sterile suspensions ready for injection,sterile dry insoluble products ready to be combined with a vehicle justprior to use and sterile emulsions. The solutions can be either aqueousor nonaqueous.

If administered intravenously, suitable carriers include physiologicalsaline or phosphate buffered saline (PBS), and solutions containingthickening and solubilizing agents, such as glucose, polyethyleneglycol, and polypropylene glycol and mixtures thereof.

Pharmaceutically acceptable carriers used in parenteral preparationsinclude aqueous vehicles, nonaqueous vehicles, antimicrobial agents,isotonic agents, buffers, antioxidants, local anesthetics, suspendingand dispersing agents, emulsifying agents, sequestering or chelatingagents and other pharmaceutically acceptable substances.

Pharmaceutical carriers also include ethyl alcohol, polyethylene glycoland propylene glycol for water miscible vehicles; and sodium hydroxide,hydrochloric acid, citric acid or lactic acid for pH adjustment.

Illustratively, intravenous or intraarterial infusion of a sterileaqueous solution containing an active compound is an effective mode ofadministration. Another embodiment is a sterile aqueous or oily solutionor suspension containing an active material injected as necessary toproduce the desired pharmacological effect.

The antibody can be suspended in micronized or other suitable form. Theform of the resulting mixture depends upon a number of factors,including the intended mode of administration and the solubility of thecompound in the selected carrier or vehicle. The effective concentrationis sufficient for ameliorating the symptoms of the condition and can beempirically determined.

In other embodiments, the pharmaceutical formulations are lyophilizedpowders, which can be reconstituted for administration as solutions,emulsions and other mixtures. They can also be reconstituted andformulated as solids or gels.

The lyophilized powder is prepared by dissolving a antibody providedherein, in a suitable solvent. In some embodiments, the lyophilizedpowder is sterile. The solvent can contain an excipient which improvesthe stability or other pharmacological component of the powder orreconstituted solution, prepared from the powder. Excipients that can beused include, but are not limited to, dextrose, sorbital, fructose, cornsyrup, xylitol, glycerin, glucose, sucrose or other suitable agent. Thesolvent can also contain a buffer, such as citrate, sodium or potassiumphosphate or other such buffer known to those of skill in the art at, inone embodiment, about neutral pH. Subsequent sterile filtration of thesolution followed by lyophilization under standard conditions known tothose of skill in the art provides the desired formulation. In oneembodiment, the resulting solution will be apportioned into vials forlyophilization. Each vial will contain a single dosage or multipledosages of the compound. The lyophilized powder can be stored underappropriate conditions, such as at about 4° C. to room temperature.

Reconstitution of this lyophilized powder with water for injectionprovides a formulation for use in parenteral administration. Forreconstitution, the lyophilized powder is added to sterile water orother suitable carrier. The precise amount depends upon the selectedcompound. Such amount can be empirically determined.

Antibodies provided herein can be formulated for local or topicalapplication, such as for topical application to the skin and mucousmembranes, such as in the eye, in the form of gels, creams, and lotionsand for application to the eye or for intracisternal or intraspinalapplication. Topical administration is contemplated for transdermaldelivery and also for administration to the eyes or mucosa, or forinhalation therapies. Nasal solutions of the active compound alone or incombination with other pharmaceutically acceptable excipients can alsobe administered.

The antibodies and other compositions provided herein can also beformulated to be targeted to a particular tissue, receptor, or otherarea of the body of the subject to be treated. Many such targetingmethods are well known to those of skill in the art. All such targetingmethods are contemplated herein for use in the instant compositions. Fornon-limiting examples of targeting methods, see, e.g., U.S. Pat. Nos.6,316,652, 6,274,552, 6,271,359, 6,253,872, 6,139,865, 6,131,570,6,120,751, 6,071,495, 6,060,082, 6,048,736, 6,039,975, 6,004,534,5,985,307, 5,972,366, 5,900,252, 5,840,674, 5,759,542 and 5,709,874. Insome embodiments, the anti-KIT antibodies described herein are targeted(or otherwise administered) to the bone marrow, such as in a patienthaving or at risk of having leukemia. In some embodiments, anti-KITantibodies described herein are targeted (or otherwise administered) tothe gastrointestinal tract, such as in a patient having or at risk ofhaving gastrointestinal stromal tumors. In some embodiments, anti-KITantibodies described herein are targeted (or otherwise administered) tothe lungs, such as in a patient having or at risk of lung cancer (e.g.,small cell lung cancer). In some embodiments, anti-KIT antibodiesdescribed herein are targeted (or otherwise administered) to the brain,such as in a patient having or at risk of having neuroblastoma. Inspecific embodiments, an anti-KIT antibody described herein is capableof crossing the blood-brain barrier.

Provided herein is a pharmaceutical pack or kit comprising one or morecontainers filled with one or more of the ingredients of thepharmaceutical compositions described herein, such as one or moreantibodies provided herein. Optionally associated with such container(s)can be a notice in the form prescribed by a governmental agencyregulating the manufacture, use or sale of pharmaceuticals or biologicalproducts, which notice reflects approval by the agency of manufacture,use or sale for human administration.

Also provided herein are kits that can be used in the above methods. Inone embodiment, a kit comprises an antibody described herein, preferablya purified antibody, in one or more containers. In a specificembodiment, the kits described herein contain a substantially isolatedKIT antigen as a control. In another specific embodiment, the kitsdescribed herein further comprise a control antibody which does notreact with the KIT antigen. In another specific embodiment, the kitsdescribed herein contain one or more elements for detecting the bindingof a modified antibody to a KIT antigen (e.g., the antibody can beconjugated to a detectable substrate such as a fluorescent compound, anenzymatic substrate, a radioactive compound or a luminescent compound,or a second antibody which recognizes the first antibody can beconjugated to a detectable substrate). In specific embodiments, the kitcan include a recombinantly produced or chemically synthesized KITantigen. The KIT antigen provided in the kit can also be attached to asolid support. In a more specific embodiment the detecting means of theabove described kit includes a solid support to which KIT antigen isattached. Such a kit can also include a non-attached reporter-labeledanti-human antibody. In this embodiment, binding of the antibody to theKIT antigen can be detected by binding of the said reporter-labeledantibody.

5.6 Methods

Provided herein are methods for impeding, preventing, treating and/ormanaging a KIT-associated disorder or disease (e.g., cancer). Suchmethods comprise administering to a subject in need thereof atherapeutically effective amount of an anti-KIT antibody describedherein (e.g., humanized antibodies, and antigen-binding fragmentsthereof, or conjugates thereof). In certain aspects, also providedherein are methods for preventing, impeding, treating or managing one ormore symptoms of a KIT-associated disorder or disease.

As used herein, “administer” or “administration” refers to the act ofinjecting or otherwise physically delivering a substance (e.g., ahumanized anti-KIT antibody provided herein or an antigen-bindingfragment thereof or a conjugate thereof) to a subject or a patient(e.g., human), such as by mucosal, topical, intradermal, intravenous,intramuscular delivery and/or any other method of physical deliverydescribed herein or known in the art.

As used herein, the terms “effective amount” or “therapeuticallyeffective amount” refer to an amount of a therapy (e.g., a humanizedantibody or pharmaceutical composition provided herein) which issufficient to reduce and/or ameliorate the severity and/or duration of agiven disease and/or a symptom related thereto. These terms alsoencompass an amount necessary for the reduction or amelioration of theadvancement or progression of a given disease, reduction or ameliorationof the recurrence, development or onset of a given disease, and/or toimprove or enhance the prophylactic or therapeutic effect(s) of anothertherapy (e.g., a therapy other than an anti-KIT antibody providedherein). In some embodiments, “effective amount” as used herein alsorefers to the amount of an antibody described herein to achieve aspecified result (e.g., inhibition (e.g., partial inhibition) of a KITbiological activity of a cell, such as inhibition of cell proliferationor cell survival, or enhancement or induction of apoptosis or celldifferentiation).

As used herein, the term “in combination” in the context of theadministration of other therapies refers to the use of more than onetherapy. The use of the term “in combination” does not restrict theorder in which therapies are administered. The therapies may beadministered, e.g., serially, sequentially, concurrently, orconcomitantly.

As used herein, the terms “manage,” “managing,” and “management” referto the beneficial effects that a subject derives from a therapy (e.g., aprophylactic or therapeutic agent), which does not result in a cure of aKIT-associated disease or disorder. In certain embodiments, a subject isadministered one or more therapies (e.g., prophylactic or therapeuticagents, such as an antibody described herein) to “manage” aKIT-associated disease (e.g., cancer, inflammatory condition, orfibrosis), one or more symptoms thereof, so as to prevent theprogression or worsening of the disease.

As used herein, the terms “impede” or “impeding” in the context of aKIT-associated disorder or disease refer to the total or partialinhibition (e.g., less than 100%, 95%, 90%, 80%, 70%, 60%, 50%, 40%,30%, 20%, 10%, or 5%) or blockage of the development, recurrence, onsetor spread of a KIT-associated disease and/or symptom related thereto,resulting from the administration of a therapy or combination oftherapies provided herein (e.g., a combination of prophylactic ortherapeutic agents, such as an antibody described herein).

As used herein, the term “prophylactic agent” refers to any agent thatcan totally or partially inhibit the development, recurrence, onset orspread of a KIT-associated disease and/or symptom related thereto in asubject. In certain embodiments, the term “prophylactic agent” refers toan antibody described herein. In certain other embodiments, the term“prophylactic agent” refers to an agent other than an antibody describedherein. Generally, a prophylactic agent is an agent which is known to beuseful to or has been or is currently being used to prevent aKIT-associated disease and/or a symptom related thereto or impede theonset, development, progression and/or severity of a KIT-associateddisease and/or a symptom related thereto. In specific embodiments, theprophylactic agent is a human anti-KIT antibody, such as a humanized ora fully human anti-KIT monoclonal antibody.

As used herein, the term “side effects” encompasses unwanted and adverseeffects of a therapy (e.g., a prophylactic or therapeutic agent).Unwanted effects are not necessarily adverse. An adverse effect from atherapy (e.g., a prophylactic or therapeutic agent) can be harmful oruncomfortable or risky. Examples of side effects include, diarrhea,cough, gastroenteritis, wheezing, nausea, vomiting, anorexia, abdominalcramping, fever, pain, loss of body weight, dehydration, alopecia,dyspenea, insomnia, dizziness, mucositis, nerve and muscle effects,fatigue, dry mouth, and loss of appetite, rashes or swellings at thesite of administration, flu-like symptoms such as fever, chills andfatigue, digestive tract problems and allergic reactions. Additionalundesired effects experienced by patients are numerous and known in theart. Many are described in the Physician's Desk Reference (63^(rd) ed.,2009).

As used herein, the terms “subject” and “patient” are usedinterchangeably. As used herein, a subject is preferably a mammal suchas a non-primate (e.g., cows, pigs, horses, cats, dogs, goats, rabbits,rats, mice, etc.) or a primate (e.g., monkey and human), most preferablya human. In one embodiment, the subject is a mammal, preferably a human,having a KIT-associated disorder or disease. In another embodiment, thesubject is a mammal, preferably a human, at risk of developing aKIT-associated disorder or disease. In another embodiment, the subjectis a non-human primate. In a specific embodiment, the subject is anadult human subject at least 18 years old.

As used herein, the terms “therapies” and “therapy” can refer to anyprotocol(s), method(s), compositions, formulations, and/or agent(s) thatcan be used in the prevention, treatment, management, or amelioration ofa condition or disorder or symptom thereof (e.g., cancer or one or moresymptoms or condition associated therewith; inflammatory condition orone or more symptoms or condition associated therewith; fibrosis or oneor more symptoms or condition associated therewith). In certainembodiments, the terms “therapies” and “therapy” refer to drug therapy,adjuvant therapy, radiation, surgery, biological therapy, supportivetherapy, and/or other therapies useful in treatment, management,prevention, or amelioration of a condition or disorder or one or moresymptoms thereof (e.g., cancer or one or more symptoms or conditionassociated therewith; inflammatory condition or one or more symptoms orcondition associated therewith; fibrosis or one or more symptoms orcondition associated therewith). In certain embodiments, the term“therapy” refers to a therapy other than an anti-KIT antibody describedherein or pharmaceutical composition thereof. In specific embodiments,an “additional therapy” and “additional therapies” refer to a therapyother than a treatment using an anti-KIT antibody described herein orpharmaceutical composition. In a specific embodiment, a therapy includesthe use of an anti-KIT antibody described herein as an adjuvant therapy.For example, using an anti-KIT antibody described herein in conjunctionwith a drug therapy, biological therapy, surgery, and/or supportivetherapy.

As used herein, the term “therapeutic agent” refers to any agent thatcan be used in the treatment, management or amelioration of aKIT-associated disease and/or a symptom related thereto. In certainembodiments, the term “therapeutic agent” refers to an anti-KIT antibodydescribed herein (e.g., any one of antibodies Hum1-Hum20), anantigen-binding fragment thereof, or a conjugate thereof. In certainother embodiments, the term “therapeutic agent” refers to an agent otherthan an antibody described herein. Preferably, a therapeutic agent is anagent which is known to be useful for, or has been or is currently beingused for the treatment, management or amelioration of a KIT-associateddisease or one or more symptoms related thereto. In specificembodiments, the therapeutic agent is a human anti-KIT antibody, such asa fully human anti-KIT monoclonal antibody.

As used herein, the terms “KIT-associated disorder” or “KIT-associateddisease” are used interchangeably and refer to any disease that iscompletely or partially caused by, associated with, or is the result of,KIT expression and/or activity or lack thereof. In one aspect, aKIT-associated disorder or disease can be known to one of skill in theart or can be ascertained by one of skill in the art. In a certainembodiment, a KIT-associated disease or disorder is associated with KITexpression and/or activity. For example, KIT expression and/or activitymay contribute, in combination with one or more other factors (e.g.,mutation or expression and/or activity of another gene), to developmentand/or progression of a KIT-associated disease or disorder. In a certainembodiment, a KIT-associated disease or disorder is associated with oneor more mutations of KIT.

In certain embodiments, a KIT-associated disease is fibrosis or aninflammatory disorder, e.g., inflammatory bowel disease (IBD), such asCrohn's disease (CD) or ulcerative colitis (UC). In other embodiments, aKIT-associated disease is cancer, such as lung cancer (e.g., small celllung cancer), leukemia, neuroblastoma, melanoma, sarcoma (e.g., Ewing'ssarcoma) or gastrointestinal stromal tumor (GIST).

As used herein, the terms “treat,” “treatment” and “treating” refer tothe reduction or amelioration of the progression, severity, and/orduration of a KIT-associated disease (e.g., cancer, inflammatorydisorder, or fibrosis) resulting from the administration of one or moretherapies (including, but not limited to, the administration of one ormore prophylactic or therapeutic agents, such as an antibody providedherein).

In specific embodiments, methods described herein for treating aKIT-associated disorder or disease provide for the reduction oramelioration of the progression, severity, and/or duration of aKIT-associated disorder or disease (e.g., cancer, inflammatorycondition, or fibrosis) resulting from the administration of one or moretherapies (including, but not limited to, the administration of one ormore prophylactic or therapeutic agents, such as an anti-KIT antibodydescribed herein). In further specific embodiments, methods describedherein for treating a KIT-associated disorder or disease relate toreducing one or more symptoms of a KIT-associated disorder or disease.In specific embodiments, an antibody described herein, for example anyone of antibodies Hum1-Hum20, e.g., antibody Hum8 or Hum4 or Hum17 orHum10, or an antigen-binding fragment thereof, or a conjugate thereof,is for use in treating or managing a KIT-associated disorder (e.g.,cancer). In a particular embodiment, a KIT-associated disease ordisorder being treated or managed with an anti-KIT antibody describedherein, or an antigen-binding fragment thereof, or a conjugate thereof,is associated with KIT expression and/or activity, e.g., involves cellsexpressing KIT and/or exhibiting KIT activity, but is not caused by orthe result of KIT expression or activity.

In a particular embodiment, provided herein is an antibody (e.g., ahumanized anti-KIT antibody), for example any one of antibodiesHum1-Hum20, or Hum17, Hum10, Hum8 or Hum4, or an antigen-bindingfragment thereof, or a conjugate thereof, for use in treating ormanaging a KIT-associated disorder (e.g., cancer), wherein the antibodycomprises (i) a VL chain region having the amino acid sequence of SEQ IDNO: 7, 8, 9, or 10, and/or (ii) a VH chain region having the amino acidsequence of SEQ ID NO: 2, 3, 4, 5, or 6. In another particularembodiment, provided herein is an antibody, or an antigen-bindingfragment thereof, for use in treating or managing a KIT-associateddisorder (e.g., cancer), wherein the antibody comprises a combination ofVH domain (e.g., H1-H5, SEQ ID NOs: 2-6) and VL domain (L1-L4, SEQ IDNOs: 7-10) selected from the group presented in Table 4. In a particularembodiment, provided herein is an antibody (e.g., a humanized anti-KITantibody) for example, any one of antibodies Hum1-Hum20, such as Hum17,Hum10, Hum8 or Hum4, or an antigen-binding fragment thereof, or aconjugate thereof, for use in treating or managing a KIT-associateddisorder (e.g., cancer), wherein the antibody comprises (i) a VL chainregion comprising the amino acid sequence of SEQ ID NO: 12 (see, e.g.,FIG. 4B), and/or (ii) a VH chain region comprising the consensus aminoacid sequence of SEQ ID NO: 11 (see, e.g., FIG. 4A). In a particularembodiment, provided herein is an antibody (e.g., a humanized anti-KITantibody) for example, any one of antibodies Hum1-Hum20, such as Hum17,Hum10, Hum8 or Hum4, or an antigen-binding fragment thereof, or aconjugate thereof, for use in treating or managing a KIT-associateddisorder (e.g., cancer), wherein the antibody comprises (i) a VL chainregion comprising an amino acid sequence set forth in Table 6A (e.g.,L1-L4 and LL1-LL62), and/or (ii) a VH chain region comprising the aminoacid sequence set forth in Table 6B (e.g., H1-H5 and HH1-HH256).

In a specific embodiment, the antibody used in the methods describedherein is internalized by the cell to which it binds. In a particularembodiment, a conjugate is used in the methods described herein, whereinthe conjugate comprises an antibody described herein (e.g., a humanizedanti-KIT antibody, for example Hum4 or Hum8), or a KIT-binding fragmentthereof. In a specific embodiment, the conjugate comprises an antibodydescribed herein (e.g., a humanized anti-KIT antibody) for example, anyone of antibodies Hum1-Hum20, such as Hum17, Hum10, Hum8 or Hum4, or aKIT-binding fragment thereof, linked, covalently or non-covalently, to atherapeutic agent, such as a toxin. In a certain embodiment, theconjugate used in the methods described herein is internalized into acell to which it binds.

In certain embodiments, KIT is aberrantly (e.g., highly) expressed bycells, for example, KIT is overexpressed. In particular embodiments, KITexpression (e.g., on the cell surface) is at least about 10%, 20%, 30%,40%, 50%, 60%, 70%, 80%, 90%, or 100% higher than KIT expression on thesurface of a control cell (e.g., a cell expressing normal levels of KIT,for example, a normal, e.g., human, mast cell, stem cell, brain cell,melanoblast, or ovary cell). In particular embodiments, KIT expressionyields at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or100% higher cell surface KIT expression than the average KIT expressionon the surface of a control cell population (e.g., a cell populationexpressing normal levels of KIT, for example, a normal, e.g., human,mast cell population, stem cell population, brain cell population,melanoblast population, or ovary cell population). In specificembodiments, such control cells can be obtained or derived from ahealthy individual (e.g., healthy human). In some embodiments, KIT canbe aberrantly upregulated in a particular cell type, whether or not KITis aberrantly expressed on the cell surface. In particular embodiments,KIT signaling or activity can be aberrantly upregulated in a particularcell type, whether or not KIT is aberrantly expressed on the cellsurface. In particular embodiments, KIT signaling is at least about 10%,20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% higher than KITsignaling of a control cell (e.g., a cell containing normal KITsignaling, for example, a mast cell, stem cell, brain cell, melanoblast,or ovary cell). In particular embodiments, KIT signaling is at leastabout 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% higher thanaverage KIT signaling of a control cell population (e.g., a cellpopulation exhibiting normal KIT signaling, for example, a normal, e.g.,human, mast cell population, stem cell population, brain cellpopulation, melanoblast population, or ovary cell population). Incertain embodiments, normal, aberrant or excessive cell signaling iscaused by binding of KIT to a KIT ligand. In other embodiments, aberrantor excessive cell signaling occurs independent of binding of KIT to aKIT ligand.

In certain aspects, a KIT-associated disorder or disease can becharacterized by gain-of-function KIT activity, increase in KITactivity, or overexpression of KIT. In one embodiment, a KIT-associateddisorder or disease is completely or partially caused by or is theresult of gain-of-function KIT activity or expression, e.g.,overexpression, of KIT. In certain embodiments, the gain-of-function KITactivity can occur independent of KIT ligand (e.g., SCF) binding KITreceptor. In particular aspects, high or overexpression of KIT in a cellrefers to an expression level which is at least about 35%, 45%, 55%, or65% more than the expression level of a reference cell known to havenormal KIT expression or KIT activity or more than the averageexpression level of KIT in a population of cells or samples known tohave normal KIT expression or KIT activity. Expression levels of KIT canbe assessed by methods described herein or known to one of skill in theart (e.g., Western blotting or immunohistorychemistry). In particularembodiments, a KIT-associated disorder or disease is characterized byKIT activity which is higher than normal KIT activity and contributes tocellular transformation, neoplasia, and tumorogenesis. In particularaspects, high or increase of KIT activity in a cell refers to a KITactivity level which is at least about 35%, 45%, 55%, or 65% more thanthe expression level of a reference cell known to have normal KITactivity or more than the average level of KIT activity in a populationof cells or samples known to have normal KIT activity. Non-limitingexamples of a KIT activity includes tyrosine phosphorylation of thecytoplasmic domain of KIT, and signaling downstream of KIT, such as Stator Akt signaling.

Non-limiting examples of disorders or KIT-associated disorders ordiseases include cancers such as breast cancer, leukemia (e.g., chronicmyelogenous leukemia, acute myeloid leukemia, mast cell leukemia), lungcancer (e.g., small cell lung cancer), neuroblastoma, gastrointestinalstromal tumors (GIST), melanoma, colorectal cancer, sarcoma (e.g.,Ewing's sarcoma), and germ cell tumors (e.g., seminoma). In a particularembodiment, a cancer which is treated or managed by the methods providedherein is characterized by a gain-of-function KIT mutation oroverexpression of KIT.

In a specific embodiment, a method described herein is for treatingcancer (e.g., GIST, lung cancer, or sarcoma (e.g., Ewing's sarcoma)),wherein said method comprises administering to a subject in need thereofa therapeutically effective amount of an antibody described herein(e.g., a humanized anti-KIT antibody) for example, any one of antibodiesHum1-Hum20, such as Hum17, Hum10, Hum8 or Hum4, or an antigen-bindingfragment thereof, or a conjugate thereof. In certain aspects, alsoprovided herein are methods for preventing, treating or managing one ormore symptoms of cancer, wherein said methods comprise administering toa subject in need thereof a therapeutically effective amount of anantibody described herein (e.g., a humanized anti-KIT antibody), forexample, any one of antibodies Hum1-Hum20, such as Hum17, Hum10, Hum8 orHum4, or an antigen-binding fragment thereof, or a conjugate thereof. Ina specific embodiment, an antibody for use in the methods of treatingcancer described herein comprises a VL domain comprising the amino acidsequence of SEQ ID NO: 8 (L2), and/or a VH domain comprising the aminoacid sequence of SEQ ID NO: 4 (H3). In a specific embodiment, anantibody for use in the methods of treating cancer described hereincomprises a VL domain comprising the amino acid sequence of SEQ ID NO: 7(L1), and/or a VH domain comprising the amino acid sequence of SEQ IDNO: 5 (H4).

In a specific embodiment, a method described herein is for treatingGIST, wherein said method comprises administering to a subject in needthereof a therapeutically effective amount of an antibody describedherein (e.g., a humanized anti-KIT antibody) for example, any one ofantibodies Hum1-Hum20, such as Hum17, Hum10, Hum8 or Hum4, or anantigen-binding fragment thereof, or a conjugate thereof. In certainaspects, also provided herein are methods for preventing, treating ormanaging one or more symptoms of GIST, wherein said methods compriseadministering to a subject in need thereof a therapeutically effectiveamount of an antibody described herein (e.g., a humanized anti-KITantibody) for example, any one of antibodies Hum1-Hum20, such as Hum17,Hum10, Hum8 or Hum4, or an antigen-binding fragment thereof, or aconjugate thereof. In a specific embodiment, an antibody for use in themethods of treating GIST described herein comprises a VL domaincomprising the amino acid sequence of SEQ ID NO: 8 (L2), and/or a VHdomain comprising the amino acid sequence of SEQ ID NO: 4 (H3). In aspecific embodiment, an antibody for use in the methods of treating GISTdescribed herein comprises a VL domain comprising the amino acidsequence of SEQ ID NO: 7 (L1), and/or a VH domain comprising the aminoacid sequence of SEQ ID NO: 5 (H4).

In a specific embodiment, a method described herein is for treating lungcancer (e.g., small cell lung carcinoma), wherein said method comprisesadministering to a subject in need thereof a therapeutically effectiveamount of an antibody described herein (e.g., a humanized anti-KITantibody) for example, any one of antibodies Hum1-Hum20, such as Hum17,Hum10, Hum8 or Hum4, or an antigen-binding fragment thereof, or aconjugate thereof. In certain aspects, also provided herein are methodsfor preventing, treating or managing one or more symptoms of lung cancer(e.g., small cell lung carcinoma), wherein said methods compriseadministering to a subject in need thereof a therapeutically effectiveamount of an antibody described herein (e.g., a humanized anti-KITantibody) for example, any one of antibodies Hum1-Hum20, such as Hum17,Hum10, Hum8 or Hum4, or an antigen-binding fragment thereof, or aconjugate thereof. In a specific embodiment, an antibody for use in themethods of treating lung cancer (e.g., small cell lung cancer) comprisesa VL domain comprising the amino acid sequence of SEQ ID NO: 8 (L2),and/or a VH domain comprising the amino acid sequence of SEQ ID NO: 4(H3). In a specific embodiment, an antibody for use in the methods oftreating lung cancer (e.g., small cell lung cancer) comprises a VLdomain comprising the amino acid sequence of SEQ ID NO: 7 (L1), and/or aVH domain comprising the amino acid sequence of SEQ ID NO: 5 (H4).

In a specific embodiment, a method described herein is for treatingmelanoma, wherein said method comprises administering to a subject inneed thereof a therapeutically effective amount of an antibody describedherein (e.g., a humanized anti-KIT antibody) for example, any one ofantibodies Hum1-Hum20, such as Hum17, Hum10, Hum8 or Hum4, or anantigen-binding fragment thereof, or a conjugate thereof. In certainaspects, also provided herein are methods for preventing, treating ormanaging one or more symptoms of melanoma, wherein said methods compriseadministering to a subject in need thereof a therapeutically effectiveamount of an antibody described herein (e.g., a humanized anti-KITantibody) for example, any one of antibodies Hum1-Hum20, such as Hum17,Hum10, Hum8 or Hum4, or an antigen-binding fragment thereof, or aconjugate thereof. In a specific embodiment, an antibody for use in themethods of treating melanoma described herein comprises a VL domaincomprising the amino acid sequence of SEQ ID NO: 8 (L2), and/or a VHdomain comprising the amino acid sequence of SEQ ID NO: 4 (H3). In aspecific embodiment, an antibody for use in the methods of treatingmelanoma described herein comprises a VL domain comprising the aminoacid sequence of SEQ ID NO: 7 (L1), and/or a VH domain comprising theamino acid sequence of SEQ ID NO: 5 (H4).

In specific embodiments, a cancer treated in accordance with the methodsdescribed herein can be any type of cancer which comprises cancer ortumor cells expressing cell surface KIT or a mutated form thereof, whichcan be confirmed by any histologically or cytologically method known toone of skill in the art.

In certain embodiments, a cancer is metastatic. In certain embodiments,a cancer is an advanced cancer which has spread outside the site ororgan of origin, either by local invasion or metastasis.

In particular embodiments, a cancer is a recurrent cancer which hasregrown, either at the initial site or at a distant site, after aresponse to initial therapy (e.g., after surgery to remove the tumor andadjuvant therapy following surgery). In some embodiments, a cancer is arefractory cancer which progresses even though an anti-tumor agent, suchas a chemotherapeutic agent, is being administered, or has beenadministered, to the cancer patient. A non-limiting example of arefractory cancer is one which is refractory to a tyrosine kinaseinhibitor, such as GLEEVEC® (imatinib mesylate), SUTENT® (SU11248 orsunitinib), IRESSA™ (gefitinib), TARCEVA® (erlotinib), NEXAVAR®(sorafenib), or VOTRIENT™ (pazopanib). In some embodiments, a cancer isa refractory cancer which progresses even though radiation orchemotherapy is being administered, or has been administered, to thecancer patient.

In specific embodiments, provided herein are methods for treating arefractory cancer in a patient in need thereof comprising administeringto the patient a therapeutically effective amount of an antibodydescribed herein, wherein the refractory cancer is refractory orresistant to an anti-cancer agent such as a tyrosine kinase inhibitor(e.g., GLEEVEC® (imatinib mesylate) or SUTENT® (SU11248 or Sunitinib)).Other non-limiting examples of tyrosine kinse inhibitors include 706 andAMNI07 (nilotinib). RAD00I, PKC412, gefitinib (IRESSA™) erlotinib(TARCEVA®), sorafenib (NEXAVAR®), pazopanib (VOTRIENT™), axitinib,bosutinib, cediranib (RECENTIN®), SPRYCEL® (dasatinib), lapatinib(TYKERB®), lestaurtinib, neratinib, nilotinib (TASIGNA®), semaxanib,toceranib (PALLADIA™), vandetanib (ZACTIMA™), and vatalanib. In certainembodiments, the refractory cancer was initially responsive to ananti-cancer agent, such as a tyrosine kinase inhibitor (e.g., GLEEVEC®or SU11248 (i.e., sunitinib)), but has developed resistance theanti-cancer agent. In certain embodiments, a subject has one or moremutations in KIT that confers resistance to an anti-cancer agent such asa tyrosine kinase inhibitor.

In particular embodiments, an antibody described herein is administeredto a patient who has previously received, or is currently receiving, oneor more anti-cancer therapies, for example, a chemotherapeutic agent, ora tyrosine kinase inhibitor (e.g., GLEEVEC® (imatinib mesylate), SUTENT®(SU11248 or sunitinib), IRESSA™ (gefitinib), TARCEVA® (erlotinib),NEXAVAR® (sorafenib), or VOTRIENT™ (pazopanib)) or a histone deacetylaseinhibitor (e.g., vorinostat or suberoylanilide hydroxamic acid (SAHA)).In other particular embodiments, an antibody described herein isadministered to a patient who is, or is suspected of being, resistant orrefractory to an anti-cancer therapy, for example, a tyrosine kinaseinhibitor, e.g., GLEEVEC® (imatinib mesylate), SUTENT® (SU11248 orsunitinib), IRESSA™ (gefitinib), TARCEVA® (erlotinib), NEXAVAR®(sorafenib), or VOTRIENT™ (pazopanib).

In particular embodiments, an antibody described herein (e.g., any oneof antibodies Hum1-Hum20, or an antigen binding fragment thereof (e.g.,KIT-binding fragment thereof), or a conjugate thereof) is administeredto a patient who has previously received, or is currently receiving, oneor more anti-cancer therapies, for example, an anti-growth factorreceptor antibody (e.g., anti-HER2 antibody, anti-EGFR antibody,anti-VEGFR antibody, or anti-KIT antibody), or anti-growth factorantibody (e.g., anti-EGF antibody, anti-VEGF antibody). In otherparticular embodiments, an antibody described herein is administered toa patient who is, or is suspected of being, resistant or refractory toan anti-cancer therapy, for example, an anti-growth factor receptorantibody (e.g., anti-HER2 antibody, anti-EGFR antibody, anti-VEGFRantibody, or anti-KIT antibody) or anti-growth factor antibody (e.g.,anti-EGF antibody, anti-VEGF antibody).

In a particular embodiment, a method described herein for treating ormanaging cancer in a subject in need thereof, can achieve at least one,two, three, four or more of the following effects due to administrationof a therapeutically effective amount of an anti-KIT antibody describedherein: (i) the reduction or amelioration of the severity of cancer(e.g., leukemia, lung cancer, or gastrointestinal stromal cancer) and/orone or more symptoms associated therewith; (ii) the reduction in theduration of one or more symptoms associated with a cancer (e.g.,leukemia, lung cancer, or gastrointestinal stromal cancer); (iii) theprevention in the recurrence of a tumor (e.g., lung tumor orgastrointestinal stromal tumor); (iv) the regression of a cancer (e.g.,leukemia, lung cancer, or gastrointestinal stromal tumor) and/or one ormore symptoms associated therewith; (v) the reduction in hospitalizationof a subject; (vi) the reduction in hospitalization length; (vii) theincrease in the survival of a subject; (viii) the inhibition of theprogression of a cancer (e.g., leukemia, lung cancer, orgastrointestinal stromal tumor) and/or one or more symptoms associatedtherewith; (ix) the enhancement or improvement of the therapeutic effectof another therapy (e.g., surgery, radiation, chemotherapy, or anothertyrosine kinase inhibitor); (x) a reduction or elimination in the cancercell population (e.g., leukemia cell population, lung cancer cellpopulation, gastrointestinal stromal tumor cell population); (xi) areduction in the growth of a tumor or neoplasm; (xii) a decrease intumor size (e.g., volume or diameter); (xiii) a reduction in theformation of a newly formed tumors; (xiv) eradication, removal, orcontrol of primary, regional and/or metastatic cancer; (xv) ease inremoval of a tumor by reducing tumor and/or edema-relatedvascularization prior to surgery; (xvi) a decrease in the number or sizeof metastases; (xvii) a reduction in mortality; (xviii) an increase intumor-free survival rate of patients; (xvix) an increase in relapse-freesurvival; (xx) an increase in the number of patients in remission; (xxi)a decrease in hospitalization rate; (xxii) the size of the tumor ismaintained and does not increase or increases by less than the increaseof a tumor after administration of a standard therapy as measured byconventional methods available to one of skill in the art, such ascomputed tomography (CT) scan, magnetic resonance imaging (MRI), dynamiccontrast-enhanced MRI (DCE-MRI), or a positron emission tomography (PET)scan; (xxiii) the prevention of the development or onset of one or moresymptoms associated cancer; (xxiv) an increase in the length ofremission in patients; (xxv) the reduction in the number of symptomsassociated with cancer; (xxvi) an increase in symptom-free survival ofcancer patients; (xxvii) a decrease in the concentration of one or moreinflammatory mediators (e.g., cytokines or interleukins) in biologicalspecimens (e.g., plasma, serum, cerebral spinal fluid, urine, or anyother biofluids) of a subject with a cancer (e.g., leukemia, lungcancer, or gastrointestinal stromal cancer); (xxviii) a decrease incirculating tumor cells (CTCs) in the blood of a subject with cancer(e.g., leukemia, lung cancer, or gastrointestinal stromal cancer);(xxix) inhibition (e.g., partial inhibition) or decrease in tumormetabolism or perfusion; and (xxx) improvement in the quality of life asassessed by methods well known in the art, e.g., questionnaires.

In certain aspects, provided herein are methods for killing cancer cellsin an individual, wherein said method comprises administering to anindividual in need thereof an effective amount of an antibody describedherein (e.g., a humanized anti-KIT antibody) for example, any one ofantibodies Hum1-Hum20, such as Hum17, Hum10, Hum8 or Hum4, or anantigen-binding fragment thereof, or a conjugate thereof. In certainaspects, provided herein are methods for inhibiting growth orproliferation of cancer cells in an individual, wherein said methodcomprises administering to an individual in need thereof an effectiveamount of an antibody described herein (e.g., a humanized anti-KITantibody) for example, any one of antibodies Hum1-Hum20, such as Hum17,Hum10, Hum8 or Hum4, or an antigen-binding fragment thereof, or aconjugate thereof. In certain embodiments, partial inhibition of growthor proliferation of cancer cells is achieved, for example, inhibition ofat least about 20% to about 55% of growth or proliferation of cancercells.

In certain aspects, provided herein are methods for reducing tumor sizeor load in an individual in need thereof, wherein said method comprisesadministering to said individual an effective amount of an antibodydescribed herein (e.g., a humanized anti-KIT antibody) for example, anyone of antibodies Hum1-Hum20, such as Hum17, Hum10, Hum8 or Hum4, or anantigen-binding fragment thereof, or a conjugate thereof.

Other non-limiting examples of KIT-associated disorders or diseasesinclude systemic mast cell disorders (e.g., mastocytosis), hematologicdisorders, fibrosis (e.g., idiopathic pulmonary fibrosis (TPF),scleroderma, or myelofibrosis) and inflammatory conditions such asasthma, rheumatoid arthritis, inflammatory bowel disease, and allergicinflammation.

In a particular embodiment, a method described herein for treating ormanaging a KIT-associated disorder, e.g., fibrosis or an inflammatorycondition (e.g., asthma, rheumatoid arthritis, inflammatory boweldisease, and allergic inflammation), in a subject in need thereof, canachieve at least one, two, three, four or more of the following effectsdue to administration of a therapeutically effective amount of ananti-KIT antibody described herein: (i) the reduction or amelioration ofthe severity of fibrosis or an inflammatory condition (e.g., asthma,rheumatoid arthritis, inflammatory bowel disease, and allergicinflammation) and/or one or more symptoms associated therewith; (ii) thereduction in the duration of one or more symptoms associated withfibrosis or an inflammatory condition (e.g., asthma, rheumatoidarthritis, inflammatory bowel disease, and allergic inflammation); (iii)the prevention in the recurrence of fibrosis or an inflammatorycondition (e.g., asthma, rheumatoid arthritis, inflammatory boweldisease, and allergic inflammation); (iv) the reduction inhospitalization of a subject; (v) the reduction in hospitalizationlength; (vi) the inhibition (e.g., partial inhibition) of theprogression of fibrosis or an inflammatory condition (e.g., asthma,rheumatoid arthritis, inflammatory bowel disease, and allergicinflammation) and/or one or more symptoms associated therewith; (vii)the enhancement or improvement of the therapeutic effect of anothertherapy (e.g., anti-inflammatory therapy such as steriods); (viii) anincrease in the number of patients in remission (i.e., a time periodcharacterized by no or minimal symptoms associated with the inflammatorycondition); (ix) an increase in the length of remission in patients; (x)a decrease in hospitalization rate; (xi) the reduction in the number ofsymptoms associated with fibrosis or an inflammatory condition (e.g.,asthma, rheumatoid arthritis, inflammatory bowel disease, and allergicinflammation); (xii) a decrease in the concentration of one or moreinflammatory mediators (e.g., cytokines or interleukins) in biologicalspecimens (e.g., plasma, serum, cerebral spinal fluid, urine, or anyother biofluids) of a subject with fibrosis or an inflammatory condition(e.g., asthma, rheumatoid arthritis, inflammatory bowel disease, andallergic inflammation); and (xiii) improvement in the quality of life asassessed by methods well known in the art, e.g., questionnaires.

In certain embodiments, an anti-KIT antibody described herein may beadministered by any suitable method to a subject in need thereof.Non-limiting examples of administration methods include mucosal,intradermal, intravenous, intratumoral, subcutaneous, intramusculardelivery and/or any other method of physical delivery described hereinor known in the art. In one embodiment, an anti-KIT antibody or apharmaceutical composition thereof is administered systemically (e.g.,parenterally) to a subject in need thereof. In another embodiment, ananti-KIT antibody or a pharmaceutical composition thereof isadministered locally (e.g., intratumorally) to a subject in needthereof. Each dose may or may not be administered by an identical routeof administration. In some embodiments, an anti-KIT antibody describedherein can be administered via multiple routes of administrationsimultaneously or subsequently to other doses of the same or a differentan anti-KIT antibody described herein.

When a disease, or a symptom thereof, is being treated, administrationof the substance typically occurs after the onset of the disease orsymptoms thereof. When a disease, or symptoms thereof, are beingprevented, administration of the substance typically occurs before theonset of the disease or symptoms thereof. In certain embodiments, ananti-KIT antibody described herein is administered prophylactically ortherapeutically to a subject. An anti-KIT antibody described herein canbe prophylactically or therapeutically administered to a subject so asto prevent, lessen or ameliorate a KIT-associated disorder or disease(e.g., cancer, inflammatory condition, fibrosis) or symptom thereof.

The dosage and frequency of administration of an anti-KIT antibodydescribed herein or a pharmaceutical composition thereof is administeredto a subject in need thereof in accordance with the methods for treatinga KIT-associated disorder or disease provided herein will be efficaciouswhile minimizing side effects. The exact dosage of an anti-KIT antibodydescribed herein to be administered to a particular subject or apharmaceutical composition thereof can be determined by a practitioner,in light of factors related to the subject that requires treatment.Factors which can be taken into account include the severity of thedisease state, general health of the subject, age, and weight of thesubject, diet, time and frequency of administration, combination(s) withother therapeutic agents or drugs, reaction sensitivities, andtolerance/response to therapy. The dosage and frequency ofadministration of an anti-KIT antibody described herein or apharmaceutical composition thereof can be adjusted over time to providesufficient levels of the anti-KIT antibody or to maintain the desiredeffect.

The precise dose to be employed in the formulation will also depend onthe route of administration, and the seriousness of a KIT-associateddisorder or disease (e.g., cancer, inflammatory condition, fibrosis),and should be decided according to the judgment of the practitioner andeach patient's circumstances.

In one embodiment, for the anti-KIT antibodies described herein, thedosage administered to a patient, to manage a KIT-associated disorder ordisease (e.g., cancer, inflammatory condition, fibrosis) is typically0.1 mg/kg to 100 mg/kg of the patient's body weight. Generally, humanantibodies have a longer half-life within the human body than antibodiesfrom other species due to the immune response to the foreignpolypeptides. Thus, lower dosages of human antibodies and less frequentadministration is often possible. Further, the dosage and frequency ofadministration of the antibodies described herein can be reduced byenhancing uptake and tissue penetration of the antibodies bymodifications such as, for example, lipidation.

In one embodiment, approximately 0.001 mg/kg (mg of antibody per kgweight of a subject) to approximately 500 mg/kg of an anti-KIT antibodydescribed herein is administered to manage a KIT-associated disorder ordisease (e.g., cancer, inflammatory condition, fibrosis).

In some embodiments, an effective amount of an antibody provided hereinis from about 0.01 mg to about 1,000 mg. In specific embodiments, an“effective amount” of an anti-KIT antibody described herein refers to anamount of an anti-KIT antibody described herein which is sufficient toachieve at least one, two, three, four or more of the following effects:(i) the reduction or amelioration of the severity of a KIT-associateddisorder or disease (e.g., cancer, inflammatory condition, fibrosis)and/or one or more symptoms associated therewith; (ii) the reduction inthe duration of one or more symptoms associated with a KIT-associateddisorder or disease (e.g., cancer, inflammatory condition, fibrosis);(iii) the prevention in the recurrence of a tumor (e.g.,gastrointestinal stromal tumor); (iv) the regression of a KIT-associateddisorder or disease (e.g., cancer, inflammatory condition, fibrosis)and/or one or more symptoms associated therewith; (v) the reduction inhospitalization of a subject; (vi) the reduction in hospitalizationlength; (vii) the increase in the survival of a subject; (viii) theinhibition (e.g., partial inhibition) of the progression of aKIT-associated disorder or disease (e.g., cancer, inflammatorycondition, fibrosis) and/or one or more symptoms associated therewith;(ix) the enhancement or improvement of the therapeutic effect of anothertherapy; (x) a reduction or elimination in the cancer cell population(e.g., leukemia cell population, lung cancer cell population,gastrointestinal stromal cancer cell population); (xi) a reduction inthe growth of a tumor or neoplasm; (xii) a decrease in tumor size (e.g.,volume or diameter); (xiii) a reduction in the formation of a newlyformed tumors; (xiv) eradication, removal, or control of primary,regional and/or metastatic cancer; (xv) ease in removal of a tumor byreducing tumor and/or edema-related vascularization prior to surgery;(xvi) a decrease in the number or size of metastases; (xvii) a reductionin mortality; (xviii) an increase in tumor-free survival rate ofpatients; (xvix) an increase in relapse-free survival; (xx) an increasein the number of patients in remission; (xxi) a decrease inhospitalization rate; (xxii) the size of the tumor is maintained anddoes not increase or increases by less than the increase of a tumorafter administration of a standard therapy as measured by conventionalmethods available to one of skill in the art, such as computedtomography (CT) scan, magnetic resonance imaging (MRI), dynamiccontrast-enhanced MRI (DCE-MRI), or a positron emission tomography (PET)scan; (xxiii) the prevention of the development or onset of one or moresymptoms associated cancer; (xxiv) an increase in the length ofremission in patients; (xxv) the reduction in the number of symptomsassociated with cancer; (xxvi) an increase in symptom-free survival ofcancer patients; (xxvii) a decrease in the concentration of one or moreinflammatory mediators (e.g., cytokines or interleukins) in biologicalspecimens (e.g., plasma, serum, cerebral spinal fluid, urine, or anyother biofluids) of a subject with a KIT-associated disorder or disease(e.g., cancer, inflammatory condition, fibrosis); (xxviii) a decrease incirculating tumor cells (CTCs) in the blood of a subject with cancer;(xxix) inhibition (e.g., partial inhibition) or decrease in tumormetabolism or perfusion; and (xxx) improvement in the quality of life asassessed by methods well known in the art, e.g., questionnaires. In someembodiments, “effective amount” as used herein also refers to the amountof an antibody described herein to achieve a specified result (e.g.,inhibition of one or more KIT biological activities of a cell, such asinhibition of cell proliferation).

In some embodiments, an anti-KIT antibody described herein isadministered as necessary, e.g., weekly, biweekly (i.e., once every twoweeks), monthly, bimonthly, trimonthly, etc., as determined by aphysician.

In some embodiments, a single dose of an anti-KIT antibody describedherein is administered one or more times to a patient to impede,prevent, manage, treat and/or ameliorate a KIT-associated disorder ordisease (e.g., cancer, inflammatory condition, fibrosis).

In particular embodiments, an anti-KIT antibody or pharmaceuticalcomposition thereof is administered to a subject in accordance with themethods for treating a KIT-associated disorder or disease (e.g., cancer,inflammatory condition, fibrosis) presented herein in cycles, whereinthe anti-KIT antibody or pharmaceutical composition is administered fora period of time, followed by a period of rest (i.e., the anti-KITantibody or pharmaceutical composition is not administered for a periodof time).

Also, presented herein are combination therapies for the treatment of aKIT-associated disorder or disease (e.g., cancer, inflammatorycondition, fibrosis) which involve the administration of an anti-KITantibody described herein (e.g., a humanized anti-KIT antibody) forexample, any one of antibodies Hum1-Hum20, such as Hum10, Hum17, Hum8 orHum4, or an antigen-binding fragment thereof (e.g., KIT-binding fragmentthereof), or an antibody conjugate thereof in combination with one ormore additional therapies (e.g., chemotherapeutic agent, tyrosine kinaseinhibitor, PGP inhibitors, HSP-90 inhibitors, proteosome inhibitors, orhistone deacetylase inhibitor) to a subject in need thereof. In aspecific embodiment, presented herein are combination therapies for thetreatment of a KIT-associated disorder or disease (e.g., cancer,inflammatory condition, fibrosis) which involve the administration of anamount (e.g., a therapeutically effective amount or a sub-optimalamount) of an anti-KIT antibody described herein in combination with anamount (e.g., a therapeutically effective amount or a sub-optimalamount) of another therapy (e.g., chemotherapeutic agent, tyrosinekinase inhibitor, or histone deacetylase inhibitor) to a subject in needthereof.

In combination therapies, one or more anti-KIT antibodies providedherein (e.g., a humanized anti-KIT antibody) for example, any one ofantibodies Hum1-Hum20, such as Hum10, Hum17, Hum8 or Hum4, or anantigen-binding fragment thereof (e.g., KIT-binding fragment thereof),or an antibody conjugate thereof can be administered prior to,concurrently with, or subsequent to the administration of one or moreadditional therapies (e.g., agents, surgery, or radiation) for use intreating, managing, and/or ameoliorating a KIT-associated disorder ordisease (e.g., cancer, inflammatory condition, fibrosis). The use of theterm “in combination” does not restrict the order in which one or moreanti-KIT antibodies and one or more additional therapies areadministered to a subject. In specific embodiments, the therapies can beadministered serially or sequentially.

In specific embodiments, one or more anti-KIT antibodies provided herein(e.g., a humanized anti-KIT antibody) for example, any one of antibodiesHum1-Hum20, such as Hum10, Hum17, Hum8 or Hum4, or an antigen-bindingfragment thereof (e.g., KIT-binding fragment thereof), or an antibodyconjugate thereof can be administered prior to, concurrently with, orsubsequent to the administration of one or more additional therapiessuch as anticancer agents, for example, tyrosine kinase inhibitors(e.g., imatinib myselyate (Gleevec®) or sunitinib (SUTENT), or histonedeacetylase inhibitors (e.g., vorinostat or suberoylanilide hydroxamicacid (SAHA)), for treating, managing, and/or ameoliorating aKIT-associated disorder or disease (e.g., cancer, for example, GIST,melanoma, or lung cancer).

In another specific embodiment, presented herein are combinationtherapies for the treatment of a KIT-associated disorder or disease(e.g., cancer, inflammatory condition, fibrosis) which involve theadministration of an amount of an anti-KIT antibody described herein(e.g., a humanized anti-KIT antibody) for example, any one of antibodiesHum1-Hum20, such as Hum10, Hum17, Hum8 or Hum4, or an antigen-bindingfragment thereof (e.g., KIT-binding fragment thereof), or an antibodyconjugate thereof in combination with an amount of another therapy(e.g., chemotherapeutic agent, tyrosine kinase inhibitor, or histonedeacetylase inhibitor) to a subject in need thereof. In a specificembodiment, the combination therapies result in a synergistic effect. Incertain embodiments, the combination therapies result in an additiveeffect.

In a specific embodiment, presented herein are combination therapies forthe treatment of cancer which involve the administration of an amount ofan anti-KIT antibody described herein in combination with an amount ofanother therapy (e.g., surgery, radiation, stem cell transplantation, orchemotherapy) to a subject in need thereof. In a specific embodiment,the combination therapies result in a synergistic effect. In anotherspecific embodiment, the combination therapies result in an additiveeffect.

In a specific embodiment, presented herein are combination therapies forthe treatment of an inflammatory condition which involve theadministration of an amount of an anti-KIT antibody described herein incombination with an amount of another therapy (e.g., anti-inflammatorytherapy, for example, steroid therapy) to a subject in need thereof. Ina specific embodiment, the combination therapies result in a synergisticeffect. In another specific embodiment, the combination therapies resultin an additive effect.

Non-limiting examples of another therapy for use in combination withantibodies described herein include, another anti-KIT antibody thatimmunospecifically binds to a different epitope of KIT, one or moreother antibodies (e.g., anti-HER2 antibody, anti-EGFR antibody,anti-VEGF antibody), anti-inflammatory therapy, chemotherapy (e.g.,microtubule disassembly blocker, antimetabolite, topisomerase inhibitor,and DNA crosslinker or damaging agent), radiation, surgery, PGPinhibitors (e.g., cyclosporine A, Verapamil), HSP-90 inhibitors (e.g.,17-AAG, STA-9090), proteosome inhibitors (e.g., Bortezomib), andtyrosine kinase inhibitors (e.g., imatinib mesylate (GLEEVEC®),sunitinib (SUTENT® or SU11248), gefitinib (IRESSA™) erlotinib(TARCEVA®), sorafenib (NEXAVAR®), pazopanib (VOTRIENT™), axitinib,bosutinib, cediranib (RECENTIN®), SPRYCEL® (dasatinib), lapatinib(TYKERB®), lestaurtinib, neratinib, nilotinib (TASIGNA®), semaxanib,toceranib (PALLADIA™), vandetanib (ZACTIMA™), and vatalanib). In aspecific embodiment, another therapy for use in combination withantibodies described herein is imatinib mesylate.

Other non-limiting examples of another therapy for use in combinationwith antibodies described herein (e.g., a humanized anti-KIT antibody)for example, any one of antibodies Hum1-Hum20, such as Hum10, Hum17,Hum8 or Hum4, or an antigen-binding fragment thereof (e.g., KIT-bindingfragment thereof), or an antibody conjugate thereof include a histonedeacetylase inhibitor, such as vorinostat or suberoylanilide hydroxamicacid (SAHA) or a compound having the chemical formula (I), (II), or(III) as set forth below. In a specific embodiment, provided herein is amethod for treating cancer (e.g., GIST or lung cancer) comprising (i)administering an antibody described herein (e.g., a humanized anti-KITantibody) for example, any one of antibodies Hum1-Hum20, such as Hum10,Hum17, Hum8 or Hum4, or an antigen-binding fragment thereof (e.g.,KIT-binding fragment thereof), or an antibody conjugate thereof; and(ii) a histone deacetylase inhibitor, for example, vorinostat orsuberoylanilide hydroxamic acid (SAHA) or a compound having the chemicalformula (I), (II), or (III) as set forth below.

In one embodiment, provided herein for use in the methods describedherein in combination with anti-KIT antibodies are compounds of Formula(I)

or a pharmaceutically acceptable salt, hydrate, or solvate thereof,wherein

-   R₁ is hydroxylamino;-   each of R₂ and R₃ are independently the same as or different from    each other, substituted or unsubstituted, branched or unbranched,    and are hydrogen, hydroxyl, alkyl, alkenyl, cycloalkyl, aryl,    alkyloxy, aryloxy, arylalkyloxy or pyridine; or R₂ and R₃ are bonded    together to form a piperidine; and-   n is an integer from 5 to 7.

In one embodiment, R₂ is hydrogen atom and R₃ is substituted orunsubstituted phenyl. In a certain embodiment, R₃ is phenyl substitutedwith methyl, cyano, nitro, trifluoromethyl, amino, aminocarbonyl,methylcyano, chloro, fluoro, bromo, iodo, 2,3-difluoro, 2,4-difluoro,2,5-difluoro, 3,4-difluoro, 3,5-difluoro, 2,6-difluoro, 1,2,3-trifluoro,2,3,6-trifluoro, 2,4,6-trifluoro, 3,4,5-trifluoro, 2,3,5,6-tetrafluoro,2,3,4,5,6-pentafluoro, azido, hexyl, t-butyl, phenyl, carboxyl,hydroxyl, methoxy, phenyloxy, benzyloxy, phenylaminooxy,phenylaminocarbonyl, methoxycarbonyl, methylaminocarbonyl,dimethylamino, dimethylaminocarbonyl, or hydroxylaminocarbonyl. Inanother embodiment, R₃ is unsubstituted phenyl. In a further embodiment,n is 6.

In one embodiment, provided herein for use in the methods describedherein in combination with anti-KIT antibodies are compounds of Formula(II)

or a pharmaceutically acceptable salt, or solvate thereof, wherein n isan integer from 5 to 8. In one embodiment n is 6.

In one embodiment, provided herein for use in the methods describedherein in combination with anti-KIT antibodies is a compound of Formula(III) (SAHA)

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

Compounds of Formulae I-III can be synthesized according to the methodsdescribed in U.S. Reissued Patent No. RE38,506 and U.S. Pat. No.6,087,367, each of which is herewith incorporated by reference in itsentirety.

In one embodiment, provided herein for use in the methods describedherein in combination with anti-KIT antibodies is a Form I polymorph ofSAHA characterized by an X-ray diffraction pattern substantially similarto that set forth in FIG. 13A of U.S. Pat. No. 7,456,219, which isherewith incorporated by reference in its entirety. In one embodimentthe Form I polymorph of SAHA is characterized by an X-ray diffractionpattern including characteristic peaks at about 9.0, 9.4, 17.5, 19.4,20.0, 24.0, 24.4, 24.8, 25.0, 28.0, and 43.3 degrees 2θ, as measuredwith a Siemens D500 Automated Powder Diffractometer (range: 4-40 degrees2θ; source: Cu; λ=1.54 Angstrom, 50 kV, 40 mA).

In a certain embodiment, the Form I polymorph of SAHA is characterizedby a Differential Scanning calorimetry (DSC) thermogram having a singlemaximum value at about 164.4±2.0° C., as measured by a Perkins Elmer DSC6 Instrument at a heating rate of 10° C./min from 50° C. to at least 30°C. above the observed melting temperature.

The Form I polymorph of SAHA can be synthesized according to the methodsdescribed in U.S. Pat. No. 7,456,219.

In one embodiment, provided herein is a crystalline compositioncomprising Lysine and SAHA characterized by an X-ray diffraction patternsubstantially similar to that set forth in FIG. 1 of InternationalPatent Application Publication No. WO2008/042146, which is herewithincorporated by reference in its entirety. In another embodiment, thecrystalline composition is characterized by an X-ray diffraction patternincluding characteristic peaks at about 6.8, 20.1 and 23.2 degrees 2θ,as measured with a PANanalytical X'Pert Pro X-ray powder diffractometer(range: 2-40 degrees 2θ; source: Cu Kα1 and Kα2). In another embodiment,the crystalline composition is characterized by an X-ray diffractionpattern including characteristic peaks at about 6.8, 12.6, 18.7, 20.123.2, and 24.0 degrees 2θ, as measured with a PANanalytical X'Pert ProX-ray powder diffractometer (range: 2-40 degrees 2θ; source: Cu Kα1 andKα2). In another embodiment, the crystalline composition ischaracterized by an X-ray diffraction pattern including characteristicpeaks at about 6.8, 12.0, 12.6, 16.4, 18.7, 20.1 23.2, 24.0, 29.3degrees 2θ, as measured with a PANanalytical X'Pert Pro X-ray powderdiffractometer (range: 2-40 degrees 2θ; source: Cu Kα1 and Kα2).

In a certain embodiment, the crystalline composition comprising Lysineand SAHA is characterized by a Differential Scanning calorimetry (DSC)thermogram, wherein the endotherm of the crytalline composition exhibitsan extrapolated onset temperature of approximately 182° C., as measuredby a TA Instruments Q1000 differential scanning calorimeter at a heatingrate of 10° C./min from room temperature to 300° C.

The crystalline composition comprising Lysine and SAHA can besynthesized according to the methods described in International PatentApplication Publication No. WO2008/042146.

In certain embodiments, combination therapies described herein result insynergy or a synergistic effect. In a specific embodiment, a synergisticeffect of a combination therapy permits the use of lower dosages (e.g.,sub-optimal doses) of an anti-KIT antibody described herein and/or anadditional therapy and/or less frequent administration of an anti-KITantibody described herein or an additional therapy to a subject. Incertain embodiments, the ability to utilize lower dosages of an anti-KITantibody and/or of an additional therapy and/or to administer ananti-KIT antibody or said additional therapy less frequently reduces thetoxicity associated with the administration of an anti-KIT antibody orof said additional therapy, respectively, to a subject without reducingthe efficacy of an anti-KIT antibody or of said additional therapy,respectively, in the treatment of a KIT-associated disorder or disease.In some embodiments, a synergistic effect results in improved efficacyof an anti-KIT antibody described herein and/or of said additionaltherapies in treating a KIT-associated disorder or disease. In someembodiments, a synergistic effect of a combination of an anti-KITantibody described herein and one or more additional therapies avoids orreduces adverse or unwanted side effects associated with the use of anysingle therapy.

Provided herein are methods for inhibiting KIT activity in a cellexpressing KIT comprising contacting the cell with an effective amountof an antibody described herein (e.g., a humanized anti-KIT antibody)for example, any one of antibodies Hum1-Hum20, such as Hum10, Hum17,Hum8 or Hum4, or an antigen-binding fragment thereof (e.g., KIT-bindingfragment thereof), or an antibody conjugate thereof. Also providedherein are methods for inducing or enhancing apoptosis in a cellexpressing KIT comprising contacting the cell with an effective amountof an antibody described herein. Also provided herein are methods forinducing or enhancing cell differentiation in a cell expressing KITcomprising contacting the cell with an effective amount of an antibodydescribed herein.

KIT activity and, for example, the effect of an antibody on KIT activitycan routinely be assessed using, e.g., cell-based assays such as thosedescribed herein.

Non-limiting examples of KIT activity which can be inhibited by themethods provided herein can include any activity of KIT known ordescribed in the art, e.g., KIT receptor dimerization, KIT receptorphosphorylation (tyrosine phosphorylation), signaling downstream of theKIT receptor (e.g., Stat, AKT, MAPK, or Ras signaling), KIT ligand(e.g., SCF) induced transcriptional regulation (e.g., SCF-inducedtranscriptional activation of c-Myc), induction or enhancement of cellproliferation, or cell survival.

In certain embodiments, a method for inhibiting (e.g., partiallyinhibiting) KIT activity in a cell expressing KIT comprises contactingthe cell with an effective amount of an antibody described herein (e.g.,a humanized anti-KIT antibody) for example, any one of antibodiesHum1-Hum20, such as Hum10, Hum17, Hum8 or Hum4, or an antigen-bindingfragment thereof (e.g., KIT-binding fragment thereof), or an antibodyconjugate thereof, sufficient to inhibit or antagonize KIT activity byat least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%,65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% as assessed by methodsdescribed herein and/or known to one of skill in the art (e.g., ELISA).In certain embodiments, a method for inhibiting (e.g., partiallyinhibiting) KIT activity in a cell expressing KIT comprises contactingthe cell with an effective amount of an antibody described herein (e.g.,a humanized anti-KIT antibody) for example, any one of antibodiesHum1-Hum20, such as Hum10, Hum17, Hum8 or Hum4, or an antigen-bindingfragment thereof (e.g., KIT-binding fragment thereof), or an antibodyconjugate thereof, sufficient to inhibit or antagonize KIT activity byat least about 25%, 35%, 45%, 50%, 55%, or 65%, as assessed by methodsdescribed herein and/or known to one of skill in the art (e.g., ELISA).Non-limiting examples of KIT activity can include KIT receptorphosphorylation, KIT receptor signaling, KIT ligand (e.g., SCF) mediatedcell proliferation, KIT ligand (e.g., SCF) mediated cell survival, andtranscriptional activation of a KIT target gene (e.g., c-Myc).

In a particular embodiment, a method for inhibiting KIT activity in acell expressing KIT comprises contacting the cell with an effectiveamount of an antibody described herein (e.g., a humanized anti-KITantibody) for example, any one of antibodies Hum1-Hum20, such as Hum10,Hum17, Hum8 or Hum4, or an antigen-binding fragment thereof (e.g.,KIT-binding fragment thereof), or an antibody conjugate thereof,sufficient to inhibit (e.g., partially inhibit) or antagonize downstreamKIT signaling, for example, signaling of a member of the Src familykinases, PI3-kinases, or Ras-MAPK.

In another particular embodiment, a method for inhibiting (e.g.,partially inhibiting) one or more KIT activities in a cell expressingKIT, comprises contacting the cell with an effective amount of anantibody described herein sufficient to inhibit or antagonize downstreamKIT signaling such as phosphorylation of MAPK, phosphorylation of AKT,or phosphorylation of Stat1, Stat3, or Stat5.

In certain embodiments, a method for inhibiting (e.g., partiallyinhibiting) KIT activity in a cell expressing KIT comprises contactingthe cell with an effective amount of an antibody described hereinsufficient to inhibit or to reduce phosphorylation of AKT (e.g., KITligand (e.g., SCF) induced phosphorylation of AKT) by at least about 5%,10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%,80%, 85%, 90%, 95%, 98%, or 99% as assessed by methods described hereinor known to one of skill in the art, e.g., Western blot or ELISA assayas described in section 6 or immunoblotting assay. In certainembodiments, a method for inhibiting e.g., partially inhibiting) KITactivity in a cell expressing KIT comprises contacting the cell with aneffective amount of an antibody described herein sufficient to inhibitor to reduce phosphorylation of AKT (e.g., KIT ligand (e.g., SCF)induced phosphorylation of AKT) by at least about 25%, 35%, 45%, 55%, or65%, as assessed by methods described herein or known to one of skill inthe art, e.g., Western blot or ELISA assay as described in section 6 orimmunoblotting assay.

In certain aspects, a method for inhibiting (e.g., partially inhibiting)KIT activity in a cell (e.g., cancer cell) expressing KIT comprisescontacting the cell with an effective amount of an antibody describedherein sufficient to inhibit proliferation of the cell. Cellproliferation assays are described in the art and can be readily carriedout by one of skill in the art. For example, cell proliferation can beassayed by measuring Bromodeoxyuridine (BrdU) incorporation (see, e.g.,Hoshino et al., 1986, Int. J. Cancer 38, 369; Campana et al., 1988, J.Immunol. Meth. 107:79) or (3H) thymidine incorporation (see, e.g.,Blechman et al., Cell, 1995, 80:103-113; Chen, J., 1996, Oncogene13:1395-403; Jeoung, J., 1995, J. Biol. Chem. 270:18367 73), by directcell count at various time intervals (e.g., 12-hour or 24-hourintervals), or by detecting changes in transcription, translation oractivity of known genes such as proto-oncogenes (e.g., fos, myc) or cellcycle markers (Rb, cdc2, cyclin A, D1, D2, D3, E, etc). The levels ofsuch protein and mRNA and activity can be determined by any method wellknown in the art. For example, protein can be quantitated by knownimmunodiagnostic methods such as ELISA, Western blotting orimmunoprecipitation using antibodies, including commercially availableantibodies. mRNA can be quantitated using methods that are well knownand routine in the art, for example, using northern analysis, RNaseprotection, or polymerase chain reaction in connection with reversetranscription.

In specific embodiments, a method for inhibiting (e.g., partiallyinhibiting) KIT activity in cells (e.g., cancer cells) expressing KITcomprises contacting the cells with an effective amount of an antibodydescribed herein sufficient to inhibit cell proliferation by at leastabout 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%,70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% as assessed by methodsdescribed herein or known to one of skill in the art (e.g., BrdUincorporation assay). In specific embodiments, a method for inhibiting(e.g., partially inhibiting) KIT activity in cells expressing KITcomprises contacting the cells with an effective amount of an antibodydescribed herein sufficient to inhibit cell proliferation by at leastabout 25%, 35%, 45%, 55%, or 65%, as assessed by methods describedherein or known to one of skill in the art (e.g., BrdU incorporationassay). In specific embodiments, a method for an inhibiting orantagonizing KIT activity in cells expressing KIT comprises contactingthe cells with an effective amount of an antibody described hereinsufficient to inhibit cell proliferation by at least about 1 fold, 1.2fold, 1.3 fold, 1.4 fold, 1.5 fold, 2 fold, 2.5 fold, 3 fold, 3.5 fold,4 fold, 4.5 fold, 5 fold, 6 fold, 7 fold, 8 fold, 9 fold, 10 fold, 15fold, 20 fold, 30 fold, 40 fold, 50 fold, 60 fold, 70 fold, 80 fold, 90fold, or 100 fold as assessed by methods described herein or known toone of skill in the art (e.g., BrdU incorporation assay).

In certain aspects, a method provided herein for inhibiting KIT activityin a cell (e.g., cancer cell) expressing KIT comprises contacting thecell with an effective amount of an antibody described herein sufficientto reduce or to inhibit survival of the cell. Cell survival assays aredescribed in the art and can be readily carried out by one of skill inthe art. For example, cell viability can be assessed by usingtrypan-blue staining or other cell death or viability markers known inthe art. In a specific embodiment, the level of cellular ATP is measuredto determined cell viability. In specific embodiments, cell viability ismeasured in three-day and seven-day periods using an assay standard inthe art, such as the CellTiter-Glo Assay Kit (Promega) which measureslevels of intracellular ATP. A reduction in cellular ATP is indicativeof a cytotoxic effect. In another specific embodiment, cell viabilitycan be measured in the neutral red uptake assay. In other embodiments,visual observation for morphological changes can include enlargement,granularity, cells with ragged edges, a filmy appearance, rounding,detachment from the surface of the well, or other changes. These changesare given a designation of T (100% toxic), PVH (partially toxic—veryheavy-80%), PH (partially toxic—heavy-60%), P (partially toxic-40%), Ps(partially toxic—slight-20%), or 0 (no toxicity-0%), conforming to thedegree of cytotoxicity seen. A 50% cell inhibitory (cytotoxic)concentration (IC₅₀) is determined by regression analysis of these data.

In specific embodiments, a method provided herein for inhibiting (e.g.,partially inhibiting) KIT activity in cells expressing KIT comprisescontacting the cells with an effective amount of an antibody describedherein sufficient to reduce or to inhibit survival of the cells by atleast about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%,65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% as assessed by methodsdescribed herein or known to one of skill in the art (e.g., trypan blueexclusion assay). In specific embodiments, a method provided herein forinhibiting (e.g., partially inhibiting) KIT activity in cells expressingKIT comprises contacting the cells with an effective amount of anantibody described herein sufficient to reduce or to inhibit survival ofthe cells by at least about 25%, 35%, 45%, 55%, or 65%, as assessed bymethods described herein or known to one of skill in the art (e.g.,trypan blue exclusion assay). In specific embodiments, a method providedherein for inhibiting KIT activity in cells expressing KIT comprisescontacting the cells with an effective amount of an antibody describedherein sufficient to reduce or to inhibit survival of the cells by atleast about 1 fold, 1.2 fold, 1.3 fold, 1.4 fold, 1.5 fold, 2 fold, 2.5fold, 3 fold, 3.5 fold, 4 fold, 4.5 fold, 5 fold, 6 fold, 7 fold, 8fold, 9 fold, 10 fold, 15 fold, 20 fold, 30 fold, 40 fold, 50 fold, 60fold, 70 fold, 80 fold, 90 fold, or 100 fold as assessed by methodsdescribed herein or known to one of skill in the art (e.g., trypan blueassay).

In a specific embodiment, a method provided herein for inhibiting (e.g.,partially inhibiting) KIT activity in cells expressing KIT comprisescontacting the cells with an effective amount of an antibody describedherein sufficient to induce apoptosis (i.e., programmed cell death).Methods for detecting apoptosis are described in the art and can bereadily carried out by one of skill in the art. For example, flowcytometry can be used to detect activated caspase 3, anapoptosis-mediating enzyme, in cells undergoing apoptosis, or Westernblotting can be used to detect cleavage of poly(ADP-ribose) polymerase(PARP (see, e.g., Smolich et al., Blood, 2001, 97:1413-1421). Cleavageof PARP is an indicator of apoptosis. In specific embodiments, a methodprovided herein for an inhibiting or antagonizing KIT activity in cellsexpressing KIT comprises contacting the cells with an effective amountof an antibody described herein sufficient to induce or enhanceapoptosis by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%,50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% asassessed by methods described herein or known to one of skill in the art(e.g., flow cytometry to detect activated caspases 3). In specificembodiments, a method provided herein for an inhibiting or antagonizingKIT activity in cells expressing KIT comprises contacting the cells withan effective amount of an antibody described herein sufficient to induceor enhance apoptosis by at least about 25%, 35%, 45%, 55%, or 65%, asassessed by methods described herein or known to one of skill in the art(e.g., flow cytometry to detect activated caspases 3). In specificembodiments, antibodies a method provided herein for inhibiting KITactivity in cells expressing KIT comprises contacting the cells with aneffective amount of an antibody described herein sufficient to induce orenhance apoptosis by at least about 1 fold, 1.2 fold, 1.3 fold, 1.4fold, 1.5 fold, 2 fold, 2.5 fold, 3 fold, 3.5 fold, 4 fold, 4.5 fold, 5fold, 6 fold, 7 fold, 8 fold, 9 fold, 10 fold, 15 fold, 20 fold, 30fold, 40 fold, 50 fold, 60 fold, 70 fold, 80 fold, 90 fold, or 100 foldas assessed by methods described herein or known to one of skill in theart (e.g., flow cytometry to detect activated caspase 3).

In a specific embodiment, a method provided herein for inhibiting (e.g.,partially inhibiting) KIT activity in a cell expressing KIT comprisescontacting the cells with an effective amount of an antibody describedherein sufficient to induce differentiation. Methods for detectingdifferentiation are described in the art and can be readily carried outby one of skill in the art. For example, flow cytometry can be used todetect expression of one or more differentiation markers, or the lack ofexpression of one or more undifferentiated markers, in a cell contactedwith an antibody described herein. Similarly, Western blotting can alsobe used to detect differentiation markers. Suitable differentiationmarkers and undifferentiated markers have been described and are one ofskill in the art.

In specific embodiments, a method provided herein for inhibiting (e.g.,partially inhibiting) KIT activity in cells expressing KIT comprisescontacting the cells with an effective amount of an antibody describedherein sufficient to induce differentiation by at least about 5%, 10%,15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%,85%, 90%, 95%, 98%, or 99% as assessed by methods described herein orknown to one of skill in the art (e.g., flow cytometry). In specificembodiments, a method provided herein for inhibiting (e.g., partiallyinhibiting) KIT activity in cells expressing KIT comprises contactingthe cells with an effective amount of an antibody described hereinsufficient to induce differentiation by at least about 25%, 35%, 45%,55%, or 65%, as assessed by methods described herein or known to one ofskill in the art (e.g., flow cytometry). In specific embodiments, amethod provided herein for inhibiting KIT activity in cells expressingKIT comprises contacting the cells with an effective amount of anantibody described herein sufficient to induce differentiation by atleast about 1 fold, 1.2 fold, 1.3 fold, 1.4 fold, 1.5 fold, 2 fold, 2.5fold, 3 fold, 3.5 fold, 4 fold, 4.5 fold, 5 fold, 6 fold, 7 fold, 8fold, 9 fold, 10 fold, 15 fold, 20 fold, 30 fold, 40 fold, 50 fold, 60fold, 70 fold, 80 fold, 90 fold, or 100 fold as assessed by methodsdescribed herein or known to one of skill in the art (e.g., flowcytometry).

Non-limiting examples of cells which can be differentiated by themethods described herein include stem cells (e.g., embryonic stem cells,hematopoietic stem cells) and progenitor cells. Exemplary hematopoieticstem cell markers include CD38, CD34, CD59, CD133, Sca-1, and ABCG2.Non-limiting examples of neural stem cell markers include Nestin,PSA-NCAM, p75 Neurotrophin R, and Vimentin. Other non-limiting examplesof stem cell markers include, Oct4, Sox2, Klf4, LIN28, Nanog, SSEA-3,SSEA-4, Notch, and Wnt.

5.7 Diagnostic Methods

Labeled or otherwise detectable antibodies, which immunospecificallybind to a KIT antigen (e.g., the D4 region of KIT, for example, humanKIT) can be used for diagnostic purposes to detect, diagnose, or monitora KIT-associated disease.

Provided herein are methods for detecting KIT expression in samplesobtained from patients with a KIT-associated disorder or disease. In aparticular embodiment, a method for detecting KIT expression in a sampleobtained from a patient comprises contacting the sample with an anti-KITantibody described herein and detecting the expression level of KIT inthe samples, for example, by correlating the binding of anti-KITantibody to KIT with KIT expression levels. Methods for detection areknown to one of skill in the art.

In certain aspects, provided herein are methods for diagnosing a patientwith a KIT-associated disorder or disease. In a certain aspect, a methodfor diagnosing a subject with a KIT-associated disorder or diseasecomprises contacting a sample obtained from the subject with an anti-KITantibody described herein (or an antigen-binding fragment thereof) anddetecting the expression level of KIT in the sample. In certainembodiments, a method for diagnosing a patient with a KIT-associateddisorder or disease is an in vitro method. In particular embodiments, amethod for diagnosing a patient with a KIT-associated disorder ordisease is an ex vivo method.

In certain aspects, provided herein are methods for the detection of aKIT-associated disease comprising: (a) assaying the expression of a KITantigen in cells or a tissue sample of a subject using one or moreantibodies described herein; and (b) comparing the level of the KITantigen with a control level, e.g., levels in normal tissue samples(e.g., from a patient not having a KIT-associated disease, or from thesame patient before disease onset), whereby an increase in the assayedlevel of KIT antigen compared to the control level of the KIT antigen isindicative of a KIT-associated disease.

Methods for detection are known to one of skill in the art. For example,the anti-KIT antibody can be conjugated to a detectable molecule (e.g.,as described in section 5.1.1), and the detectable molecule can bevisualized using standard techniques (e.g., microscopy). Antibodiesdescribed herein can be used to assay KIT antigen levels in a biologicalsample using classical immunohistological methods as described herein oras known to those of skill in the art (e.g., see Jalkanen et al., 1985,J. Cell. Biol. 101:976-985; and Jalkanen et al., 1987, J. Cell. Biol.105:3087-3096). Other antibody-based methods useful for detectingprotein gene expression include immunoassays, such as ELISA and theradioimmunoassay (RIA). Suitable antibody assay labels are known in theart and include enzyme labels, such as, glucose oxidase; radioisotopes,such as iodine (¹²⁵I, ¹²¹I) carbon (¹⁴C), sulfur (³⁵S), tritium (³H),indium (¹²¹In), and technetium (⁹⁹Tc); luminescent labels, such asluminol; and fluorescent labels, such as fluorescein and rhodamine, andbiotin. In specific embodiments, diagnostic methods described hereininvolve using naked or unlabeled antibodies not conjugated to adetectable marker, and the naked or unlabeled antibodies are detectedindirectly, e.g., by using a secondary antibody, which can be labeled.

In certain embodiments, high expression of KIT in a sample relative to anormal control sample (e.g., sample obtained from a healthy patient notsuffering from a KIT-associated disorder or disease) indicates that thepatient is suffering from a KIT-associated disorder or disease.

A method for diagnosing a patient with a KIT-associated disorder ordisease, such as cancer, in a sample obtained from a patient comprisescontacting the sample with an anti-KIT antibody described herein anddetecting the expression level of KIT in the sample. In certainembodiments, high expression of KIT in a sample relative to a normalcontrol sample (e.g., sample obtained from a healthy patient notsuffering from a KIT-associated disorder or disease) indicates that thepatient is suffering from a KIT-associated disorder or disease.

In certain embodiments, a sample can be a tumor sample derived from, orcomprising tumor cells from, a patient's tumor. Examples of tumorsamples herein include, but are not limited to, tumor biopsies,circulating tumor cells, circulating plasma proteins, ascitic fluid,primary cell cultures or cell lines derived from tumors or exhibitingtumor-like properties, as well as preserved tumor samples, such asformalin-fixed, paraffin-embedded tumor samples or frozen tumor samples.In certain embodiments, a sample is a fixed tumor sample which has beenhistologically preserved using a fixative. In some embodiments, a sampleis a formalin-fixed tumor sample which has been preserved usingformaldehyde as the fixative. In certain embodiments, a sample is anembedded tumor sample which is surrounded by a firm and generally hardmedium such as paraffin, wax, celloidin, or a resin. Embedding makespossible the cutting of thin sections for microscopic examination or forgeneration of tissue microarrays (TMAs). In particular embodiments, asample is a paraffin-embedded tumor sample which is surrounded by apurified mixture of solid hydrocarbons derived from petroleum. Incertain embodiments, a sample is a frozen tumor sample which is, or hasbeen, frozen. In a specific embodiment, a sample, for example, aparaffin-embedded sample or frozen sample, is sectioned.

In certain aspects, a cancer or biological sample which displays KITexpression, amplification, or activation is one which, in a diagnostictest, expresses (including overexpresses) a KIT receptor, has amplifiedKIT gene, and/or otherwise demonstrates activation or phosphorylation ofa KIT receptor.

Also provided herein is the detection and diagnosis of a KIT-associateddisease in a human. In one embodiment, diagnosis comprises: a)administering (for example, parenterally, subcutaneously, orintraperitoneally) to a subject an effective amount of a labeledantibody described herein; b) waiting for a time interval following theadministering for permitting the labeled antibody to preferentiallyconcentrate at sites in the subject where the KIT antigen is expressed(and for unbound labeled molecule to be cleared to background level); c)determining background level; and d) detecting the labeled antibody inthe subject, such that detection of labeled antibody above thebackground level indicates that the subject has a KIT-mediated disease.Background level can be determined by various methods including,comparing the amount of labeled molecule detected to a standard valuepreviously determined for a particular system.

It will be understood in the art that the size of the subject and theimaging system used will determine the quantity of imaging moiety neededto produce diagnostic images. In the case of a radioisotope moiety, fora human subject, the quantity of radioactivity injected will normallyrange from about 5 to 20 millicuries of ⁹⁹Tc. The labeled antibody willthen preferentially accumulate at the location of cells which containthe specific protein. In vivo tumor imaging is described in S. W.Burchiel et al., “Immunopharmacokinetics of Radiolabeled Antibodies andTheir Fragments.” (Chapter 13 in Tumor Imaging: The RadiochemicalDetection of Cancer, S. W. Burchiel and B. A. Rhodes, eds., MassonPublishing Inc. (1982)).

Depending on several variables, including the type of label used and themode of administration, the time interval following the administrationfor permitting the labeled antibody to preferentially concentrate atsites in the subject and for unbound labeled antibody to be cleared tobackground level is 6 to 48 hours or 6 to 24 hours or 6 to 12 hours. Inanother embodiment the time interval following administration is 5 to 20days or 5 to 10 days.

In one embodiment, monitoring of a KIT-mediated disease is carried outby repeating the method for diagnosing the a KIT-mediated disease, forexample, one month after initial diagnosis, six months after initialdiagnosis, one year after initial diagnosis, etc.

Presence of the labeled molecule can be detected in the subject usingmethods known in the art for in vivo scanning. These methods depend uponthe type of label used. Skilled artisans will be able to determine theappropriate method for detecting a particular label. Methods and devicesthat can be used in the diagnostic methods of the invention include, butare not limited to, computed tomography (CT), whole body scan such asposition emission tomography (PET), magnetic resonance imaging (MRI),and sonography.

In a specific embodiment, the molecule is labeled with a radioisotopeand is detected in the patient using a radiation responsive surgicalinstrument (Thurston et al., U.S. Pat. No. 5,441,050). In anotherembodiment, the molecule is labeled with a fluorescent compound and isdetected in the patient using a fluorescence responsive scanninginstrument. In another embodiment, the molecule is labeled with apositron emitting metal and is detected in the patient using positronemission-tomography. In yet another embodiment, the molecule is labeledwith a paramagnetic label and is detected in a patient using magneticresonance imaging (MRI).

6. EXAMPLES

The examples in this section (i.e., section 6) are offered by way ofillustration, and not by way of limitation.

6.1 Example 1: Generating Anti-KIT Antibodies

Anti-KIT antibodies were designed using Composite Human Antibody™technology (Antitope Ltd., Cambridge, United Kingdom) and the amino acidsequence of the mouse antibody 37M (U.S. patent application Ser. No.13/358,210 filed Jan. 25, 2012) which immunospecifically binds to ahuman KIT D4 region, to produce anti-KIT antibodies with human aminoacid sequences, wherein the antibodies bind a human KIT D4 region. Fiveheavy chain variable region sequences (H1, H2, H3, H4 and H5) and fourlight chain variable region sequences (L1, L2, L3 and L4) were selectedto be used for gene synthesis, expression in mammalian cells and testingfor direct binding to recombinant KIT domains as well as activity inblocking stem cell factor (SCF)-induced phosphorylation. Amino acidsequences for H1-H5, L1-L4 and nucleic acid sequences encoding them areshown in FIGS. 3A-3I.

Nucleic acid molecules encoding the H (heavy chain) and L (light chain)variable region amino acid sequences were cloned directly intoexpression vectors for human IgG1 VH chains and human V_(κ) chains. Allconstructs were confirmed by sequencing. Vectors encoding IgG1 VH(H1-H5) and V_(κ) (L1-L4) chains were transfected into CHO cells (e.g.,CHOdhfr-cells) in different combinations to produce twenty antibodies(see Table 4, antibodies Hum1-Hum20). Vectors encoding the chimericantibody 37C, a chimeric antibody with human constant domains and mouse37M variable domains (U.S. patent application Ser. No. 13/358,210 filedJan. 25, 2012), were also transfected into CHO cells. Cells transientlytransfected with non-linearized DNA were incubated for four days priorto harvesting supernatants which were used directly in assays or forpurification. Stable transfections to establish cell lines expressingthe antibodies were carried out using linearized DNA and weresubsequently drug-selected. Supernatants from drug-resistant coloniesfor each construct were tested for IgG titre using an IgG1 ELISA, andthe best expressing lines were selected based on an above-background(usually >0.1 μg/ml) IgG titre in the supernatant, and expanded in thepresence of drug selection through 24-well and 6-well plates, T75 andT175 tissue culture flasks, with screening for IgG expression at everystage. Titers of 0.1-1 μg/ml are typical for non-optimised CHOdhfr-celllines. Antibody expression was confirmed by Coomassie Blue stainedSDS-PAGE.

In these particular cells, a majority of the antibodies were expressedwith a titer in the range of 0.1-1.0 μg/ml, and in particular, antibodyHum4 was expressed at a titer of 1.2 μg/ml.

6.2 Example 2: Binding Affinity to Human KIT Ig-Like Domains D4/D5

The binding affinity of the anti-KIT antibodies to the target antigenKIT Ig-like domains D4/D5 was assessed by direct binding ELISA. Adilution series (three-fold) of chimeric antibody 37C and Hum1-Hum20antibodies from approximately 1×10⁻⁸M to 4.7×10⁻¹³ M was incubated for 1hour at room temperature on a flat bottom microtitre plate pre-coatedwith 50 ng/well recombinant c-Kit Ig-like domains D4/D5 (see FIG. 2)diluted in borate buffer and pre-blocked for 1 hour with 1% BSA. Boundantibody was detected with anti-human Ig-HRP followed by detection usingTMB substrate. Results are presented in Table 7 below.

TABLE 7 Binding characterization of anti-KIT antibodies. RelativeRelative Relative Relative binding binding binding binding activityactivity activity activity assay #1 assay #2 assay #3 assay #4 Antibody(sup) (sup) (purified) (purified) Hum1 0.64 Hum2 0.79 Hum3 0.88 Hum40.91 1.07 0.83 Hum5 0.93 Hum6 1.15 0.70 Hum7 1.12 0.80 Hum8 1.02 0.620.89 0.75 Hum9 1.08 1.00 0.85 Hum10 1.10 0.88 0.87 0.72 Hum11 0.74 Hum121.23 0.72 Hum13 1.11 0.78 Hum14 1.14 1.03 0.74 Hum15 0.87 0.76 0.87Hum16 1.2 1.02 Hum17 1.17 0.76 0.98 0.72 Hum18 1.22 0.79 0.99 Hum19 1.111.05 0.95 0.85 Hum20 0.80 0.70 EC₅₀ (pM) 380.74 ± 18.3 411.66 ± 183.7462.35 ± 28 567.76 chimeric (x4) (x5) (x2) (x1) (replicates) EC50 values(pM) were calculated for anti-KIT antibodies Hum1-20, and values forantibodies were normalized against those for the chimeric antibody 37Cin the corresponding experiment. Higher values indicate stronger bindingactivity. Actual EC₅₀ values for the chimeric antibody in eachexperiment are shown at the foot of the table along with the number ofreplicates averaged to achieve that value. (sup) = supernatantcontaining antibody; (purified) = antibody purified from supernatant.

The binding activity of certain of the antibodies as well as chimericantibody 37C was further characterized by solid phase ELISA using anantigen containing the D4/D5 region (see FIG. 2) of human KIT. Thegeneral protocol used for the solid phase ELISA experiments is describedbelow.

Materials:

-   -   Recombinant antigen: Recombinant IG domain four and five of the        extracellular region of KIT    -   TBS-T: 50 mM Tris pH 7.4, 150 mM NaCl, 0.1% Tween 20    -   TBS: 50 mM Tris pH 7.4, 150 mM NaCl    -   Blocking solution: 1% bovine serum albumin (BSA) in TBS    -   Dilution buffer: 1% BSA in TBS-T    -   Detection antibody solution: Goat anti-mouse IgG HRP antibody        and Pierce goat anti-human F(ab′)₂ specific conjugated with        horseradish peroxidase (Thermo scientific 31414)    -   Detection Substrate: TMB (3,3′,5,5′-tetramethylbenzidine)        Substrate kit (Thermo scientific #34021)

Recombinant antigen corresponding to the D4/D5 region of the KITextracellular domain (see FIG. 2) was absorbed onto 96-well microtiterplates. In particular, recombinant antigen (5 μg) were diluted into 10mL of borate buffer, and 100 μL of the antigen solution were added toeach well of a 96 well plate and were incubated at 4° C. overnight.

Serial dilutions of antibody samples were prepared with dilution bufferfor ELISA.

ELISA: Following one rinse with TBS-T, blocking buffer (200 μL) wasadded to each well of the plate with the adsorbed antigen and wasincubate at room temperature for one hour. Then, the blocking buffer wasremoved, and the serially diluted solutions of test antibodies andcontrols were added to the plate in a volume of 50 μL and incubated atroom temperature for one hour. The antibody solutions were removed, andthe plate was washed three times with 100 μL of wash buffer on a platewasher. After the last wash, the plate was blotted dry. Secondaryantibody solution was diluted 1:8000 and was added to each well in avolume of 100 μL and allowed to incubate for one hour at roomtemperature. The diluted secondary antibody solution was removed, andthe plate was washed three times with 100 μL of wash buffer on a platewasher. Then, freshly mixed TMB substrate solution was added to eachwell in a volume of 100 μL and was allowed to incubate at roomtemperature for 30 minutes. Subsequently, 100 μL of 2N H₂SO₄ were addedto each well and immediately read on the plate reader. An irrelevantantibody served as the negative control, and an anti-KIT antibodyagainst the D4 and/or D5 domain of the extracellular region of KITserved as the positive control. OD values for each sample were obtainedat a wavelength of 450 nm.

Results were analyzed using Graph Pad Prism and Excel to obtain theconcentration of antibodies at 50% binding to antigen.

FIG. 5 depicts a graph plotting 0D₄₅₀ versus log concentration (M) ofanti-KIT antibodies. The effective concentration at 50% binding (EC₅₀)for the binding affinity of a chimera of antibody 37M and antibodiesHum17, Hum8, Hum4, and Hum10 to the D4/D5 region of human KIT wascalculated to be approximately 12 pM, 6.6 pM, 11 pM, 7.5 pM, and 23 pM,respectively.

The results presented in FIG. 5 show that the binding affinities of achimera of antibody 37M and and antibodies Hum17, Hum8, Hum4, and Hum10are comparable.

Additional binding assays demonstrated that Hum17, Hum8, Hum4, and Hum10exhibited specific binding to canine KIT and monkey KIT, in addition tohuman KIT, but they did not exhibit specific binding to murine KIT.

6.3 Example 3: Binding Affinity of Anti-KIT Antibodies for Human KITExpressed on CHO Cells

To confirm that the anti-KIT antibodies can bind to KIT expressed on thesurface of cells, flow cytometry assays were carried out using CHO cellsthat do (CHO/KIT-WT) and do not (parental CHO cells) exogenously expressthe full-length, wild-type human KIT receptor. Briefly, parental CHOcells and CHO/KIT-WT cells were washed and incubated with 0.01 nM, 0.1nM, 1 nM or 10 nM of a chimeric (human-mouse) 37M antibody, antibodyHum17, Hum8, Hum4, or Hum10, a negative control isotype IgG antibody, ora commercial anti-KIT antibody as a positive control. The samples wereprocessed for flow cytometry analysis. More specifically, cells wereremoved from the culture flasks using EDTA, and washed with PBS. Then,the cells were resuspended in media and counted. Each sample containingapproximately 200,000 to 250,000 cells was spun, the media was removed,and the cells were resuspended in FC buffer (1% BSA, 0.01% sodium azidein 1XPBS) for the blocking step. The cells were incubated in FC bufferfor 1 hour on ice. Then, primary antibody (e.g., a chimeric(human-mouse) 37M antibody, Hum17, Hum8, Hum4, Hum10, positive controlanti-KIT antibody, or negative control antibody) was added to the cellsin FC buffer as described above. The samples were mixed and incubated onice for 1 hour, followed by washing the cells with 0.5-1 mL FC buffer.The FC buffer was removed by spinning the cells at 1200 rpm for 3minutes at 4° C., decanting the liquid. The cell pellets wereresuspended in 200 μL FC buffer, and secondary antibody (DyLight 488AffiniPure Goat Anti-Mouse IgG Jackson Laboratories) was added to thecells at a 1:1000 to 1:2000 dilution. The samples were mixed andincubated on ice for 1 hour, and then washed as described above. Thesamples were run on a fluorescence activated cell sorter (FACS) machine(Accuri FlowCytometer C6). Samples were analyzed by following channelFLA-1 for DyLight-conjugated samples.

FIG. 6 summarizes the results from the flow cytometry analysis. Theeffective concentration at 50% binding (EC₅₀) for the binding affinityof a chimera (human-mouse) of antibody 37M and antibodies Hum17, Hum8,Hum4, and Hum10 to the D4/D5 region of human KIT was calculated to beapproximately 47 pM, 139 pM, 83 pM, 106 pM, and 132 pM, respectively.

The results presented in FIG. 6 show that the binding affinities of thechimeric 37M antibody and antibodies Hum17, Hum8, Hum4, and Hum10 forcell surface expressed human KIT are comparable.

6.4 Example 4: Inhibition of KIT Phosphorylation Induced by SCF inCell-Based Phospho-KIT Assays

The inhibition of stem cell factor (SCF)-mediated phosphorylation ofcell-surface KIT by anti-KIT chimeric 37M antibody and certain anti-KITantibodies described herein was assessed in a cell-based assay asfollows: CHO-KIT cells, sorted for high cell surface antigen expression,were cultured overnight in 24-well or 96-well plates in the absence ofserum before addition of a three-fold dilution series from1×10⁻⁸M-1.4×10⁻¹¹ M of test antibody (chimeric or anti-KIT antibodiesdescribed herein purified from supernatant) or control blocking antibody(BioLegend, clone A3C6E2).

Following incubation for 2 hours at 37° C., cells were stimulated with30 ng/mL SCF (R&D Systems, cat. no. 255-SC/CF) for 10 min at 37° C.,lysed in the presence of protease and phosphatase inhibitors, and KITprotein was captured from whole lysates onto white-walled 96-wellMaxisorp plates pre-coated with KIT capture antibody (Thermo Scientific,cat. no. LVMS289-PABX). For the 96-well format, duplicate wells were setup for each condition and lysed and transferred separately to thecapture plate whilst for the 24-well format, duplicate samples of lysatewere taken from the same well. Following overnight incubation at 4° C.and extensive washing of the plate, tyrosine phosphorylated KIT wasdetected using HRP-conjugated anti-phosphotyrosine clone 4G10(Millipore, cat. no. 16-105) and West PICO chemiluminescent substrate(Fisher, cat. no. PN34087). The results are presented in Table 8 below.

TABLE 8 Blocking Assays Relative Relative Relative Relative blockingblocking blocking blocking activity, activity, activity, activity, assay#1 assay #2 assay #3 assay #4 Antibody (24-well) (24-well) (96-well)(96-well) Hum4 1.2 0.86 Hum8 1.01 1.12 Hum9 1.05 Hum10 0.82 0.86 Hum131.00 Hum14 0.94 Hum15 0.98 0.99 Hum17 1.39 1.07 Hum18 1.22 Hum19 1.090.98 1.40 IC₅₀ values (pM) were calculated for these antibodies andvalues for were normalized against those for the chimeric 37M antibodyin the corresponding experiment. Higher values indicate strongerblocking activity. “(96-well)” refers to assays carried out in 96-wellplate format as opposed to 24-well format (24-well).

The results in Table 8 shows that the blocking activities of antibodiesHum4, Hum8, Hum9, Hum10, Hum13, Hum14, Hum15, Hum17, Hum18, and Hum19are comparable to the blocking activity of a chimera of antibody 37M.

To further characterize the effect of these antibodies on KIT activity,specifically, SCF-induced tyrosine phosphorylation of the cytoplasmicdomain of KIT, cell-based phospho-KIT assays were carried out asfollows.

Materials:

-   -   CHO cells stably transfected with a plasmid encoding full-length        human KIT (see FIG. 1), which was cloned from a human ovary cDNA        library (OriGene, Rockville, Md.)    -   Complete cell culture media (see Table 9)    -   Starving media: Cell culture media described in Table 9 without        FBS    -   Trypsin-EDTA    -   PBS    -   SCF solution: rhSCF (RD Systems 255-SC/CF); final concentration        30 ng/mL    -   Lysis buffer: 50 mM Tris pH 7.4, 150 mM NaCl, 1 mM EDTA, 1%        Triton X-100, protease inhibitor cocktail tables EDTA free        (Roche Diagnostics 04693132001), 1 mM NaVO₄    -   TBS-T: 50 mM Tris pH 7.4, 150 mM NaCl, 0.1% Tween 20    -   Blocking solution: 5% bovine serum albumin (BSA) in TBS-T    -   Dilution buffer: 1% BSA in TBS-T containing 1 mM NaVO₄    -   Detection antibody solution: anti-phospho-tyrosine antibody        conjugated with horse radish peroxidase (Millipore, 4G10);        dilution factor 1:500    -   Capture antibody: anti-KIT antibody Ab3 from Thermo Scientific        (MS-289-PABX)

TABLE 9 Cell Culture Media Cell line CHO (parental or KIT transfected)Basic medium Gibco F12 Nutrient Mixture (Ham) 1X 11765Penicillin/Streptomycin 50 IU/mL penicillin (Cellgro 30-001-CI) 50 μg/mLstreptomycin 100X GlutaMAX ™-I 1X GlutaMAX ™ (Gibco 35050) Geneticin(Invitrogen 1 mg/mL Geneticin (for selection of 10131027) transfectedcells only)

Passaging of CHO/KIT-WT cells: Confluent cells were washed once withsterile PBS, incubated with 0.25% Trypsin-EDTA at room temperature untilcells detached from the plastic tissue culture plates. Complete culturemedium, which contains FBS, was added to the plate to end the trypticdigestion.

Counting Cells: Ten microliters of cell suspension were mixed with 10 μLof 0.4% trypan blue. Half of this mixture (10 μL) was transferred into acell counting chamber (Invitrogen), and the cells were counted. Cells(200,000 per well) were transferred into a 24-well cell culture plate,and were cultivated in complete medium (Table 9) for 24 hours undernormal cell culture conditions (i.e., humidified 95% air and 5% CO₂atmosphere at 37° C.).

Cell Treatment: After the cells were plated in the 24-well plates andcultured overnight, the medium was removed, and the cell monolayer waswashed once with starvation medium. The cells were then cultured for 24hours in starvation medium under normal cell culture conditions. Thenthe cells were treated with a chimeric (human-mouse) 37M antibody, Hum4,Hum8, Hum10, Hum17, or control antibody solutions for 2 hours undernormal cell culture conditions. The final concentration for the antibodysolution was 100 nM (5 μg/mL) or less. Subsequently, SCF solution wasadded to the cells pretreated with anti-KIT antibodies or controlantibody at a final concentration of 30 ng/mL for 10 minutes undernormal cell culture conditions.

Controls:

-   -   Negative controls: starved, untreated and non-stimulated cells    -   Positive control: starved, untreated and SCF-stimulated cells    -   Drug control: starved cells, treated with 1 μM Gleevec and        stimulated with SCF    -   Antibody control: cells starved, treated with 100 nM blocking        antibody (purified mouse anti-human KIT antibody (BioLegend        A3C6E2) that binds to the SCF binding site)

Preparation of cell lysates: After stimulation, cells in the 24-wellplate were placed on ice immediately, the cells were washed once withcold PBS, and lysed with 100 μL of cold lysis buffer.

Preparation of 96-well ELISA plate with capture antibody: Captureantibody (5 μL) was diluted in 10 mL 50 mM Borate buffer, and thecapture antibody solution (100 μL or 50 ng/well) was added to each wellof the 96-well ELISA plate. The 96-well plate was incubated at roomtemperature for 5-6 hours or overnight at 4° C. The capture antibodysolution was removed prior to the blocking step. Blocking was carriedout by adding 100 μL of blocking solution to each well and allowed toincubate at room temperature for 1 hour. The blocking solution wasremoved, the wells were washed once with dilution buffer, and 50 μL ofdilution buffer were added to each well.

Phospho-KIT assay: 50 μL of the cell lysates of each sample from a wellof the 24-well plate were transferred into 1 well of the prepared96-well plate containing 50 μL dilution buffer, and the 96-well platewas incubated overnight at 4° C. Following the overnight incubation, thesupernatant was removed, and the plate was washed 3 times (5 minuteincubation each time) with TBS-T. Detection antibody dilution (100 μL)was added to each well and incubated for 1 hour at room temperature inthe dark. The plate was washed 3 times with TBS-T, washed once with TBS,and the TBS was removed. The “SuperSignal West Dura Extended DurationSubstrate” reagents (Thermo Scientific) were mixed (1:1), and 100 μL ofthe mix were added to each well.

Luminescence was detected in the ELISA plate reader using the GEN5™protocol “Luminescence Glow” and the data were analyzed using MicrosoftExcel.

FIG. 7 depicts a graph plotting the data from these experiments. Thegraph is a plot of arbitrary luminescence units versus log concentration(M) of either a chimera (human-mouse) of antibody 37M or antibody Hum17,Hum8, Hum4, or Hum10. The 50% inhibition concentrations (IC₅₀) of thechimera 37M, Hum17, Hum8, Hum4, and Hum10 antibodies were calculated tobe approximately 344 pM, 510 pM, 542 pM, 470 pM, and 510 pM,respectively. The results indicate that antibodies Hum17, Hum8, Hum4,and Hum10, like the 37M chimera antibody, are effective inhibitors ofligand (SCF)-induced tyrosine phosphorylation of the cytoplasmic domainof KIT.

These anti-KIT antibodies can be expressed in a variety of differentcell types without substantially affecting the properties of theantibody, for example, binding activity and blocking activity. Forexample, anti-KIT antibodies Hum17, Hum8, Hum4, and Hum10 were expressedin a different recombinant expression system based on HEK293-Freestyle(293F) cells, and exhibited blocking activity as determined by KITphosphorylation inhibition assays. These results indicate that a varietyof cell systems can be used for expressing anti-KIT antibodies describedherein, such as antibodies Hum1-Hum20, without compromising antibodyactivity.

6.5 Example 5: Antibody Internalization by CHO Cells ExpressingWild-Type KIT

Immunofluorescence staining assays were carried out to assessinternalization of antibodies Hum4, Hum10, Hum17, and Hum8 by CHO cellsexpressing wild-type KIT (“CHO/KIT-WT”).

The immunofluorescence staining assays were carried out essentially asdescribed below. Materials and reagents for the immunofluorescenceassays included the following:

-   -   Primary antibodies: antibodies Hum4, Hum8, Hum10, Hum17, 37M,        and β-Tubulin (9F3) rabbit monoclonal antibody(mAb) (Cell        Signaling #2128).    -   Secondary antibodies: goat anti-mouse antibody conjugated to        Oregon Green® 488 (Invitrogen #011038), goat anti-rabbit        antibody conjugated to Texas Red (Invitrogen #T2767), and goat        anti-human antibody conjugated to Alexa Fluor 488 (Invitrogen        #A11013).    -   Fixative: 4% paraformaldehyde (PFA) (store 40% PFA microscopy        grade in fridge and dilute 1:10 with PBS just before use)    -   Permeabilization solution: PBS with 0.1% Triton X-100 and 0.5%        BSA, sterile filtered    -   Blocking/dilution solution: 2% BSA in PBS, sterile filtered    -   Mounting media: ProLong® Gold antifade reagent with DAPI (P36931        Invitrogen) (4′,6-diamidino-2-phenylindole)    -   CHO cells engineered to express exogenous human, wild-type KIT        (full-length) (“CHO/KIT-WT”)

CHO cells (e.g., 75,000 cells per well) were seeded into a 24-welltissue culture plate containing one round glass coverslip per well. Thecells were cultivated for at least 6 hours before overnight starvationin media containing no fetal bovine serum. Following starvation, theculture media was removed from the cells and antibody 37M, Hum4, Hum10,Hum17, or Hum8 diluted to 33.3 nM in starvation media containing 1%bovine serum albumin, was transferred onto the cell layer at time 0minute, 30 minutes, 45 minutes or 55 minutes to generate a time course.Cells were incubated for the indicated times under standard cultureconditions (37° C. and 5% CO₂). Cell layers were washed once with PBS(room temperature) 5 to 60 minutes after addition of the antibody. Celllayers were fixed for 20 minutes with 4% PFA at room temperature, andwere washed 3 times with PBS. Cell membranes were permeabilized by theaddition of permeabilization solution for 3 minutes followed by 3 washeswith PBS. Blocking solution was added to each well, and cells wereblocked for 20 minutes at room temperature. The f3-Tubulin (9F3) rabbitmAb was diluted 1:100 in dilution solution and incubated with the celllayers for 1 hour at room temperature followed by 2 washes with PBS andone with blocking solution. Both secondary antibodies were dilutedtogether at 1:200 in dilution solution before being added to the cells.Cells were incubated in secondary antibody in the dark at roomtemperature for 1 hour followed by 3 PBS washes. The cells on thecoverslips were mounted against the glass slides using one drop ofProLong® Gold antifade reagent with DAPI and were kept at roomtemperature overnight. Internalization of the antibody was analyzed byfluorescence microscopy at various time point, e.g., 5 minutes and 60minutes of exposure to antibody 37M, Hum4, Hum10, Hum17, or Hum8.

The immunofluorescence staining assays demonstrated that, in CHO/KIT-WTcells, antibodies Hum4, Hum10, Hum17, and Hum8, similarly to antibody37M, bound to the surface of these cells, and were internalized by thesecells. In particular, images of cells exposed to these antibodies showstaining of membrane-associated structures at early time points, such asat 5 minutes after exposure to anti-KIT antibodies, and show staining ofinternal structures (e.g., vesicles) at later time points, such as at 60minutes after exposure to antibody. In contrast, images of cells exposedwith anti-β-Tubulin antibody, as a control, showed staining of elongatedstructures throughout the cytoplasm of the cells. These results indicatethat antibodies Hum4, Hum10, Hum17, and Hum8 are internalized by cellsexpressing KIT. Effective internalization of antibodies is useful, e.g.,for delivering toxins to cells, for example cancer cells, expressingKIT.

6.6 Example 6: Stability Data

Successful development of therapeutic antibodies is, in part, dependenton the characterization of the antibody stability in vivo. To this end,both the relative thermal stability and relative stability undermimicked physiological conditions (i.e., serum, 37° C.) of a subset ofanti-KIT antibodies described herein was characterized.

Differential Scanning Calorimetry:

Differential Scanning calorimetry (DSC) is a thermoanalytical techniqueused to determine the point at which a sample of interest undergoesphase transition, such as melting or crystallization. Therefore, DSC isa useful tool to compare the relative thermal stability of multipleantibodies. To this end, a subset of anti-KIT antibodies describedherein (e.g., antibodies Hum1-Hum20) were analyzed using DSC, and themelting temperatures of these antibodies were determined. The meltingprofiles of each anti-KIT antibody revealed one major melting peak, andone or two minor peaks. The prevalent melting points ranged from 85.7°C. to 86.6° C., while the minor peaks were calculated to be from 71.6°C.−71.9° C. These results, showing that the melting temperatures aresignificantly higher than 37° C., indicate that these anti-KITantibodies can be stable in a therapeutic setting, for example, at 37°C.

Serum Stability:

To better understand the stability of anti-KIT antibodies describedherein under physiological conditions, antibody activity was assessedfollowing long-term incubation in fetal calf serum at 37° C. Briefly,anti-KIT antibodies were diluted to 0.2 mg/mL in serum-free media ormedia containing 50% fetal calf serum. Samples were incubated at 37° C.for 1, 2 and 3 weeks, at which point aliquots were compared to antibodystored at 4° C. for the same duration in both binding ELISA andcell-based phosphorylation assays as described in earlier examples.Using the 4° C. antibody as a reference, binding ELISA assays revealedthat following one week, the maximum change in EC₅₀ value was 4-fold,but was as low as 1.1-fold, while after two weeks, the maximum changewas 4-fold, using the 4° C. antibody as a control. Consistently, IC₅₀values in cell-based phosphorylation assays for these same anti-KITantibodies stored at 37° C. with or without serum varied by less thantwo-fold from those of the antibodies stored at 4° C.

Together, these data suggest long-term stability of anti-KIT antibodiesdescribed herein, as the binding and blocking activity of each antibodyis maintained following incubation both in serum and at an elevatedtemperature. These results indicate that anti-KIT antibodies describedherein (e.g., Hum1-Hum20) can exhibit maintained activity and can, forexample, be used in a less-frequent dosing regimen.

6.7 Example 7: Blocking Ligand-Induced AKT Phosphorylation

Anti-KIT antibodies described herein (e.g., Hum1-Hum20) are assayed forthe ability to inhibit or block AKT phosphorylation, which is adownstream signaling event of KIT signaling. The assay is carried out asdescribed above with the following modifications. First, a mouseanti-AKT antibody is immobilized on ELISA plates as a capture antibody.Second, the detection of AKT phosphorylation (phospho-AKT) is performedusing a two-step method. After incubation of the cell lysates with thecoated ELISA plate, a biotinylated mouse monoclonal antibody recognizingphospho-AKT (Ser473) is added to each well for 1 hour at roomtemperature at a dilution of 1:500. Following this incubation andsubsequent washes, the phospho-AKT antibody is detected with ProteinWestern C Streptavidin-HRP antibody (BioRad) at a dilution of 1:2500.The final detection step with TMB substrate solution is performed asdescribed herein (e.g., sections 6.2 and 6.4).

6.8 Example 8: Animal Model Study of Anti-KIT Antibodies in TreatingCancer

The anti-tumor effects of anti-KIT antibodies described herein areconfirmed using mouse models, such as xenograft mouse models, of humantumors. Various mouse models for studying cancer have been described(see, e.g., Fernandez et al., J. Clin. Invest., 2007, 117(12):4044-4054). Below, mouse models, e.g., xenograft mouse models, derivedfrom a variety of patient-derived, human cell lines are described. Mousemodels for assessing toxicity are also described below.

Gastrointestional Stromal Tumor (GIST)

Mouse models of GIST have been described, for example, see, Fernández etal, J. Clin. Invest., 2007, 117(12): 4044-4054. For example, GIST cellsare harvested from subconfluent cultures by a brief exposure to 0.05%trypsin-EDTA (Invitrogen). Trypsinization is stopped with mediumcontaining 10% FBS. The cells are then washed twice in serum-free mediumand resuspended in serum-free HBSS (Invitrogen). Single-cell suspensionswith greater than 95% viability, as determined by Trypan blue exclusion,are used for the injections. To produce tumors, 1×10⁵ to 1×10⁷ GISTcells, for example 6×10⁶ GIST cells per 100 μl are injectedsubcutaneously into the unilateral flank of each SCID mouse (e.g.,female C.B-17/IcrHsd-Prkdc^(SCID) mice purchased from Harlan SpragueDawley Inc.; housed in facilities approved by and in accordance with theAmerican Association for Assessment and Accreditation of LaboratoryAnimal Care, the United States Department of Agriculture, the UnitedStates Department of Health and Human Services, and the NIH; and usedaccording to institutional guidelines). Five to ten mice per group inthe vehicle and anti-KIT antibody groups are used. Once tumors arepalpable (e.g., approximately 8-11 weeks from injection), mice arestarted on therapy with injections of normal saline (vehicle) oranti-KIT antibodies (e.g., antibodies Hum1-Hum20 or antibody-drugconjugates thereof), for example, daily, weekly, or bi-weeklyintraperitoneal injections. Treatment is continued for a period of time,e.g., approximately 6 weeks, with weekly 2-dimensional measurements oftumor size. Imaging methods for detecting tumor size can also be used,e.g., MRI. All mice are sacrificed when the tumor size approachapproximately 1.5 cm in the control group. Tumors are collected, arefixed in formalin, and are analyzed by H&E staining. Representativeimages are taken from each tumor using a light microscope at ×40 and×100 magnification.

A graph of tumor size or volume of each mouse plotted against time(e.g., days or weeks) after tumor injection is generated to ascertainthe effect of the anti-KIT antibodies on tumor growth in the micerelative to the vehicle negative control.

Non-limiting examples of GIST cells which may be used in these mousemodels include, GIST 430 cells (human GIST cells that express mutatedKIT having a deletion of exon 11 (V560-L576) and V654A mutation in exon13) and GIST882 cells (immortal GIST cells that possess a homozygousexon 13 missense mutation (i.e., K642E) in KIT (see, e.g., Tuveson etal., Oncogene, 2001, 20: 5054-5058)).

Leukemia

To study the effects of anti-KIT antibodies on leukemia, a xenograftmouse model using human leukemia cells (e.g., K562, HEL, or HL60 cells)is established essentially as described above, except that leukemiacells (e.g., K562, HEL, or HL60 cells) are injected into the miceinstead of GIST cells. In particular, the tumor cells are collected fromsubconfluent suspensions. To produce tumors, 1×10⁵ to 1×10⁷ tumor cellsper 100₁A1 are injected into each SCID mouse. The mice are thenrandomized into the following groups (n=5-10 per group): (a) normalsaline daily; and (b) anti-KIT antibodies (e.g., antibodies Hum1-Hum20or antibody-drug conjugates thereof). The mice are started on therapy(e.g., at day 0, 7, or 14 or when tumors are detectable) with injectionsof normal saline (vehicle) or anti-KIT antibodies (e.g., daily, weekly,or bi-weekly intraperitoneal injections). Treatment is continued for aperiod of time, e.g., approximately 6 weeks, with weekly 2-dimensionalmeasurements of tumor size. Imaging methods for detecting tumor size canalso be used, e.g., MRI. Tumors are measured weekly during treatment andat necropsy.

A graph of tumor size or volume of each mouse plotted against time(e.g., days or weeks) after tumor injection is generated to ascertainthe effect of the anti-KIT antibodies on tumor growth in the micerelative to the vehicle negative control.

Mouse models of human leukemia also can be generated by injecting humanleukemia cells into nude mice or irradiated mice, via other routes, suchas intravenous route, and monitoring animal death as an indication ofprogression of leukemia in the presence or absence of treatment withanti-KIT antibodies. A survival curve is generated for each mouse toascertain the effect of anti-KIT antibodies on survival.

Lung Cancer (e.g., Small Cell Lung Cancer)

A xenograft mouse model using human lung cancer cells, e.g., human smallcell lung carcinoma cells (e.g., H526 cells, WBA cells, or NCI-H209cells) is established essentially as described above, except for a fewmodifications. For example, lung cancer cells (e.g., small cell lungcancer cells) are injected into mice instead of GIST cells. Lung cancercells, e.g., H526 tumor cells, are collected, and 1×10⁵ to 1×10⁷ lungcancer cells per 100 μl are injected into each mouse (e.g., SCID mouse).The mice are then randomized into the following groups (e.g. n=5-10 pergroup): (a) normal saline daily; and (b) anti-KIT antibodies (e.g.,antibodies Hum1-Hum20 or antibody-drug conjugates thereof). The mice arestarted on therapy (e.g., at day 0, 7, or 14 or when tumors aredetectable) with injections (e.g., daily, weekly, or bi-weeklyintraperitoneal injections) of normal saline (vehicle) or anti-KITantibodies. Treatment is continued for a period of time (e.g.,approximately 6 weeks or more), with weekly 2-dimensional measurementsof tumor size. Imaging methods for detecting tumor size can also beused, e.g., MRI. Tumors are measured weekly during treatment and atnecropsy.

A graph of tumor size or volume of each mouse plotted against time(e.g., days or weeks) after tumor injection is generated to ascertainthe effect of the anti-KIT antibodies on tumor growth in the micerelative to the vehicle negative control. A survival curve is generatedto ascertain the effect of the anti-KIT antibodies (e.g., any one ofantibodies Hum1-Hum20, or an antigen-binding fragment thereof, or aconjugate thereof) on animal survival.

Mouse models for lung cancer (e.g., small cell lung cancer) have beendescribed (see, e.g., Garton et al., 2006, Cancer Res. 66(2):1015-24;and Wolff et al., 2004, Clin Cancer Res. 10:3528-3534), and may beadapted accordingly to study the effects of anti-KIT antibodiesdescribed herein.

Sarcoma

Xenograft models are established using cell lines derived from Ewing'sfamily of tumors, such as RD-ES, SK-ES-1 or SK-N-MC, orrhabdomyosarcomas, such as A-673. Cell lines are available from theAmerican Type Culture Collection (ATCC; Manassas, Va.). Generally,methods similar to those described above are utilized. For example,2.5-5×10⁶ cells are suspended with trypsin/EDTA or re-suspended in100-200 μL growth medium and implanted subcutaneously into the flank of6-8 week old immunodeficient mice (NuNu, SCID) (Charles RiverLaboratories, Wilmington, Mass.). Five to ten mice per group in both thevehicle and anti-KIT antibody groups are used. Once tumors are palpableor have reached 100-200 mm³, mice are started on therapy with injections(e.g., daily, weekly, or bi-weekly intraperitoneal injections) of normalsaline (vehicle) or anti-KIT antibodies (e.g., antibodies Hum1-Hum20 orantibody-drug conjugates thereof). Treatment is continued for a periodof time, e.g., approximately 6 weeks or more, and tumor size isevaluated (e.g., twice weekly by way of 2-dimensional measurements).Imaging methods for detecting tumor size can be used, e.g., MRI. Miceare sacrificed when the tumor size approach a certain size (e.g.,approximately 1.5 cm) in the control group. Tumors are collected, arefixed in formalin, and are analyzed by H&E staining. Representativeimages are taken from each tumor using a light microscope at, e.g., at×40 and ×100 magnification.

A graph of tumor size or volume of each mouse plotted against time(e.g., days or weeks) after tumor injection is generated to ascertainthe effect of the anti-KIT antibodies on tumor growth in the micerelative to the vehicle negative control.

Mouse models for sarcoma (e.g., Ewing's sarcoma) have been described,for example, see the following list of publications, and may be adaptedaccordingly to evaluate the effects of anti-KIT antibodies (e.g., anyone of antibodies Hum1-Hum20):

González et al., 2004, Clin Cancer Res.10(2):751-61;

Landuzzi et al., 2000, Am J Pathol. 157(6):2123-31 (6647 cells);

Merchant et al., 2002, JNCI 94(22):1673-1679 (TC71 cells);

Sturla et al., 2000, Cancer Res. 60(21):6160-70 (TC32 and RD-ES cells);

Powis et al., 2006, Mol Cancer Ther. 5(3):630-636 (A-673 cells);

Watanabe et al., 2008, Hum Gene Ther. 19(3):300-10 (A-673 cells);

Rouleau et al., 2008, Clin Cancer Res. 14(22):7223-7236 (A-673 cells);

Karmakar et al, 2011, World J Oncol. 2(2):53-63 (RD-ES and SK-N-MCcells);

Wang et al., 2009, In vivo 23(6):903-9 (TC71 cells); and

Ikeda et al., 2010, Mol Cancer Ther. (3):653-60 (TC71 cells and A4573cells).

Humanized Mouse Model

Studies with anti-KIT antibodies, including anti-KIT antibody drugconjugates, for example, Hum1-Hum20 antibodies, including antibody-drugconjugates thereof are carried out with mouse models generated byengraftment of immunodeficient mice with components of human immunesystem, e.g., humanized NSG mice (The Jackson Laboratory, Bar Harbor,Me.). Humanized NSG mice are NOD scid IL-2 receptor gamma chain knockoutmice (NSG) engrafted with human hematopoietic stem cells (hCD34⁺ cells)to reconstitute a human immune system.

These mice can serve as a platform for studying toxicity of anti-KITantibodies. For example, groups of mice (e.g., 1-5 mice) are injectedwith various concentrations of anti-KIT antibodies over a period of time(e.g., 4-16 weeks). The mice are assessed for toxicity indicators, e.g.,body weight, survival length.

6.9 Example 9: Inhibition of Colony Formation by KIT Expressing CHOCells in Soft Agar Assays

Anti-KIT antibodies described herein, for example Hum1-Hum20, are testedfor their ability to inhibit anchorage independent cell growth in softagar assays of CHO/KIT-WT cells. Soft agar assay for colony formation isan anchorage independent growth assay, which is a useful assay fordetecting malignant transformation of cells. In vitro transformation isassociated with certain phenotypic changes such as loss of contactinhibition (cells can grow over one another) and anchorage independence(cells form colonies in soft agar). In general, nontransformed cellsfail to grow when suspended in a viscous fluid or gel (e.g. agar oragarose), however when these cells are transformed, they are able togrow in a viscous fluid or gel and become anchorage-independent. Theprocess by which these phenotypic changes occur, is assumed to beclosely related to the process of in vivo carcinogenesis.

The soft agar assays are carried out as follows. Base agar layer(containing agar and cell culture medium) is added to each well of a 96well plate. Cell agar layer (containing agar, cell culture medium andcell suspension) is added on top of the base agar layer. Anti-KITantibodies are diluted in cell culture medium and pipetted on top of thelayers. The control samples do not contain any antibodies. Plates areincubated at 37° C. and 5% CO₂ for 5-8 days in the presence or absenceof 30 ng/mL SCF. The ligand SCF and anti-KIT antibodies (100 nM) areadded concurrently to the agar.

When treatment is completed, the agar is solubilized and the cells arelysed. The green fluorescent Cyquant® GR dye is mixed with the lysates.This dye exhibits fluorescence when bound to cellular nucleic acids.Fluorescence is measured at 480 nm excitation and 520 nm emission.

The embodiments described herein are intended to be merely exemplary,and those skilled in the art will recognize, or be able to ascertainusing no more than routine experimentation, numerous equivalents to thespecific procedures described herein. All such equivalents areconsidered to be within the scope of the present invention and arecovered by the following claims. Furthermore, as used in thisspecification and claims, the singular forms “a,” “an” and “the” includeplural forms unless the content clearly dictates otherwise. Thus, forexample, reference to “an antibody” includes a mixture of two or moresuch antibodies, and the like. Additionally, ordinarily skilled artisanswill recognize that operational sequences must be set forth in somespecific order for the purpose of explanation and claiming, but thepresent invention contemplates various changes beyond such specificorder.

All references (including patent applications, patents, andpublications) cited herein are incorporated herein by reference in theirentirety and for all purposes to the same extent as if each individualpublication or patent or patent application was specifically andindividually indicated to be incorporated by reference in its entiretyfor all purposes.

The invention claimed is:
 1. A polynucleotide comprising nucleotidesequences encoding a heavy chain variable region (“VH”), a light chainvariable region (“VL”), or both a VL and a VH, of an antibody whichimmunospecifically binds to a D4 region of human KIT, wherein (i) the VLcomprises the amino acid sequence of SEQ ID NO: 8 and the VH comprisesthe amino acid sequence of SEQ ID NO: 4; (ii) the VL comprises the aminoacid sequence of SEQ ID NO: 10 and the VH comprises the amino acidsequence of SEQ ID NO: 3; (iii) the VL comprises the amino acid sequenceof SEQ ID NO: 8 and the VH comprises the amino acid sequence of SEQ IDNO: 6; (iv) the VL comprises the amino acid sequence of SEQ ID NO: 7 andthe VH comprises the amino acid sequence of SEQ ID NO: 5; (v) the VLcomprises the amino acid sequence of SEQ ID NO: 7 and the VH comprisesthe amino acid sequence of SEQ ID NO: 2; (vi) the VL comprises the aminoacid sequence of SEQ ID NO: 7 and the VH comprises the amino acidsequence of SEQ ID NO: 3; (vii) the VL comprises the amino acid sequenceof SEQ ID NO: 7 and the VH comprises the amino acid sequence of SEQ IDNO: 4; (viii) the VL comprises the amino acid sequence of SEQ ID NO: 7and the VH comprises the amino acid sequence of SEQ ID NO: 6; (ix) theVL comprises the amino acid sequence of SEQ ID NO: 8 and the VHcomprises the amino acid sequence of SEQ ID NO: 2; (x) the VL comprisesthe amino acid sequence of SEQ ID NO: 8 and the VH comprises the aminoacid sequence of SEQ ID NO: 3; (xi) the VL comprises the amino acidsequence of SEQ ID NO: 8 and the VH comprises the amino acid sequence ofSEQ ID NO: 5; (xii) the VL comprises the amino acid sequence of SEQ IDNO: 9 and the VH comprises the amino acid sequence of SEQ ID NO: 2;(xiii) the VL comprises the amino acid sequence of SEQ ID NO: 9 and theVH comprises the amino acid sequence of SEQ ID NO: 3; (xiv) the VLcomprises the amino acid sequence of SEQ ID NO: 9 and the VH comprisesthe amino acid sequence of SEQ ID NO: 4; (xv) the VL comprises the aminoacid sequence of SEQ ID NO: 9 and the VH comprises the amino acidsequence of SEQ ID NO: 5; (xvi) the VL comprises the amino acid sequenceof SEQ ID NO: 9 and the VH comprises the amino acid sequence of SEQ IDNO: 6; (xvii) the VL comprises the amino acid sequence of SEQ ID NO: 10and the VH comprises the amino acid sequence of SEQ ID NO: 2; (xviii)the VL comprises the amino acid sequence of SEQ ID NO: 10 and the VHcomprises the amino acid sequence of SEQ ID NO: 4; (xix) the VLcomprises the amino acid sequence of SEQ ID NO: 10 and the VH comprisesthe amino acid sequence of SEQ ID NO: 5; or (xx) the VL comprises theamino acid sequence of SEQ ID NO: 10 and the VH comprises the amino acidsequence of SEQ ID NO:
 6. 2. A vector comprising the polynucleotide ofclaim
 1. 3. A host cell comprising the polynucleotide of claim
 1. 4. Amethod of making an antibody which immunospecifically binds to a D4region of human KIT comprising culturing, and/or expressing the antibodyin the host cell of claim
 3. 5. A polynucleotide comprising nucleotidesequences encoding a VH, a VL, or both a VL and a VH, of an antibodywhich immunospecifically binds to a D4 region of human KIT, wherein saidantibody comprises: (i) a VL comprising a VL CDR1, VL CDR2, and VL CDR3comprising the amino acid sequences of SEQ ID NOs: 19, 20, and 21,respectively; and a VH comprising the amino acid sequence of SEQ ID NO:2; (ii) a VL comprising a VL CDR1, VL CDR2, and VL CDR3 comprising theamino acid sequences of SEQ ID NOs: 19, 20, and 21, respectively; and aVH comprising the amino acid sequence of SEQ ID NO: 3; (iii) a VLcomprising a VL CDR1, VL CDR2, and VL CDR3 comprising the amino acidsequences of SEQ ID NOs: 19, 20, and 21, respectively; and a VHcomprising the amino acid sequence of SEQ ID NO: 4; (iv) a VL comprisinga VL CDR1, VL CDR2, and VL CDR3 comprising the amino acid sequences ofSEQ ID NOs: 19, 20, and 21, respectively; and a VH comprising the aminoacid sequence of SEQ ID NO: 5; (v) a VL comprising a VL CDR1, VL CDR2,and VL CDR3 comprising the amino acid sequences of SEQ ID NOs: 19, 20,and 21, respectively; and a VH comprising the amino acid sequence of SEQID NO: 6; (vi) a VL comprising a VL CDR1, VL CDR2, and VL CDR3comprising the amino acid sequences of SEQ ID NOs: 59, 60, and 61,respectively; and a VH comprising the amino acid sequence of SEQ ID NO:2; (vii) a VL comprising a VL CDR1, VL CDR2, and VL CDR3 comprising theamino acid sequences of SEQ ID NOs: 59, 60, and 61, respectively; and aVH comprising the amino acid sequence of SEQ ID NO: 3; (viii) a VLcomprising a VL CDR1, VL CDR2, and VL CDR3 comprising the amino acidsequences of SEQ ID NOs: 59, 60, and 61, respectively; and a VHcomprising the amino acid sequence of SEQ ID NO: 4; (ix) a VL comprisinga VL CDR1, VL CDR2, and VL CDR3 comprising the amino acid sequences ofSEQ ID NOs: 59, 60, and 61, respectively; and a VH comprising the aminoacid sequence of SEQ ID NO: 5; (x) a VL comprising a VL CDR1, VL CDR2,and VL CDR3 comprising the amino acid sequences of SEQ ID NOs: 59, 60,and 61, respectively; and a VH comprising the amino acid sequence of SEQID NO: 6; (xi) a VL comprising a VL CDR1, VL CDR2, and VL CDR3comprising the amino acid sequences of SEQ ID NOs: 66, 67, and 68,respectively; and a VH comprising the amino acid sequence of SEQ ID NO:2; (xii) a VL comprising a VL CDR1, VL CDR2, and VL CDR3 comprising theamino acid sequences of SEQ ID NOs: 66, 67, and 68, respectively; and aVH comprising the amino acid sequence of SEQ ID NO: 3; (xiii) a VLcomprising a VL CDR1, VL CDR2, and VL CDR3 comprising the amino acidsequences of SEQ ID NOs: 66, 67, and 68, respectively; and a VHcomprising the amino acid sequence of SEQ ID NO: 4; (xiv) a VLcomprising a VL CDR1, VL CDR2, and VL CDR3 comprising the amino acidsequences of SEQ ID NOs: 66, 67, and 68, respectively; and a VHcomprising the amino acid sequence of SEQ ID NO: 5; (xv) a VL comprisinga VL CDR1, VL CDR2, and VL CDR3 comprising the amino acid sequences ofSEQ ID NOs: 66, 67, and 68, respectively; and a VH comprising the aminoacid sequence of SEQ ID NO: 6; (xvi) a VL comprising the amino acidsequence of SEQ ID NO: 7, and a VH comprising a VH CDR1, VH CDR2, and VHCDR3 comprising the amino acid sequences of SEQ ID NOs: 16, 17, and 18,respectively; (xvii) a VL comprising the amino acid sequence of SEQ IDNO: 8, and a VH comprising a VH CDR1, VH CDR2, and VH CDR3 comprisingthe amino acid sequences of SEQ ID NOs: 16, 17, and 18, respectively;(xviii) a VL comprising the amino acid sequence of SEQ ID NO: 9, and aVH comprising a VH CDR1, VH CDR2, and VH CDR3 comprising the amino acidsequences of SEQ ID NOs: 16, 17, and 18, respectively; (xix) a VLcomprising the amino acid sequence of SEQ ID NO: 10, and a VH comprisinga VH CDR1, VH CDR2, and VH CDR3 comprising the amino acid sequences ofSEQ ID NOs: 16, 17, and 18, respectively; (xx) a VL comprising the aminoacid sequence of SEQ ID NO: 7, and a VH comprising a VH CDR1, VH CDR2,and VH CDR3 comprising the amino acid sequences of SEQ ID NOs: 56, 57,and 58, respectively; (xxi) a VL comprising the amino acid sequence ofSEQ ID NO: 8, and a VH comprising a VH CDR1, VH CDR2, and VH CDR3comprising the amino acid sequences of SEQ ID NOs: 56, 57, and 58,respectively; (xxii) a VL comprising the amino acid sequence of SEQ IDNO: 9, and a VH comprising a VH CDR1, VH CDR2, and VH CDR3 comprisingthe amino acid sequences of SEQ ID NOs: 56, 57, and 58, respectively;(xxiii) a VL comprising the amino acid sequence of SEQ ID NO: 10, and aVH comprising a VH CDR1, VH CDR2, and VH CDR3 comprising the amino acidsequences of SEQ ID NOs: 56, 57, and 58, respectively; (xxiv) a VLcomprising the amino acid sequence of SEQ ID NO: 7, and a VH comprisinga VH CDR1, VH CDR2, and VH CDR3 comprising the amino acid sequences ofSEQ ID NOs: 56, 62, and 63, respectively; (xxv) a VL comprising theamino acid sequence of SEQ ID NO: 8, and a VH comprising a VH CDR1, VHCDR2, and VH CDR3 comprising the amino acid sequences of SEQ ID NOs: 56,62, and 63, respectively; (xxvi) a VL comprising the amino acid sequenceof SEQ ID NO: 9, and a VH comprising a VH CDR1, VH CDR2, and VH CDR3comprising the amino acid sequences of SEQ ID NOs: 56, 62, and 63,respectively; (xxvii) a VL comprising the amino acid sequence of SEQ IDNO: 10, and a VH comprising a VH CDR1, VH CDR2, and VH CDR3 comprisingthe amino acid sequences of SEQ ID NOs: 56, 62, and 63, respectively;(xxviii) a VL comprising the amino acid sequence of SEQ ID NO: 7, and aVH comprising a VH CDR1, VH CDR2, and VH CDR3 comprising the amino acidsequences of SEQ ID NOs: 64, 65, and 58, respectively; (xxix) a VLcomprising the amino acid sequence of SEQ ID NO: 8, and a VH comprisinga VH CDR1, VH CDR2, and VH CDR3 comprising the amino acid sequences ofSEQ ID NOs: 64, 65, and 58, respectively; (xxx) a VL comprising theamino acid sequence of SEQ ID NO: 9, and a VH comprising a VH CDR1, VHCDR2, and VH CDR3 comprising the amino acid sequences of SEQ ID NOs: 64,65, and 58, respectively; (xxxi) a VL comprising the amino acid sequenceof SEQ ID NO: 10, and a VH comprising a VH CDR1, VH CDR2, and VH CDR3comprising the amino acid sequences of SEQ ID NOs: 64, 65, and 58,respectively; (xxxii) a VL comprising the amino acid sequence of SEQ IDNO: 7, and a VH comprising a VH CDR1, VH CDR2, and VH CDR3 comprisingthe amino acid sequences of SEQ ID NOs: 70, 71, and 72, respectively;(xxxiii) a VL comprising the amino acid sequence of SEQ ID NO: 8, and aVH comprising a VH CDR1, VH CDR2, and VH CDR3 comprising the amino acidsequences of SEQ ID NOs: 70, 71, and 72, respectively; or (xxxiv) a VLcomprising the amino acid sequence of SEQ ID NO: 9, and a VH comprisinga VH CDR1, VH CDR2, and VH CDR3 comprising the amino acid sequences ofSEQ ID NOs: 70, 71, and 72, respectively.
 6. A vector comprising thepolynucleotide of claim
 5. 7. A host cell comprising the polynucleotideof claim
 5. 8. A method of making an antibody which immunospecificallybinds to a D4 region of human KIT comprising culturing, and/orexpressing the antibody in the host cell of claim 7.